Details of Disease

General Information of Disease (ID: DIS7DPX1)

• Disease Name: Breast cancer
• Synonyms: mammary neoplasm; primary breast cancer; breast tumour; breast tumor; mammary tumour; mammary tumor; mammary cancer; malignant tumour of breast; malignant tumor of the breast; cancer of breast; malignant breast neoplasm; malignant breast tumor; malignant neoplasm of breast; malignant tumor of breast; malignant neoplasm of the breast; malignant tumour of the breast; breast cancer; malignant breast tumour
• Disease Class: 2C60-2C6Y: Breast cancer
• Definition: A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males.
• Disease Hierarchy:
  DIS4GB9P: Thymic cancer
  DIS0QDLG: Mammary tumour
  DISAT1Z9: Advanced cancer
  DIS7DPX1: Breast cancer
• ICD Code:
  ICD-11: ICD-11: 2C60-2C65
  ICD-10: ICD-10: C50, C79.51
  Expand ICD-9: 174175198.5
• Disease Identifiers:
  MONDO ID: MONDO_0007254
  MESH ID: D001943
  UMLS CUI: C0006142
  OMIM ID: 114480
  MedGen ID: 651
  SNOMED CT ID: 254837009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 60 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
99mTc-sestamibi	DMVZO01	Approved	Small molecular drug	[1]
99mTc-tetrofosmin	DM89JEQ	Approved	NA	[1]
Alpelisib	DMEXMYK	Approved	Small molecular drug	[2]
Anastrozole	DMNP60F	Approved	Small molecular drug	[3]
Arcitumomab	DM9GH25	Approved	Antibody	[4]
ARZOXIFENE	DMOKCVI	Approved	Small molecular drug	[5]
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[6]
Bavencio	DMU9C8F	Approved	Monoclonal antibody	[6]
Bosutinib	DMTI8YE	Approved	Small molecular drug	[7]
Cabazitaxel	DMPAZHC	Approved	Small molecular drug	[8]
Capecitabine	DMTS85L	Approved	Small molecular drug	[9]
Capivasertib	DM9SKW8	Approved	Small molecular drug	[10]
Danazol	DML8KTN	Approved	Small molecular drug	[11]
Dexrazoxane	DMD7X1O	Approved	Small molecular drug	[12]
Dostarlimab	DM78NWP	Approved	Antibody	[13]
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[14]
Eflapegrastim	DMACVEI	Approved	NA	[15]
Elacestrant	DM8RLJ5	Approved	NA	[16]
Eribulin	DM1DX4Q	Approved	Small molecular drug	[17]
Esterified estrogens	DM9KZDO	Approved	NA	[1]
Estradiol	DMUNTE3	Approved	Small molecular drug	[18]
FADROZOLE	DM3C5GZ	Approved	Small molecular drug	[19]
Fluoxymesterone	DMUHCF1	Approved	Small molecular drug	[20]
Fulvestrant	DM0YZC6	Approved	Small molecular drug	[21]
Gestrinone	DMP0OVQ	Approved	Small molecular drug	[1]
Goserelin	DMAT8CG	Approved	Small molecular drug	[22]
Halaven	DM7JNTV	Approved	NA	[23]
Ixabepilone	DM2OZ3G	Approved	Small molecular drug	[24]
Lapatinib	DM3BH1Y	Approved	Small molecular drug	[25]
Levormeloxifene	DM2XVNI	Approved	Small molecular drug	[26]
Lobaplatin	DM3UWDA	Approved	Small molecular drug	[1]
LY2835219	DM93VBZ	Approved	Small molecular drug	[27]
Megesterol acetate	DMQ1Q37	Approved	NA	[1]
Megestrol	DMDH9KX	Approved	Small molecular drug	[28]
Merimepodib	DM0HS92	Approved	Small molecular drug	[29]
Mitomycin	DMH0ZJE	Approved	Small molecular drug	[30]
Nomegestrol acetate	DMRJ7D1	Approved	Small molecular drug	[31]
Oxidized glutathione	DM9EQC0	Approved	Small molecular drug	[1]
Palbociclib	DMD7L94	Approved	Small molecular drug	[32]
Pembrolizumab	DMFQEA6	Approved	Monoclonal antibody	[6]
Peplomycin	DMN6SDD	Approved	Small molecular drug	[1]
Pertuzumab	DMHJV0X	Approved	Monoclonal antibody	[33]
Pirarubicin	DMGTW1I	Approved	Small molecular drug	[1]
Pralatrexate	DMAO80I	Approved	Small molecular drug	[34]
Prosorba	DML0EUS	Approved	NA	[1]
Quinestrol	DMJ6H1Z	Approved	Small molecular drug	[35]
Radium-223 chloride	DMG21CZ	Approved	NA	[6]
Ribociclib Succinate	DM9CIUW	Approved	Small molecular drug	[27]
Sacituzumab govitecan	DMUWFD8	Approved	Antibody drug conjugate	[36]
Satumomab Pendetide	DMRSKMZ	Approved	Monoclonal antibody	[37]
Talaporfin	DMCB7ZZ	Approved	Small molecular drug	[1]
Talazoparib	DM1KS78	Approved	Small molecular drug	[38]
Tamoxifen	DMLB0EZ	Approved	Small molecular drug	[39]
Taxol	DMUOT9V	Approved	Small molecular drug	[40]
Testolactone	DMVY4GN	Approved	Small molecular drug	[41]
Thiotepa	DMIZKOP	Approved	Small molecular drug	[42]
Toremifene	DMQYUWG	Approved	Small molecular drug	[43]
Trastuzumab	DMZQOUX	Approved	Antibody	[44]
Virulizin	DM0REZS	Approved	NA	[45]
YN-968D1	DMMP3Y2	Approved	Small molecular drug	[46]

This Disease is Treated as An Indication in 235 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Abexinostat	DM91LGU	Phase 3	Small molecular drug	[6]
ABP 980	DMEH3LA	Phase 3	NA	[47]
ABT-888	DM4HYMS	Phase 3	Small molecular drug	[48]
Acolbifene	DM3UQ9K	Phase 3	Small molecular drug	[49]
Adagloxad simolenin	DMICKCQ	Phase 3	Vaccine	[50]
AMG 386	DMQJXL4	Phase 3	Small molecular drug	[51]
Amonafide	DMAH59S	Phase 3	Small molecular drug	[52]
Brivanib	DM942HP	Phase 3	Small molecular drug	[53]
Buparlisib	DM1WEHC	Phase 3	Small molecular drug	[54]
Cotellic	DMF9M57	Phase 3	Small molecular drug	[6]
Custirsen	DMIQ31Y	Phase 3	Small molecular drug	[55]
Datopotamab deruxtecan	DMO4GTC	Phase 3	Antibody drug conjugate	[56]
Dendritic cell therapy	DMFGZIV	Phase 3	NA	[57]
EG12014	DMLFYI7	Phase 3	NA	[58]
Etirinotecan pegol	DMQHX1Y	Phase 3	Small molecular drug	[59]
GDC-0032	DMT4QHD	Phase 3	Small molecular drug	[6]
GDC-0068	DMWBZJD	Phase 3	Small molecular drug	[6]
Gilotrif	DM6NIZD	Phase 3	NA	[6]
Giredestrant	DMBSFFK	Phase 3	Small molecule	[60]
GM3 ganglioside vaccine	DM7Z4K1	Phase 3	NA	[61]
GTx-024	DMZXF05	Phase 3	Small molecular drug	[6]
HKI-272	DM6QOVN	Phase 3	Small molecular drug	[62]
I3C	DMIGFOR	Phase 3	Small molecular drug	[63]
Imlunestrant	DMYBWL9	Phase 3	Small molecule	[64]
Kadcyla	DM6W717	Phase 3	NA	[6]
LEE011	DMMX75K	Phase 3	Small molecular drug	[6]
MK-4827	DMLYGH4	Phase 3	Small molecular drug	[6]
Nelipepimut S	DMDBY30	Phase 3	Small molecular drug	[50]
NeuVax	DMYTC4I	Phase 3	Vaccine	[65]
Onzeald	DM4P72R	Phase 3	NA	[6]
OPT-822/OPT-821	DM8EJ3S	Phase 3	NA	[66]
Oraxol	DMNDH3J	Phase 3	NA	[6]
OSE2101	DM4ORRQ	Phase 3	NA	[67]
PF-05280014	DM23BUP	Phase 3	NA	[68]
Rostaporfin	DM7SAKN	Phase 3	Small molecular drug	[69]
Sapacitabine	DM704AN	Phase 3	Small molecular drug	[6]
SBG	DMG57EV	Phase 3	NA	[70]
SNDX-275	DMH7W9X	Phase 3	Small molecular drug	[71]
SYD985	DM0JC9L	Phase 3	Antibody drug conjugate	[72]
Taxol/Paraplatin/Herceptin	DML6GAN	Phase 3	NA	[73]
Tesetaxel	DM9LFYN	Phase 3	Small molecular drug	[6]
Trastuzumab duocarmazine	DM6GBKI	Phase 3	Antibody drug conjugate	[6]
Trastuzumab-DM1	DMLB3I4	Phase 3	Antibody drug conjugate	[74]
TRC105	DM1874J	Phase 3	Monoclonal antibody	[47]
Tusamitamab ravtansine	DMMPSA1	Phase 3	Antibody drug conjugate	[75]
Imetelstat	DMONWJ4	Phase 2/3	Small molecular drug	[76]
Imprime PGG	DMIUA3M	Phase 2/3	NA	[6]
MGCD516	DM752PU	Phase 2/3	NA	[77]
Varlitinib	DMDG8Q3	Phase 2/3	Small molecular drug	[78]
18F-fluorothymidine	DM1X1QZ	Phase 2	Small molecular drug	[79]
2X-121	DMX9MSL	Phase 2	NA	[6]
AE-37	DMMRSK1	Phase 2	Small molecular drug	[80]
AE37 peptide vaccine	DME1WNB	Phase 2	NA	[81]
AE37/GP2 peptide vaccine	DM15QZ4	Phase 2	NA	[6]
Afimoxifene	DMFORDT	Phase 2	Small molecular drug	[82]
AFP464	DM1FJ2B	Phase 2	Small molecular drug	[83]
Alovudine	DMJPV5X	Phase 2	Small molecular drug	[84]
AMG 479	DM0DRAZ	Phase 2	NA	[85]
ANG1005	DMV5ENT	Phase 2	NA	[86]
Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells	DMPRIHK	Phase 2	Antibody	[87]
Apristor	DMWFD3K	Phase 2	NA	[6]
ARC-100	DMF6GK1	Phase 2	Small molecular drug	[88]
ARN-810	DML3PJF	Phase 2	NA	[89]
AS-1402	DMMX1EJ	Phase 2	Antibody	[90]
AZD8931	DMFLCW4	Phase 2	Small molecular drug	[91]
BAY 86-5044	DMRZLU4	Phase 2	Small molecular drug	[92]
BGB-324	DMDI43Y	Phase 2	siRNA drug	[6]
BIIB 2024	DM44Z9R	Phase 2	NA	[93]
BIIB-021	DMPAJ41	Phase 2	Small molecular drug	[94]
BMS-906024	DMEYR4K	Phase 2	Small molecular drug	[95]
Breast cancer vaccine	DMLAOTB	Phase 2	NA	[96]
Brostallicin	DMUI5PA	Phase 2	Small molecular drug	[97]
BZL-101	DMTRONK	Phase 2	NA	[98]
CB-103	DMLW115	Phase 2	Small molecular drug	[99]
CB-839	DM094UH	Phase 2	NA	[6]
CFI-400945	DM3BN4W	Phase 2	Small molecular drug	[100]
Coumate	DMVKW0N	Phase 2	Small molecular drug	[101]
CV-301	DMSJZB9	Phase 2	NA	[102]
Dalotuzumab	DMHEQQL	Phase 2	Monoclonal antibody	[103]
Debio 1347	DMZW50O	Phase 2	NA	[6]
DS-8201	DMYCAN7	Phase 2	NA	[6]
Dusigitumab	DM1ZJYS	Phase 2	NA	[47]
Efungumab	DMBHP56	Phase 2	Antibody	[104]
Endoxifen	DMTX8IZ	Phase 2	Small molecular drug	[105]
EP-101	DM69NF1	Phase 2	Small molecular drug	[6]
EP-302	DM3UHGF	Phase 2	Small molecular drug	[6]
Ertumaxomab	DM5Z3VP	Phase 2	Antibody	[106]
FANG vaccine	DM0OV22	Phase 2	Vaccine	[47]
G1T38	DMQO2IT	Phase 2	NA	[6]
GDC-0077	DMY6WUV	Phase 2	NA	[6]
GDC0941	DM1YAK6	Phase 2	Small molecular drug	[107]
Gimatecan	DMSKMET	Phase 2	Small molecular drug	[108]
GPI-0100	DMB6BGT	Phase 2	Small molecular drug	[109]
GPX-150D	DMHNIGB	Phase 2	NA	[110]
GSK3326595	DMJRD7A	Phase 2	NA	[111]
HE3235	DMV50R1	Phase 2	Small molecular drug	[112]
HER-2 Protein AutoVac	DM8TOS0	Phase 2	NA	[113]
HER2 antigen-specific cancer immunotherapeutic	DMZAYYD	Phase 2	NA	[114]
HER2/neu peptide vaccine	DMISETH	Phase 2	Vaccine	[115]
ICARITIN	DMGHQ37	Phase 2	Small molecular drug	[116]
ICO-25	DMC13BQ	Phase 2	Antibody	[117]
ImmunoPulse IL-12	DM0W3B4	Phase 2	NA	[47]
INK128	DMGO7QT	Phase 2	Small molecular drug	[6]
IPI-549	DMG5Q7F	Phase 2	NA	[6]
IRX-2	DMODLN7	Phase 2	NA	[47]
KN026	DMNLH9W	Phase 2	Antibody	[118]
Ladiratuzumab vedotin	DM00R2I	Phase 2	NA	[6]
LADIRUBICIN	DM7063I	Phase 2	Small molecular drug	[119]
LCL161	DMTM4QA	Phase 2	NA	[6]
LOR-2040	DMX2TEM	Phase 2	NA	[120]
LY2784544	DMZASMP	Phase 2	Small molecular drug	[121]
Maraciclatide	DMLZJSJ	Phase 2	Small molecular drug	[122]
MCLA-128	DM0W3R7	Phase 2	NA	[6]
MCS-110	DM0CL4I	Phase 2	NA	[47]
MM-111	DMO7MBS	Phase 2	Monoclonal antibody	[123]
MM-121	DMDJRU1	Phase 2	NA	[124]
NSC-645809	DMPJQZG	Phase 2	Small molecular drug	[125]
OGX-427	DMJTU8D	Phase 2	Antisense drug	[126]
ONAPRISTONE	DMT6E5N	Phase 2	Small molecular drug	[127]
P-276	DMMJUHD	Phase 2	Small molecular drug	[128]
Patritumab deruxtecan	DMNIAWS	Phase 2	Antibody drug conjugate	[129]
PD-0325901	DM27D4J	Phase 2	Small molecular drug	[130]
PEG-SN38	DMX9ZM4	Phase 2	Small molecular drug	[131]
POL-6326	DM4OT29	Phase 2	NA	[6]
Polyamine	DMUXEBQ	Phase 2	NA	[132]
PTX-200	DM0ZIT2	Phase 2	NA	[6]
Racotumomab	DM79YAS	Phase 2	Monoclonal antibody	[133]
REM-001	DMYA0T8	Phase 2	NA	[6]
RO-4929097	DMXA6B3	Phase 2	Small molecular drug	[134]
Sagopilone	DM6JXWL	Phase 2	Small molecular drug	[135]
SAR439859	DMR5CSZ	Phase 2	Small molecular drug	[136]
Seviteronel	DM9IMEZ	Phase 2	NA	[6]
SFV IL-12 gene therapy	DMVIWNK	Phase 2	NA	[137]
SFX-01	DMAQW9M	Phase 2	NA	[138]
SR 16234	DMRFO34	Phase 2	Small molecular drug	[139]
Tanespimycin	DMNLQHK	Phase 2	Small molecular drug	[140]
TgDCC-E1A	DMPU168	Phase 2	NA	[141]
Tigatuzumab	DMKYJJC	Phase 2	Monoclonal antibody	[142]
TPI-287	DMC5TV6	Phase 2	Small molecular drug	[143]
TPIV200	DM4UZRE	Phase 2	NA	[50]
Trastuzumab emtansine	DMU1LXS	Phase 2	Antibody drug conjugate	[47]
Upamostat	DMFZULI	Phase 2	Small molecular drug	[144]
VER 50589	DMFLZPC	Phase 2	Small molecular drug	[145]
Vx-001	DMDKWA3	Phase 2	Vaccine	[146]
Xentuzumab	DM4ZIDH	Phase 2	NA	[147]
XL880	DMHJTR2	Phase 2	Small molecular drug	[148]
YM155	DM5Q1W4	Phase 2	Small molecular drug	[149]
ZW25	DMRLZA1	Phase 2	Antibody	[150]
Aderbasib	DMYOMSC	Phase 1/2	Small molecular drug	[151]
ADXS-HER2	DMW8C1D	Phase 1/2	NA	[152]
Anti-MUC1 CAR T Cells	DM0C1IX	Phase 1/2	CAR T Cell Therapy	[153]
ARV-471	DM276Y8	Phase 1/2	Small molecular drug	[154]
AVX901	DM7O29W	Phase 1/2	NA	[155]
Bria-IMT	DMX7NQF	Phase 1/2	NA	[6]
BriaVax	DM0M0N8	Phase 1/2	NA	[47]
CT84.66	DM6078F	Phase 1/2	NA	[156]
DCC-2036	DMJKFNU	Phase 1/2	Small molecular drug	[6]
FCN-437	DMQ8VUW	Phase 1/2	NA	[157]
H3B-6545	DMIFCY2	Phase 1/2	NA	[158]
HER-2-targeting CAR T Cells	DM1U6VX	Phase 1/2	CAR T Cell Therapy	[159]
LJM716	DMGTB5N	Phase 1/2	Antibody	[160]
ME-344	DM6JN19	Phase 1/2	Small molecular drug	[6]
NB1011	DM5O4GR	Phase 1/2	Small molecular drug	[161]
OBP-301	DM9MF08	Phase 1/2	NA	[162]
OP-1250	DMIU26T	Phase 1/2	Small interfering RNA	[163]
P10s-Padre/Montanide ISA 51 vaccine	DMCSXHW	Phase 1/2	NA	[164]
Samuraciclib	DM54FQA	Phase 1/2	Small molecule	[165]
SV-BR-1-GM cancer vaccine	DM70TX5	Phase 1/2	Vaccine	[166]
TC-510	DMSPG60	Phase 1/2	Cell therapy	[167]
ZN-c5	DMVG4OC	Phase 1/2	Small molecular drug	[168]
177Lu-AMBA	DMFG1YA	Phase 1	NA	[169]
AC0682	DM49FVF	Phase 1	PROTAC	[170]
Ad.hIL-12	DM40OOG	Phase 1	NA	[171]
ADPT01	DMS6DPF	Phase 1	Antibody	[172]
Afeletecan	DMNF3GW	Phase 1	Small molecular drug	[173]
AIP-303	DMHCBI0	Phase 1	Radiopharmaceutical therapy agent	[174]
ARX788	DMQ9VJW	Phase 1	NA	[47]
Autologous T Cells Expressing MET scFv CAR	DMZ763A	Phase 1	CAR T Cell Therapy	[175]
AZD9496	DMPMDTH	Phase 1	NA	[6]
BP-C1	DMSG08M	Phase 1	NA	[176]
BTSCAN	DM4R2YC	Phase 1	NA	[177]
CAR-T cells recognizing EpCAM	DMC7Y5F	Phase 1	CAR T Cell Therapy	[178]
CT-P6	DM1L7OU	Phase 1	NA	[47]
D-0502	DMGA1DS	Phase 1	Small molecular drug	[179]
DAN-222	DMJD93K	Phase 1	NA	[180]
Demobesin	DMPXLMB	Phase 1	NA	[181]
DHES0815A	DM4OKDB	Phase 1	NA	[6]
DPX-0907	DM2XVCE	Phase 1	NA	[182]
EP-301	DMVLI4R	Phase 1	Vaccine	[183]
ETBX-021	DM4XL4C	Phase 1	NA	[6]
G1T-48	DMRGP72	Phase 1	NA	[184]
GDC-9545	DMDIU0M	Phase 1	NA	[6]
GMI-1359	DML1KSA	Phase 1	Small molecular drug	[185]
HC-5404	DMKFZW5	Phase 1	Small molecule	[186]
HHCYH33	DMRQ4L6	Phase 1	Small molecular drug	[187]
HuMNC2-CAR44 T cells	DMVGBA1	Phase 1	CAR T Cell Therapy	[188]
IMT-1012 immunotherapeutic vaccine	DM3JYBZ	Phase 1	NA	[6]
IMT1012	DMG5PF0	Phase 1	Vaccine	[189]
INO-1400	DMLN5E4	Phase 1	NA	[50]
IRX4204	DM9SCME	Phase 1	Small molecular drug	[6]
JCAR024	DMQ1TK0	Phase 1	NA	[47]
LSZ102	DMS1DMA	Phase 1	NA	[6]
LV305	DMP0TQA	Phase 1	NA	[190]
LY3484356	DMY8W3S	Phase 1	NA	[191]
LY3849524	DM8I68X	Phase 1	NA	[192]
Mesothelin-targeted T cells	DMHXA79	Phase 1	CAR T Cell Therapy	[193]
MM-302	DMYSJTR	Phase 1	NA	[194]
MVA HER-2 AutoVac	DM3JUXW	Phase 1	Vaccine	[195]
OBT076	DMW4JRY	Phase 1	Antibody drug conjugate	[196]
Odetiglucan	DMH8IO5	Phase 1	Antibody	[197]
OTSSP167	DMF5KNO	Phase 1	Small molecular drug	[6]
pbi-shRNA STMN1	DM529QO	Phase 1	Short hairpin RNA	[132]
PCA062	DM1GNEH	Phase 1	NA	[6]
PEV-6A	DMN2SF8	Phase 1	NA	[198]
PF-06873600	DMRZHV6	Phase 1	NA	[6]
PF-07248144	DM5P0PC	Phase 1	Small molecule	[199]
PF-07260437	DMU7LYP	Phase 1	Antibody	[200]
PU-H71	DMIYHAW	Phase 1	Small molecular drug	[6]
Quinazoline derivative 9	DMP3QSA	Phase 1	Small molecular drug	[201]
RAD-140	DMNVDI2	Phase 1	Small molecular drug	[6]
RGT-419B	DMD2MND	Phase 1	Small molecule	[202]
Runimotamab	DML6BK5	Phase 1	Bispecific antibody	[203]
Sch-58500	DMHE7R4	Phase 1	NA	[204]
SCO-120	DMB1MZS	Phase 1	NA	[205]
SGN LIV1A	DMVBQ2L	Phase 1	Antibody	[206]
Sialyl Lea-KLH conjugate vaccine	DMCU3Z2	Phase 1	NA	[207]
TPIV 100/110 vaccine	DM4K0KW	Phase 1	NA	[50]
TPIV 110	DMIO289	Phase 1	NA	[47]
Trodusquemine	DMQ7UN6	Phase 1	Small molecular drug	[6]
TTC-352	DM7CHZ2	Phase 1	NA	[6]
VIMO-001	DMY4LTE	Phase 1	Small molecular drug	[208]
XmAb20717	DMJIH83	Phase 1	Antibody	[209]
XMT-1522	DMPVP4D	Phase 1	NA	[6]
KH064	DMR1NYF	Clinical trial	Small molecular drug	[210]
Methylselenocysteine	DMAAB9A	Clinical Trial	Small molecular drug	[211]

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID28460551-Compound-1	DMHV75N	Patented	Small molecular drug	[212]

This Disease is Treated as An Indication in 38 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
FORMESTANE	DMWIDJK	Withdrawn from market	Small molecular drug	[1]
Nomifensine	DMCP2TS	Withdrawn from market	Small molecular drug	[213]
Idoxifene	DMRXUY7	Discontinued in Phase 3	Small molecular drug	[214]
99mTc-RP-527	DM6QRLF	Discontinued in Phase 2	NA	[215]
AVE-1642	DMUQ6IL	Discontinued in Phase 2	Antibody	[216]
Droloxifene	DM9JPUD	Discontinued in Phase 2	Small molecular drug	[217]
Epothilone D	DM1WGUT	Discontinued in Phase 2	Small molecular drug	[218]
ERA-923	DM6NTAS	Discontinued in Phase 2	Small molecular drug	[219]
Her-2-Bi-armed ATC	DM5JZW2	Discontinued in Phase 2	Antibody	[220]
KW-2170	DM5YHJ2	Discontinued in Phase 2	Small molecular drug	[221]
LOSOXANTRONE	DMM843E	Discontinued in Phase 2	Small molecular drug	[222]
Mirostipen	DMKI8AC	Discontinued in Phase 2	NA	[223]
Recombinant pox virus vaccine	DM5NCIK	Discontinued in Phase 2	NA	[224]
RHIZOXIN	DMQ4IKZ	Discontinued in Phase 2	Small molecular drug	[225]
SMART ABL-364	DMY87J3	Discontinued in Phase 2	NA	[226]
SU-14813	DMNRW68	Discontinued in Phase 2	Small molecular drug	[227]
Tesmilifene	DMPB36I	Discontinued in Phase 2	Small molecular drug	[228]
YM-511	DM7WDAG	Discontinued in Phase 2	Small molecular drug	[229]
KW-2450	DM7QGSX	Discontinued in Phase 1/2	NA	[230]
SF-1	DMAZXN5	Discontinued in Phase 1/2	NA	[231]
AS-1403	DMSI81F	Discontinued in Phase 1	NA	[232]
AZD-4992	DMNI7BA	Discontinued in Phase 1	NA	[233]
GSK1059615	DMI6KQM	Discontinued in Phase 1	Small molecular drug	[234]
HER-2VAX	DMXLQE6	Discontinued in Phase 1	NA	[235]
NRLU-10	DMLIMQ5	Discontinued in Phase 1	NA	[236]
Anatumomab mafenatox	DMMLDG8	Terminated	Antibody	[245]
CMB-401	DMN1KKT	Terminated	NA	[246]
Datelliptium chloride	DMR80AL	Terminated	Small molecular drug	[247]
Doxorubicin-CEA conjugate	DM4BPFV	Terminated	NA	[248]
GW-974	DMPLYHU	Terminated	NA	[249]
Herzyme	DMMUBT3	Terminated	NA	[250]
ICI-164384	DMYN3WG	Terminated	Small molecular drug	[251]
MB-300	DM8BQAY	Terminated	NA	[252]
MX-6162	DMV1SGP	Terminated	NA	[253]
MX-781	DMNZ356	Terminated	NA	[254]
Rogletimide	DM6JO30	Terminated	Small molecular drug	[255]
VT-1	DMU30D6	Terminated	Small molecular drug	[256]
Zindoxifene	DM81DJV	Terminated	Small molecular drug	[257]

This Disease is Treated as An Indication in 12 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Kanjinti	DM3YJNL	Application submitted	NA	[6]
SB3	DM90HIN	Application submitted	NA	[6]
(R)-PFI-2	DMIUZEX	Preclinical	Small molecular drug	[237]
111In-hEGF	DM9TQDE	Preclinical	NA	[238]
2-Amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid	DM1R3VC	Preclinical	Small molecular drug	[239]
2-Ethoxypropanoic acid	DMAM4FE	Preclinical	Small molecular drug	[240]
AA-102	DM0N111	Preclinical	NA	[241]
BIX-01294	DM5CBNY	Preclinical	Small molecular drug	[237]
Cu-anti-hAXL	DMKVW25	Preclinical	Antibody	[242]
EDD7H9	DMELPJM	Preclinical	Antibody	[243]
SP-MET-1	DMO2UKI	Preclinical	NA	[244]
YW327.6S2	DMH0I9N	Preclinical	Antibody	[242]

This Disease is Treated as An Indication in 41 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
76Br-16alpha,17alpha-dioxolane progestin	DMNQK9Y	Investigative	NA	[132]
AFPep	DMC5ZSR	Investigative	NA	[132]
AntiHer2-XTEN-Docetaxel	DM8QOBV	Investigative	NA	[132]
ARX-AHD	DM15KLR	Investigative	Antibody	[258]
ASP4131	DM9B6WH	Investigative	NA	[132]
Beta 1-6 glucan-conjugated trastuzumab	DMUGJY3	Investigative	Monoclonal antibody	[132]
BreMel/rGel	DMUSJNA	Investigative	NA	[132]
BreMel/TNF alpha	DMW6JJN	Investigative	NA	[132]
BW-42	DMSBVGB	Investigative	NA	[132]
Crodox	DMJ5X3T	Investigative	NA	[132]
Cu64-CNND1-B	DM902DU	Investigative	NA	[132]
EGF-SLiP fusion protein	DMCFQRZ	Investigative	NA	[132]
ETP-45658	DM79XSF	Investigative	Small molecular drug	[259]
Foxy-5	DM8NIEE	Investigative	NA	[132]
Fsn-1006	DM8W096	Investigative	NA	[132]
GBP-1a	DMGKZ1I	Investigative	NA	[132]
GSK-2302024A	DM3733M	Investigative	NA	[132]
Hedgehog labelled stem cells	DMATT2T	Investigative	NA	[132]
HM-2002	DM5CXKR	Investigative	NA	[132]
HMAG-1 targeting GRSA	DM4MEVL	Investigative	NA	[132]
HTERT-VISA-BikDD nanoparticles	DMZ121A	Investigative	NA	[132]
ITL-1636	DMBH3L7	Investigative	NA	[132]
IVVS-1001	DMS69AB	Investigative	NA	[132]
KW-2581	DM1P5DP	Investigative	Small molecular drug	[132]
mabionHER2	DMJX2CS	Investigative	Antibody	[258]
MAGE-101	DMMJEEG	Investigative	NA	[132]
MS1943	DMTPGQ3	Investigative	Small molecular drug	[237]
ON-04	DMRNE3B	Investigative	NA	[132]
PINS	DM9Y198	Investigative	NA	[132]
Plant-based oncology candidate	DMY5Z5D	Investigative	NA	[132]
RG6046	DMGYWIK	Investigative	NA	[1]
RL-6A	DMPT1YA	Investigative	NA	[132]
ScFv23/rGel	DM02XLI	Investigative	NA	[132]
SLX-1016	DMN7HEK	Investigative	NA	[132]
SNG-8023	DM6O9DQ	Investigative	Antibody	[261]
SR-13654	DMZN18C	Investigative	NA	[132]
TB-010	DMUY0EY	Investigative	NA	[132]
Tc99-labeled 14F7 humanized mab	DM45HCT	Investigative	Monoclonal antibody	[132]
Tetanolic acid	DMI2JHN	Investigative	NA	[132]
VM-505	DMXSY75	Investigative	NA	[132]
Zn-DPA-B	DMB98OG	Investigative	NA	[132]

This Disease is Treated as An Indication in 1 Investigative Agents

Drug Name	Drug ID	Highest Status	Drug Type	REF
Sapanisertib	DMYZFNH	Investigative	Small molecular drug	[260]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 3128 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
XRCC2	OTJB2PV4	Disputed	Autosomal dominant	[265]
AAMP	OTZXBSS4	Limited	Altered Expression	[1785]
AATF	OT1QOKLD	Limited	Biomarker	[1786]
ACOX2	OT3VH359	Limited	Biomarker	[1787]
ACSL1	OTB06ESI	Limited	Biomarker	[1788]
ACTN1	OTUCLNXH	Limited	Altered Expression	[1789]
ADAM22	OT452ZDC	Limited	Biomarker	[1790]
ADAM23	OTVWT6JZ	Limited	Biomarker	[1791]
ADAMTS12	OTG7HEA2	Limited	Biomarker	[1792]
ADGRE2	OTUYJVYG	Limited	Biomarker	[1793]
ADGRF5	OTWU7AOO	Limited	Biomarker	[1794]
ADSL	OTSNJALL	Limited	Biomarker	[1795]
AGBL2	OTCX9987	Limited	Altered Expression	[1796]
AIF1L	OTDEOB80	Limited	Altered Expression	[1797]
AK6	OT84OHHP	Limited	Biomarker	[1798]
AKAP4	OTL4Z99V	Limited	Altered Expression	[1799]
ALDH3A1	OTAYZZE6	Limited	Biomarker	[356]
ALPP	OTZU4G9W	Limited	Biomarker	[700]
AMPD1	OTU17BCI	Limited	Genetic Variation	[1800]
ANAPC4	OTVW4DW1	Limited	Altered Expression	[1801]
ANK3	OTJ3IRBP	Limited	Biomarker	[1802]
ANKHD1	OTVYQ7ZL	Limited	Altered Expression	[1803]
ANKRD36B	OT3MW415	Limited	Biomarker	[1804]
ANKRD6	OTM86B04	Limited	Biomarker	[1805]
AP1S2	OTZHJFYI	Limited	Biomarker	[1806]
API5	OTYX9YCZ	Limited	Altered Expression	[1807]
AQP10	OT8Q5UWS	Limited	Altered Expression	[279]
ARHGAP8	OT19H5Q9	Limited	Altered Expression	[1808]
ARHGEF28	OT3F32IU	Limited	Biomarker	[1809]
ARL6IP5	OTYZ6BEQ	Limited	Biomarker	[1810]
ARRDC3	OTAKW7R9	Limited	Biomarker	[1811]
ASAH1	OT1DNGXL	Limited	Biomarker	[1812]
ASH2L	OT3HG324	Limited	Altered Expression	[1813]
ATG5	OT4T5SMS	Limited	Genetic Variation	[698]
ATOX1	OT05LF59	Limited	Altered Expression	[1814]
ATP2B4	OTMWFDAC	Limited	Altered Expression	[1815]
ATP6V1C1	OT2LI8ZG	Limited	Altered Expression	[1816]
AURKA	OTMX0HYT	Limited	Autosomal dominant	[265]
AZIN2	OT8OB7CG	Limited	Biomarker	[1817]
B3GAT1	OTXFP98E	Limited	Biomarker	[296]
BCCIP	OTFFKG79	Limited	Altered Expression	[1818]
BCL10	OT47MCLI	Limited	Genetic Variation	[392]
BCL2L10	OTYXQJ3I	Limited	Biomarker	[1105]
BCL3	OT1M5B95	Limited	Altered Expression	[1819]
BRCC3	OTK0ZN7Y	Limited	Biomarker	[1820]
BRI3	OT1RWIH7	Limited	Biomarker	[1821]
BRINP1	OTEUVSCP	Limited	Biomarker	[1822]
BTN3A3	OTKMSJRA	Limited	Biomarker	[1823]
BVES	OT4GT1WC	Limited	Biomarker	[1824]
CAP2	OTC1WFNO	Limited	Altered Expression	[1825]
CAPG	OTJ86KI6	Limited	Altered Expression	[1826]
CAPRIN1	OTEJAMS3	Limited	Altered Expression	[1827]
CARMIL3	OT4ZN0K3	Limited	Altered Expression	[1828]
CARTPT	OTTE4V9S	Limited	Biomarker	[1829]
CAV2	OT1FGRQX	Limited	Altered Expression	[1830]
CBX2	OTOQ5WS4	Limited	Biomarker	[1831]
CBX3	OTOP9RLD	Limited	Altered Expression	[293]
CCDC106	OTWUTA1W	Limited	Biomarker	[1832]
CCDC170	OTNQOJ6S	Limited	Biomarker	[1833]
CCDC85A	OT2GLF5Z	Limited	Genetic Variation	[1834]
CCL27	OTUZYC61	Limited	Biomarker	[700]
CCL4L2	OTDBSXOU	Limited	Altered Expression	[1835]
CCL7	OTDIS99H	Limited	Altered Expression	[756]
CCN3	OTOW5YL4	Limited	Biomarker	[1836]
CCNA1	OTX4HD45	Limited	Biomarker	[1837]
CCNB2	OTIEXTDK	Limited	Altered Expression	[1656]
CCNG2	OTII38K2	Limited	Biomarker	[1838]
CCS	OTXHT3QO	Limited	Altered Expression	[1839]
CD177	OTS79FNF	Limited	Biomarker	[1840]
CD1D	OT3ROU4J	Limited	Biomarker	[1841]
CDC6	OTX93FE7	Limited	Biomarker	[1842]
CDCP1	OTD7RRWK	Limited	Altered Expression	[1843]
CDH4	OT8LH3HN	Limited	Genetic Variation	[1844]
CEP135	OT1O9XYJ	Limited	Biomarker	[1845]
CEP70	OTMY5KAE	Limited	Biomarker	[1846]
CFAP97	OT0RSQO4	Limited	Biomarker	[1847]
CHAC1	OTJGE772	Limited	Altered Expression	[1848]
CHD1	OT9R9G0H	Limited	Posttranslational Modification	[1849]
CHI3L2	OT26R3HQ	Limited	Altered Expression	[1850]
CHL1	OT6E6E8P	Limited	Posttranslational Modification	[1851]
CHSY1	OTB1XSSF	Limited	Biomarker	[720]
CHSY3	OT8ERGMH	Limited	Biomarker	[720]
CISD1	OT0MTVGF	Limited	Biomarker	[1852]
CITED2	OT812TV7	Limited	Biomarker	[1853]
CKS2	OTPTMHIV	Limited	Altered Expression	[1854]
CLCA2	OTF191LZ	Limited	Biomarker	[1855]
CLDN2	OTRF3D6Y	Limited	Biomarker	[1856]
CLDN3	OT71MN9S	Limited	Altered Expression	[1857]
CLEC4G	OTUGTR0H	Limited	Biomarker	[1823]
CLGN	OTEWVFQV	Limited	Biomarker	[1858]
CLIC3	OT5KUZ3A	Limited	Biomarker	[1859]
CMTM1	OTKN7E89	Limited	Biomarker	[1860]
COPS2	OTDSCPVV	Limited	Genetic Variation	[1861]
CORO1B	OT7C4BMQ	Limited	Altered Expression	[363]
CORO1C	OTXDF9T3	Limited	Biomarker	[1862]
COX3	OTNNGBYJ	Limited	Genetic Variation	[1863]
COX4I1	OTU0FC24	Limited	Biomarker	[1864]
CPQ	OTTNZNLD	Limited	Altered Expression	[1386]
CPSF4	OT53UK5L	Limited	Biomarker	[1865]
CREB3L4	OTSGQGT2	Limited	Biomarker	[1866]
CRIP1	OT0EICG3	Limited	Biomarker	[1867]
CRISPLD2	OTVSFHTL	Limited	Biomarker	[1868]
CSPP1	OTNX7GD4	Limited	Altered Expression	[1869]
CSRP2	OT4SW0HI	Limited	Biomarker	[1870]
CSTA	OT1K68KE	Limited	Biomarker	[1871]
CT62	OTV9N4KM	Limited	Biomarker	[1872]
CT83	OTQEGHAB	Limited	Altered Expression	[1873]
CYBA	OT16N9ZO	Limited	Genetic Variation	[1874]
CYLD	OT37FKH0	Limited	Biomarker	[1875]
DAB1	OTPL9MA3	Limited	Biomarker	[1876]
DACT1	OT19Z704	Limited	Altered Expression	[1877]
DBT	OT4KZ5R9	Limited	Biomarker	[1878]
DCDC2	OTSUFH1H	Limited	Biomarker	[1879]
DDT	OTF5HTYL	Limited	Biomarker	[1880]
DDX56	OTGURA53	Limited	Biomarker	[1881]
DEF6	OTIRBYVK	Limited	Altered Expression	[1882]
DENR	OTXP9HOY	Limited	Biomarker	[490]
DESI1	OTFNIW98	Limited	Genetic Variation	[1883]
DHRS11	OTU3J0ZL	Limited	Biomarker	[362]
DHX9	OT5AAOQI	Limited	Altered Expression	[1884]
DIAPH3	OTPOT23F	Limited	Altered Expression	[1885]
DMXL2	OTB4JWN3	Limited	Altered Expression	[1886]
DNAJC15	OTNDUKAA	Limited	Biomarker	[1887]
DOCK4	OTH3XY8B	Limited	Biomarker	[1888]
DOK5	OT2XWUPN	Limited	Altered Expression	[1519]
DOK7	OTR2V7HO	Limited	Altered Expression	[1889]
DSE	OTQ108VJ	Limited	Biomarker	[720]
DST	OTHZBM4X	Limited	Biomarker	[1890]
E2F6	OT2PN28R	Limited	Biomarker	[1891]
E2F7	OTWW358N	Limited	Altered Expression	[1892]
E2F8	OTQKZGFP	Limited	Altered Expression	[1892]
ECRG4	OTHZYUXX	Limited	Posttranslational Modification	[753]
ECT2	OTQDUCT6	Limited	Biomarker	[1893]
EFEMP2	OT0I2B4J	Limited	Altered Expression	[1894]
EHF	OTY6TPWD	Limited	Altered Expression	[1895]
EIF2B5	OTV3R4RB	Limited	Biomarker	[1896]
EIF3E	OTI0WG98	Limited	Biomarker	[1897]
EIF3H	OT61RBF5	Limited	Genetic Variation	[1898]
EIF4A2	OT08H03R	Limited	Altered Expression	[1899]
EIPR1	OTNQKNL3	Limited	Biomarker	[1900]
ELK4	OTVSSEOE	Limited	Altered Expression	[1901]
EMB	OT67E3Q1	Limited	Biomarker	[1902]
EN2	OT7EZCM2	Limited	Biomarker	[1903]
EPB41L5	OTPPQPLU	Limited	Biomarker	[1904]
EPS15	OT7NPP8U	Limited	Altered Expression	[1905]
ESRP1	OTNCS4SL	Limited	Biomarker	[1906]
ETV3	OTEN03BM	Limited	Altered Expression	[1901]
ETV6	OTCZMG61	Limited	Genetic Variation	[1907]
FANCC	OTTIDM3P	Limited	Autosomal dominant	[265]
FBH1	OTDJBKO1	Limited	Genetic Variation	[1908]
FBLIM1	OTFHXMON	Limited	Genetic Variation	[1909]
FBXO28	OTKTMVC4	Limited	Genetic Variation	[1910]
FBXO39	OTPRR6SK	Limited	Biomarker	[1911]
FERMT3	OTFQOT3C	Limited	Altered Expression	[1912]
FGFRL1	OT8HZ3ZL	Limited	Biomarker	[1913]
FIG4	OT501PY9	Limited	Biomarker	[422]
FKBPL	OTR9ND6K	Limited	Biomarker	[1914]
FLI1	OT0EV3LX	Limited	Altered Expression	[1915]
FLNB	OTPCOYL6	Limited	Biomarker	[1916]
FLVCR1	OT9XCFOC	Limited	Biomarker	[1917]
FMR1	OTWEV0T5	Limited	Biomarker	[1918]
FOXA2	OTJOCVOY	Limited	Altered Expression	[1342]
FOXF2	OTV20NGX	Limited	Biomarker	[1919]
FOXN4	OTE3MWYJ	Limited	Altered Expression	[1920]
FOXP2	OTVX6A59	Limited	Biomarker	[1921]
FSIP1	OTYLL6GM	Limited	Biomarker	[1922]
FTL	OTYQA8A6	Limited	Biomarker	[1923]
FUNDC1	OTA6IVKQ	Limited	Biomarker	[1924]
GAB1	OTQKE6V4	Limited	Altered Expression	[1925]
GADL1	OTJM4A0R	Limited	Biomarker	[1817]
GALNT14	OT9BSDDQ	Limited	Biomarker	[1926]
GATAD2B	OTJL128N	Limited	Biomarker	[1881]
GBP1	OTUM7RPJ	Limited	Biomarker	[1927]
GC	OTWS63BY	Limited	Genetic Variation	[1928]
GFPT1	OTQBDO45	Limited	Biomarker	[1929]
GLRX3	OTUPAU1N	Limited	Biomarker	[1930]
GLYR1	OTY0VAVL	Limited	Altered Expression	[1931]
GMPR2	OTKZSZPE	Limited	Altered Expression	[1932]
GNA12	OT3IRZH3	Limited	Biomarker	[1933]
GNB1	OTLL7L74	Limited	Biomarker	[308]
GNL3	OTILGYO4	Limited	Altered Expression	[1934]
GNMT	OT0O2OQO	Limited	Biomarker	[1935]
GOT2	OT6XBWN0	Limited	Altered Expression	[1936]
GPAT2	OTZ8VP2Y	Limited	Altered Expression	[1937]
GPAT3	OTJUGPK0	Limited	Biomarker	[1938]
GPHN	OTAKK1SV	Limited	Biomarker	[1939]
GPM6B	OT8Q1582	Limited	Biomarker	[1940]
GPR151	OT7EACU6	Limited	Biomarker	[399]
GPX2	OTXI2NTI	Limited	Biomarker	[1941]
GTF2H2	OTK72L9I	Limited	Genetic Variation	[1942]
H1-0	OTRLJK4Z	Limited	Biomarker	[1943]
H2AZ1	OT3KJJNQ	Limited	Biomarker	[764]
H2BC10	OTLQH0D6	Limited	Altered Expression	[1944]
H2BC5	OTXDTDHN	Limited	Altered Expression	[1944]
H6PD	OTO7TNDD	Limited	Altered Expression	[1945]
HADHA	OTO557N2	Limited	Altered Expression	[1946]
HAS1	OTJIAG1W	Limited	Genetic Variation	[1947]
HAVCR1	OT184CRZ	Limited	Altered Expression	[1948]
HDDC3	OTIX7RRB	Limited	Genetic Variation	[1949]
HERC4	OTU4DSDE	Limited	Biomarker	[1950]
HES6	OTWO5SCF	Limited	Biomarker	[1951]
HGS	OTCYYCAC	Limited	Biomarker	[1952]
HIP1	OT7AKCFQ	Limited	Altered Expression	[1953]
HLA-DOB	OTKADDUB	Limited	Genetic Variation	[1954]
HLA-E	OTX1CTFB	Limited	Genetic Variation	[1040]
HMGB4	OT28OBR2	Limited	Altered Expression	[1955]
HOXA1	OTMSOJ7D	Limited	Altered Expression	[1956]
HOXA6	OTHJP8M2	Limited	Biomarker	[1957]
HOXB5	OTU74TB8	Limited	Altered Expression	[1958]
HPX	OT14T7Q1	Limited	Biomarker	[1959]
HSD17B6	OTSB55D2	Limited	Genetic Variation	[1960]
HSPH1	OTVRR73T	Limited	Biomarker	[1961]
HTR3C	OT65ZLIJ	Limited	Biomarker	[1962]
HUS1	OTY1XON9	Limited	Biomarker	[1963]
ID4	OTPMJ39I	Limited	Altered Expression	[1964]
IFI30	OT9DERT1	Limited	Biomarker	[1965]
IFI6	OTWOOAM4	Limited	Biomarker	[1966]
IFITM1	OTECO1G8	Limited	Altered Expression	[1967]
IFITM10	OTU2YGKP	Limited	Altered Expression	[1968]
IGBP1	OTTHH4YE	Limited	Biomarker	[1969]
IGFBP4	OT2HZRBD	Limited	Biomarker	[979]
IKBKG	OTNWJWSD	Limited	Altered Expression	[1970]
IL20RA	OTSIVBVS	Limited	Altered Expression	[1971]
ILF3	OTKMZ5K5	Limited	Altered Expression	[1972]
ING5	OTRNNSFM	Limited	Altered Expression	[1973]
ISG20	OTCWRJJW	Limited	Biomarker	[1087]
ISYNA1	OT49ONSE	Limited	Altered Expression	[1262]
ITGAX	OTOGIMHE	Limited	Biomarker	[1974]
ITGB4	OT28UK84	Limited	Altered Expression	[1975]
KAT5	OTL7257A	Limited	Biomarker	[1976]
KDM3B	OTZU5J5S	Limited	Altered Expression	[1977]
KDM8	OTCN5ST8	Limited	Biomarker	[1978]
KHDRBS3	OTUG02U7	Limited	Altered Expression	[1979]
KIF1A	OT3JVEGV	Limited	Posttranslational Modification	[1980]
KIF2A	OT2WQ6QD	Limited	Biomarker	[1981]
KIF4A	OT3UWL7D	Limited	Altered Expression	[1982]
KLF17	OT5NWVP7	Limited	Altered Expression	[1983]
KLHL1	OTAX6SAD	Limited	Biomarker	[645]
KMT2D	OTTVHCLY	Limited	Posttranslational Modification	[1984]
KPNA2	OTU7FOE6	Limited	Biomarker	[1893]
LAMA5	OTIIXE4M	Limited	Altered Expression	[1985]
LARP7	OTLLOZTL	Limited	Altered Expression	[1986]
LCOR	OT1K7DKB	Limited	Biomarker	[1987]
LDHB	OT9B1CT3	Limited	Altered Expression	[1044]
LGR6	OTPZ1PWR	Limited	Biomarker	[399]
LHX2	OTK61NP8	Limited	Biomarker	[1988]
LHX6	OT47UQZ5	Limited	Altered Expression	[1989]
LIG3	OT48SKET	Limited	Genetic Variation	[1990]
LINGO2	OT3N88Q1	Limited	Genetic Variation	[365]
LOXL4	OT6XY2JL	Limited	Altered Expression	[1991]
LRPPRC	OTXSK5LP	Limited	Biomarker	[1992]
LRRC75B	OTAHOBSS	Limited	Altered Expression	[1993]
LXN	OTZQ2M6Y	Limited	Altered Expression	[1796]
MACIR	OTPSW8Y8	Limited	Biomarker	[1015]
MACROH2A1	OTV2DQDD	Limited	Altered Expression	[1994]
MAGEA12	OT8ULELL	Limited	Biomarker	[1995]
MAP1S	OT5WUD4C	Limited	Biomarker	[1996]
MAP2K3	OTI2OREX	Limited	Biomarker	[1997]
MAP3K12	OT5HODDD	Limited	Biomarker	[1998]
MARK4	OT6Z2TGV	Limited	Biomarker	[1999]
MB	OTYWYL2D	Limited	Altered Expression	[2000]
MCCC2	OTQDHSMI	Limited	Biomarker	[2001]
MCM2	OTGGORIQ	Limited	Biomarker	[2002]
MCU	OTQZAYWQ	Limited	Altered Expression	[2003]
MED19	OTT9RT5N	Limited	Biomarker	[2004]
MEF2A	OTV2SF6E	Limited	Biomarker	[2005]
MFAP4	OT5W64QY	Limited	Altered Expression	[2006]
MFN2	OTPYN8A3	Limited	Biomarker	[2007]
MIP	OTEBLU3E	Limited	Biomarker	[2008]
MLC1	OTCNZLSP	Limited	Biomarker	[1401]
MLF2	OTU3B4WU	Limited	Biomarker	[2009]
MLIP	OTMT7AII	Limited	Biomarker	[1798]
MLLT11	OTG5RVHC	Limited	Altered Expression	[2010]
MMS22L	OTJI0HM9	Limited	Biomarker	[2011]
MOSPD2	OTTN4NR7	Limited	Biomarker	[2012]
MRGPRX3	OTRKCCDS	Limited	Biomarker	[399]
MRGPRX4	OTOBHZVA	Limited	Biomarker	[399]
MRPL58	OTPTWLZY	Limited	Biomarker	[2013]
MSH6	OT46FP09	Limited	Autosomal dominant	[265]
MT1G	OTAV1OCR	Limited	Biomarker	[1233]
MT1M	OTVT8PLU	Limited	Biomarker	[1233]
MT1X	OT9AKFVS	Limited	Biomarker	[1233]
MTBP	OTWLCW9C	Limited	Altered Expression	[2014]
MTO1	OT7HCZ1D	Limited	Biomarker	[2015]
MTUS1	OTBPALMU	Limited	Biomarker	[2016]
MUSTN1	OTKO05K3	Limited	Genetic Variation	[1949]
MYH10	OTXN2WXS	Limited	Altered Expression	[2017]
MYO5A	OTMWLP3E	Limited	Biomarker	[2018]
MYOD1	OTV2S79X	Limited	Biomarker	[2019]
NAIP	OTLA925F	Limited	Altered Expression	[2020]
NCR3LG1	OT15YWU7	Limited	Biomarker	[2021]
NCS1	OT6JHAWM	Limited	Biomarker	[2022]
NDC80	OTS7D306	Limited	Biomarker	[2023]
NDST1	OT9E10W2	Limited	Altered Expression	[2024]
NECTIN1	OTTE5ZR6	Limited	Biomarker	[2025]
NEIL2	OTV6JEON	Limited	Genetic Variation	[2026]
NFAT5	OTKIE59S	Limited	Biomarker	[2027]
NFIL3	OTQH9HM3	Limited	Altered Expression	[2028]
NGB	OTW0SIUY	Limited	Altered Expression	[2029]
NKD1	OTY3MO97	Limited	Biomarker	[2030]
NKD2	OTCYT3I6	Limited	Biomarker	[2031]
NMI	OTYVG3NM	Limited	Biomarker	[441]
NMT1	OT42GQ3D	Limited	Altered Expression	[2032]
NR2F6	OTNVO2B6	Limited	Altered Expression	[2033]
NRARP	OTMYHUV2	Limited	Biomarker	[2034]
NRF1	OTOXWNV8	Limited	Biomarker	[2035]
NUCB2	OTHO6JWN	Limited	Altered Expression	[2036]
NUCKS1	OTL4VJC5	Limited	Altered Expression	[2037]
NUS1	OT4DQ82L	Limited	Altered Expression	[2038]
NXF1	OTEFHXG6	Limited	Biomarker	[2039]
OPN1LW	OTFNUZ7O	Limited	Biomarker	[917]
OXA1L	OTS0BFRD	Limited	Genetic Variation	[2040]
OXT	OT48M72Z	Limited	Biomarker	[2041]
P3H3	OTRC8QCM	Limited	Altered Expression	[2042]
PADI1	OT13WAQX	Limited	Biomarker	[2043]
PAG1	OTFOJUIQ	Limited	Biomarker	[917]
PARVA	OTLKEWRY	Limited	Biomarker	[2044]
PC	OT6O0V51	Limited	Altered Expression	[2045]
PCP4	OTM1XXYX	Limited	Altered Expression	[2046]
PDIA2	OTC2WMXS	Limited	Biomarker	[2043]
PDLIM2	OTEURRPD	Limited	Altered Expression	[2047]
PDLIM4	OT23LZYY	Limited	Biomarker	[2048]
PDLIM7	OTAZVODU	Limited	Genetic Variation	[2049]
PEBP4	OTKDCVC6	Limited	Biomarker	[2050]
PHLPP2	OTXB1OUI	Limited	Biomarker	[2051]
PI4K2A	OTL9L6MX	Limited	Biomarker	[2052]
PIAS3	OT3TWH9R	Limited	Biomarker	[2053]
PIH1D1	OTDKEDUA	Limited	Biomarker	[2054]
PIPOX	OTWTCOTN	Limited	Biomarker	[1935]
PLA2G10	OTRZ2L5A	Limited	Biomarker	[2055]
PLA2G15	OT6VJTPA	Limited	Biomarker	[1705]
PLA2G2D	OTU604XM	Limited	Biomarker	[2056]
PLAC8	OT3SYRUJ	Limited	Biomarker	[2057]
PLPP4	OTH5EXZC	Limited	Altered Expression	[2058]
PLS3	OTYBM4PK	Limited	Biomarker	[2059]
PMS2	OTNLWTMI	Limited	Autosomal dominant	[265]
PNPLA2	OTR3ERMR	Limited	Altered Expression	[2060]
POC1A	OTXAG4PL	Limited	Biomarker	[2061]
POLD3	OTEQEFQ2	Limited	Biomarker	[1881]
POTEE	OTSQ6J24	Limited	Biomarker	[1959]
PPBP	OT1FHGQS	Limited	Biomarker	[2062]
PPP1R12C	OT9Q86JO	Limited	Biomarker	[2063]
PPP1R13L	OTNCPLWE	Limited	Biomarker	[2064]
PPP1R15B	OTL5RWA8	Limited	Biomarker	[2065]
PRIM1	OTWWP8Y6	Limited	Altered Expression	[2066]
PRIMA1	OT9ITT3P	Limited	Biomarker	[2067]
PRKAG2	OTHTAM54	Limited	Genetic Variation	[2068]
PRM1	OT6HWA11	Limited	Altered Expression	[1946]
PROSER2	OT1SX3LS	Limited	Altered Expression	[1993]
PRPF38B	OTQLH551	Limited	Biomarker	[2069]
PTPN12	OT5WA666	Limited	Genetic Variation	[2070]
PTPN23	OT5WDPXB	Limited	Altered Expression	[2071]
PTPRK	OTAP5AT3	Limited	Altered Expression	[2072]
PTX3	OTPXHRKU	Limited	Biomarker	[2073]
PUF60	OTG90DYF	Limited	Altered Expression	[2074]
PUM2	OT2H7NXV	Limited	Biomarker	[1276]
RAB21	OTH3WGLG	Limited	Altered Expression	[2075]
RAB31	OTMLXQZ0	Limited	Genetic Variation	[2076]
RAD1	OT886MA8	Limited	Biomarker	[1963]
RAD21	OTQS84ZF	Limited	Biomarker	[2077]
RAD52	OT0OTDHI	Limited	Biomarker	[2078]
RAG2	OTG9UYTW	Limited	Biomarker	[2079]
RAI1	OTKLQU00	Limited	Genetic Variation	[2080]
RAI2	OTR8LX4J	Limited	Altered Expression	[2081]
RANBP9	OTM8COM5	Limited	Altered Expression	[2082]
RASAL1	OTAHUNN7	Limited	Autosomal dominant	[265]
RASD1	OT2BAJHK	Limited	Biomarker	[2083]
RASGRP3	OTEMEV3P	Limited	Biomarker	[2084]
RBMS3	OTFSC9MR	Limited	Altered Expression	[2085]
RCOR1	OTREADPC	Limited	Biomarker	[2086]
RECQL5	OTVZMP1Q	Limited	Autosomal dominant	[265]
RFX1	OTZUDMPR	Limited	Altered Expression	[2087]
RGCC	OTYJMLWM	Limited	Biomarker	[2088]
RGS11	OTIAZ36F	Limited	Biomarker	[1806]
RHBDF1	OTCQ7UDS	Limited	Biomarker	[1247]
RNF17	OTKOEPRW	Limited	Biomarker	[1911]
RNF8	OTRR43PZ	Limited	Biomarker	[2089]
ROBO3	OTPVG40S	Limited	Biomarker	[314]
ROPN1L	OTRWZJ68	Limited	Genetic Variation	[698]
ROS1	OTDSKUGE	Limited	Autosomal dominant	[265]
RPAP1	OTL31TWE	Limited	Genetic Variation	[2090]
RPL5	OTM8EBRI	Limited	Biomarker	[2091]
RPS27	OTFXKY7P	Limited	Altered Expression	[1069]
RPS6	OTT4D1LN	Limited	Biomarker	[2092]
RTCA	OTSJRVTD	Limited	Biomarker	[2093]
RTP4	OTPHXVTY	Limited	Altered Expression	[2094]
SARNP	OTE0OVK5	Limited	Altered Expression	[2095]
SARS1	OTFKXQ1O	Limited	Biomarker	[2096]
SARS2	OTU4T99W	Limited	Biomarker	[2096]
SASH1	OTQA8BD4	Limited	Biomarker	[2097]
SCN1B	OTGD78J3	Limited	Altered Expression	[2098]
SCNN1A	OTE2KVZV	Limited	Biomarker	[1968]
SDCBP	OTS3NCC5	Limited	Biomarker	[2099]
SEC62	OTCWEL5F	Limited	Altered Expression	[2100]
SEMA4A	OT8901H3	Limited	Biomarker	[2101]
SENP7	OTQJ05ZS	Limited	Genetic Variation	[2102]
SERPINB1	OT5RDUFO	Limited	Altered Expression	[2103]
SETDB1	OTWVUA1B	Limited	Biomarker	[2104]
SFTPC	OTIZJD09	Limited	Biomarker	[1975]
SGMS2	OT3NHO99	Limited	Altered Expression	[2105]
SGTA	OTKOJ3JB	Limited	Biomarker	[2106]
SHARPIN	OTU1J2KH	Limited	Biomarker	[2107]
SHC1	OT1J5IRN	Limited	Biomarker	[1254]
SHMT2	OT5NCAZN	Limited	Biomarker	[2108]
SIGLEC1	OTNWSQA9	Limited	Biomarker	[2109]
SIL1	OTDI85I5	Limited	Biomarker	[2110]
SLC16A4	OT1YXBKC	Limited	Biomarker	[1247]
SLC25A41	OTVFKZXV	Limited	Altered Expression	[1801]
SLC2A4RG	OTW3LX8D	Limited	Altered Expression	[2111]
SLC35G1	OTKZUA8O	Limited	Genetic Variation	[1883]
SLFN5	OTT1AESL	Limited	Altered Expression	[2112]
SLX4	OTF6236I	Limited	Biomarker	[2113]
SMARCAD1	OT90AZTX	Limited	Biomarker	[2114]
SMARCC1	OTUOMBE7	Limited	Biomarker	[2115]
SMIM10L2B	OT04IG2N	Limited	Biomarker	[2116]
SMR3B	OTL5HNM8	Limited	Altered Expression	[2117]
SND1	OTT734JN	Limited	Biomarker	[2118]
SOCS7	OT503VJG	Limited	Biomarker	[2119]
SOHLH2	OTB9EM6C	Limited	Biomarker	[2120]
SOS1	OTTCWXC3	Limited	Altered Expression	[2111]
SOX7	OTOZOFAG	Limited	Biomarker	[2121]
SOX8	OTEJXYZM	Limited	Altered Expression	[2122]
SPARCL1	OT74DWMV	Limited	Biomarker	[2123]
SPATA2	OTOA45GL	Limited	Altered Expression	[2124]
SPRR1A	OTJMI34A	Limited	Altered Expression	[2125]
SPRR2A	OT62ZU6B	Limited	Biomarker	[2126]
SRI	OT4R3EAC	Limited	Biomarker	[2127]
SRSF3	OTOFT707	Limited	Altered Expression	[2128]
SRSF6	OTGLOSYE	Limited	Biomarker	[2129]
SRY	OT516T6D	Limited	Biomarker	[1490]
ST7L	OT0I8XNI	Limited	Biomarker	[2130]
ST8SIA1	OTGND2YZ	Limited	Altered Expression	[2131]
STAT2	OTO9G2RZ	Limited	Biomarker	[2132]
STOML1	OTSIO2QA	Limited	Altered Expression	[1993]
SUMF1	OTALXO2A	Limited	Altered Expression	[2133]
SUN1	OTIU8V4U	Limited	Altered Expression	[2134]
SYCE1L	OTXU44F3	Limited	Biomarker	[645]
SYNJ2BP	OT2Q677P	Limited	Biomarker	[2135]
SYNPO2	OTC3U0YH	Limited	Genetic Variation	[588]
TACC2	OTW4M7HI	Limited	Biomarker	[2136]
TAF7L	OTPDZ6XV	Limited	Biomarker	[2137]
TANC2	OTDXY7PX	Limited	Biomarker	[2138]
TAP2	OTWSYFI7	Limited	Altered Expression	[2139]
TAS2R38	OTX5MM36	Limited	Biomarker	[335]
TBX1	OTQLBPRA	Limited	Biomarker	[2140]
TDRD10	OT5WIRLE	Limited	Biomarker	[2141]
TENM2	OTPLUYEF	Limited	Altered Expression	[2142]
TENM4	OT91K3FC	Limited	Altered Expression	[2142]
TES	OTL8PP6V	Limited	Biomarker	[809]
TET3	OT76U3YF	Limited	Altered Expression	[2143]
TFDP3	OTI4K6MN	Limited	Biomarker	[2144]
THEMIS2	OTI1OBLN	Limited	Biomarker	[2145]
THOC1	OTVABJ4Z	Limited	Biomarker	[2146]
THY1	OTVONVTB	Limited	Biomarker	[2147]
TINAGL1	OTZZO56M	Limited	Biomarker	[2148]
TM6SF1	OTQR4I2N	Limited	Biomarker	[2149]
TMED3	OTNOPHHC	Limited	Biomarker	[2150]
TMEM126A	OTLP76WE	Limited	Altered Expression	[2151]
TMEM132C	OT3297S6	Limited	Biomarker	[2141]
TMEM43	OTM9RS9G	Limited	Biomarker	[2152]
TMEM54	OTPQEFR0	Limited	Biomarker	[2153]
TMPRSS7	OTW938I4	Limited	Genetic Variation	[2154]
TMX1	OTX4FHYQ	Limited	Biomarker	[2155]
TMX2	OTM9O21K	Limited	Biomarker	[2156]
TNFAIP8	OT1G9297	Limited	Altered Expression	[2157]
TNFAIP8L2	OTII0RM0	Limited	Biomarker	[2158]
TNP1	OTKQH7E5	Limited	Biomarker	[2159]
TNRC6A	OT493IOM	Limited	Biomarker	[2160]
TP53I11	OTFPDYZU	Limited	Biomarker	[2161]
TP53INP1	OT2363Z9	Limited	Altered Expression	[2162]
TPD52L2	OTTOG0NK	Limited	Biomarker	[2163]
TRAF1	OTTLM5RU	Limited	Biomarker	[2164]
TRAF7	OTW8Q5TF	Limited	Biomarker	[2165]
TRAP1	OTNG0L8J	Limited	Biomarker	[2166]
TRAPPC9	OTF0CVMC	Limited	Altered Expression	[1882]
TRIM21	OTA4UJCF	Limited	Genetic Variation	[2167]
TRIM25	OT35SG1R	Limited	Altered Expression	[2168]
TRIM33	OT0KS4J7	Limited	Altered Expression	[2169]
TRIM56	OTFGU8E3	Limited	Altered Expression	[2170]
TRIP4	OTA8OASA	Limited	Biomarker	[1659]
TRMT11	OTRK0IOR	Limited	Biomarker	[1015]
ACYP2	OTRB4S6X	Disputed	Genetic Variation	[2171]
ADAMTS9	OTV3Q0DS	Disputed	Posttranslational Modification	[2172]
AP2B1	OTL6LZJ4	Disputed	Biomarker	[2173]
APIP	OT8ZABOU	Disputed	Biomarker	[500]
ARHGAP31	OTUYTF4I	Disputed	Biomarker	[2174]
ATG4D	OTSWUO4R	Disputed	Altered Expression	[2175]
BLM	OTEJOAJX	Disputed	Autosomal dominant	[265]
CCL16	OTOOQI1F	Disputed	Biomarker	[2176]
CDK15	OT8S67QS	Disputed	Altered Expression	[495]
CDK16	OTUBXIIT	Disputed	Altered Expression	[495]
CILK1	OTWOYEYP	Disputed	Altered Expression	[495]
CLTC	OTBFASMA	Disputed	Biomarker	[500]
COL15A1	OTTFKK18	Disputed	Altered Expression	[2177]
CREM	OTJIJ5AL	Disputed	Biomarker	[500]
DNAH8	OTGES2OU	Disputed	Altered Expression	[2178]
FAM133B	OTQH2A95	Disputed	Biomarker	[500]
FANCM	OTNJG99Z	Disputed	Autosomal dominant	[265]
FH	OTEQWU6Q	Disputed	Biomarker	[501]
LPXN	OTUNV3CK	Disputed	Altered Expression	[2179]
MAGEH1	OTVE05K7	Disputed	Altered Expression	[2177]
MAP1LC3C	OTM4ECDK	Disputed	Biomarker	[2175]
MEPE	OTXJRUW0	Disputed	Genetic Variation	[2180]
MINDY4	OTBZ2SZB	Disputed	Altered Expression	[693]
MLH1	OTG5XDD8	Disputed	Autosomal dominant	[265]
MORC2	OT52A8BJ	Disputed	Altered Expression	[2181]
MSH2	OT10H1AB	Disputed	Autosomal dominant	[265]
NEFH	OTMSCW5I	Disputed	Biomarker	[2182]
NEFM	OT8VCBNF	Disputed	Biomarker	[2182]
NOP14	OTKPM0Z5	Disputed	Biomarker	[2183]
PIBF1	OTCBT1A1	Disputed	Genetic Variation	[2184]
PRKACG	OTKOQYF8	Disputed	Altered Expression	[495]
PTBP3	OTVVYKIF	Disputed	Altered Expression	[2185]
RBFOX2	OTXY1WVH	Disputed	Genetic Variation	[2186]
RECQL	OTPCH3JH	Disputed	Autosomal dominant	[265]
RFC3	OT1MS7AO	Disputed	Biomarker	[2187]
RINT1	OTMO19ZD	Disputed	Autosomal dominant	[265]
RTN1	OTCX1SMK	Disputed	Biomarker	[499]
SPECC1	OTPEML48	Disputed	Biomarker	[499]
TADA3	OTNUAIO9	Disputed	Altered Expression	[2188]
TFAP2B	OTR1T8E9	Disputed	Biomarker	[2173]
TLK1	OTICTXI8	Disputed	Altered Expression	[495]
TMEM88	OTA96YEL	Disputed	Altered Expression	[2189]
ABI2	OT8GIIS5	moderate	Genetic Variation	[519]
ACP1	OTJ9CKLU	moderate	Altered Expression	[2190]
ACSM3	OT0AE1IV	moderate	Biomarker	[2191]
ACTL8	OTUDD0QT	moderate	Biomarker	[2192]
ACTN4	OTCNZAJ5	moderate	Altered Expression	[2193]
ACTRT1	OTHFKSIZ	moderate	Genetic Variation	[519]
ADAM11	OTPTVW5W	moderate	Biomarker	[2194]
ADAM15	OTZ7VLTP	moderate	Altered Expression	[2195]
ADCY4	OTHBLJA7	moderate	Biomarker	[2196]
AFDN	OTTRU341	moderate	Biomarker	[1856]
AKAP3	OT42QOFG	moderate	Biomarker	[2197]
AMBP	OTLU8GU8	moderate	Biomarker	[2198]
AMELX	OTIN26MM	moderate	Altered Expression	[2199]
ANGPTL2	OTB6JG41	moderate	Biomarker	[274]
ANKRD11	OTV0V70M	moderate	Biomarker	[2200]
ANLN	OTXJY54C	moderate	Altered Expression	[2201]
APAF1	OTJWIVY0	moderate	Altered Expression	[2202]
APBB1	OTZPVSSC	moderate	Biomarker	[2203]
AQP5	OT77GBY8	moderate	Biomarker	[511]
ARF4	OT3GMDHA	moderate	Biomarker	[2204]
ARHGEF7	OT9BPJCL	moderate	Altered Expression	[2205]
ARID4B	OTYLPILE	moderate	Biomarker	[2206]
ARL13B	OT9PYPV1	moderate	Biomarker	[2207]
ARL6IP1	OT536XAV	moderate	Genetic Variation	[519]
ARNT	OTMSIEZY	moderate	Altered Expression	[2208]
ARPP21	OTWXZN5I	moderate	Biomarker	[2209]
ARSF	OTC0L12N	moderate	Biomarker	[2210]
ARSI	OTIANNWW	moderate	Genetic Variation	[2211]
ASAP1	OT4DLRYY	moderate	Biomarker	[2212]
ASXL1	OTX931AW	moderate	Genetic Variation	[2213]
ASXL2	OTNG4E2M	moderate	Biomarker	[2214]
ASXL3	OTNDJWEZ	moderate	Biomarker	[2213]
ATAD3B	OTL508AF	moderate	Biomarker	[2215]
ATG12	OTJRO09Y	moderate	Altered Expression	[2216]
ATG4A	OTDHXAPG	moderate	Biomarker	[2217]
ATP1B1	OTTO6ZP4	moderate	Biomarker	[2218]
ATP8	OTYQQR53	moderate	Biomarker	[2219]
B4GALT1	OTBCXEK7	moderate	Altered Expression	[2220]
BCL9L	OTTWI90E	moderate	Biomarker	[2221]
BDH1	OT62RL5P	moderate	Altered Expression	[574]
BID	OTOSHSHU	moderate	Biomarker	[2222]
BMP5	OTC0Y6E0	moderate	Biomarker	[2223]
BRI3BP	OTWCFPRM	moderate	Biomarker	[2224]
BRWD3	OT3BM9B0	moderate	Altered Expression	[2225]
BTRC	OT2EZDGR	moderate	Genetic Variation	[2226]
C4orf3	OT6TFN1O	moderate	Altered Expression	[2227]
CALM2	OTNYA92F	moderate	Biomarker	[2228]
CAMK1	OTRN55RE	moderate	Biomarker	[2229]
CAMK2B	OTS9YK3E	moderate	Altered Expression	[2230]
CANX	OTYP1F6J	moderate	Altered Expression	[2231]
CAPNS1	OT95EBBD	moderate	Altered Expression	[2232]
CAVIN2	OTFHHDRU	moderate	Altered Expression	[2233]
CAVIN3	OTOLBK79	moderate	Altered Expression	[2234]
CBX1	OT2L4XZX	moderate	Biomarker	[2235]
CBX6	OTO1I9W0	moderate	Biomarker	[2236]
CCL8	OTCTWYN8	moderate	Biomarker	[2237]
CCN4	OT69BER9	moderate	Biomarker	[2238]
CCNJ	OTCR4WVV	moderate	Biomarker	[2239]
CCT2	OTW1VV4E	moderate	Biomarker	[1302]
CD200R1	OT65Q9M6	moderate	Biomarker	[2240]
CDC42BPB	OTO6NT7Q	moderate	Altered Expression	[526]
CDH23	OTOJGQ7S	moderate	Altered Expression	[2241]
CDK2AP2	OTR99SJ8	moderate	Genetic Variation	[1416]
CEMIP	OTK80FYN	moderate	Biomarker	[2242]
CENPA	OT0NEJ4X	moderate	Altered Expression	[2243]
CERS6	OTOP4GV1	moderate	Altered Expression	[2244]
CFHR1	OT72R16T	moderate	Biomarker	[2245]
CHPT1	OT4FJ0K3	moderate	Biomarker	[2246]
CKAP2	OTCLTC0J	moderate	Altered Expression	[2247]
CLCA4	OTCRR1M9	moderate	Altered Expression	[2248]
CLIP2	OTSCIQIY	moderate	Biomarker	[2249]
CNTROB	OTR7C7NR	moderate	Genetic Variation	[2250]
COL12A1	OTHLTV53	moderate	Altered Expression	[2251]
CPSF7	OT4WE5J7	moderate	Altered Expression	[2251]
CRABP2	OTY01V9G	moderate	Biomarker	[2252]
CSHL1	OTQKU2F5	moderate	Biomarker	[619]
CTHRC1	OTV88X2G	moderate	Altered Expression	[2253]
CTR9	OTP151PZ	moderate	Biomarker	[2254]
CYP2U1	OT6RXLXS	moderate	Biomarker	[2255]
DAAM1	OT0VHIYZ	moderate	Altered Expression	[2256]
DAB2IP	OTF456VC	moderate	Genetic Variation	[519]
DCAF6	OT3EYK1J	moderate	Altered Expression	[2257]
DDIAS	OTTGG2PM	moderate	Biomarker	[2258]
DGCR8	OT62LXE4	moderate	Genetic Variation	[2259]
DLGAP1	OTF2PUUI	moderate	Biomarker	[2260]
DNALI1	OTTB3L8N	moderate	Altered Expression	[2261]
DOK6	OTX55OIF	moderate	Biomarker	[2262]
DRAM1	OTIJTXEN	moderate	Genetic Variation	[2263]
DROSHA	OTCE68KZ	moderate	Genetic Variation	[2264]
DZIP1	OTBVPO66	moderate	Biomarker	[2265]
EBAG9	OTTQLQCP	moderate	Biomarker	[2266]
ECHS1	OTS0593S	moderate	Altered Expression	[2267]
ECM1	OT1K65VW	moderate	Biomarker	[2268]
EEF1E1	OTRA6XOB	moderate	Biomarker	[515]
EIF4E3	OTTWVS2R	moderate	Altered Expression	[2269]
ENY2	OTTNU8RK	moderate	Biomarker	[2270]
EPHA10	OT1XJGFG	moderate	Biomarker	[2271]
FAM107B	OT5RG4J0	moderate	Biomarker	[2249]
FAM171A1	OT33BHEP	moderate	Biomarker	[2272]
FAM83A	OTBI16V7	moderate	Altered Expression	[2273]
FANCL	OTJC7QPQ	moderate	Genetic Variation	[2274]
FBLN2	OTEHR7N7	moderate	Altered Expression	[2275]
FBP1	OTQBANEP	moderate	Altered Expression	[2276]
FBRS	OTUVH446	moderate	Biomarker	[2277]
FBXL17	OT8R6KYN	moderate	Biomarker	[2278]
FBXO10	OTAGWV4B	moderate	Genetic Variation	[2279]
FGF9	OT2SKDGM	moderate	Biomarker	[2280]
FOXE1	OT5IR5IT	moderate	Biomarker	[2281]
FOXG1	OTAW57J4	moderate	Altered Expression	[2282]
FOXN2	OTBPLTCM	moderate	Biomarker	[2283]
FZD1	OTZATHVS	moderate	Altered Expression	[2284]
GABARAP	OTAQUX6E	moderate	Altered Expression	[2285]
GABARAPL1	OT4U7SBG	moderate	Biomarker	[2286]
GALNT6	OTOQQVH1	moderate	Altered Expression	[2287]
GATA2	OTBP2QQ2	moderate	Altered Expression	[2288]
GDPD5	OTUM65JL	moderate	Altered Expression	[2289]
GEMIN4	OTX7402E	moderate	Genetic Variation	[2259]
GFRA1	OT3WBVYB	moderate	Biomarker	[2290]
GINS2	OT974IYI	moderate	Altered Expression	[2291]
GLS2	OT08MSHL	moderate	Altered Expression	[2292]
GOLGA2	OT5S9KYM	moderate	Biomarker	[2293]
GOSR1	OTX8TMVU	moderate	Altered Expression	[2261]
GPN3	OTZ4584O	moderate	Biomarker	[2294]
GPRC5A	OTPOCWR7	moderate	Biomarker	[2295]
HACE1	OTEZULKD	moderate	Biomarker	[2296]
HAP1	OT6SG0JQ	moderate	Biomarker	[2297]
HLA-C	OTV38BUJ	moderate	Genetic Variation	[2298]
HLA-DOA	OTZE5Q7R	moderate	Genetic Variation	[2299]
HNRNPDL	OTB3BFCV	moderate	Altered Expression	[2300]
HOXA10	OTB6GQ09	moderate	Genetic Variation	[2301]
HOXB1	OTGC0EKI	moderate	Biomarker	[2302]
HOXD1	OTN4V9ZF	moderate	Biomarker	[2303]
HTRA4	OT58M21J	moderate	Biomarker	[2304]
HVCN1	OT4ALYU4	moderate	Altered Expression	[2305]
HYAL1	OT2SJN0X	moderate	Biomarker	[2306]
HYLS1	OT3SW5UC	moderate	Genetic Variation	[2307]
IARS1	OT9WXH5N	moderate	Biomarker	[2308]
IFNE	OTXO5MHZ	moderate	Biomarker	[2309]
IFNGR1	OTCTQBWW	moderate	Biomarker	[2310]
IGF2BP3	OTB97VIK	moderate	Biomarker	[2244]
INPPL1	OTCDAVBQ	moderate	Altered Expression	[2311]
IQCC	OTVNC81X	moderate	Biomarker	[2312]
ITM2A	OT590V63	moderate	Biomarker	[2313]
ITSN1	OT8YF3S5	moderate	Biomarker	[2314]
KBTBD11	OTBOY3WH	moderate	Biomarker	[2315]
KDM2B	OTDMCVW7	moderate	Altered Expression	[2316]
KIF1B	OTI1XQTO	moderate	Biomarker	[2317]
KIFC1	OTNQDS00	moderate	Altered Expression	[2318]
KRT13	OTTYSKGX	moderate	Altered Expression	[2319]
KRT2	OTG2EZEN	moderate	Altered Expression	[2320]
L3MBTL1	OT8M52QY	moderate	Altered Expression	[2321]
LAMTOR1	OTIBJBW9	moderate	Biomarker	[515]
LETMD1	OTZTZ4RD	moderate	Biomarker	[2224]
LIMS1	OT729S0T	moderate	Biomarker	[2322]
LMNB1	OT100T3P	moderate	Biomarker	[2323]
LOXL3	OTLLY1QI	moderate	Altered Expression	[2324]
LRIG1	OTY5HZN5	moderate	Altered Expression	[2325]
LRMDA	OTIPNKTU	moderate	Genetic Variation	[2326]
LRP1B	OT4YZG2N	moderate	Altered Expression	[2327]
LRRC26	OTXEFL76	moderate	Biomarker	[2328]
LTBP4	OTC8WL2V	moderate	Altered Expression	[2329]
LYPD5	OTGP7UKA	moderate	Biomarker	[2330]
MAD2L2	OT24ZO59	moderate	Biomarker	[2331]
MAFK	OTZJUE4P	moderate	Biomarker	[515]
MAGEF1	OTUU40U3	moderate	Biomarker	[1804]
MAGI2	OTXDDKZS	moderate	Genetic Variation	[519]
MAML1	OTQA4DDN	moderate	Altered Expression	[2332]
MAP1LC3B	OTUYHB84	moderate	Biomarker	[2333]
MAP3K7CL	OT9J7RLC	moderate	Genetic Variation	[2334]
MARCHF5	OTBK6BBM	moderate	Biomarker	[2335]
MAVS	OTTQ0J64	moderate	Biomarker	[2336]
MCM3AP	OT895FEC	moderate	Genetic Variation	[2337]
MDC1	OTEUQH4J	moderate	Biomarker	[1274]
MEGF9	OTDQWTY4	moderate	Biomarker	[2239]
MICAL3	OTD229X7	moderate	Biomarker	[2338]
MICB	OTS2DVDW	moderate	Biomarker	[2339]
MICU1	OTS7N0LE	moderate	Altered Expression	[2340]
MIEN1	OTCQ8DAD	moderate	Biomarker	[2341]
MORC4	OTJBEHNE	moderate	Altered Expression	[2342]
MPRIP	OT5FV5NS	moderate	Altered Expression	[2343]
MR1	OTZU3XX7	moderate	Altered Expression	[2344]
MRPL41	OTG5URO4	moderate	Altered Expression	[2345]
MUC4	OTLT11V1	moderate	Biomarker	[2346]
MUC5B	OTPW6K5C	moderate	Biomarker	[2347]
MXD1	OTS5CTHX	moderate	Altered Expression	[2348]
MYO1D	OTP2RGPN	moderate	Biomarker	[2349]
MYOCD	OTSJNHTH	moderate	Biomarker	[2350]
NAP1L1	OTI7WBZV	moderate	Biomarker	[2351]
ND2	OTG9OHOX	moderate	Genetic Variation	[2352]
NDN	OTYBYJ82	moderate	Altered Expression	[2353]
NECTIN3	OTS8N7MK	moderate	Altered Expression	[2354]
NEK3	OTKWD5FY	moderate	Altered Expression	[2355]
NEK5	OTHDXCYZ	moderate	Biomarker	[762]
NEO1	OTGJ1997	moderate	Biomarker	[2356]
NEUROD1	OTZQ7QJ2	moderate	Altered Expression	[2357]
NGDN	OTBXTCN5	moderate	Altered Expression	[2358]
NINL	OTWIK6HT	moderate	Biomarker	[2359]
NLK	OT2LETFS	moderate	Altered Expression	[2360]
NMU	OTW9X7BQ	moderate	Biomarker	[1259]
NOB1	OTW0YNSL	moderate	Biomarker	[2361]
NOC2L	OTNT7R33	moderate	Biomarker	[2362]
NONO	OTN36Q6U	moderate	Biomarker	[2363]
NOS1AP	OTDFOBRU	moderate	Biomarker	[641]
NPNT	OTFZAO1G	moderate	Altered Expression	[2364]
NRSN1	OT1KKXC8	moderate	Biomarker	[2365]
NRXN3	OTJ0I7HJ	moderate	Genetic Variation	[2366]
NSD3	OT3677ZG	moderate	Biomarker	[2367]
NUMB	OTMB586Q	moderate	Altered Expression	[2368]
ODAM	OTT666SJ	moderate	Biomarker	[2369]
OGA	OT7ZBWT1	moderate	Biomarker	[2370]
OPTN	OT2UXWH9	moderate	Biomarker	[2351]
OR2AG1	OTEITRP4	moderate	Biomarker	[2371]
ORMDL3	OTAB7MZF	moderate	Genetic Variation	[2372]
OTP	OTS0JN6Y	moderate	Posttranslational Modification	[2373]
PA2G4	OT7IG7HT	moderate	Biomarker	[2374]
PAK5	OT32WQGL	moderate	Biomarker	[894]
PAQR3	OTTKJ9Y4	moderate	Posttranslational Modification	[2375]
PBLD	OTI3A8RS	moderate	Biomarker	[2376]
PCLAF	OTMVIOUU	moderate	Biomarker	[2377]
PCSK1N	OT7ZRW2F	moderate	Biomarker	[2378]
PDC	OT1UUVYY	moderate	Biomarker	[2379]
PDCD5	OT6T2DDL	moderate	Biomarker	[2380]
PDLIM1	OT4EGCPG	moderate	Biomarker	[2381]
PDS5B	OT3U3X8Z	moderate	Altered Expression	[2382]
PENK	OT8P3HMP	moderate	Biomarker	[2383]
PINK1	OT50NR57	moderate	Genetic Variation	[2384]
PIR	OT8ALXHU	moderate	Biomarker	[2385]
PLAAT4	OTI66SAJ	moderate	Biomarker	[314]
PLCG2	OTGVC9MY	moderate	Genetic Variation	[2386]
PLEK	OTB73XXA	moderate	Biomarker	[2387]
PMP22	OTXWYWCZ	moderate	Biomarker	[2388]
PPP1R1A	OTGTAGCV	moderate	Biomarker	[2389]
PPP1R7	OTY5IE69	moderate	Biomarker	[2390]
PPP2R2A	OT9297OG	moderate	Altered Expression	[2391]
PPP4C	OT4B0TNV	moderate	Biomarker	[2392]
PRDM14	OTWZKY4L	moderate	Biomarker	[2393]
PRDM2	OT8L7CGX	moderate	Posttranslational Modification	[2394]
PREX2	OTYT1J6J	moderate	Biomarker	[2395]
PRMT2	OT63JZCI	moderate	Biomarker	[2396]
PRPF4	OTK0XRQN	moderate	Altered Expression	[2397]
PRRX2	OT8UR4AU	moderate	Biomarker	[2398]
PRSS23	OT6DQAM1	moderate	Biomarker	[2399]
PSD4	OTEFB87Z	moderate	Biomarker	[2400]
PSMC3	OTSKT0JI	moderate	Biomarker	[2401]
PTPRA	OTZA82J1	moderate	Biomarker	[497]
PTPRM	OTCEL6PN	moderate	Biomarker	[2402]
PTPRO	OTFLKWOY	moderate	Biomarker	[2403]
PUM3	OTN1IPNS	moderate	Biomarker	[2378]
PYCR1	OTQHB52T	moderate	Biomarker	[2404]
PYGB	OT2ZTJT0	moderate	Biomarker	[2405]
QSOX1	OT4ZPK4P	moderate	Biomarker	[2406]
RAB1B	OTAFCUAS	moderate	Altered Expression	[2407]
RAB2A	OT6SK83U	moderate	Biomarker	[2408]
RASGRF1	OTNWJ7EN	moderate	Altered Expression	[2111]
RBM10	OTES2MES	moderate	Biomarker	[2409]
RCAN3	OTTS3CQA	moderate	Altered Expression	[2410]
RCHY1	OTAE7504	moderate	Altered Expression	[2411]
RECQL4	OT59LSW7	moderate	Genetic Variation	[2412]
REV1	OTHIKICX	moderate	Biomarker	[947]
REV3L	OT0OP8EJ	moderate	Altered Expression	[2413]
RFTN1	OT8875JE	moderate	Altered Expression	[2414]
RHOC	OTOLE1FT	moderate	Altered Expression	[2415]
RHOXF1	OT3SC14T	moderate	Altered Expression	[2416]
RILPL2	OTL2KPRO	moderate	Biomarker	[2417]
RMDN3	OTKO7AUM	moderate	Biomarker	[2418]
RNF144A	OTCG27CT	moderate	Biomarker	[2419]
ROM1	OTE7H0YV	moderate	Biomarker	[2420]
RPP14	OT4OYFSK	moderate	Genetic Variation	[1416]
RPTOR	OT4TQZ9F	moderate	Biomarker	[2421]
RRS1	OTTNCZN6	moderate	Altered Expression	[2422]
RSU1	OTO5GHT1	moderate	Biomarker	[2423]
RUNX1T1	OT30DED5	moderate	Genetic Variation	[1717]
RUSC1	OTYB8ZMT	moderate	Biomarker	[2424]
S100A16	OT3ERKQI	moderate	Genetic Variation	[2425]
SALL4	OTC08PR5	moderate	Biomarker	[2426]
SCAI	OTAK3TMO	moderate	Biomarker	[2427]
SDF4	OTQ7WFYW	moderate	Genetic Variation	[2428]
SEC14L2	OTJST64D	moderate	Biomarker	[2039]
SELENOF	OT2JFB3S	moderate	Genetic Variation	[2429]
SELENON	OTSGKO5M	moderate	Genetic Variation	[2430]
SELENOS	OTUEWIU9	moderate	Genetic Variation	[2430]
SEMA6B	OT3VVVUO	moderate	Altered Expression	[2431]
SENP2	OTPQJXIR	moderate	Genetic Variation	[2102]
SEPTIN4	OTD16B30	moderate	Biomarker	[2432]
SF3B6	OTPRKS6S	moderate	Genetic Variation	[1416]
SFR1	OTSRFFUV	moderate	Biomarker	[2433]
SIN3A	OTM8OZWV	moderate	Genetic Variation	[2434]
SIN3B	OTFB59FK	moderate	Altered Expression	[2435]
SIRT7	OT5M4OT4	moderate	Biomarker	[2436]
SKA3	OTLHEVJD	moderate	Biomarker	[2437]
SLC25A52	OT5DI4DL	moderate	Genetic Variation	[1678]
SMARCA1	OT0Y6PTU	moderate	Biomarker	[2438]
SMARCA5	OT5GR4Z2	moderate	Altered Expression	[2439]
SMC4	OTEJE6AG	moderate	Biomarker	[2328]
SMG1	OTTS3SXE	moderate	Biomarker	[543]
SMN2	OT54RLO1	moderate	Altered Expression	[2440]
SMPX	OTLSHGBF	moderate	Biomarker	[619]
SMURF1	OT5UIZR8	moderate	Altered Expression	[2441]
SNRPD1	OTWKZV4E	moderate	Biomarker	[2442]
SNW1	OTKWG3PS	moderate	Biomarker	[2443]
SPACA9	OTVRFX49	moderate	Genetic Variation	[2444]
SPAG9	OT45AHMB	moderate	Altered Expression	[2445]
SPC25	OTCAS0OH	moderate	Biomarker	[2446]
SPG21	OTMKJSYS	moderate	Genetic Variation	[2444]
SRXN1	OTYDBO4L	moderate	Genetic Variation	[2447]
SYN1	OTMNPWC1	moderate	Biomarker	[2448]
SYNPO	OTICDJAB	moderate	Biomarker	[2449]
TACC1	OTGX20TE	moderate	Biomarker	[2450]
TBATA	OTGDMAAL	moderate	Biomarker	[2451]
TDRD9	OTS4UBI8	moderate	Genetic Variation	[2307]
TFAM	OTXXV5V7	moderate	Biomarker	[2035]
TFF2	OTRXB19X	moderate	Biomarker	[2452]
THBS4	OTA1T9KK	moderate	Altered Expression	[2453]
THRSP	OTKYE01L	moderate	Altered Expression	[2454]
THSD7A	OT7249HH	moderate	Altered Expression	[2455]
TMED5	OT70W1J8	moderate	Altered Expression	[2261]
TMEM132E	OTHCX3RI	moderate	Genetic Variation	[1678]
TMEM45A	OT54KJG6	moderate	Altered Expression	[2456]
TMOD4	OTXLGJ4R	moderate	Biomarker	[2457]
TMPO	OTL68EL4	moderate	Biomarker	[2458]
TNFRSF10D	OTOSRDJT	moderate	Biomarker	[2459]
TNFSF9	OTV9L89D	moderate	Biomarker	[492]
TNS3	OTPG2D8Z	moderate	Biomarker	[2460]
TPPP2	OTI3WA6X	moderate	Biomarker	[515]
TRDMT1	OTAYQ8ZF	moderate	Genetic Variation	[539]
TRIM14	OTLQKUG0	moderate	Altered Expression	[2461]
TRIM16	OTLRXYOZ	moderate	Biomarker	[2462]
TRIM22	OTJBLG5R	moderate	Altered Expression	[2463]
TRIM63	OTUSWA74	moderate	Biomarker	[2464]
TRO	OTRZQMU8	moderate	Biomarker	[1804]
TSPAN33	OTH6C0WU	moderate	Biomarker	[2378]
A1CF	OTJBKFA1	Strong	Altered Expression	[2465]
A2ML1	OTWNUXIS	Strong	Altered Expression	[2466]
AADAC	OT8VACT2	Strong	Posttranslational Modification	[2467]
AANAT	OTUBJ7SX	Strong	Genetic Variation	[1234]
ABCB10	OT1C44F9	Strong	Biomarker	[2468]
ABCC12	OTYB58S2	Strong	Altered Expression	[2469]
ABCE1	OTH19LOA	Strong	Biomarker	[2470]
ABHD14B	OTFIYC6Y	Strong	Biomarker	[1464]
ABHD8	OT736H1Q	Strong	Genetic Variation	[743]
ABI1	OT5H4M62	Strong	Altered Expression	[2471]
ABR	OTZQK8JF	Strong	Biomarker	[2472]
ACACA	OT5CQPZY	Strong	Biomarker	[1273]
ACAD8	OT3JI5GB	Strong	Genetic Variation	[2473]
ACADM	OTA4P0FC	Strong	Altered Expression	[2474]
ACADSB	OTDO6HBG	Strong	Genetic Variation	[2475]
ACAT2	OTZ092ZJ	Strong	Altered Expression	[2476]
ACBD3	OTMYNY7A	Strong	Biomarker	[2477]
ACCS	OTHIHI9D	Strong	Biomarker	[1705]
ACKR2	OTWYY14H	Strong	Biomarker	[2478]
ACKR4	OTZPWT2N	Strong	Genetic Variation	[2479]
ACOT7	OT7C68YV	Strong	Genetic Variation	[651]
ACSBG1	OTM040MW	Strong	Altered Expression	[2480]
ACSL5	OT3L9XO3	Strong	Biomarker	[2481]
ACTA1	OTOVGLPG	Strong	Altered Expression	[2482]
ACTA2	OTEDLG8E	Strong	Biomarker	[2483]
ACTB	OT1MCP2F	Strong	Biomarker	[2484]
ACTBL2	OTD6B81U	Strong	Genetic Variation	[651]
ACTC1	OTJU04B1	Strong	Biomarker	[2485]
ACTG2	OTRDWUO0	Strong	Genetic Variation	[651]
ACTR1B	OTGBCKLO	Strong	Biomarker	[1300]
ACTR2	OT3C8U5T	Strong	Biomarker	[274]
ACVR1C	OTOTYERF	Strong	Biomarker	[2486]
ADAM12	OTZKOTDB	Strong	Altered Expression	[2487]
ADAM29	OTGLTTKU	Strong	Biomarker	[2488]
ADAMTS17	OTCFITM9	Strong	Biomarker	[2489]
ADAMTS18	OTRMFI04	Strong	Biomarker	[2490]
ADAMTS2	OTTK22NO	Strong	Biomarker	[2491]
ADAMTS3	OT2U6VF5	Strong	Biomarker	[659]
ADAMTS6	OTSZE6L4	Strong	Biomarker	[2492]
ADAMTS8	OT2KFY1S	Strong	Biomarker	[2493]
ADAR	OTQNOHR8	Strong	Biomarker	[2494]
ADARB1	OTGKSZEV	Strong	Altered Expression	[2495]
ADGRE5	OTTSB84Q	Strong	Biomarker	[1793]
ADGRL2	OTCXD2YR	Strong	Altered Expression	[2496]
ADIPOR1	OT65ZFZN	Strong	Biomarker	[2497]
ADIPOR2	OT2HDTL8	Strong	Biomarker	[2498]
ADPRS	OTI1KPN6	Strong	Biomarker	[2499]
ADRM1	OTOU4EY6	Strong	Altered Expression	[2500]
AEBP1	OTBI1RZ6	Strong	Biomarker	[2501]
AFAP1	OTR473H8	Strong	Biomarker	[2502]
AFF3	OTR0705Z	Strong	Altered Expression	[2503]
AFM	OTPOR8IO	Strong	Biomarker	[2504]
AGFG1	OTI8ZKC4	Strong	Biomarker	[2505]
AGO3	OTNQGROH	Strong	Biomarker	[2506]
AGO4	OTKXQD70	Strong	Biomarker	[2506]
AHNAK	OT6KH1WG	Strong	Biomarker	[2507]
AHRR	OTSJ12W6	Strong	Altered Expression	[2508]
AHSA1	OTC7AFHT	Strong	Altered Expression	[370]
AIFM1	OTKPWB7Q	Strong	Altered Expression	[2509]
AIFM3	OTSWKCAO	Strong	Altered Expression	[2510]
AIM2	OT86QUI8	Strong	Biomarker	[1542]
AIRE	OTA7G1Y1	Strong	Altered Expression	[2511]
AK4	OTA0T02Q	Strong	Biomarker	[2512]
AKAP1	OTIIB2JB	Strong	Altered Expression	[2513]
AKAP10	OTPNFTOU	Strong	Genetic Variation	[2514]
AKAP12	OTCVRDDX	Strong	Altered Expression	[2515]
AKAP13	OTOZAR14	Strong	Biomarker	[2516]
AKAP8	OTK3EQAI	Strong	Biomarker	[1307]
AKAP9	OT7Z2YRP	Strong	Biomarker	[453]
AKIP1	OT7XPG27	Strong	Biomarker	[2517]
AKT1S1	OT4JHN4Y	Strong	Posttranslational Modification	[2518]
ALDH1A3	OT1C9NKQ	Strong	Altered Expression	[1156]
ALDOA	OTWRFTIB	Strong	Biomarker	[817]
ALG2	OT77B384	Strong	Biomarker	[2519]
ALG3	OTPOL1QW	Strong	Biomarker	[2520]
ALKBH2	OTSQW0BG	Strong	Posttranslational Modification	[2521]
ALKBH3	OTS1CD9Z	Strong	Biomarker	[2521]
ALKBH8	OTXN70DV	Strong	Biomarker	[2522]
ALPK1	OTBW6SGD	Strong	Biomarker	[2523]
ALX1	OTZVARA5	Strong	Biomarker	[2524]
ALX3	OTXZ25PZ	Strong	Biomarker	[2525]
ALX4	OTNS9A29	Strong	Posttranslational Modification	[2526]
AMBRA1	OTY0YGT9	Strong	Biomarker	[2527]
AMFR	OTQRX7LC	Strong	Biomarker	[2528]
AMH	OT5FH4BD	Strong	Altered Expression	[2529]
AMIGO2	OTPAIT1O	Strong	Altered Expression	[2530]
AMOTL1	OT40G45S	Strong	Altered Expression	[2531]
ANAPC11	OTK2SJXR	Strong	Altered Expression	[2532]
ANGPTL1	OTXIN6V5	Strong	Biomarker	[2533]
ANKK1	OT0OM1O0	Strong	Genetic Variation	[2534]
ANKLE1	OTQ7WN9J	Strong	Biomarker	[2535]
ANKLE2	OTHCYR6Y	Strong	Biomarker	[2536]
ANKRD12	OTK16BL9	Strong	Biomarker	[2200]
ANKRD30A	OTJXYAE5	Strong	Biomarker	[2537]
ANKRD34A	OTI00ROL	Strong	Biomarker	[674]
ANKRD46	OTG8X76U	Strong	Altered Expression	[2538]
ANO8	OT07SRRX	Strong	Genetic Variation	[743]
ANP32A	OTRHPFO2	Strong	Altered Expression	[2539]
ANP32B	OT3SQMLU	Strong	Biomarker	[484]
ANTXR1	OT5W1GPC	Strong	Biomarker	[2540]
ANXA13	OTM33P73	Strong	Biomarker	[2541]
ANXA3	OTDD8OI7	Strong	Altered Expression	[2542]
ANXA4	OTUCRYXL	Strong	Biomarker	[2271]
ANXA6	OT9KIQ0Y	Strong	Biomarker	[1235]
ANXA7	OTLMD0TK	Strong	Altered Expression	[2543]
AP2A1	OTEFZB21	Strong	Biomarker	[2544]
AP2A2	OTD1UGUN	Strong	Biomarker	[2545]
AP3B1	OTYTIH5Q	Strong	Biomarker	[2546]
APBA3	OTAAATXF	Strong	Biomarker	[2547]
APBB3	OTNUTR0N	Strong	Biomarker	[2548]
APCDD1	OTV9AD0L	Strong	Biomarker	[2549]
APOBEC3A	OTYO6F5P	Strong	Genetic Variation	[2550]
APPBP2	OTLNFV4J	Strong	Biomarker	[2551]
APPL1	OT8VR95S	Strong	Biomarker	[2552]
AQP4	OTA9MYD5	Strong	Biomarker	[2553]
AQP8	OT99JKME	Strong	Altered Expression	[2554]
ARAP3	OTUWZTH7	Strong	Biomarker	[2555]
ARF3	OTYYQX85	Strong	Biomarker	[2556]
ARF6	OTVV7KJO	Strong	Altered Expression	[2557]
ARFGEF1	OTPAU0L4	Strong	Biomarker	[2558]
ARFGEF2	OTM3CQZT	Strong	Biomarker	[2558]
ARFGEF3	OTGQV0CU	Strong	Biomarker	[491]
ARGLU1	OTRVRZ4Z	Strong	Altered Expression	[2559]
ARHGAP1	OT0H2ZBZ	Strong	Biomarker	[2560]
ARHGAP10	OT84ATF5	Strong	Altered Expression	[2561]
ARHGAP11A	OTVQCFVP	Strong	Altered Expression	[2562]
ARHGAP17	OTEABPLV	Strong	Biomarker	[2563]
ARHGAP18	OTYMJP6H	Strong	Altered Expression	[2564]
ARHGAP26	OTNGQU7A	Strong	Biomarker	[816]
ARHGAP5	OTOQELUN	Strong	Altered Expression	[2565]
ARHGAP9	OTJNHX96	Strong	Biomarker	[2566]
ARHGDIA	OTEXWJDO	Strong	Biomarker	[2567]
ARHGDIB	OT9PD6CS	Strong	Altered Expression	[363]
ARHGDIG	OT07JK0M	Strong	Biomarker	[2568]
ARHGEF1	OTXU4HBW	Strong	Biomarker	[1323]
ARHGEF11	OTDOMEH6	Strong	Biomarker	[2569]
ARHGEF12	OTM2D3LT	Strong	Biomarker	[2570]
ARHGEF2	OTBQTFRT	Strong	Altered Expression	[2111]
ARID3B	OTUP9MS4	Strong	Altered Expression	[2571]
ARID4A	OT1XKBZ0	Strong	Genetic Variation	[2572]
ARL11	OTF6UDDB	Strong	Genetic Variation	[2573]
ARMH1	OTTJC0D6	Strong	Altered Expression	[1148]
ARNT2	OTAQD3YV	Strong	Altered Expression	[2574]
ARPC1B	OTYE3DN2	Strong	Altered Expression	[2575]
ARPC2	OTSOKOMY	Strong	Biomarker	[2576]
ARPIN	OTNNYP9A	Strong	Biomarker	[2577]
ARSD	OTAHW9M8	Strong	Biomarker	[2578]
ARTN	OTWIWGL6	Strong	Biomarker	[2579]
ASAH2B	OT2M9WWQ	Strong	Biomarker	[2580]
ASB6	OTFAJPSF	Strong	Altered Expression	[2581]
ASCC1	OTH4VAP9	Strong	Altered Expression	[2205]
ASCC2	OT3B204T	Strong	Biomarker	[1337]
ASCL1	OTI4X44G	Strong	Altered Expression	[2582]
ASCL2	OT3D62WB	Strong	Biomarker	[2583]
ASF1B	OTKXX12I	Strong	Biomarker	[2584]
ASL	OTI2NGQR	Strong	Altered Expression	[2585]
ASPG	OT5E2EKR	Strong	Altered Expression	[2586]
ASPM	OTKXQMNA	Strong	Genetic Variation	[698]
ASS1	OT4ZMG0Q	Strong	Altered Expression	[289]
ATAD1	OTJ02XFL	Strong	Genetic Variation	[2587]
ATAD3A	OTWF6HBP	Strong	Altered Expression	[2588]
ATF5	OT03QCLM	Strong	Biomarker	[2589]
ATF6	OTAFHAVI	Strong	Altered Expression	[2590]
ATG10	OTVRPC5X	Strong	Biomarker	[674]
ATG3	OT28VBVK	Strong	Biomarker	[2591]
ATG4C	OTD9HN3X	Strong	Biomarker	[2592]
ATN1	OTNZFLKY	Strong	Biomarker	[2593]
ATP1B2	OTYTBYVU	Strong	Biomarker	[2594]
ATP2A3	OTFYDEES	Strong	Altered Expression	[2595]
ATP2B3	OT9DIEOP	Strong	Biomarker	[2596]
ATP2C2	OTGIHTYQ	Strong	Biomarker	[2597]
ATP6	OTPHOGLX	Strong	Genetic Variation	[2598]
ATP6AP2	OT0IABVV	Strong	Altered Expression	[2599]
ATP6V0A2	OTJBDX0Y	Strong	Biomarker	[2600]
ATRNL1	OTY5JUX2	Strong	Biomarker	[700]
ATRX	OT77RSQW	Strong	Genetic Variation	[2601]
ATXN1	OTQF0HNR	Strong	Altered Expression	[2602]
ATXN7	OTL3YF1H	Strong	Biomarker	[2603]
ATXN7L3B	OTUYOYAR	Strong	Biomarker	[2604]
AXIN1	OTRGZGZ5	Strong	Biomarker	[2605]
AZIN1	OTX5W77I	Strong	Biomarker	[1343]
AZU1	OTHXU264	Strong	Altered Expression	[2606]
B3GALNT2	OTOF6O2B	Strong	Altered Expression	[2607]
B3GALT4	OTLKSMQE	Strong	Altered Expression	[2608]
B4GAT1	OT5NH9TD	Strong	Biomarker	[674]
BABAM1	OTCFPER6	Strong	Genetic Variation	[2609]
BABAM2	OTOY7FNT	Strong	Biomarker	[2610]
BAD	OT63ERYM	Strong	Posttranslational Modification	[383]
BAG1	OTRQNIA4	Strong	Altered Expression	[2611]
BAG3	OTVXYUDQ	Strong	Biomarker	[2612]
BANP	OT1JMTBD	Strong	Biomarker	[2613]
BARHL1	OTIUTWBD	Strong	Altered Expression	[2614]
BARX2	OT0R3QD3	Strong	Biomarker	[2615]
BASP1	OTF4VS5G	Strong	Altered Expression	[2616]
BATF3	OTI61WXQ	Strong	Altered Expression	[889]
BAZ1B	OTD5KR2J	Strong	Biomarker	[2617]
BCAP31	OTKSACR4	Strong	Biomarker	[2618]
BCAS1	OTQKJR81	Strong	Biomarker	[2619]
BCAS4	OT596N5E	Strong	Altered Expression	[2620]
BCDIN3D	OTLO1EOO	Strong	Altered Expression	[2621]
BCL2L11	OTNQQWFJ	Strong	Biomarker	[2622]
BCL2L12	OTS6IFZY	Strong	Altered Expression	[2623]
BCL7A	OTYFUJTP	Strong	Altered Expression	[2624]
BCORL1	OTPTFQN5	Strong	Biomarker	[2625]
BCS1L	OT5PY5CY	Strong	Biomarker	[2626]
BEST1	OTWHE1ZC	Strong	Biomarker	[888]
BEX2	OT4G5SIC	Strong	Biomarker	[2627]
BGLAP	OTK1YLWQ	Strong	Altered Expression	[1262]
BHLHA15	OTY7IER8	Strong	Altered Expression	[2628]
BHLHE22	OTZUQY5L	Strong	Biomarker	[2629]
BHLHE40	OTITX14U	Strong	Biomarker	[2630]
BHLHE41	OTY9GJ1Y	Strong	Biomarker	[2631]
BIK	OTTH1T3D	Strong	Altered Expression	[2632]
BIN1	OTK8O0X8	Strong	Biomarker	[2633]
BIRC6	OTCQJAB0	Strong	Biomarker	[2634]
BLCAP	OTGJVU0C	Strong	Altered Expression	[2635]
BLID	OT479VJV	Strong	Biomarker	[2636]
BMF	OT90NSLI	Strong	Biomarker	[2637]
BMP8B	OTJC3AB9	Strong	Altered Expression	[652]
BMPR1A	OTQOA4ZH	Strong	Biomarker	[2638]
BMPR1B	OTGFN0OD	Strong	Altered Expression	[867]
BNC1	OTGJ5WUF	Strong	Biomarker	[2639]
BNIP1	OT7USYCY	Strong	Altered Expression	[2640]
BNIP3	OT4SO7J4	Strong	Altered Expression	[2641]
BNIP3L	OTJKOMXE	Strong	Altered Expression	[2642]
BOD1	OTQL6F4R	Strong	Altered Expression	[2643]
BOK	OTDQPDIX	Strong	Biomarker	[2644]
BPY2	OT2WQPNQ	Strong	Biomarker	[2645]
BRAP	OTB7BAFQ	Strong	Biomarker	[2646]
BRF1	OTQC6DMG	Strong	Altered Expression	[2647]
BRF2	OT2C6TH2	Strong	Biomarker	[2648]
BRMS1L	OTJIW47U	Strong	Biomarker	[2649]
BTC	OTW4B2O0	Strong	Biomarker	[2650]
BTD	OTJYTQ69	Strong	Biomarker	[2651]
BTF3	OT5ZZFJL	Strong	Altered Expression	[2652]
BTG2	OTZF6K1H	Strong	Biomarker	[2653]
BTG4	OTT3TKPI	Strong	Biomarker	[288]
BTN3A2	OT3DIBU3	Strong	Biomarker	[2654]
BUB1B	OT8KME51	Strong	Genetic Variation	[2655]
BYSL	OTPTLZJT	Strong	Altered Expression	[2656]
C10orf88	OT5KV1OA	Strong	Genetic Variation	[2475]
C10orf90	OT6DNZC4	Strong	Altered Expression	[2657]
C1GALT1	OT2ZSZ6P	Strong	Biomarker	[2658]
C1orf52	OT8RQW3W	Strong	Altered Expression	[2659]
C1QL1	OTNQ0G3E	Strong	Biomarker	[534]
C1QL3	OT4TZH3J	Strong	Biomarker	[2660]
C4BPA	OTHNH6Y8	Strong	Biomarker	[2661]
CA10	OTC3N1F6	Strong	Genetic Variation	[2662]
CABIN1	OT4G5CIK	Strong	Genetic Variation	[2663]
CACUL1	OT6P1ZVP	Strong	Biomarker	[2664]
CACYBP	OTJMZD2T	Strong	Biomarker	[2665]
CALD1	OTNJKJ6Q	Strong	Biomarker	[2618]
CALML3	OTM8DNQU	Strong	Altered Expression	[2666]
CALML6	OTHVPDSD	Strong	Biomarker	[2667]
CALU	OTSYQN71	Strong	Biomarker	[2271]
CAMK1D	OTU24HAU	Strong	Biomarker	[2668]
CAMKMT	OTLJBRUW	Strong	Biomarker	[2228]
CAMLG	OTTSRY39	Strong	Biomarker	[2669]
CAMTA1	OTAN1S5B	Strong	Biomarker	[2670]
CAP1	OTYM8A2N	Strong	Biomarker	[1162]
CAPN5	OTQ8QM7K	Strong	Genetic Variation	[2671]
CARD10	OT2RPM4I	Strong	Biomarker	[2672]
CARD16	OT4NUHWB	Strong	Biomarker	[2673]
CARD8	OTXXZYWU	Strong	Altered Expression	[2674]
CASC3	OTLK3K4U	Strong	Biomarker	[2675]
CASD1	OT1YB54Z	Strong	Biomarker	[1671]
CASP14	OTKY93H9	Strong	Altered Expression	[2676]
CAST	OTBXZZGF	Strong	Biomarker	[2677]
CBFA2T2	OTNOIB23	Strong	Biomarker	[2063]
CBFA2T3	OTOJ10S1	Strong	Altered Expression	[2678]
CBFB	OTIAC6W4	Strong	Biomarker	[2679]
CBLC	OT3RKZI9	Strong	Biomarker	[2680]
CBLL1	OTZUQBYX	Strong	Altered Expression	[2681]
CBX4	OT4XVRRF	Strong	Biomarker	[2682]
CBX5	OT8VYY84	Strong	Posttranslational Modification	[2683]
CBX8	OT4U5V1T	Strong	Biomarker	[2684]
CCAR2	OTLUDG5T	Strong	Biomarker	[1822]
CCBE1	OTO4UIDB	Strong	Altered Expression	[2685]
CCDC116	OTYMNP3C	Strong	Genetic Variation	[2686]
CCDC181	OTPE3H8B	Strong	Biomarker	[2687]
CCDC54	OTW5WCX9	Strong	Altered Expression	[2688]
CCDC8	OTO295IH	Strong	Altered Expression	[2231]
CCDC88A	OT3SSYYC	Strong	Biomarker	[2689]
CCDC88C	OTIU02BS	Strong	Genetic Variation	[2609]
CCL1	OT23NON8	Strong	Biomarker	[2690]
CCL14	OT8QETQU	Strong	Biomarker	[2691]
CCL18	OT7JYSK9	Strong	Altered Expression	[2692]
CCL19	OTQ2UJMH	Strong	Biomarker	[2693]
CCL25	OTLWJ8CJ	Strong	Biomarker	[771]
CCL28	OTY6XNQ7	Strong	Biomarker	[2694]
CCL4	OT6B8P25	Strong	Altered Expression	[1835]
CCN5	OTADU8JJ	Strong	Biomarker	[2695]
CCN6	OTRFHQ2Z	Strong	Biomarker	[2696]
CCND2	OTDULQF9	Strong	Biomarker	[2697]
CCNF	OTJFVU43	Strong	Biomarker	[2698]
CCNH	OTKDU3SR	Strong	Biomarker	[1015]
CCNL1	OTAJSS3D	Strong	Biomarker	[2699]
CCR10	OT7ZWSSD	Strong	Biomarker	[2700]
CCT3	OTL6EOS1	Strong	Biomarker	[2701]
CCT4	OT5D452X	Strong	Altered Expression	[2702]
CCT5	OTPZ38BT	Strong	Biomarker	[2703]
CCT6A	OTCYWL5F	Strong	Biomarker	[2704]
CD109	OTDADBM4	Strong	Biomarker	[827]
CD226	OT4UG0KB	Strong	Altered Expression	[2705]
CD3D	OTRBLP0R	Strong	Biomarker	[2706]
CD5L	OTPY4WQR	Strong	Biomarker	[2707]
CD63	OT2UGZA9	Strong	Biomarker	[2708]
CD68	OTOYEY3J	Strong	Biomarker	[2709]
CD8A	OTDWQJXK	Strong	Altered Expression	[2710]
CD99	OTPUZ5DE	Strong	Biomarker	[2711]
CDC14A	OTL10OY6	Strong	Biomarker	[2712]
CDC27	OTDT45XJ	Strong	Altered Expression	[2713]
CDC42	OT5QBC5M	Strong	Biomarker	[2714]
CDC42EP3	OTUZ3U9Z	Strong	Biomarker	[2715]
CDC5L	OTTPFUU5	Strong	Altered Expression	[2716]
CDCA4	OT0AAXAC	Strong	Biomarker	[2717]
CDCA5	OTZLCQ5U	Strong	Altered Expression	[2718]
CDCA7	OT12HDZY	Strong	Altered Expression	[2719]
CDH13	OTD2CYM5	Strong	Posttranslational Modification	[2720]
CDH15	OTJ1TO02	Strong	Genetic Variation	[2721]
CDH17	OT9EV2XK	Strong	Biomarker	[2722]
CDH22	OTQEUWQN	Strong	Altered Expression	[2723]
CDK10	OTKP7TTR	Strong	Biomarker	[2724]
CDK14	OT385ZH1	Strong	Altered Expression	[2725]
CDK2AP1	OTNFOHDJ	Strong	Altered Expression	[2726]
CDKAL1	OTA0SGNE	Strong	Genetic Variation	[2727]
CDKN2B	OTAG24N1	Strong	Posttranslational Modification	[1416]
CDKN3	OTBE3H07	Strong	Biomarker	[2728]
CDO1	OTLG1P77	Strong	Altered Expression	[2729]
CDT1	OTVY53VG	Strong	Altered Expression	[1842]
CDYL2	OTGUD2XL	Strong	Genetic Variation	[2730]
CEACAM19	OTMECF5R	Strong	Altered Expression	[2731]
CEACAM7	OTKFDTZY	Strong	Biomarker	[803]
CEACAM8	OTLL9WWO	Strong	Altered Expression	[530]
CEBPD	OTNBIPMY	Strong	Altered Expression	[2732]
CELF2	OTLJJ4VT	Strong	Posttranslational Modification	[2672]
CEMIP2	OT9I1XUO	Strong	Altered Expression	[2733]
CENPF	OT7AG0SW	Strong	Altered Expression	[2734]
CENPH	OTPOO9LK	Strong	Biomarker	[2735]
CENPI	OTWRIMZ3	Strong	Biomarker	[2736]
CENPK	OTKPUF8K	Strong	Altered Expression	[2737]
CENPU	OTQ4TZRS	Strong	Biomarker	[2738]
CEP131	OT6PF80T	Strong	Biomarker	[2739]
CEP55	OTGSG2PA	Strong	Biomarker	[2740]
CEP57	OTPOHLIX	Strong	Genetic Variation	[2741]
CEP85L	OTSHJFOT	Strong	Biomarker	[500]
CERS2	OTRAHYYP	Strong	Biomarker	[2742]
CERS4	OTV5ENAX	Strong	Biomarker	[2743]
CERT1	OTNUCNHX	Strong	Altered Expression	[2744]
CETN1	OTGQ8JOZ	Strong	Biomarker	[2667]
CFAP20	OTIG8TR5	Strong	Altered Expression	[2745]
CFAP54	OTS4SW4H	Strong	Genetic Variation	[743]
CFL1	OTT6D5MH	Strong	Biomarker	[2746]
CFL2	OTE2W0DH	Strong	Altered Expression	[2747]
CGRRF1	OTLMNRCL	Strong	Biomarker	[2748]
CHAF1A	OTXSSY4H	Strong	Biomarker	[376]
CHAF1B	OTOMK4KH	Strong	Biomarker	[2749]
CHCHD2	OTL5PA3Y	Strong	Altered Expression	[2750]
CHD1L	OT7CZK7C	Strong	Biomarker	[2751]
CHD3	OTDBU4F3	Strong	Biomarker	[1738]
CHD4	OTBDEHDP	Strong	Biomarker	[2752]
CHD5	OTS5EVHH	Strong	Altered Expression	[2753]
CHD8	OTS7A6AF	Strong	Genetic Variation	[2754]
CHFR	OTRAD2TT	Strong	Altered Expression	[2755]
CHGB	OT7SAQT2	Strong	Biomarker	[2756]
CHMP3	OT0963JJ	Strong	Altered Expression	[2757]
CHORDC1	OT3W6F1U	Strong	Biomarker	[2758]
CHP2	OT4UMKUR	Strong	Biomarker	[2759]
CHRAC1	OTBXN4YZ	Strong	Genetic Variation	[2760]
CHRDL1	OTGMWVVA	Strong	Biomarker	[2761]
CHST11	OTNJJ5Q1	Strong	Biomarker	[2762]
CHST9	OT1DEZRM	Strong	Genetic Variation	[2730]
CIAPIN1	OTWS90F9	Strong	Altered Expression	[2763]
CIB1	OT4BVCRU	Strong	Biomarker	[1798]
CIB2	OT9ZJX1I	Strong	Altered Expression	[1798]
CIC	OTFXCHNZ	Strong	Biomarker	[2764]
CIP2A	OTVS2GXA	Strong	Biomarker	[2765]
CIRBP	OTXWTPBL	Strong	Biomarker	[2766]
CISD2	OTVS7S2H	Strong	Biomarker	[2064]
CISH	OT8T5NYL	Strong	Biomarker	[1486]
CITED1	OTUJQ3VL	Strong	Altered Expression	[2767]
CITED4	OTR6NHI2	Strong	Altered Expression	[2768]
CKAP4	OTDUC9ME	Strong	Biomarker	[1174]
CKB	OTUCKOTT	Strong	Biomarker	[2769]
CKS1B	OTNUPLUJ	Strong	Biomarker	[2770]
CLDN10	OT2CVAKY	Strong	Genetic Variation	[2771]
CLDN12	OTO55YZI	Strong	Biomarker	[2772]
CLDN16	OTTHAIKR	Strong	Altered Expression	[2773]
CLDN5	OTUX60YO	Strong	Altered Expression	[2774]
CLDN7	OTNE0XHQ	Strong	Altered Expression	[1217]
CLEC14A	OT0UJQ4O	Strong	Biomarker	[2775]
CLEC3A	OTTOAEGT	Strong	Biomarker	[2776]
CLEC4D	OTT7X1UC	Strong	Biomarker	[872]
CLIC4	OT6KTPKD	Strong	Altered Expression	[2777]
CLIP1	OTTGAEJE	Strong	Altered Expression	[2177]
CLPTM1L	OTDJWQXI	Strong	Genetic Variation	[2778]
CLTA	OTLHOXMQ	Strong	Genetic Variation	[1026]
CLUL1	OTYIXQ36	Strong	Biomarker	[1293]
CMC2	OTRYIO1J	Strong	Biomarker	[2703]
CMTR1	OTG0N8GA	Strong	Biomarker	[1572]
CMTR2	OT82FBWS	Strong	Biomarker	[2779]
CNBP	OTTGM9NK	Strong	Altered Expression	[2780]
CNGB1	OTA5DE38	Strong	Biomarker	[1169]
CNKSR1	OTSNAEQ9	Strong	Biomarker	[2781]
CNKSR2	OTAGERJ2	Strong	Altered Expression	[2782]
CNOT3	OT4D5Z9L	Strong	Genetic Variation	[2783]
CNOT7	OTJBKCPI	Strong	Biomarker	[2749]
CNOT8	OT6CMCS0	Strong	Biomarker	[2749]
CNOT9	OT1NIIQD	Strong	Biomarker	[2784]
CNTN3	OTC1274J	Strong	Biomarker	[2558]
CNTN4	OTULXVE0	Strong	Biomarker	[2558]
COIL	OTP4I4DL	Strong	Altered Expression	[2785]
COL10A1	OTC4G2YC	Strong	Biomarker	[2786]
COL11A1	OTB0DRMS	Strong	Altered Expression	[2787]
COL11A2	OT3BQUBH	Strong	Genetic Variation	[2788]
COL4A2	OTJK1LKN	Strong	Biomarker	[2789]
COL4A5	OTHG60RE	Strong	Genetic Variation	[2790]
COL5A1	OT24078H	Strong	Altered Expression	[2791]
COP1	OT6J2K12	Strong	Biomarker	[2792]
COPS6	OTG9AAG0	Strong	Altered Expression	[2793]
COPS8	OTNAD2S4	Strong	Genetic Variation	[2794]
CORT	OTX3GUHB	Strong	Biomarker	[2795]
COTL1	OT6YCNLF	Strong	Altered Expression	[2666]
COX1	OTG3O9BN	Strong	Altered Expression	[2796]
COX11	OT0N3WL9	Strong	Genetic Variation	[2797]
COX5A	OTP0961M	Strong	Biomarker	[2798]
COX5B	OTDP94F3	Strong	Biomarker	[2799]
COX6C	OT3V7JE5	Strong	Genetic Variation	[2800]
COX7A2L	OTY21FKV	Strong	Altered Expression	[2801]
COX8A	OTU0NR39	Strong	Biomarker	[2798]
CP	OTM8JE4Y	Strong	Biomarker	[2802]
CPD	OT2CS64Y	Strong	Altered Expression	[395]
CPEB1	OTLCXC6H	Strong	Biomarker	[2803]
CPEB2	OTKES4YR	Strong	Altered Expression	[2804]
CPEB4	OTW1SCZW	Strong	Biomarker	[2805]
CPED1	OTJJPZOZ	Strong	Biomarker	[1833]
CPNE3	OTCR3WG2	Strong	Biomarker	[2806]
CPOX	OTIAY121	Strong	Biomarker	[2798]
CPSF6	OTM6QYNQ	Strong	Altered Expression	[2807]
CPT1A	OTI862QH	Strong	Altered Expression	[2808]
CPT1C	OT8F1MBF	Strong	Altered Expression	[2809]
CPT2	OTIN6G20	Strong	Altered Expression	[2810]
CPXM1	OTRCSQPG	Strong	Biomarker	[2811]
CRB3	OTQKPTMU	Strong	Altered Expression	[2812]
CRCP	OT4K9BT7	Strong	Biomarker	[2813]
CREB3L1	OT2JHIHM	Strong	Altered Expression	[2814]
CREBZF	OTO3TOEU	Strong	Biomarker	[2815]
CRIP2	OTVVJSYX	Strong	Biomarker	[1867]
CRLS1	OT7XNL0K	Strong	Genetic Variation	[2816]
CROCC	OTVNOZSM	Strong	Biomarker	[2817]
CRYL1	OT0SJSJM	Strong	Biomarker	[1713]
CSGALNACT1	OTBML9D9	Strong	Altered Expression	[2818]
CSH1	OT33HTRR	Strong	Altered Expression	[2819]
CSH2	OTW8JVAN	Strong	Biomarker	[2819]
CSMD1	OTIVDSC4	Strong	Altered Expression	[2820]
CSN1S1	OTXOW6XJ	Strong	Biomarker	[2821]
CSNK2B	OT2WW7R1	Strong	Biomarker	[796]
CSRP3	OTECBJMV	Strong	Altered Expression	[2666]
CST6	OTZVHJTF	Strong	Altered Expression	[2822]
CSTF1	OTYSXAX6	Strong	Genetic Variation	[2823]
CT45A1	OT80VTZO	Strong	Altered Expression	[2824]
CT47A11	OTQHGP0S	Strong	Altered Expression	[2825]
CT55	OTQC0H27	Strong	Biomarker	[2382]
CTAG1B	OTIQGW6U	Strong	Genetic Variation	[845]
CTBP1	OTVYH2DH	Strong	Altered Expression	[2826]
CTBP2	OTGZGT87	Strong	Altered Expression	[2827]
CTNNA1	OTFC725Z	Strong	Genetic Variation	[2828]
CTNNBIP1	OTX9SBJG	Strong	Biomarker	[2829]
CTNND2	OTYKE30Y	Strong	Altered Expression	[2830]
CTRL	OTB6NA5O	Strong	Altered Expression	[2831]
CTSO	OTFL6VRO	Strong	Genetic Variation	[2832]
CTSZ	OTSCX2LL	Strong	Biomarker	[2833]
CTTN	OTJRG4ES	Strong	Biomarker	[479]
CTU1	OTNTM9D1	Strong	Biomarker	[2834]
CTU2	OT323X9J	Strong	Biomarker	[2522]
CUEDC1	OTQ7V4FF	Strong	Biomarker	[2835]
CUEDC2	OTWMOLAJ	Strong	Altered Expression	[2836]
CUL1	OTXPE1UZ	Strong	Biomarker	[2837]
CUL2	OTPF83PG	Strong	Altered Expression	[2664]
CUL4A	OTTBV70J	Strong	Altered Expression	[2664]
CUL4B	OT2QX4DO	Strong	Altered Expression	[2664]
CUL5	OTMTZD47	Strong	Biomarker	[2664]
CUL9	OTPUCLZT	Strong	Altered Expression	[2664]
CUX1	OTU1LCNJ	Strong	Biomarker	[1337]
CXCL14	OTM189TA	Strong	Biomarker	[2478]
CXCL16	OTD49T9R	Strong	Altered Expression	[1310]
CXCL3	OTSL94KH	Strong	Biomarker	[2838]
CYB5D2	OTX10KKR	Strong	Biomarker	[2839]
CYBRD1	OTUTVBES	Strong	Biomarker	[2840]
CYCS	OTBFALJD	Strong	Biomarker	[2841]
CYFIP1	OTOBEH24	Strong	Biomarker	[2842]
CYFIP2	OTCAY35T	Strong	Genetic Variation	[2843]
CYGB	OTX153DQ	Strong	Altered Expression	[2844]
CYP2A7	OTRJ3P2Z	Strong	Genetic Variation	[1942]
CYP2D7	OTYJTL3S	Strong	Biomarker	[2845]
CYP2W1	OTXSB1AE	Strong	Altered Expression	[1721]
CYP4Z1	OTKRGJBG	Strong	Biomarker	[2846]
DAB2	OTRMQTMZ	Strong	Biomarker	[2847]
DACH1	OTMKNAGG	Strong	Biomarker	[2848]
DACT2	OTNLCC0K	Strong	Posttranslational Modification	[2849]
DAP	OT5YLL7E	Strong	Biomarker	[2850]
DAP3	OTNPEZYM	Strong	Biomarker	[2851]
DAPK1	OTNCNUCO	Strong	Genetic Variation	[2852]
DAPK2	OTWODUQG	Strong	Biomarker	[490]
DBR1	OTLTWLTE	Strong	Genetic Variation	[2853]
DCAF1	OT3ZDVOE	Strong	Biomarker	[2854]
DCC	OT2C1SHW	Strong	Genetic Variation	[2855]
DCD	OTV5PBGJ	Strong	Biomarker	[2856]
DCLRE1B	OT2LFW7A	Strong	Genetic Variation	[2857]
DCLRE1C	OTW3KB1I	Strong	Biomarker	[2858]
DCTN4	OTM7C943	Strong	Biomarker	[2859]
DCX	OTISR7K3	Strong	Genetic Variation	[2860]
DDA1	OTAZIAIH	Strong	Genetic Variation	[743]
DDB2	OTO8HVVB	Strong	Biomarker	[540]
DDHD2	OTUP0WHF	Strong	Biomarker	[2861]
DDIT3	OTI8YKKE	Strong	Biomarker	[2862]
DDX1	OT3U8FD0	Strong	Genetic Variation	[2863]
DDX10	OTH48438	Strong	Biomarker	[2864]
DDX17	OTXRMMBP	Strong	Altered Expression	[2865]
DDX20	OT6G8YF3	Strong	Biomarker	[2866]
DDX21	OTV73GMZ	Strong	Altered Expression	[2867]
DDX3X	OTDO4TRX	Strong	Biomarker	[2868]
DDX53	OTHK3EGZ	Strong	Biomarker	[2869]
DDX54	OTVOJU6G	Strong	Biomarker	[2870]
DEFA1	OT5N1B9B	Strong	Altered Expression	[2871]
DEPDC1B	OTMVFOT1	Strong	Biomarker	[2872]
DEPP1	OTB36PHJ	Strong	Altered Expression	[2873]
DERL1	OTJUS74N	Strong	Altered Expression	[514]
DERL2	OTI3TUUZ	Strong	Genetic Variation	[2874]
DERL3	OTRZRT6Q	Strong	Altered Expression	[2875]
DES	OTI09KBW	Strong	Biomarker	[2483]
DHDDS	OTVLYBUS	Strong	Biomarker	[2246]
DHRS2	OTFHWIY8	Strong	Biomarker	[2876]
DHX32	OTDYB66V	Strong	Altered Expression	[2877]
DIP2A	OTXPTR8R	Strong	Biomarker	[2645]
DIP2C	OTVNSS2T	Strong	Altered Expression	[2878]
DIRAS3	OT3XHLQA	Strong	Altered Expression	[2879]
DKC1	OTX7DJR6	Strong	Altered Expression	[2880]
DLAT	OT9LBJVN	Strong	Genetic Variation	[2881]
DLD	OT378CU9	Strong	Biomarker	[1103]
DLG3	OTH591WK	Strong	Biomarker	[2882]
DLG5	OTU9Z17K	Strong	Altered Expression	[2883]
DLK2	OT56Y83S	Strong	Biomarker	[2884]
DLX2	OTKC2DQ0	Strong	Biomarker	[2885]
DLX4	OTLWVCN4	Strong	Biomarker	[2886]
DLX5	OTEEFBEU	Strong	Biomarker	[2885]
DMBT1	OTVNU9D9	Strong	Genetic Variation	[2887]
DMP1	OTBWBWW7	Strong	Biomarker	[2888]
DNAAF4	OTVDYBJE	Strong	Altered Expression	[2889]
DNAJA3	OT61924T	Strong	Altered Expression	[2890]
DNAJB6	OTMHIIAN	Strong	Altered Expression	[2891]
DNAJC10	OTD2EG0R	Strong	Genetic Variation	[2892]
DNAJC12	OTNU59PT	Strong	Altered Expression	[889]
DNAJC13	OTYAVVJ6	Strong	Biomarker	[2893]
DNAJC2	OT3JDA0R	Strong	Biomarker	[2894]
DNAJC27	OTJRPCUR	Strong	Altered Expression	[2895]
DNAJC3	OT7ROIJF	Strong	Altered Expression	[2896]
DND1	OTHLC8TA	Strong	Biomarker	[2897]
DNER	OT2GH2E5	Strong	Biomarker	[730]
DNM1L	OTXK1Q1G	Strong	Biomarker	[490]
DOCK1	OTCFV3ON	Strong	Altered Expression	[2898]
DOCK11	OTFSTN6A	Strong	Genetic Variation	[2899]
DOCK3	OTF3YS2W	Strong	Biomarker	[2900]
DOCK8	OTNQLL21	Strong	Genetic Variation	[2901]
DOK1	OTGVRLW6	Strong	Altered Expression	[1500]
DOK2	OTIJ38UF	Strong	Altered Expression	[2902]
DOP1A	OTBKLQH5	Strong	Biomarker	[2903]
DPF3	OTEWLMNB	Strong	Biomarker	[2904]
DPP3	OTUIVL1C	Strong	Biomarker	[2905]
DPT	OTINRFC7	Strong	Biomarker	[2906]
DPYS	OTLTUIVL	Strong	Biomarker	[2775]
DPYSL3	OTINJV20	Strong	Biomarker	[2907]
DRG1	OTIFYMI3	Strong	Biomarker	[2908]
DSC1	OTNII6GZ	Strong	Biomarker	[2909]
DSC2	OTODVH8K	Strong	Altered Expression	[2910]
DSC3	OTYG47F8	Strong	Biomarker	[2911]
DSPP	OT1TYNDN	Strong	Altered Expression	[2912]
DTX3	OTSUUV9N	Strong	Biomarker	[1685]
DUOX1	OTQ2AEW0	Strong	Posttranslational Modification	[2913]
DUOXA1	OTNG3HH4	Strong	Altered Expression	[2640]
DUSP16	OTK7S078	Strong	Altered Expression	[903]
DUSP2	OTH54FMR	Strong	Biomarker	[2594]
DUSP22	OTEZ3U85	Strong	Biomarker	[2914]
DUSP23	OTE2PG54	Strong	Altered Expression	[2915]
DUSP4	OT6WAO12	Strong	Biomarker	[2916]
DUSP6	OT4H6RKW	Strong	Biomarker	[2917]
DUSP7	OT6Z5AHP	Strong	Altered Expression	[2918]
DVL1	OTD67RF1	Strong	Biomarker	[2919]
DVL3	OTPRROHJ	Strong	Biomarker	[2920]
DYM	OTQ670WI	Strong	Biomarker	[2921]
DYNC2H1	OTLC8K6B	Strong	Biomarker	[2483]
DYNLL2	OTLIT58K	Strong	Biomarker	[1395]
E2F4	OTB3JFH4	Strong	Biomarker	[2922]
E2F5	OT1XWING	Strong	Altered Expression	[1892]
EBF1	OTZ61YYH	Strong	Biomarker	[2923]
EBNA1BP2	OTBRVMZH	Strong	Altered Expression	[1148]
ECPAS	OT1C0KOI	Strong	Altered Expression	[2924]
EDA	OTAKS5WS	Strong	Posttranslational Modification	[2925]
EDA2R	OTJLAIIH	Strong	Posttranslational Modification	[2925]
EDAR	OT3W2UQS	Strong	Altered Expression	[2925]
EDC4	OTBBNIUJ	Strong	Genetic Variation	[2926]
EDIL3	OTDVVNS0	Strong	Biomarker	[2927]
EDN3	OTN7Q9BE	Strong	Altered Expression	[2928]
EEF1A1	OT00THXS	Strong	Altered Expression	[2929]
EEF1A2	OT9Z23K5	Strong	Altered Expression	[2930]
EEF1B2	OTW64NPU	Strong	Biomarker	[817]
EEF2	OTZ7SZ39	Strong	Biomarker	[817]
EEPD1	OTTOGO05	Strong	Biomarker	[2931]
EFEMP1	OTZVUOOB	Strong	Altered Expression	[2932]
EFNA2	OTEAUKRX	Strong	Biomarker	[2933]
EFNA3	OTJGOUMZ	Strong	Biomarker	[2934]
EFNA5	OTOH4DRR	Strong	Biomarker	[2935]
EFNB2	OT0DCUOM	Strong	Altered Expression	[2936]
EGR3	OTGPJIRA	Strong	Altered Expression	[2937]
EHD2	OTTX391J	Strong	Altered Expression	[2938]
EI24	OTD4NOYS	Strong	Biomarker	[2939]
EID3	OTAND0C7	Strong	Altered Expression	[2940]
EIF1	OTB4GZ0V	Strong	Biomarker	[967]
EIF2A	OTWXELQP	Strong	Biomarker	[2941]
EIF2B1	OT4NCVY1	Strong	Biomarker	[1266]
EIF2B2	OTQQMHM1	Strong	Biomarker	[1266]
EIF2B4	OTTM5SX1	Strong	Biomarker	[1266]
EIF2S1	OTM0GDTP	Strong	Posttranslational Modification	[1126]
EIF2S2	OTXF0B09	Strong	Biomarker	[1266]
EIF2S3	OTARRES9	Strong	Posttranslational Modification	[1126]
EIF3C	OTR8RF9X	Strong	Biomarker	[2942]
EIF3G	OT5L1SRY	Strong	Biomarker	[2943]
EIF4A1	OTMTBX6N	Strong	Biomarker	[2944]
EIF4B	OTE8TXA8	Strong	Altered Expression	[2945]
EIF4G1	OT2CF1E6	Strong	Altered Expression	[1899]
EIF4G2	OTEO98CR	Strong	Altered Expression	[1462]
EIF5B	OTZTT22W	Strong	Genetic Variation	[2946]
EIF6	OTEXMUED	Strong	Biomarker	[1685]
ELAVL2	OT6EJ8MQ	Strong	Altered Expression	[2404]
ELF1	OTV5LKIA	Strong	Biomarker	[2933]
ELF3	OTUTLEQO	Strong	Biomarker	[2947]
ELF4	OT167PR5	Strong	Biomarker	[2948]
ELF5	OTLRU8YF	Strong	Altered Expression	[2949]
ELK1	OTH9MXD6	Strong	Altered Expression	[2950]
ELL	OTCBN5LF	Strong	Genetic Variation	[1861]
ELOC	OT0XHHWP	Strong	Biomarker	[2951]
ELOF1	OT8BXS5U	Strong	Biomarker	[2933]
ELP1	OTYEWBF7	Strong	Biomarker	[2522]
ELP3	OTT5UKSZ	Strong	Biomarker	[2522]
EMD	OTR8ZANE	Strong	Biomarker	[2952]
EMID1	OTJ27FQ1	Strong	Genetic Variation	[2730]
EMILIN2	OTOYK5A8	Strong	Biomarker	[2953]
EMP1	OTSZHUHQ	Strong	Altered Expression	[2954]
EMP2	OTPS2H0L	Strong	Biomarker	[449]
EMP3	OTODMJ1D	Strong	Altered Expression	[2955]
EMSY	OTBQ3KQE	Strong	Biomarker	[2956]
ENGASE	OTKXNR5B	Strong	Biomarker	[2957]
ENHO	OT91QASK	Strong	Biomarker	[2958]
ENO1	OTB1KWJS	Strong	Biomarker	[2959]
ENO2	OTRODL0T	Strong	Biomarker	[2960]
ENTPD5	OTFH05B9	Strong	Altered Expression	[2961]
EPB41	OTGCFPV8	Strong	Altered Expression	[2962]
EPB41L2	OT6UABPM	Strong	Altered Expression	[2962]
EPB41L3	OTS6CHG2	Strong	Biomarker	[2963]
EPB41L4B	OT2K30P7	Strong	Biomarker	[2964]
EPG5	OT3P5HQD	Strong	Genetic Variation	[2965]
EPRS1	OTXK0FLB	Strong	Biomarker	[2966]
EPS8	OTZ6ES6V	Strong	Biomarker	[2967]
EPSTI1	OT75I1UH	Strong	Biomarker	[2968]
ERAL1	OTSH78HD	Strong	Biomarker	[2969]
ERAS	OT528IZO	Strong	Biomarker	[2970]
ERCC1	OTNPYQHI	Strong	Biomarker	[2971]
ERCC3	OTVAW3P1	Strong	Biomarker	[2972]
ERCC6	OT2QZKSF	Strong	Biomarker	[2973]
ERCC6L	OTE9V7D9	Strong	Altered Expression	[2974]
ERG	OTOTX9VU	Strong	Altered Expression	[2975]
ERLIN2	OT551BVG	Strong	Altered Expression	[2976]
ERO1A	OTVKOQWM	Strong	Altered Expression	[2977]
ERP29	OTNKANMH	Strong	Altered Expression	[2978]
ERRFI1	OT7VZ2IZ	Strong	Altered Expression	[2979]
ERV3-1	OT4CW64T	Strong	Genetic Variation	[2980]
ESPL1	OTMGEVOK	Strong	Altered Expression	[2981]
ESRP2	OTVTKJ4I	Strong	Altered Expression	[2982]
ESS2	OTZ08VCZ	Strong	Biomarker	[2983]
ETF1	OTH8C5U5	Strong	Biomarker	[2984]
ETFA	OTXX61VZ	Strong	Biomarker	[2985]
ETV1	OT6PMJIK	Strong	Biomarker	[2986]
ETV4	OT8C98UZ	Strong	Altered Expression	[2987]
ETV5	OTE2OBM4	Strong	Biomarker	[2988]
ETV7	OTIAADPA	Strong	Biomarker	[1887]
EVL	OTZ8ZDNY	Strong	Biomarker	[827]
EXO1	OTI87RS5	Strong	Altered Expression	[764]
EXOSC6	OTAC10N6	Strong	Biomarker	[2989]
EXT1	OTRPALJK	Strong	Biomarker	[2990]
EXTL3	OT2BRUBN	Strong	Biomarker	[2991]
FA2H	OT8HA13U	Strong	Biomarker	[2992]
FABP7	OTRE2H4G	Strong	Altered Expression	[2993]
FADD	OTV7GFHH	Strong	Biomarker	[835]
FAH	OTGZA1YR	Strong	Genetic Variation	[2994]
FAM124B	OTL2A8O8	Strong	Altered Expression	[2995]
FAM13A	OTZ6GN0Q	Strong	Genetic Variation	[2996]
FAM3C	OTBR6U9G	Strong	Biomarker	[2997]
FAM53A	OT92WJE6	Strong	Biomarker	[2998]
FAN1	OT1LM1HZ	Strong	Biomarker	[2999]
FANCD2	OTVEB5LF	Strong	Biomarker	[3000]
FANCI	OTW8E3SC	Strong	Biomarker	[3001]
FASTK	OTTHFZMP	Strong	Biomarker	[3002]
FASTKD2	OTD635WX	Strong	Altered Expression	[3003]
FAT4	OT7QONNV	Strong	Altered Expression	[3004]
FBL	OTRODIE5	Strong	Altered Expression	[3005]
FBLN1	OT5MHHOP	Strong	Altered Expression	[3006]
FBXL14	OTBTN6WS	Strong	Biomarker	[3007]
FBXL7	OTNUK1DJ	Strong	Biomarker	[3008]
FBXO22	OTEJ5MO0	Strong	Altered Expression	[3009]
FBXO31	OTF96IC2	Strong	Altered Expression	[3010]
FBXO32	OTUE978R	Strong	Biomarker	[3011]
FBXO5	OTTR957W	Strong	Biomarker	[3012]
FBXO8	OTZNGJGW	Strong	Biomarker	[2277]
FBXW4	OTEGSZOX	Strong	Posttranslational Modification	[2467]
FBXW8	OTJG15EO	Strong	Genetic Variation	[3013]
FCER1A	OTIRUOHF	Strong	Genetic Variation	[3014]
FCGR3B	OTSLSPZG	Strong	Biomarker	[3015]
FEN1	OT6QGG7O	Strong	Biomarker	[3016]
FERMT1	OT626PBA	Strong	Biomarker	[3017]
FERMT2	OTZNPWWX	Strong	Biomarker	[3018]
FEZ1	OTWCXPRE	Strong	Genetic Variation	[3019]
FGA	OTMIHY80	Strong	Biomarker	[3020]
FGD1	OTV3T64P	Strong	Altered Expression	[3021]
FGD3	OTIH6283	Strong	Biomarker	[3022]
FGD4	OTYXJQCW	Strong	Biomarker	[3023]
FGD5	OT5VIRP2	Strong	Altered Expression	[3024]
FGF13	OTHNNVSG	Strong	Biomarker	[907]
FGF17	OTAQSFZ2	Strong	Altered Expression	[3025]
FGF5	OTQXGHBY	Strong	Biomarker	[3026]
FGL1	OTT0QHQ1	Strong	Biomarker	[2546]
FHL2	OT0OAYWT	Strong	Altered Expression	[3027]
FHL3	OTMPRLZ5	Strong	Biomarker	[3028]
FHL5	OT6C00Z1	Strong	Genetic Variation	[651]
FHOD1	OTROM7N3	Strong	Biomarker	[3029]
FLACC1	OTZN9TZV	Strong	Biomarker	[674]
FLCN	OTVM78XM	Strong	Genetic Variation	[3030]
FLG	OTE9QDV6	Strong	Biomarker	[3031]
FLII	OT7G9JG6	Strong	Biomarker	[3032]
FLOT1	OT0JPPJZ	Strong	Altered Expression	[3033]
FLT3LG	OTU0YGC4	Strong	Biomarker	[3034]
FMN1	OT9CID5R	Strong	Genetic Variation	[743]
FMOD	OT9EJ5H8	Strong	Biomarker	[3035]
FNBP1L	OTH1S2P2	Strong	Altered Expression	[3036]
FOSB	OTW6C05J	Strong	Biomarker	[1616]
FOXD1	OT80PRHS	Strong	Altered Expression	[3037]
FOXD3	OTXYV6GO	Strong	Biomarker	[3038]
FOXF1	OT2CJZ5K	Strong	Biomarker	[3039]
FOXJ1	OT7LLBZ7	Strong	Biomarker	[3040]
FOXK1	OTLZGS7J	Strong	Altered Expression	[3041]
FOXK2	OTFXDZ3R	Strong	Altered Expression	[3042]
FOXL1	OT89XFPN	Strong	Biomarker	[3043]
FOXP4	OTHCGIEZ	Strong	Altered Expression	[3044]
FOXS1	OTPM9TZ5	Strong	Altered Expression	[3045]
FRAT1	OT1PS84E	Strong	Altered Expression	[3046]
FRK	OTEKV1SC	Strong	Biomarker	[3047]
FRS2	OTDMD800	Strong	Biomarker	[3048]
FRY	OT74IAG2	Strong	Altered Expression	[3049]
FRZB	OTTO3DPY	Strong	Genetic Variation	[3050]
FSD1	OT8P6PT3	Strong	Altered Expression	[3051]
FSD1L	OTBQ48RF	Strong	Altered Expression	[3051]
FUBP1	OT77SC9N	Strong	Altered Expression	[3052]
FUCA1	OTW71IK4	Strong	Biomarker	[3053]
FUT1	OTODG57A	Strong	Biomarker	[3054]
FUT2	OTLXM6WI	Strong	Biomarker	[3054]
FUT6	OTBZUQ7F	Strong	Altered Expression	[3055]
FXYD3	OT9PPRHE	Strong	Biomarker	[3056]
FXYD5	OT81DIOD	Strong	Biomarker	[3057]
FYB1	OT6345CH	Strong	Altered Expression	[3058]
FZD3	OTIWDN78	Strong	Biomarker	[3059]
FZD4	OTGLZIE0	Strong	Biomarker	[399]
FZD5	OTXFFY56	Strong	Altered Expression	[2284]
FZD6	OTBCPII8	Strong	Genetic Variation	[3060]
FZR1	OT0WGWZS	Strong	Altered Expression	[3061]
G0S2	OT8FL49L	Strong	Biomarker	[3062]
G3BP2	OTAWW3KI	Strong	Biomarker	[3063]
GAB2	OTBFN705	Strong	Biomarker	[3064]
GADD45A	OTDRV63V	Strong	Altered Expression	[3065]
GADD45G	OT8V1J4M	Strong	Biomarker	[3066]
GAL3ST1	OTSFFZRD	Strong	Altered Expression	[3067]
GALNT16	OTUBTPGE	Strong	Genetic Variation	[3068]
GALNT4	OT6WKC13	Strong	Biomarker	[3069]
GALNT9	OTFRD9RI	Strong	Biomarker	[502]
GAS1	OTKJXG52	Strong	Biomarker	[3070]
GAS7	OT0M5TNY	Strong	Biomarker	[2842]
GAS8	OT8KT2AK	Strong	Genetic Variation	[3071]
GATA1	OTX1R7O1	Strong	Biomarker	[3072]
GATA5	OTO81B63	Strong	Altered Expression	[3073]
GATA6	OTO2BC0F	Strong	Altered Expression	[3073]
GBP2	OTVU4G07	Strong	Biomarker	[3074]
GBX2	OTW0ZI4D	Strong	Biomarker	[3075]
GCM2	OTSKNPTI	Strong	Biomarker	[3076]
GCNT2	OTRUIMC4	Strong	Biomarker	[3077]
GCSH	OTNC1OKA	Strong	Biomarker	[3078]
GDF1	OTZ1VRBH	Strong	Genetic Variation	[3079]
GDF10	OTEVXGJ7	Strong	Biomarker	[3080]
GDF11	OTOSNMND	Strong	Biomarker	[1301]
GDF3	OTD3KGJK	Strong	Altered Expression	[3081]
GDPD2	OTKEPVWI	Strong	Altered Expression	[3082]
GEMIN2	OT4L6TLL	Strong	Biomarker	[3083]
GEN1	OT1XFQXF	Strong	Biomarker	[3084]
GFM1	OTUN4V3N	Strong	Biomarker	[3085]
GGN	OTKPYNWP	Strong	Genetic Variation	[3086]
GGNBP2	OT7K9YZV	Strong	Altered Expression	[3086]
GIGYF2	OTFNVEJ4	Strong	Posttranslational Modification	[2784]
GINS1	OTVQZMMQ	Strong	Altered Expression	[3087]
GIPC1	OTXLVCPJ	Strong	Biomarker	[3088]
GIPC2	OT68YFO1	Strong	Altered Expression	[3089]
GIT1	OTHO92S5	Strong	Altered Expression	[3090]
GLCE	OTPRSHX5	Strong	Genetic Variation	[3091]
GLI3	OTKDOE94	Strong	Biomarker	[3092]
GLUD1	OTXKOCUH	Strong	Altered Expression	[3093]
GNA13	OTVDL515	Strong	Altered Expression	[3094]
GNAI2	OTTLGRGH	Strong	Biomarker	[3095]
GNLY	OTZJKA8C	Strong	Biomarker	[3096]
GOLGA1	OTBBPBG0	Strong	Altered Expression	[3097]
GOLM1	OTOZSV6O	Strong	Altered Expression	[3098]
GOLPH3	OTDLGYM3	Strong	Biomarker	[3099]
GOPC	OTRBGH71	Strong	Genetic Variation	[1909]
GORASP1	OTQS91S7	Strong	Biomarker	[1605]
GPAA1	OTWVRR35	Strong	Altered Expression	[3100]
GPATCH2	OT09TY4W	Strong	Biomarker	[3101]
GPC1	OTQKRSSV	Strong	Altered Expression	[3102]
GPC2	OT3WSQE1	Strong	Altered Expression	[3103]
GPC6	OTNJBESF	Strong	Biomarker	[3104]
GPLD1	OTUUQOVY	Strong	Biomarker	[3105]
GPR161	OT80FYA3	Strong	Biomarker	[3106]
GPR19	OTR7MUS5	Strong	Altered Expression	[3107]
GPR42	OTEB0ROY	Strong	Biomarker	[399]
GPR50	OT0EJBM4	Strong	Altered Expression	[3108]
GPSM2	OT6RPMRM	Strong	Biomarker	[3109]
GPT2	OTS5VF7N	Strong	Biomarker	[3110]
GPX4	OTRAFFX2	Strong	Biomarker	[3111]
GPX7	OTINT9Z4	Strong	Altered Expression	[3112]
GRAMD1B	OTCG1GX2	Strong	Biomarker	[3113]
GRAP2	OTS5NIZ3	Strong	Altered Expression	[370]
GRB14	OTFET2YM	Strong	Biomarker	[3114]
GRB7	OTF8Y9XY	Strong	Altered Expression	[3115]
GRID1	OTJ3WIKC	Strong	Genetic Variation	[743]
GRID2	OTJ3R10R	Strong	Genetic Variation	[743]
GRIN3B	OT7T1OJP	Strong	Biomarker	[935]
GRK4	OTUU8V2S	Strong	Biomarker	[3116]
GSDMB	OTWA7P10	Strong	Altered Expression	[3117]
GSDME	OT1ZWY32	Strong	Biomarker	[3118]
GSE1	OT3J7CJB	Strong	Biomarker	[3119]
GSPT1	OT18H1B0	Strong	Genetic Variation	[3120]
GSTM5	OTMMBFY8	Strong	Genetic Variation	[1753]
GTF2H1	OTCRXC6B	Strong	Biomarker	[2859]
GTF2H4	OTPD1DIU	Strong	Genetic Variation	[1861]
GTF2I	OTUYL1TQ	Strong	Biomarker	[3121]
GTF3A	OTVROUVQ	Strong	Biomarker	[3122]
GTSE1	OTPP742Z	Strong	Altered Expression	[3123]
GUCY1A2	OTR6DVAA	Strong	Biomarker	[827]
GYPA	OTABU4YV	Strong	Biomarker	[3124]
GYPB	OTESHUIX	Strong	Biomarker	[3125]
GYPE	OTBHAG6A	Strong	Biomarker	[3125]
GZMM	OTEC5CWT	Strong	Altered Expression	[3126]
H1-2	OT0AVI4M	Strong	Biomarker	[2703]
H2AC20	OTEIVLM1	Strong	Altered Expression	[3127]
H2AJ	OTVA4XTW	Strong	Biomarker	[3128]
H2AX	OT18UX57	Strong	Altered Expression	[3129]
H2BC12	OTQ8V0KG	Strong	Biomarker	[2703]
H2BC21	OT0FDCUC	Strong	Altered Expression	[3130]
H4C1	OTB71W46	Strong	Genetic Variation	[3131]
HACD1	OTEC7EP7	Strong	Biomarker	[1162]
HADHB	OT4Y1I62	Strong	Biomarker	[1293]
HAPLN3	OTB853Z1	Strong	Biomarker	[3132]
HAPLN4	OTZQOG9A	Strong	Biomarker	[674]
HAS2	OTTD3PAL	Strong	Biomarker	[3133]
HAT1	OT307KEN	Strong	Altered Expression	[3134]
HAVCR2	OTOL603T	Strong	Biomarker	[3135]
HBP1	OTDPGGDV	Strong	Biomarker	[3136]
HCLS1	OTX7WGYN	Strong	Altered Expression	[1088]
HDLBP	OTKDEEYX	Strong	Biomarker	[3137]
HEATR6	OTD3MYS0	Strong	Altered Expression	[3138]
HEBP1	OTR9MPDX	Strong	Altered Expression	[2606]
HECW1	OT1PVAZA	Strong	Biomarker	[3139]
HELLS	OTVVV668	Strong	Biomarker	[1672]
HELQ	OTL1STJT	Strong	Genetic Variation	[3140]
HEPH	OTZ2F15Z	Strong	Altered Expression	[3141]
HERC2	OTNQYKOB	Strong	Altered Expression	[3142]
HES1	OT8P19W2	Strong	Altered Expression	[3143]
HEY1	OTJQL0I3	Strong	Biomarker	[3144]
HEY2	OTU4J3ZI	Strong	Biomarker	[3144]
HEYL	OTN7BH79	Strong	Genetic Variation	[3145]
HFM1	OTHV3EFE	Strong	Biomarker	[3146]
HHEX	OTLIUVYX	Strong	Genetic Variation	[1094]
HHIP	OT77RQYS	Strong	Genetic Variation	[1385]
HIC1	OTI9TWY4	Strong	Biomarker	[3147]
HIVEP2	OTVOMCW4	Strong	Biomarker	[3148]
HIVEP3	OTM3QT3L	Strong	Altered Expression	[3149]
HJURP	OTWMV16B	Strong	Altered Expression	[3150]
HJV	OT4235J2	Strong	Altered Expression	[1389]
HLA-DRA	OT7KZMP2	Strong	Altered Expression	[3058]
HLA-DRB3	OT5PM9N7	Strong	Genetic Variation	[3151]
HLA-DRB5	OTUX5TWM	Strong	Genetic Variation	[3152]
HLCS	OTPDUX30	Strong	Biomarker	[2841]
HM13	OTGEO1LP	Strong	Altered Expression	[3153]
HMGB3	OTCJ2EZY	Strong	Biomarker	[3154]
HMGN2	OTN20MEF	Strong	Biomarker	[3155]
HMGN5	OTUUAHVQ	Strong	Biomarker	[3156]
HNF4G	OTTSIHJP	Strong	Genetic Variation	[2730]
HNRNPC	OT47AK4C	Strong	Biomarker	[3157]
HNRNPF	OTSMBXMF	Strong	Biomarker	[3158]
HNRNPK	OTNPRM8U	Strong	Biomarker	[1293]
HNRNPL	OT0DJX74	Strong	Genetic Variation	[3159]
HNRNPM	OTFU3OEZ	Strong	Altered Expression	[3160]
HNRNPR	OT3FITK2	Strong	Biomarker	[1293]
HOPX	OTBSR6C9	Strong	Biomarker	[3161]
HOXA4	OTNVTQDT	Strong	Posttranslational Modification	[3162]
HOXA9	OTKNK5H0	Strong	Biomarker	[2301]
HOXB2	OTTD6HMV	Strong	Biomarker	[3163]
HOXB4	OTH1HRW5	Strong	Biomarker	[3164]
HOXB7	OTC7WYU8	Strong	Altered Expression	[3165]
HOXB8	OTKHOD17	Strong	Biomarker	[3166]
HOXB9	OTMVHQOU	Strong	Biomarker	[3167]
HOXC10	OT5WF17M	Strong	Biomarker	[3168]
HOXC11	OT8NMHM6	Strong	Biomarker	[3169]
HOXC6	OTBCRAZV	Strong	Altered Expression	[3170]
HOXC8	OTJUYU8J	Strong	Biomarker	[3171]
HOXD10	OT0NOWU2	Strong	Altered Expression	[3172]
HOXD11	OT9XGA4G	Strong	Biomarker	[3173]
HOXD3	OTBUZ35T	Strong	Altered Expression	[3174]
HPR	OTXSC9UB	Strong	Biomarker	[2146]
HPS1	OTKS5I7T	Strong	Biomarker	[2546]
HPS5	OTLO2374	Strong	Biomarker	[1879]
HPSE2	OTGEPP8V	Strong	Genetic Variation	[3175]
HRG	OTPLUFOG	Strong	Biomarker	[3176]
HRNR	OT560QR5	Strong	Altered Expression	[3177]
HS3ST2	OTWFA0GJ	Strong	Altered Expression	[3178]
HS3ST3A1	OTUOM1GV	Strong	Biomarker	[3179]
HS3ST3B1	OTK53GUD	Strong	Biomarker	[3178]
HS6ST3	OTTW9PDL	Strong	Biomarker	[3180]
HSDL2	OT4IN0MV	Strong	Biomarker	[3181]
HSPA2	OTSDET7B	Strong	Altered Expression	[2419]
HSPA4	OT5HR0AR	Strong	Biomarker	[3182]
HSPB2	OTS01646	Strong	Biomarker	[1060]
HTN3	OTEUXA81	Strong	Biomarker	[3183]
HTRA2	OTC7616F	Strong	Altered Expression	[3184]
HUWE1	OTFH6BJS	Strong	Biomarker	[3185]
HYAL2	OTTVINXW	Strong	Posttranslational Modification	[3186]
HYOU1	OTBGBSOV	Strong	Altered Expression	[3187]
IBSP	OT29944Y	Strong	Biomarker	[3188]
ICAM4	OT1BI27E	Strong	Genetic Variation	[3189]
ICAM5	OTDGGAFH	Strong	Genetic Variation	[3190]
IFI16	OT4SPU0U	Strong	Altered Expression	[3191]
IFI44	OTOKSZVA	Strong	Altered Expression	[3192]
IFIT5	OTYTSO77	Strong	Altered Expression	[1126]
IFITM3	OT2QP8D3	Strong	Biomarker	[3193]
IFNA1	OTPMKY0L	Strong	Biomarker	[1505]
IFNLR1	OTWWWK45	Strong	Altered Expression	[3194]
IGDCC3	OTGR1KA4	Strong	Biomarker	[3195]
IGF2BP1	OT9G360P	Strong	Altered Expression	[3196]
IGF2BP2	OT4ZSEEE	Strong	Biomarker	[3197]
IGFBPL1	OTY4HVN8	Strong	Posttranslational Modification	[3198]
IGHMBP2	OTAZFPF5	Strong	Genetic Variation	[1294]
IKBKE	OT5VYOSM	Strong	Biomarker	[3199]
IL17B	OTS86H50	Strong	Biomarker	[3200]
IL17RB	OT0KDNSF	Strong	Altered Expression	[3201]
IL18BP	OTW0LRYZ	Strong	Biomarker	[1835]
IL18R1	OT83XMPQ	Strong	Altered Expression	[3202]
IL27	OTIS3OF8	Strong	Genetic Variation	[3203]
IL3	OT0CQ35N	Strong	Genetic Variation	[3204]
IL6R	OTCQL07Z	Strong	Biomarker	[3205]
IL6ST	OT1N9C70	Strong	Biomarker	[3206]
ILF2	OTWWVM9X	Strong	Altered Expression	[3207]
ILKAP	OT2A6FSA	Strong	Altered Expression	[3208]
ILRUN	OTE8FHQD	Strong	Altered Expression	[3209]
IMMP1L	OTA6LOLR	Strong	Altered Expression	[3196]
IMPACT	OTQ923OB	Strong	Biomarker	[3210]
INAVA	OTGXNB86	Strong	Biomarker	[3211]
INCENP	OT9HFRYK	Strong	Genetic Variation	[3212]
ING1	OTEZBRKW	Strong	Altered Expression	[3213]
ING2	OT6H0EWF	Strong	Altered Expression	[3214]
ING4	OT0VVG4V	Strong	Biomarker	[3215]
INHBB	OT2QLD11	Strong	Genetic Variation	[3216]
INPP4B	OTLROA7G	Strong	Biomarker	[3217]
INPP5F	OTPKUY50	Strong	Biomarker	[3218]
INSRR	OT3F75WA	Strong	Genetic Variation	[3219]
INTS6	OT6GDV46	Strong	Biomarker	[2867]
INTU	OTXB13E6	Strong	Altered Expression	[3220]
IPO13	OT887N3O	Strong	Biomarker	[3221]
IPO9	OT1DGLQE	Strong	Altered Expression	[3222]
IQGAP1	OTZRWTGA	Strong	Biomarker	[3223]
IQGAP3	OT4RZV2M	Strong	Altered Expression	[3224]
IQSEC1	OTK1PBFD	Strong	Biomarker	[3225]
IQUB	OTT1VKEF	Strong	Altered Expression	[3226]
IRF5	OT8SIIAP	Strong	Altered Expression	[3227]
IRF6	OTKJ44EV	Strong	Genetic Variation	[3228]
IRF7	OTC1A2PQ	Strong	Altered Expression	[579]
IRF9	OTK4MYQJ	Strong	Altered Expression	[3229]
IRS4	OTTOL40K	Strong	Biomarker	[3230]
IRX3	OTLJ48FG	Strong	Genetic Variation	[3231]
ISCU	OTSW6DQP	Strong	Biomarker	[3232]
ISL1	OTVNVKAX	Strong	Biomarker	[3233]
ISOC1	OTAO7Z87	Strong	Altered Expression	[3234]
IST1	OTSFEZ2O	Strong	Altered Expression	[3235]
ITFG1	OTX0PCR3	Strong	Biomarker	[3236]
ITGA2B	OT4Y17PY	Strong	Biomarker	[3237]
ITGA7	OTTBTAYW	Strong	Altered Expression	[3238]
ITGB3BP	OT6Q7GR3	Strong	Altered Expression	[3239]
ITGB5	OT21MF51	Strong	Biomarker	[3240]
ITIH2	OTG3WBBE	Strong	Altered Expression	[829]
ITIH4	OT460OO1	Strong	Biomarker	[3020]
ITIH5	OTP46PZM	Strong	Biomarker	[922]
ITM2B	OTMXEPXB	Strong	Biomarker	[3241]
ITPKA	OTX5ERUD	Strong	Altered Expression	[3242]
ITSN2	OT8S0OO8	Strong	Biomarker	[3095]
JMJD6	OTILR7E4	Strong	Biomarker	[3243]
JMJD7	OT8EJRD8	Strong	Biomarker	[3244]
JPH1	OTCAILYU	Strong	Altered Expression	[1373]
JPT1	OT6CRZEU	Strong	Altered Expression	[3245]
JPT2	OTJGPA4T	Strong	Biomarker	[3246]
JTB	OT314JB6	Strong	Altered Expression	[3247]
JUNB	OTG2JXV5	Strong	Biomarker	[3248]
JUND	OTNKACJD	Strong	Biomarker	[3249]
KANK1	OT2E7A6W	Strong	Altered Expression	[3250]
KANK2	OT3SZIWM	Strong	Biomarker	[2665]
KAT2A	OTN0W2SW	Strong	Biomarker	[3251]
KAT7	OTUN98IC	Strong	Biomarker	[3252]
KCNH4	OTHJ8WTU	Strong	Altered Expression	[2950]
KCNH8	OT3I5FLB	Strong	Altered Expression	[2950]
KCNIP3	OTCQPEM4	Strong	Biomarker	[3253]
KCNK1	OTBXPTKX	Strong	Genetic Variation	[3254]
KCNK5	OT68V64E	Strong	Biomarker	[3255]
KDM4B	OT5P1UPY	Strong	Altered Expression	[3256]
KDM6A	OTZM3MJJ	Strong	Biomarker	[3257]
KHSRP	OTDHZARB	Strong	Altered Expression	[1088]
KIDINS220	OTLBH2MA	Strong	Genetic Variation	[3258]
KIF12	OTTALNDD	Strong	Altered Expression	[3259]
KIF14	OTXHT4JM	Strong	Altered Expression	[3260]
KIF15	OTJRJEXL	Strong	Biomarker	[3261]
KIF17	OTHASX9G	Strong	Biomarker	[3262]
KIF20A	OTXOQHE0	Strong	Altered Expression	[3263]
KIF22	OTY6X6BL	Strong	Biomarker	[3264]
KIF23	OTY850JC	Strong	Biomarker	[3261]
KIF2C	OTJ8G3NP	Strong	Altered Expression	[3265]
KIF5B	OTT34MT8	Strong	Altered Expression	[3266]
KIN	OTB2DNQU	Strong	Biomarker	[3267]
KIR2DL5B	OTSV0JL9	Strong	Biomarker	[3268]
KIR3DL1	OTPOSXFX	Strong	Genetic Variation	[384]
KL	OTD4VWU6	Strong	Altered Expression	[3269]
KLC1	OTSTTTW7	Strong	Altered Expression	[3266]
KLF10	OT4F4UGS	Strong	Altered Expression	[3270]
KLF11	OTKVQDJD	Strong	Biomarker	[3271]
KLF15	OTGMQMVR	Strong	Altered Expression	[3272]
KLF5	OT1ABI9N	Strong	Biomarker	[3273]
KLF6	OTQY9S7F	Strong	Altered Expression	[3274]
KLF8	OTUC5CDB	Strong	Altered Expression	[3275]
KLHDC10	OTLDF1OX	Strong	Biomarker	[674]
KLHDC7A	OTZAAF38	Strong	Biomarker	[674]
KLHDC7B	OT2H5BNX	Strong	Altered Expression	[3276]
KLHL22	OTNRE2DW	Strong	Altered Expression	[3277]
KLHL7	OT2OF1O8	Strong	Altered Expression	[3278]
KLK10	OTD573EL	Strong	Biomarker	[3279]
KLK11	OT5PKX7Y	Strong	Altered Expression	[3280]
KLK12	OTNYK59J	Strong	Altered Expression	[3281]
KLK13	OT8LOD2U	Strong	Altered Expression	[3282]
KLK15	OT7BVG17	Strong	Biomarker	[3283]
KLK9	OTGJWBIF	Strong	Biomarker	[3284]
KMT2B	OTMMAZQX	Strong	Biomarker	[3285]
KRIT1	OT58AP1I	Strong	Biomarker	[2228]
KRR1	OTCMJ3K3	Strong	Biomarker	[3286]
KRT1	OTIOJWA4	Strong	Biomarker	[3287]
KRT14	OTUVZ1DW	Strong	Altered Expression	[2530]
KRT18	OTVLQFIP	Strong	Altered Expression	[3288]
KRT20	OT4RB40L	Strong	Biomarker	[3289]
KRT5	OTVGI9HT	Strong	Genetic Variation	[1857]
KRT80	OTAU54U3	Strong	Biomarker	[3290]
KRT81	OTMKIK2S	Strong	Altered Expression	[3291]
L3MBTL4	OTERBGKR	Strong	Biomarker	[3292]
LACTB	OTRWGNBF	Strong	Biomarker	[3293]
LAD1	OT6YGTVX	Strong	Biomarker	[1103]
LAMA3	OTFME7HT	Strong	Posttranslational Modification	[3294]
LAMP3	OTN0XL3W	Strong	Altered Expression	[3295]
LAMTOR5	OTER0U8L	Strong	Biomarker	[3296]
LARP6	OTUQ9QS9	Strong	Biomarker	[3297]
LATS1	OTOOCG4R	Strong	Biomarker	[1950]
LBR	OT1HG3HG	Strong	Altered Expression	[2323]
LBX1	OTQJHICM	Strong	Biomarker	[3298]
LCN1	OT8BWXTV	Strong	Biomarker	[3299]
LDB1	OT20EAPR	Strong	Altered Expression	[3300]
LDHAL6B	OT3T9D1S	Strong	Biomarker	[817]
LDLRAD1	OTG1GL9H	Strong	Genetic Variation	[2671]
LEF1	OTWS5I5H	Strong	Altered Expression	[3301]
LEPROT	OT2EENVA	Strong	Biomarker	[2497]
LGALS3BP	OT9AGQKH	Strong	Biomarker	[3302]
LGALS4	OTKQCG0H	Strong	Altered Expression	[398]
LGALS7	OTMSVI7R	Strong	Altered Expression	[3303]
LGALS8	OT71LJ8T	Strong	Biomarker	[673]
LGALSL	OTC983KJ	Strong	Biomarker	[3304]
LHB	OT5GBOVJ	Strong	Biomarker	[3305]
LIG1	OTEEQS43	Strong	Altered Expression	[3306]
LIMA1	OTONPC9R	Strong	Altered Expression	[3307]
LIMD2	OTSIFTD8	Strong	Biomarker	[3308]
LIN28B	OTVWP0FN	Strong	Biomarker	[3309]
LIN9	OTLHW00C	Strong	Altered Expression	[3310]
LLGL1	OTAIQSXZ	Strong	Biomarker	[856]
LLGL2	OTU8ZDC4	Strong	Biomarker	[1471]
LMLN	OTQF0JPY	Strong	Biomarker	[3311]
LMO4	OT5NDCT9	Strong	Biomarker	[3121]
LOXL1	OTA0NEJU	Strong	Altered Expression	[2324]
LPIN1	OTQ75KF2	Strong	Altered Expression	[3312]
LPP	OT6TU8SE	Strong	Posttranslational Modification	[3313]
LRATD2	OTEZBUUL	Strong	Biomarker	[3314]
LRG1	OTLD0KWA	Strong	Altered Expression	[3315]
LRP8	OTZ71YV2	Strong	Altered Expression	[3316]
LRRC1	OTSVD30Q	Strong	Biomarker	[3317]
LRRC37A	OT41U0KO	Strong	Biomarker	[674]
LRRC37A2	OT9UI93T	Strong	Biomarker	[674]
LRRC3B	OT9VDGPR	Strong	Biomarker	[674]
LRRC4	OT7XJ70N	Strong	Altered Expression	[2659]
LRRC49	OT9SOV66	Strong	Posttranslational Modification	[3318]
LRRC59	OT6BQJ5E	Strong	Biomarker	[3319]
LRTOMT	OTMLESUJ	Strong	Genetic Variation	[3320]
LSM2	OTHL77NY	Strong	Biomarker	[3321]
LSP1	OTSPSIFO	Strong	Genetic Variation	[3322]
LSR	OTR8Y32X	Strong	Biomarker	[3323]
LUM	OTSRC874	Strong	Biomarker	[3324]
LY6E	OTMG16BZ	Strong	Altered Expression	[3325]
LYPD4	OTYNO8BS	Strong	Biomarker	[3326]
LZTFL1	OTIEIOEW	Strong	Altered Expression	[3327]
LZTS1	OTXXL864	Strong	Biomarker	[3328]
MACC1	OTV3DLX0	Strong	Genetic Variation	[3329]
MACF1	OTVIHD77	Strong	Altered Expression	[3330]
MACROD1	OTWFEVRW	Strong	Altered Expression	[3331]
MADD	OTUFYVGG	Strong	Altered Expression	[3332]
MAEA	OTPA2FDE	Strong	Altered Expression	[3333]
MAEL	OTZ2VU30	Strong	Altered Expression	[3334]
MAGED2	OTMEWNSE	Strong	Biomarker	[1804]
MAGED4B	OTO37U7W	Strong	Genetic Variation	[1179]
MAGEE2	OTL3E0G7	Strong	Biomarker	[567]
MAGI3	OTDJ5QUH	Strong	Biomarker	[3335]
MAGT1	OTQSAV5C	Strong	Biomarker	[676]
MAK16	OTD546E5	Strong	Biomarker	[3336]
MAL	OTBM30SW	Strong	Biomarker	[1980]
MAL2	OTVPEI80	Strong	Biomarker	[3337]
MAN1A1	OT6LIGJP	Strong	Biomarker	[3338]
MAN2C1	OT17VT8D	Strong	Biomarker	[674]
MANEA	OTV7L8I6	Strong	Altered Expression	[3339]
MAP1LC3A	OTPMGIU4	Strong	Altered Expression	[3340]
MAP2	OT6UYT3X	Strong	Biomarker	[3341]
MAP2K4	OTZPZX11	Strong	Altered Expression	[3342]
MAP3K13	OTS93BTX	Strong	Biomarker	[1998]
MAP9	OTZD5099	Strong	Biomarker	[3343]
MAPK13	OT0W9GE7	Strong	Biomarker	[3344]
MAPK15	OT8SW0L7	Strong	Biomarker	[3345]
MAPK6	OTDDNF3Q	Strong	Biomarker	[3346]
MAPRE1	OTCVQD60	Strong	Biomarker	[3347]
MARCHF8	OTH7PNN2	Strong	Genetic Variation	[3348]
MARCKSL1	OT13J2FM	Strong	Altered Expression	[1200]
MARVELD1	OT5CPOJE	Strong	Altered Expression	[3349]
MASTL	OTQ7YKK5	Strong	Altered Expression	[3350]
MATK	OTVOJJLJ	Strong	Biomarker	[3351]
MATN1	OTBRTCTQ	Strong	Biomarker	[3352]
MAX	OTKZ0YKM	Strong	Biomarker	[3353]
MBD1	OTD19VO6	Strong	Genetic Variation	[1746]
MBD4	OTWR9YXE	Strong	Posttranslational Modification	[3354]
MCAT	OTH07FIW	Strong	Biomarker	[1449]
MCC	OTQVI1EM	Strong	Genetic Variation	[3355]
MCF2L	OTEURA8N	Strong	Biomarker	[3356]
MCF2L2	OTOGFMIH	Strong	Biomarker	[3357]
MCM10	OTV0O3JN	Strong	Biomarker	[3358]
MCM8	OTC93H3S	Strong	Genetic Variation	[3359]
MCPH1	OTYT3TT5	Strong	Biomarker	[1449]
MCTS1	OT7SAOJP	Strong	Altered Expression	[821]
ME3	OT3XMLYG	Strong	Biomarker	[3360]
MECOM	OTP983W8	Strong	Biomarker	[770]
MED1	OTOO24C4	Strong	Altered Expression	[3361]
MED12	OTQZ4D2X	Strong	Genetic Variation	[3362]
MED18	OT6M6CQ8	Strong	Genetic Variation	[3363]
MED23	OTKZQT0R	Strong	Biomarker	[3364]
MED25	OTDBY87B	Strong	Biomarker	[3365]
MED28	OTEDM1L5	Strong	Biomarker	[3366]
MED7	OTGF64SM	Strong	Altered Expression	[3367]
MEF2B	OT880SE6	Strong	Altered Expression	[1185]
MEIS1	OTH9DKAD	Strong	Altered Expression	[3368]
MEN1	OTN6U6V0	Strong	Altered Expression	[3369]
MEOX1	OTJEMT2D	Strong	Biomarker	[3370]
MEST	OT8Q4U8Y	Strong	Biomarker	[3371]
METTL3	OTSXP1M3	Strong	Biomarker	[3372]
METTL6	OTYAOD1Q	Strong	Biomarker	[1685]
MFAP1	OTZN4FT3	Strong	Biomarker	[1734]
MFAP5	OT46VXSG	Strong	Altered Expression	[778]
MGA	OTTLB216	Strong	Altered Expression	[3373]
MGAT3	OTXI5X4T	Strong	Altered Expression	[3374]
MGAT5	OTU4DD4G	Strong	Biomarker	[3375]
MGP	OTZWU3FU	Strong	Biomarker	[3376]
MGRN1	OTFZC41K	Strong	Biomarker	[2421]
MIB1	OT5C404P	Strong	Biomarker	[3377]
MIB2	OTJCC3HS	Strong	Biomarker	[3378]
MICAL1	OTJEDVWA	Strong	Biomarker	[3379]
MICAL2	OT04OQQJ	Strong	Biomarker	[3380]
MIER3	OTL5BGOB	Strong	Genetic Variation	[3381]
MIIP	OT79EXZ7	Strong	Altered Expression	[3382]
MINAR1	OTV1X2R0	Strong	Altered Expression	[3383]
MLH3	OT91PPBI	Strong	Genetic Variation	[3384]
MLKL	OTDSLC81	Strong	Altered Expression	[3385]
MLN	OTBZ5SE5	Strong	Biomarker	[2524]
MLXIP	OT30UNI7	Strong	Genetic Variation	[3348]
MMD	OTB5I4OC	Strong	Biomarker	[3386]
MMP26	OT9O89KU	Strong	Biomarker	[3387]
MMRN1	OT7ZNYHT	Strong	Biomarker	[3388]
MMUT	OTBBBV70	Strong	Biomarker	[3389]
MNAT1	OTXLOYCB	Strong	Altered Expression	[3390]
MNT	OTPC4ANL	Strong	Biomarker	[3391]
MNX1	OTXP9FH1	Strong	Biomarker	[3392]
MPC1	OT6DYFUO	Strong	Altered Expression	[3393]
MPEG1	OT7DAO0F	Strong	Altered Expression	[1069]
MPG	OTAHW80B	Strong	Altered Expression	[3394]
MPHOSPH10	OT8DJTO7	Strong	Biomarker	[3395]
MPST	OTCDPH5D	Strong	Altered Expression	[1186]
MPZL2	OTKFNDUI	Strong	Genetic Variation	[3396]
MRE11	OTGU8TZM	Strong	Biomarker	[3397]
MRPL13	OT6D8Y9G	Strong	Biomarker	[1293]
MRPL19	OTRBKF6R	Strong	Biomarker	[1293]
MRPL28	OT4LUTZU	Strong	Posttranslational Modification	[1416]
MRPL34	OTOR0EVV	Strong	Genetic Variation	[743]
MRPL36	OTZ9QV3U	Strong	Genetic Variation	[3398]
MRPL9	OT3I6W77	Strong	Biomarker	[1293]
MRPS18A	OTFCBPX2	Strong	Altered Expression	[3399]
MRPS18C	OTL868QS	Strong	Genetic Variation	[3140]
MRPS22	OTIVNAJL	Strong	Biomarker	[1293]
MRPS23	OTDVWT5V	Strong	Biomarker	[3400]
MRPS28	OT8CLJ6M	Strong	Biomarker	[1293]
MRPS30	OTDXIAGG	Strong	Genetic Variation	[3401]
MRPS7	OT57AX7G	Strong	Biomarker	[1293]
MSH4	OTJZMG1Z	Strong	Genetic Variation	[3402]
MSN	OTZJ4J6G	Strong	Altered Expression	[3403]
MSRB3	OT4UZXMN	Strong	Biomarker	[3404]
MST1	OTOC4UNG	Strong	Altered Expression	[490]
MSTO1	OT37XCNP	Strong	Altered Expression	[1186]
MSX2	OT1WDKE1	Strong	Altered Expression	[3405]
MT1B	OTUA4FFH	Strong	Biomarker	[1233]
MT1E	OTXJKU4Y	Strong	Biomarker	[1233]
MT1F	OTZVUYG1	Strong	Biomarker	[1233]
MT1H	OT0MVBM6	Strong	Biomarker	[1233]
MT3	OTVCZ7HI	Strong	Altered Expression	[3406]
MTA2	OTCCYIQJ	Strong	Biomarker	[3407]
MTA3	OTIA6C79	Strong	Biomarker	[3408]
MTFR2	OTLOR68D	Strong	Altered Expression	[3409]
MTHFD1	OTMKHVWC	Strong	Genetic Variation	[3410]
MTHFD2	OT1LQSGX	Strong	Biomarker	[3411]
MTMR3	OTBIT23O	Strong	Altered Expression	[3412]
MTPN	OT5N60RU	Strong	Altered Expression	[3413]
MTSS1	OT5DTDO2	Strong	Biomarker	[3414]
MTX1	OTLSDNZO	Strong	Biomarker	[3415]
MUC19	OTM06UGV	Strong	Altered Expression	[3416]
MUC2	OT3X4QVX	Strong	Biomarker	[3417]
MUC3A	OTI4XUDY	Strong	Biomarker	[1237]
MUC6	OTPVL723	Strong	Biomarker	[3418]
MUCL1	OT9QUFL3	Strong	Biomarker	[3419]
MUS81	OTVZ4E60	Strong	Genetic Variation	[3420]
MVP	OTJGHJRB	Strong	Biomarker	[3421]
MXI1	OTUQ9E0D	Strong	Altered Expression	[3422]
MYBBP1A	OTIVEMIU	Strong	Biomarker	[3287]
MYBL2	OTZ3JX8Q	Strong	Biomarker	[3423]
MYCBPAP	OT3W21WR	Strong	Biomarker	[2212]
MYCL	OT1MFQ5U	Strong	Genetic Variation	[1949]
MYDGF	OT9HRPL6	Strong	Biomarker	[3424]
MYEOV	OTDC7UHL	Strong	Biomarker	[3425]
MYH11	OTVNVWY3	Strong	Genetic Variation	[3426]
MYH9	OT94Z706	Strong	Altered Expression	[3427]
MYL4	OTURFCSE	Strong	Altered Expression	[2755]
MYLIP	OTL0PFGV	Strong	Genetic Variation	[3348]
MYO10	OTHB78ZQ	Strong	Biomarker	[3428]
MYO1C	OT69L39Y	Strong	Altered Expression	[3429]
MYO9B	OTQ94R5K	Strong	Genetic Variation	[743]
MYOF	OTRFC3IJ	Strong	Altered Expression	[2322]
MYT1L	OTV45MAS	Strong	Altered Expression	[3430]
MZF1	OTMVZCPW	Strong	Altered Expression	[3431]
NAA10	OTYB9R6I	Strong	Biomarker	[3432]
NAA16	OTWMA7LK	Strong	Biomarker	[1460]
NABP1	OTFTNFHW	Strong	Biomarker	[3433]
NAF1	OTMJKJAK	Strong	Biomarker	[2064]
NANOS1	OT3UNZZY	Strong	Altered Expression	[3434]
NANS	OTMQ2FUH	Strong	Biomarker	[3435]
NAV1	OT667KTL	Strong	Biomarker	[2995]
NBPF1	OTAZ55UQ	Strong	Posttranslational Modification	[3436]
NBR1	OTVRL7J9	Strong	Biomarker	[3437]
NCAM2	OT8LBJN8	Strong	Biomarker	[3438]
NCAPG2	OTZYENKO	Strong	Biomarker	[3439]
NCBP2	OTQNZTE4	Strong	Altered Expression	[2640]
NCKAP1	OTEZQXXJ	Strong	Altered Expression	[3440]
NCKIPSD	OT24UORN	Strong	Biomarker	[968]
NCOA1	OTLIUJQD	Strong	Biomarker	[3441]
NCOA5	OTOGWTWB	Strong	Biomarker	[3442]
NCOA6	OTOMIGTV	Strong	Altered Expression	[3443]
NCOA7	OT2CNBOG	Strong	Genetic Variation	[3444]
NCOR1	OT04XNOU	Strong	Biomarker	[3445]
NCOR2	OTY917X0	Strong	Genetic Variation	[3446]
NCR2	OT2H13BX	Strong	Altered Expression	[3447]
NCSTN	OT5QBTA4	Strong	Biomarker	[3448]
ND3	OT1OC3K3	Strong	Genetic Variation	[2598]
ND4	OT4RQVAA	Strong	Genetic Variation	[3449]
ND5	OT45LW1K	Strong	Genetic Variation	[3450]
NDP	OTGDJ4US	Strong	Altered Expression	[3451]
NDRG1	OTVO66BO	Strong	Biomarker	[835]
NDRG2	OT5L6KD7	Strong	Biomarker	[3452]
NDRG3	OTJTJCHD	Strong	Altered Expression	[3453]
NDUFB3	OTDV12IF	Strong	Genetic Variation	[3454]
NECAB3	OTRASC9G	Strong	Altered Expression	[2640]
NECTIN2	OTIE0W6O	Strong	Therapeutic	[3455]
NEDD4L	OT1B19RU	Strong	Altered Expression	[3456]
NEFL	OTQESJV4	Strong	Biomarker	[2182]
NEK10	OTN0JAYL	Strong	Genetic Variation	[3457]
NELFB	OTCFH88S	Strong	Biomarker	[3458]
NEMP1	OTWN3S47	Strong	Altered Expression	[3459]
NET1	OTZHNMJV	Strong	Altered Expression	[3460]
NEUROG3	OT6DIPWC	Strong	Biomarker	[3461]
NF1	OTC29NHH	Strong	Genetic Variation	[3462]
NFATC1	OT4TMERS	Strong	Altered Expression	[3463]
NFATC4	OTTDCUAO	Strong	Altered Expression	[3464]
NFE2L1	OT1QHOS2	Strong	Biomarker	[3465]
NFE2L3	OT1MGXT0	Strong	Altered Expression	[3466]
NFIB	OTX94PD0	Strong	Biomarker	[3467]
NFIC	OTLMCUIB	Strong	Biomarker	[1453]
NFYA	OTWFFOVH	Strong	Biomarker	[3468]
NHS	OTKE8QAT	Strong	Biomarker	[3469]
NIBAN2	OTVDQSPI	Strong	Biomarker	[3470]
NID1	OTKLBLS6	Strong	Biomarker	[3471]
NIN	OTVH3M4Z	Strong	Genetic Variation	[3472]
NIPBL	OTF6OOLU	Strong	Altered Expression	[3473]
NKAP	OT7K7I8Q	Strong	Altered Expression	[3474]
NKX2-1	OTCMEJTA	Strong	Altered Expression	[3475]
NLGN4X	OTDJGBK8	Strong	Altered Expression	[3476]
NMBR	OTBJEGPN	Strong	Altered Expression	[3477]
NME2	OTCYGLHV	Strong	Biomarker	[1782]
NOG	OTGRHHPG	Strong	Biomarker	[3478]
NOL3	OT1K0L0D	Strong	Biomarker	[3479]
NOL9	OTCCIJ8I	Strong	Biomarker	[3480]
NOP16	OT2829ZC	Strong	Altered Expression	[2093]
NOP9	OTA3O9QW	Strong	Biomarker	[827]
NOVA1	OT6A9KHY	Strong	Altered Expression	[3481]
NOVA2	OTQ2X3Q4	Strong	Biomarker	[3482]
NOX3	OT0FFJH8	Strong	Altered Expression	[1266]
NOX5	OTHTH59G	Strong	Biomarker	[3483]
NPAS2	OTMRT2TS	Strong	Biomarker	[310]
NPAS4	OTA3HH6W	Strong	Altered Expression	[3484]
NPC2	OTE9UEJC	Strong	Biomarker	[3485]
NPPA	OTMQNTNX	Strong	Altered Expression	[1088]
NPS	OTEG25A2	Strong	Biomarker	[3486]
NPTN	OTAQKSAU	Strong	Genetic Variation	[3487]
NR1D2	OT9CVF41	Strong	Biomarker	[310]
NR2E1	OTW47GKM	Strong	Biomarker	[783]
NR2E3	OTO3GBHQ	Strong	Biomarker	[3488]
NR2F1	OTGWZWYL	Strong	Biomarker	[3489]
NR2F2	OTJFS67N	Strong	Altered Expression	[3490]
NRBF2	OTXSUYCD	Strong	Genetic Variation	[3491]
NRCAM	OT80HHQ2	Strong	Genetic Variation	[3492]
NRDC	OTWBBCXO	Strong	Biomarker	[3493]
NRG2	OTMDE844	Strong	Altered Expression	[3494]
NRG3	OTIFZ5CT	Strong	Biomarker	[3495]
NRIP1	OTIZOJQV	Strong	Altered Expression	[3496]
NRM	OTK7F9XZ	Strong	Genetic Variation	[1990]
NSD2	OTQ6SW4R	Strong	Biomarker	[3497]
NSMCE2	OTJXLDC9	Strong	Biomarker	[3498]
NSUN2	OTZCNM33	Strong	Biomarker	[3499]
NSUN6	OTPBRUH6	Strong	Biomarker	[3500]
NT5C3A	OT67KZJA	Strong	Biomarker	[3501]
NTMT1	OTLRH78U	Strong	Biomarker	[3502]
NTN4	OTDRRMP3	Strong	Biomarker	[1464]
NTS	OTPGDNQS	Strong	Altered Expression	[1282]
NUDT1	OTZSES3W	Strong	Biomarker	[3503]
NUDT17	OTE8FOEW	Strong	Biomarker	[674]
NUDT2	OTMHM1DH	Strong	Biomarker	[3504]
NUDT5	OTHYCBA6	Strong	Biomarker	[3505]
NUMA1	OTTKAVG4	Strong	Genetic Variation	[3506]
NUP214	OTWEA19O	Strong	Biomarker	[3507]
NUP43	OTDF5K8Y	Strong	Biomarker	[3508]
NUP62	OTMN63DH	Strong	Biomarker	[2859]
NUP88	OT647WOR	Strong	Altered Expression	[3509]
NUP98	OTNT12G2	Strong	Altered Expression	[3510]
NUPR1	OT4FU8C0	Strong	Altered Expression	[3511]
NUSAP1	OT85HIJ5	Strong	Biomarker	[1081]
NXT1	OT0VO6AY	Strong	Posttranslational Modification	[1416]
OAS3	OT6E5FYS	Strong	Biomarker	[1337]
OAZ1	OTPT0PKZ	Strong	Biomarker	[3512]
OBP2A	OTBIJ5TI	Strong	Biomarker	[3264]
OCA2	OTDWIGBF	Strong	Genetic Variation	[3513]
OCLN	OTSUTVWL	Strong	Altered Expression	[3514]
OGDHL	OT1AZK6R	Strong	Genetic Variation	[3515]
OGN	OTKP5S4L	Strong	Altered Expression	[3516]
OGT	OT1Z1ZXE	Strong	Altered Expression	[3517]
OIP5	OTI5C2DE	Strong	Biomarker	[3518]
OMA1	OT0JRVY7	Strong	Altered Expression	[3519]
OPCML	OT93PQ6Y	Strong	Altered Expression	[3520]
OPN5	OTCYGHDA	Strong	Genetic Variation	[3521]
OPRPN	OT6K1ZD6	Strong	Biomarker	[3522]
OR10A4	OTYYB8SY	Strong	Genetic Variation	[3523]
OR2T6	OTJNNJ0M	Strong	Altered Expression	[3524]
ORC4	OT3ACTST	Strong	Genetic Variation	[2946]
OSCP1	OTZ4IFGJ	Strong	Altered Expression	[3525]
OSGIN1	OT9KIVZW	Strong	Biomarker	[3526]
OTUB1	OT8WWM9O	Strong	Biomarker	[3527]
OTUD1	OTE6O5XB	Strong	Biomarker	[3528]
OTUD3	OTHUWQHP	Strong	Genetic Variation	[3529]
OTUD4	OT7U62SW	Strong	Biomarker	[3530]
OTX1	OTRGSGH9	Strong	Altered Expression	[3531]
OTX2	OTTV05B1	Strong	Altered Expression	[3532]
P2RX5	OTLBR20R	Strong	Biomarker	[3533]
P4HB	OTTYNYPF	Strong	Biomarker	[2043]
PADI2	OTT40K94	Strong	Altered Expression	[3534]
PAF1	OTDDGUBQ	Strong	Genetic Variation	[3535]
PAGR1	OTXR5PQ8	Strong	Biomarker	[3536]
PAICS	OTMZN747	Strong	Biomarker	[3537]
PAIP1	OTL2F5T5	Strong	Altered Expression	[3538]
PAK6	OTAHPZTT	Strong	Altered Expression	[3539]
PALD1	OTLGUM8H	Strong	Biomarker	[3540]
PALLD	OTZ2MUJZ	Strong	Biomarker	[3540]
PAMR1	OT83ZH5U	Strong	Posttranslational Modification	[3541]
PANX1	OTXPEDOK	Strong	Altered Expression	[3542]
PAPOLG	OTIV69YA	Strong	Biomarker	[3543]
PAPPA	OTTTG9PG	Strong	Biomarker	[3544]
PARD3	OTH5BPLO	Strong	Altered Expression	[943]
PARN	OTTG4PE3	Strong	Altered Expression	[430]
PARP6	OTWSXW4O	Strong	Biomarker	[3545]
PARP9	OT7K4494	Strong	Biomarker	[3546]
PARVB	OT9OGVWX	Strong	Biomarker	[3547]
PAX2	OTKP1N8F	Strong	Biomarker	[3548]
PAX8	OTRPD9MI	Strong	Biomarker	[3549]
PAX9	OT25J0F7	Strong	Genetic Variation	[2730]
PAXIP1	OTRHTKG3	Strong	Altered Expression	[3550]
PBOV1	OT67PERT	Strong	Altered Expression	[3551]
PBX1	OTORABGO	Strong	Biomarker	[3552]
PBXIP1	OTEAAUBY	Strong	Biomarker	[3553]
PCARE	OTUSRSB5	Strong	Biomarker	[3554]
PCBP1	OTHN0TD7	Strong	Altered Expression	[2713]
PCBP4	OTDLL4NB	Strong	Biomarker	[917]
PCDH10	OT2GIT0E	Strong	Posttranslational Modification	[3555]
PCDH17	OTRK0M05	Strong	Altered Expression	[3556]
PCDH7	OTP091X8	Strong	Altered Expression	[3557]
PCDH8	OTDDOQM2	Strong	Biomarker	[3558]
PCDHGB6	OT1Y20JS	Strong	Biomarker	[3173]
PCGF2	OTIY1J5L	Strong	Biomarker	[3559]
PCNT	OTW4Z65J	Strong	Biomarker	[3560]
PDCD10	OTCHJTSF	Strong	Biomarker	[3561]
PDCD4	OTZ6NXUX	Strong	Biomarker	[1446]
PDCD6	OT2YA5M8	Strong	Altered Expression	[3562]
PDCD6IP	OTS8T6A7	Strong	Biomarker	[3563]
PDHB	OT2NHE5E	Strong	Biomarker	[1146]
PDHX	OTG7O271	Strong	Biomarker	[3564]
PDIA3	OTHPQ0Q3	Strong	Altered Expression	[3565]
PDIA6	OT8YBR17	Strong	Altered Expression	[3566]
PDIK1L	OTISF4KG	Strong	Biomarker	[3567]
PDK4	OTCMHMBZ	Strong	Biomarker	[3568]
PDLIM3	OTVXQC81	Strong	Biomarker	[700]
PDLIM5	OTLQVV22	Strong	Altered Expression	[1158]
PDPN	OTBUV19I	Strong	Altered Expression	[3569]
PDS5A	OT34P56Z	Strong	Biomarker	[3570]
PEAK1	OTVVM637	Strong	Biomarker	[538]
PEG10	OTWD2278	Strong	Biomarker	[3571]
PEG3	OTHQW98S	Strong	Biomarker	[3572]
PER2	OTU2B1DJ	Strong	Biomarker	[3573]
PER3	OTVKYVJA	Strong	Biomarker	[310]
PERP	OTP0YL53	Strong	Altered Expression	[2666]
PES1	OTMZK7XE	Strong	Altered Expression	[3574]
PEX14	OT98BZHE	Strong	Genetic Variation	[3575]
PFDN4	OT5NRHER	Strong	Altered Expression	[3576]
PFKFB4	OTQYEXL2	Strong	Biomarker	[3577]
PFKM	OT1QY9JM	Strong	Genetic Variation	[3578]
PFKP	OTFP7AA8	Strong	Altered Expression	[3579]
PFN1	OTHTGA1H	Strong	Biomarker	[3580]
PFN2	OT5SSSA7	Strong	Biomarker	[3581]
PGAM1	OTZ5DB06	Strong	Biomarker	[3582]
PGAP3	OTH9A75E	Strong	Biomarker	[1338]
PGK1	OT6V1ICH	Strong	Altered Expression	[3583]
PHB2	OTCAX3AW	Strong	Biomarker	[1800]
PHF2	OTJCIQR2	Strong	Biomarker	[3584]
PHF20	OTCBVH5P	Strong	Biomarker	[3378]
PHF20L1	OTCLYOCL	Strong	Biomarker	[3585]
PHF5A	OTS94JFM	Strong	Biomarker	[3586]
PHLDA1	OTFTWMIQ	Strong	Biomarker	[3587]
PHLDA3	OTXFUDO2	Strong	Altered Expression	[3588]
PHLDB1	OTIRCB6I	Strong	Biomarker	[2996]
PHPT1	OTFYWNFX	Strong	Biomarker	[3589]
PHRF1	OT21KEGX	Strong	Biomarker	[3590]
PI3	OT47MTC3	Strong	Altered Expression	[3591]
PIAS1	OTZVAHZI	Strong	Biomarker	[3592]
PIEZO1	OTBG1FU4	Strong	Biomarker	[3593]
PIEZO2	OTQ7AT38	Strong	Altered Expression	[3594]
PIGT	OTWA8819	Strong	Biomarker	[3595]
PIGX	OTUN0WC4	Strong	Biomarker	[3596]
PIK3C2A	OTFBU4GD	Strong	Biomarker	[3597]
PIK3C2B	OTY2PROB	Strong	Biomarker	[3598]
PIK3C3	OTLUM9L7	Strong	Biomarker	[3599]
PIK3IP1	OTWE5G4T	Strong	Biomarker	[3600]
PIK3R1	OT5BZ1J9	Strong	Biomarker	[764]
PIK3R2	OTZSUQK5	Strong	Biomarker	[3601]
PIK3R3	OTXGJ8N1	Strong	Altered Expression	[3602]
PIMREG	OTKC8T3E	Strong	Biomarker	[3603]
PIP4K2C	OTHRWR93	Strong	Biomarker	[425]
PIP5K1C	OT3LPG1R	Strong	Biomarker	[3604]
PITPNM1	OTIUYAG5	Strong	Biomarker	[3605]
PITPNM3	OTHLZY8D	Strong	Biomarker	[3606]
PITX1	OTA0UN4C	Strong	Altered Expression	[3607]
PKD1	OT5ALRZ5	Strong	Altered Expression	[920]
PKD2	OTIXBU8H	Strong	Biomarker	[920]
PKIB	OT7C8GFN	Strong	Biomarker	[3608]
PLAAT3	OTVXXJ5K	Strong	Biomarker	[3609]
PLAGL1	OTZAO900	Strong	Altered Expression	[3610]
PLAGL2	OT6AP4V2	Strong	Biomarker	[3611]
PLB1	OTZ6TTYV	Strong	Biomarker	[1325]
PLCB4	OTPA0QHW	Strong	Biomarker	[2485]
PLCD1	OT6WFVXZ	Strong	Altered Expression	[3612]
PLCD4	OT14EZVB	Strong	Altered Expression	[3613]
PLEKHB1	OTC7TNAX	Strong	Biomarker	[3614]
PLEKHD1	OTGYUZKM	Strong	Biomarker	[674]
PLEKHG6	OTZWA27A	Strong	Biomarker	[3615]
PLIN2	OTRXJ9UN	Strong	Biomarker	[3616]
PLK3	OT19CT2Z	Strong	Altered Expression	[3617]
PLPP5	OTHT51D6	Strong	Biomarker	[3618]
PLPPR5	OTVL01TR	Strong	Biomarker	[3543]
PLVAP	OTAQGWYA	Strong	Genetic Variation	[743]
PLXNA1	OTN0BING	Strong	Biomarker	[1836]
PLXNA3	OTMZIBVG	Strong	Biomarker	[3619]
PLXNB1	OTCA7JIT	Strong	Biomarker	[3620]
PMAIP1	OTXEE550	Strong	Altered Expression	[3621]
PMEPA1	OTY8Z9UF	Strong	Biomarker	[3622]
PNCK	OT35ZL74	Strong	Altered Expression	[3623]
PNKD	OT6G9UXN	Strong	Altered Expression	[3624]
PNO1	OT010GIS	Strong	Biomarker	[3336]
PODXL	OTPNQXF3	Strong	Altered Expression	[3625]
POFUT1	OTOBJZIT	Strong	Altered Expression	[3626]
POLDIP2	OT8SZSJ6	Strong	Altered Expression	[370]
POLE	OTFM3MMU	Strong	Genetic Variation	[3627]
POLI	OTBA4DCE	Strong	Biomarker	[3628]
POLK	OTKZ38JH	Strong	Genetic Variation	[1528]
POLL	OTZ24QGM	Strong	Genetic Variation	[1528]
POLQ	OTBHK0E6	Strong	Altered Expression	[3629]
POMP	OTMPM1P5	Strong	Altered Expression	[3630]
POT1	OTNBXJCQ	Strong	Posttranslational Modification	[3631]
POTED	OTAUSTUK	Strong	Altered Expression	[3632]
POTEF	OTV3WXYE	Strong	Altered Expression	[3633]
POTEM	OT7L2HGH	Strong	Genetic Variation	[651]
POU1F1	OTXT8A5C	Strong	Biomarker	[1677]
POU2F1	OTK7ELJ0	Strong	Biomarker	[1453]
POU2F3	OTIOOJWD	Strong	Biomarker	[3634]
POU5F1	OTDHHN7O	Strong	Biomarker	[3635]
POU5F1B	OT0FKQ51	Strong	Genetic Variation	[2730]
PPA1	OTHZK1QB	Strong	Biomarker	[3636]
PPARGC1A	OTHCDQ22	Strong	Biomarker	[3637]
PPFIA1	OTYYFA9C	Strong	Altered Expression	[3638]
PPIG	OTZ8BTTM	Strong	Genetic Variation	[3639]
PPIL2	OTL9Y4IO	Strong	Altered Expression	[3640]
PPM1E	OTXRH3YA	Strong	Posttranslational Modification	[3641]
PPP1R12B	OTONIS87	Strong	Biomarker	[3642]
PPP1R13B	OTC88VQO	Strong	Biomarker	[2063]
PPP1R14C	OTZ3F6D2	Strong	Altered Expression	[3643]
PPP1R1B	OTSIJMQ9	Strong	Altered Expression	[3644]
PPP1R2	OTNLOUQR	Strong	Altered Expression	[3645]
PPP1R26	OTAKR0DQ	Strong	Altered Expression	[3646]
PPP1R3B	OTVCRXEZ	Strong	Biomarker	[3647]
PPP1R3C	OTEU05TX	Strong	Biomarker	[3647]
PPP1R8	OTH5KB2P	Strong	Altered Expression	[3432]
PPP1R9B	OTDCTHTT	Strong	Altered Expression	[3648]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[3649]
PPP2R1B	OTFIHQGD	Strong	Genetic Variation	[3650]
PPP2R2B	OTSFVC82	Strong	Biomarker	[2068]
PPP2R5E	OT8GPFT5	Strong	Biomarker	[3649]
PPP3R1	OTGQNFJQ	Strong	Biomarker	[3651]
PRAC2	OT56IBFQ	Strong	Biomarker	[2141]
PRAP1	OT48QD82	Strong	Biomarker	[497]
PRB2	OTAD4JZ0	Strong	Altered Expression	[3652]
PRC1	OTHD0XS0	Strong	Altered Expression	[3653]
PRDM1	OTQLSVBS	Strong	Biomarker	[3654]
PRDX1	OTZ3BEC4	Strong	Biomarker	[3655]
PRDX2	OTLWCY9T	Strong	Biomarker	[3656]
PRDX3	OTLB2WEU	Strong	Biomarker	[3657]
PRDX6	OTS8KC8A	Strong	Biomarker	[3658]
PRICKLE4	OT19NLJR	Strong	Altered Expression	[3659]
PRIM2	OTGT0KTF	Strong	Altered Expression	[1126]
PRKAA1	OT7TNF0L	Strong	Altered Expression	[3660]
PRKAA2	OTU1KZPV	Strong	Altered Expression	[3660]
PRKAB1	OT1OG4QZ	Strong	Altered Expression	[3660]
PRKAG3	OTS1A2VE	Strong	Genetic Variation	[3661]
PRKD2	OTIFSVI8	Strong	Altered Expression	[3662]
PRKD3	OT987HJI	Strong	Altered Expression	[3662]
PRKRA	OTUTVZZU	Strong	Biomarker	[3663]
PRLH	OTJBP360	Strong	Biomarker	[3664]
PRMT6	OT5V3XIN	Strong	Biomarker	[3665]
PROCR	OTRHED17	Strong	Biomarker	[3666]
PROK2	OT70IFEZ	Strong	Biomarker	[3667]
PROX1	OT68R6IO	Strong	Altered Expression	[3668]
PRPF3	OTUA4OLZ	Strong	Genetic Variation	[3669]
PRPF31	OTSJ0Z1Y	Strong	Biomarker	[3670]
PRPF8	OTU39JZI	Strong	Biomarker	[462]
PRPS1	OTN3A6CN	Strong	Biomarker	[3671]
PRR11	OT2JJ08Z	Strong	Altered Expression	[3672]
PRR5	OTYHSGJL	Strong	Biomarker	[3673]
PRR5L	OTQ1Z0OU	Strong	Genetic Variation	[2727]
PRRT1	OTN0YIS3	Strong	Biomarker	[3674]
PRRT2	OTCJUBDO	Strong	Altered Expression	[765]
PRRX1	OTTZK5G8	Strong	Genetic Variation	[3675]
PRSS3	OTN3S5YB	Strong	Biomarker	[3676]
PRSS50	OTC5JAVO	Strong	Altered Expression	[3677]
PRUNE1	OTQ3UHWQ	Strong	Biomarker	[3678]
PSAP	OTUOEKY7	Strong	Biomarker	[3679]
PSG2	OT2EIXAI	Strong	Biomarker	[803]
PSMB4	OTOJ9OHA	Strong	Biomarker	[3680]
PSMC3IP	OT9UB5UO	Strong	Biomarker	[2401]
PSMD1	OTW258OV	Strong	Biomarker	[3681]
PSMD14	OTJWHMZ5	Strong	Altered Expression	[3682]
PSMD2	OT6HZHN7	Strong	Biomarker	[3683]
PSMD3	OT585WY8	Strong	Biomarker	[3684]
PSMD4	OTH1VZTM	Strong	Biomarker	[3685]
PSMD7	OT7PZZ4K	Strong	Altered Expression	[1148]
PSMD8	OTY6X27P	Strong	Altered Expression	[2454]
PSME3	OTSTC4YY	Strong	Altered Expression	[3686]
PSMG1	OTZ5I6UM	Strong	Altered Expression	[660]
PSORS1C2	OTK43GE4	Strong	Altered Expression	[3687]
PTBP2	OTF4S7NE	Strong	Biomarker	[1365]
PTGES3	OTPPQWI0	Strong	Biomarker	[799]
PTMA	OT2W4T1M	Strong	Altered Expression	[3688]
PTOV1	OT94WT5X	Strong	Biomarker	[3689]
PTPA	OTRGFOI7	Strong	Biomarker	[435]
PTPN22	OTDCNTC3	Strong	Biomarker	[3690]
PTPN3	OTSLZBVY	Strong	Posttranslational Modification	[3691]
PTPN5	OT2H1KDK	Strong	Biomarker	[3692]
PTPN9	OTNAR1I2	Strong	Biomarker	[3693]
PTPRD	OTZPJ3GX	Strong	Biomarker	[3694]
PTPRF	OTH5KF2D	Strong	Genetic Variation	[3695]
PTPRG	OT9N2WOF	Strong	Genetic Variation	[3696]
PTPRN2	OTL6SH28	Strong	Biomarker	[3697]
PTPRU	OTHDO0QG	Strong	Biomarker	[1679]
PTRH2	OTBU39Q1	Strong	Biomarker	[3698]
PTTG1	OTIMYS4W	Strong	Biomarker	[3699]
PTTG1IP	OTX21QTE	Strong	Genetic Variation	[3700]
PVR	OT3N91T7	Strong	Altered Expression	[3701]
PXDNL	OT52SSS5	Strong	Biomarker	[3702]
PXN	OTVMMUOF	Strong	Altered Expression	[3703]
PYCARD	OT67RON3	Strong	Biomarker	[3704]
PYGO2	OTZHB2OI	Strong	Biomarker	[3705]
PYHIN1	OT30GD05	Strong	Biomarker	[3706]
QRSL1	OTJDU2UG	Strong	Biomarker	[3707]
QTRT1	OTC33MCV	Strong	Biomarker	[3708]
RAB11A	OTC4FW0J	Strong	Biomarker	[3709]
RAB11FIP1	OT0T71OW	Strong	Altered Expression	[3710]
RAB11FIP3	OTDFFCZA	Strong	Altered Expression	[1905]
RAB1A	OTKPHRD0	Strong	Biomarker	[3711]
RAB25	OTW0W6NP	Strong	Biomarker	[3712]
RAB27A	OT9SQRWY	Strong	Biomarker	[3713]
RAB27B	OTPF9D0K	Strong	Altered Expression	[3714]
RAB34	OTHKTSA0	Strong	Biomarker	[3715]
RAB3A	OT2GIUO5	Strong	Altered Expression	[3716]
RAB3D	OTGKRR3C	Strong	Biomarker	[3717]
RAB5A	OTFR2KM4	Strong	Biomarker	[3718]
RAB5B	OT06PN42	Strong	Biomarker	[3719]
RAB6B	OT5N57RK	Strong	Altered Expression	[3720]
RAB6C	OTA66R5E	Strong	Posttranslational Modification	[3721]
RABEPK	OTCZSREH	Strong	Altered Expression	[1148]
RABGEF1	OTWC3Z3R	Strong	Biomarker	[3722]
RABL6	OTJLVIQ1	Strong	Altered Expression	[3723]
RACGAP1	OTQE8IEH	Strong	Biomarker	[3724]
RAD17	OT1I93DT	Strong	Biomarker	[3725]
RAD23B	OT0PGOG3	Strong	Genetic Variation	[3726]
RAD54B	OTMWB2P2	Strong	Biomarker	[3727]
RAD9A	OTJ3AJQU	Strong	Altered Expression	[1963]
RAE1	OT54OKC3	Strong	Biomarker	[3728]
RAI14	OT6USGBK	Strong	Biomarker	[3729]
RALGAPB	OTY8CGA3	Strong	Altered Expression	[2466]
RALY	OT78NNWY	Strong	Genetic Variation	[3730]
RALYL	OT232N7Q	Strong	Biomarker	[1293]
RAN	OT2TER5M	Strong	Biomarker	[3731]
RAP1A	OT5RH6TI	Strong	Biomarker	[3722]
RAP1B	OTHEIIMM	Strong	Altered Expression	[3720]
RAP1GDS1	OTH70UHD	Strong	Biomarker	[3732]
RAP2A	OT0JB5S4	Strong	Biomarker	[3733]
RAP2B	OTD2NDQP	Strong	Altered Expression	[3720]
RAPGEF6	OTR1QQA3	Strong	Biomarker	[3734]
RAPH1	OTMQXW7S	Strong	Biomarker	[3735]
RAPSN	OTGMSWDQ	Strong	Biomarker	[2421]
RARRES1	OTETUPP5	Strong	Altered Expression	[3736]
RASA2	OTL06RG2	Strong	Biomarker	[3737]
RASAL2	OTGMMX6W	Strong	Biomarker	[3738]
RASGRP1	OTX9WN2E	Strong	Biomarker	[3739]
RASGRP2	OTABVLVQ	Strong	Altered Expression	[2359]
RASSF3	OT4V9SRK	Strong	Altered Expression	[3740]
RASSF6	OT25GVWY	Strong	Biomarker	[3741]
RASSF8	OTXKGIB3	Strong	Altered Expression	[3742]
RASSF9	OTCY4KST	Strong	Altered Expression	[3743]
RB1CC1	OTZK8PFX	Strong	Biomarker	[3744]
RBBP6	OTTVG4HU	Strong	Biomarker	[3663]
RBBP7	OTLB56HX	Strong	Altered Expression	[3745]
RBL1	OTDEBFYC	Strong	Posttranslational Modification	[3746]
RBM14	OTO9GMBD	Strong	Biomarker	[2665]
RBM3	OTAJ7R31	Strong	Biomarker	[2576]
RBM38	OTPO8EXU	Strong	Biomarker	[3172]
RBM39	OTCMPTF9	Strong	Altered Expression	[2599]
RBM4	OT5SFQA3	Strong	Biomarker	[3747]
RBM5	OTCBWHHV	Strong	Altered Expression	[3748]
RBMS2	OTTX6071	Strong	Biomarker	[3749]
RBMY1A1	OTM2F25H	Strong	Biomarker	[3750]
RBP1	OTRP1MFC	Strong	Altered Expression	[3751]
RCC1	OT25AGMB	Strong	Biomarker	[3752]
RCC2	OTUJVTLS	Strong	Biomarker	[3753]
RCCD1	OT60N06L	Strong	Biomarker	[674]
RDM1	OTBSJEAG	Strong	Biomarker	[3754]
REG1A	OTMHUH1D	Strong	Biomarker	[1679]
RELA	OTUJP9CN	Strong	Biomarker	[1605]
RELB	OTU3QYEF	Strong	Biomarker	[3755]
RELN	OTLKMW1O	Strong	Altered Expression	[3756]
REM1	OTUXL0HC	Strong	Biomarker	[3757]
REPIN1	OTVTPXNX	Strong	Biomarker	[3758]
REPS2	OTSE3TRP	Strong	Biomarker	[3759]
REST	OTLL92LQ	Strong	Biomarker	[3760]
RETN	OTW5Z1NH	Strong	Altered Expression	[3761]
REXO4	OT2NNFKZ	Strong	Altered Expression	[3762]
RFC2	OTJ9N6BD	Strong	Biomarker	[3763]
RGMB	OT2DROYU	Strong	Biomarker	[3764]
RGN	OTD04KB1	Strong	Biomarker	[3765]
RGS17	OT5RVUDS	Strong	Biomarker	[3766]
RGS20	OT6CGYHW	Strong	Altered Expression	[3767]
RGS3	OTYG5OXI	Strong	Altered Expression	[3768]
RGSL1	OTNNYLGW	Strong	Genetic Variation	[1392]
RHBDD1	OTL5J132	Strong	Biomarker	[3769]
RHEB	OTFLTSEC	Strong	Altered Expression	[3770]
RHNO1	OTYKRRGE	Strong	Genetic Variation	[3771]
RHOBTB1	OTGE8K45	Strong	Altered Expression	[3772]
RHOBTB2	OT2DATFX	Strong	Biomarker	[3773]
RHOD	OTALMEIN	Strong	Biomarker	[3774]
RHOJ	OTWI65OA	Strong	Biomarker	[3775]
RHOQ	OTUBTU57	Strong	Biomarker	[3776]
RHPN1	OTYZ1NV8	Strong	Biomarker	[3777]
RIBC2	OTDB4FM2	Strong	Biomarker	[1293]
RIN2	OTCY73U9	Strong	Biomarker	[1595]
RIOK1	OT1OS3H3	Strong	Altered Expression	[3778]
RIOX1	OTN41QXP	Strong	Genetic Variation	[3779]
RIOX2	OT2YFPI2	Strong	Genetic Variation	[3779]
RMC1	OT7K8MTJ	Strong	Altered Expression	[3780]
RMDN1	OTE1NB6U	Strong	Altered Expression	[3781]
RMDN2	OTK5WSFI	Strong	Altered Expression	[3781]
RMND1	OT7I6RBT	Strong	Biomarker	[674]
RNASE3	OTVE2XD1	Strong	Biomarker	[3782]
RNASEH1	OTT7L25X	Strong	Altered Expression	[3783]
RNASEH2C	OTJL9ZRN	Strong	Biomarker	[3784]
RNF11	OTFBJSKQ	Strong	Altered Expression	[3785]
RNF115	OT35B6L5	Strong	Biomarker	[3786]
RNF126	OTTECSYY	Strong	Biomarker	[3787]
RNF169	OTLS6875	Strong	Altered Expression	[3788]
RNF182	OT08FLHZ	Strong	Biomarker	[827]
RNF19A	OTKWCV80	Strong	Altered Expression	[370]
RNF2	OTFPLOIN	Strong	Biomarker	[3653]
RNF20	OT9NK6ZT	Strong	Biomarker	[3789]
RNF31	OT4BZONL	Strong	Biomarker	[3790]
RNF5	OTDQGI37	Strong	Biomarker	[3791]
RNH1	OT6EC79B	Strong	Genetic Variation	[3079]
RO60	OTLGM5A8	Strong	Altered Expression	[3792]
RPA2	OTZ54WAF	Strong	Altered Expression	[3793]
RPAIN	OTBMXAYK	Strong	Biomarker	[2854]
RPH3AL	OT9VFJEL	Strong	Genetic Variation	[3794]
RPL10	OTBHOZGC	Strong	Biomarker	[1836]
RPL13	OTFKNTD6	Strong	Biomarker	[3795]
RPL17	OTTYMPS6	Strong	Altered Expression	[3796]
RPL23	OTXI1YLM	Strong	Altered Expression	[3796]
RPL23A	OTPYLCCX	Strong	Biomarker	[1293]
RPL24	OTCY9DEB	Strong	Altered Expression	[3797]
RPL29	OTUFIBJL	Strong	Genetic Variation	[1385]
RPL31	OTV9E1OE	Strong	Biomarker	[1293]
RPL36A	OT1LYV85	Strong	Altered Expression	[2979]
RPL39	OTL8TZHQ	Strong	Genetic Variation	[3798]
RPL7A	OT6E6UKF	Strong	Altered Expression	[3799]
RPLP2	OT2YBK3W	Strong	Biomarker	[674]
RPN2	OTJ1SKOA	Strong	Biomarker	[3800]
RPRD1A	OTXTV6FU	Strong	Altered Expression	[3801]
RPRD1B	OTB41D5K	Strong	Biomarker	[3802]
RPS14	OTB90KV5	Strong	Altered Expression	[2454]
RPS15A	OT0BUA12	Strong	Altered Expression	[1196]
RPS16	OTVGZOB5	Strong	Altered Expression	[3803]
RPS19	OTBKGP48	Strong	Biomarker	[737]
RPS27A	OTIIGGZ2	Strong	Altered Expression	[3804]
RPS27L	OTZWHU0N	Strong	Biomarker	[3805]
RPS4X	OTIH80EK	Strong	Altered Expression	[1322]
RPS6KA4	OTTK8MUO	Strong	Biomarker	[3806]
RPS7	OTIK25WI	Strong	Biomarker	[1293]
RPS8	OTEBS4HZ	Strong	Biomarker	[1293]
RPS9	OTPV69Q0	Strong	Biomarker	[3807]
RRAD	OTW2O4GD	Strong	Biomarker	[3808]
RRAS	OTBBF28C	Strong	Biomarker	[2970]
RRAS2	OT83NCEB	Strong	Genetic Variation	[3809]
RRM2B	OTE8GBUR	Strong	Genetic Variation	[1345]
RRN3	OTKGOZ49	Strong	Altered Expression	[3810]
RRP1B	OTHDRVML	Strong	Genetic Variation	[3488]
RSPO2	OT3HHXU0	Strong	Altered Expression	[456]
RSPO4	OTFX5N3G	Strong	Altered Expression	[456]
RTCB	OTUED31V	Strong	Altered Expression	[3811]
RTKN	OTSS8XR6	Strong	Biomarker	[3812]
RTL1	OTOT33IM	Strong	Biomarker	[1220]
RTL10	OTHGB81W	Strong	Biomarker	[3813]
RTRAF	OTJ6NVMW	Strong	Biomarker	[1896]
RUVBL1	OTWV19L7	Strong	Altered Expression	[3236]
RUVBL2	OTGWJ4T4	Strong	Biomarker	[3814]
RYBP	OTZZ4P2Z	Strong	Altered Expression	[3815]
RYR3	OT4EHIP4	Strong	Genetic Variation	[3816]
S100A1	OT1F2G4J	Strong	Biomarker	[3817]
S100A10	OTI71243	Strong	Altered Expression	[3818]
S100A11	OTI57KDN	Strong	Altered Expression	[3819]
S100A14	OTVFJJ91	Strong	Altered Expression	[3820]
S100A2	OTTGHJ1H	Strong	Biomarker	[3821]
S100A7A	OTNM8DCP	Strong	Biomarker	[3822]
SACM1L	OT6ORKTD	Strong	Altered Expression	[3823]
SAE1	OT18HFX5	Strong	Biomarker	[3824]
SAFB	OTGRV2LW	Strong	Biomarker	[3825]
SAFB2	OTQ1IH80	Strong	Biomarker	[3826]
SAGE1	OT4H6FFA	Strong	Biomarker	[3827]
SALL1	OTYYZGLH	Strong	Biomarker	[3828]
SALL2	OTQWI68Q	Strong	Biomarker	[3829]
SARDH	OTQ49Q27	Strong	Biomarker	[3830]
SART1	OTHMOGO1	Strong	Genetic Variation	[3831]
SART3	OTC1AM7S	Strong	Biomarker	[1337]
SAT2	OT28QL7H	Strong	Genetic Variation	[3832]
SATB2	OT2W80XC	Strong	Biomarker	[3833]
SCAF1	OT16TM3N	Strong	Biomarker	[3834]
SCAF11	OTX59D0X	Strong	Biomarker	[3083]
SCAMP1	OTFS4IKJ	Strong	Biomarker	[3414]
SCARA3	OT46I38Y	Strong	Altered Expression	[3835]
SCARA5	OTOVA96E	Strong	Altered Expression	[3836]
SCD5	OTSSUQ3Z	Strong	Biomarker	[1419]
SCGB2A1	OT9L87U9	Strong	Altered Expression	[3837]
SCGB3A1	OTIR98RB	Strong	Genetic Variation	[3838]
SCIN	OT6U09OL	Strong	Altered Expression	[3839]
SCN4B	OT3JSUWO	Strong	Altered Expression	[3840]
SCO2	OTJQQDRS	Strong	Altered Expression	[1582]
SCP2	OTPAFCPQ	Strong	Biomarker	[3841]
SCPEP1	OT43LYEZ	Strong	Genetic Variation	[3842]
SDC4	OTKUVUGZ	Strong	Biomarker	[3843]
SDF2	OTSLRFRF	Strong	Altered Expression	[3844]
SDHA	OTOJ8QFF	Strong	Altered Expression	[3845]
SDHAF2	OT0UG9H5	Strong	Biomarker	[3846]
SDHB	OTRE1M1T	Strong	Biomarker	[3847]
SDS	OT5WTJ2M	Strong	Biomarker	[1488]
SEC14L1	OTA75FET	Strong	Altered Expression	[3848]
SEC16A	OTFNQ1ZU	Strong	Biomarker	[3849]
SEC16B	OT244C1N	Strong	Genetic Variation	[3850]
SEL1L	OTC0FB7T	Strong	Biomarker	[3851]
SELENOP	OT02B8IR	Strong	Biomarker	[1760]
SELENOW	OTVSKPAN	Strong	Altered Expression	[3852]
SEM1	OTASLBM1	Strong	Biomarker	[3853]
SEMA3B	OTCZCPMS	Strong	Biomarker	[1158]
SEMA3C	OTEGUY7F	Strong	Biomarker	[3854]
SEMA3F	OTQFMS8S	Strong	Altered Expression	[3855]
SEMA4C	OTF5JHQ0	Strong	Altered Expression	[3856]
SEMA4F	OTVP97ZV	Strong	Biomarker	[3619]
SEMA6A	OTDQ7QAW	Strong	Biomarker	[3857]
SEMA7A	OT0ZJK64	Strong	Biomarker	[3858]
SEPHS2	OTTFXROR	Strong	Biomarker	[3859]
SEPTIN2	OT3G33TM	Strong	Altered Expression	[1428]
SEPTIN7	OTJI08YX	Strong	Biomarker	[3860]
SEPTIN9	OT1VMRFQ	Strong	Biomarker	[3861]
SERPINA3	OT9BP2S0	Strong	Genetic Variation	[651]
SERPINA5	OTTZXPGD	Strong	Genetic Variation	[3862]
SERPINB6	OT7G55IK	Strong	Biomarker	[1162]
SERPINE2	OTYF5340	Strong	Biomarker	[3863]
SERTAD1	OTBHKZQP	Strong	Biomarker	[2697]
SESN2	OT889IXY	Strong	Altered Expression	[740]
SETBP1	OTKGCOSR	Strong	Biomarker	[1317]
SETD4	OTBMCZQA	Strong	Biomarker	[3864]
SETD6	OTH5APN1	Strong	Posttranslational Modification	[3865]
SETD9	OT4961W1	Strong	Genetic Variation	[3866]
SF3B3	OTAC9LZT	Strong	Biomarker	[2648]
SFN	OTLJCZ1U	Strong	Biomarker	[1121]
SFRP1	OT0U9G41	Strong	Altered Expression	[3801]
SFRP5	OTLCVVSH	Strong	Biomarker	[3867]
SFXN1	OTL66767	Strong	Genetic Variation	[3868]
SGK3	OTQ6QO99	Strong	Biomarker	[3869]
SGSM3	OTIB1P8A	Strong	Biomarker	[3870]
SH2D1A	OTLU49I5	Strong	Biomarker	[688]
SH2D3C	OTAGXO0N	Strong	Altered Expression	[3142]
SH3BP4	OTVIRKW7	Strong	Biomarker	[3871]
SH3GL2	OTOE443G	Strong	Altered Expression	[3872]
SH3GLB1	OTAZ5OP8	Strong	Biomarker	[3873]
SH3KBP1	OTIUA60B	Strong	Biomarker	[3874]
SHC2	OTTWMRNQ	Strong	Biomarker	[540]
SHC3	OT305NPA	Strong	Genetic Variation	[3079]
SHLD1	OTPKJQ0D	Strong	Altered Expression	[3875]
SHOC1	OTP51XIP	Strong	Altered Expression	[1695]
SHOX2	OTLCZZJW	Strong	Biomarker	[3876]
SHROOM4	OT33GO6E	Strong	Genetic Variation	[743]
SIAH1	OT29A838	Strong	Altered Expression	[3877]
SIAH2	OTKED2XN	Strong	Altered Expression	[3878]
SIGIRR	OTNC3XFD	Strong	Altered Expression	[3879]
SIGLEC7	OTNDLURR	Strong	Altered Expression	[1088]
SIM1	OTYKFPKZ	Strong	Biomarker	[2687]
SIM2	OT0QWHK4	Strong	Biomarker	[3880]
SIX1	OT70YYWM	Strong	Biomarker	[3881]
SIX2	OTYOVGSC	Strong	Altered Expression	[3882]
SIX6	OTD1RD9D	Strong	Biomarker	[3883]
SKA2	OTVYF4XT	Strong	Altered Expression	[3672]
SKI	OT4KJ8F6	Strong	Biomarker	[3884]
SLAMF1	OTBTT3ZQ	Strong	Genetic Variation	[2760]
SLBP	OTVYYQRT	Strong	Altered Expression	[2606]
SLC22A18	OT9C3KR4	Strong	Biomarker	[3885]
SLC25A43	OTY6MWVD	Strong	Biomarker	[3886]
SLFN11	OTJWFPMY	Strong	Biomarker	[3887]
SLIT3	OTU8MKEU	Strong	Posttranslational Modification	[3888]
SLN	OTERIU75	Strong	Biomarker	[3889]
SLURP1	OT89YD2E	Strong	Genetic Variation	[536]
SMAD2	OTC6VB4K	Strong	Altered Expression	[3890]
SMAD5	OTQNSVCQ	Strong	Biomarker	[3891]
SMARCE1	OTAX4ITH	Strong	Biomarker	[3892]
SMC6	OT3IBHQD	Strong	Biomarker	[2712]
SMIM22	OTTX8AH1	Strong	Biomarker	[1497]
SMPD3	OTHQBETH	Strong	Altered Expression	[1483]
SMS	OT8JYKNH	Strong	Biomarker	[2018]
SMUG1	OT2YIOCQ	Strong	Biomarker	[3893]
SMURF2	OT3TRVL7	Strong	Biomarker	[3894]
SMYD4	OTT349CJ	Strong	Altered Expression	[3895]
SMYD5	OTE5VET6	Strong	Biomarker	[3896]
SNAI1	OTDPYAMC	Strong	Biomarker	[3897]
SNAI2	OT7Y8EJ2	Strong	Biomarker	[3898]
SNAPC1	OTAPN1NI	Strong	Biomarker	[3899]
SNCB	OTELSEK6	Strong	Biomarker	[3900]
SNRPN	OTQB1ID1	Strong	Posttranslational Modification	[3901]
SNTA1	OTUICTGZ	Strong	Altered Expression	[3902]
SNX27	OTVPS7S0	Strong	Biomarker	[1224]
SNX32	OTIXXIHF	Strong	Biomarker	[674]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[3903]
SOCS2	OTBPNKJQ	Strong	Biomarker	[3904]
SOCS5	OTN1ABYR	Strong	Altered Expression	[1486]
SOD3	OTIOZQAB	Strong	Posttranslational Modification	[3905]
SORBS1	OTWH8762	Strong	Altered Expression	[3906]
SOSTDC1	OTAKDNSM	Strong	Altered Expression	[2028]
SOX10	OTF25ULQ	Strong	Altered Expression	[3907]
SOX11	OT4LG7LA	Strong	Biomarker	[3908]
SOX12	OT93P8C9	Strong	Biomarker	[3909]
SOX17	OT9H4WWE	Strong	Altered Expression	[3910]
SOX18	OTPUMHWA	Strong	Altered Expression	[3911]
SOX3	OT1CRCOB	Strong	Biomarker	[3912]
SOX4	OTSS40SS	Strong	Biomarker	[3913]
SOX9	OTVDJFGN	Strong	Altered Expression	[3914]
SPA17	OT8J7T7U	Strong	Altered Expression	[3915]
SPAG5	OTCLJ56M	Strong	Biomarker	[3916]
SPAG8	OTZC5XP9	Strong	Altered Expression	[3917]
SPAM1	OTMPOB4E	Strong	Biomarker	[3918]
SPATA18	OTOEHTHU	Strong	Altered Expression	[3919]
SPC24	OT1HVYV4	Strong	Biomarker	[3920]
SPIN1	OT69VAOX	Strong	Biomarker	[3921]
SPINK1	OTSUVAL2	Strong	Biomarker	[3922]
SPINT1	OT1CLR5L	Strong	Genetic Variation	[3923]
SPINT2	OTQV7BKQ	Strong	Biomarker	[3924]
SPRED1	OTKX7P8G	Strong	Biomarker	[3925]
SPRY2	OTH0CRCZ	Strong	Altered Expression	[3926]
SPRY4	OT2VK9N0	Strong	Biomarker	[3927]
SPSB1	OTGY26U4	Strong	Biomarker	[3928]
SPSB2	OT7ZVT8R	Strong	Biomarker	[3433]
SRA1	OTYOGMTG	Strong	Altered Expression	[3929]
SRARP	OTR3TNTJ	Strong	Altered Expression	[3930]
SRF	OTW18FQN	Strong	Biomarker	[3931]
SRGAP2	OTUWFMCQ	Strong	Genetic Variation	[3932]
SRL	OT7IEBWZ	Strong	Biomarker	[3830]
SRRM2	OTSIMMC9	Strong	Biomarker	[3336]
SRSF1	OTF61HOV	Strong	Biomarker	[3933]
SRSF2	OTVDHO6U	Strong	Genetic Variation	[3934]
SRSF5	OTC5WP98	Strong	Altered Expression	[3935]
SSH1	OT4BE2M4	Strong	Altered Expression	[3936]
SSR1	OTQ6GDL2	Strong	Biomarker	[3937]
SSX2	OT2Z6RLL	Strong	Altered Expression	[3938]
ST13	OTNML6UP	Strong	Biomarker	[3161]
ST18	OTPRIMTA	Strong	Biomarker	[3430]
ST3GAL1	OTFCO8QX	Strong	Altered Expression	[3939]
ST3GAL3	OTOORKUE	Strong	Biomarker	[3940]
ST6GAL1	OT7US3NO	Strong	Altered Expression	[3941]
ST6GAL2	OTXIBF4D	Strong	Altered Expression	[3941]
ST6GALNAC1	OT3JQD99	Strong	Altered Expression	[3942]
ST6GALNAC2	OT9PBQVT	Strong	Biomarker	[3943]
ST6GALNAC5	OTH91ETM	Strong	Altered Expression	[3944]
ST7	OTZG8RC6	Strong	Genetic Variation	[3945]
ST8SIA2	OTRBBBD8	Strong	Altered Expression	[631]
STAC2	OTRJ9PG0	Strong	Biomarker	[3946]
STAG1	OT564IX4	Strong	Altered Expression	[3947]
STAM2	OT9OBWPH	Strong	Altered Expression	[2606]
STAP2	OTEB1VVI	Strong	Posttranslational Modification	[3948]
STARD10	OTWVNFV4	Strong	Altered Expression	[3949]
STARD13	OTB4U1HY	Strong	Biomarker	[1395]
STARD3	OTSTC5B5	Strong	Altered Expression	[3950]
STARD8	OTY9IAKW	Strong	Biomarker	[827]
STIM1	OT8CLQ1W	Strong	Altered Expression	[3951]
STIM2	OTYNXAW0	Strong	Biomarker	[3952]
STK24	OTGUHOIL	Strong	Altered Expression	[1187]
STK25	OT4YPNTF	Strong	Biomarker	[1478]
STK3	OTLNSCQD	Strong	Biomarker	[3953]
STN1	OT8UWRA3	Strong	Genetic Variation	[3359]
STPG4	OT5K4UFL	Strong	Genetic Variation	[3954]
STUB1	OTSUYI9A	Strong	Altered Expression	[3955]
STX18	OTW4GF3X	Strong	Biomarker	[3956]
STX1A	OTSBUZB4	Strong	Biomarker	[3827]
STX3	OT4CIWLJ	Strong	Biomarker	[3957]
STYX	OT8W6Y1J	Strong	Altered Expression	[3958]
SUB1	OTK71JYU	Strong	Biomarker	[3959]
SULF1	OTJCNCO0	Strong	Biomarker	[3960]
SULT4A1	OT7AL3KJ	Strong	Biomarker	[3961]
SUMO1	OTJFD4P5	Strong	Biomarker	[2260]
SUN2	OT2IQJUC	Strong	Altered Expression	[2134]
SUPT20H	OTTMC0LH	Strong	Altered Expression	[1690]
SUSD3	OTERJTUL	Strong	Biomarker	[3962]
SUV39H2	OTU0F4LL	Strong	Altered Expression	[3963]
SYBU	OT3FQV7N	Strong	Altered Expression	[3781]
SYCP2	OTBH622S	Strong	Biomarker	[3964]
SYF2	OTY2ZW1H	Strong	Biomarker	[3965]
SYNE1	OTSBSLUH	Strong	Biomarker	[827]
SYNJ2	OTLRHXP1	Strong	Biomarker	[3966]
SYNM	OTOI8TRJ	Strong	Altered Expression	[3967]
SYNPR	OTNCJ9L0	Strong	Genetic Variation	[743]
SYP	OTFJKMO4	Strong	Biomarker	[3968]
SYT1	OTVTPOI6	Strong	Biomarker	[1605]
TAB2	OTPZK76F	Strong	Biomarker	[3969]
TAC1	OTM842YW	Strong	Biomarker	[474]
TAF7	OT43QHS3	Strong	Altered Expression	[3970]
TAF8	OTWWGCHV	Strong	Altered Expression	[3899]
TAFA4	OT0RHMNG	Strong	Biomarker	[3173]
TAL1	OTX4K6QZ	Strong	Altered Expression	[3971]
TALDO1	OTDKV2S2	Strong	Altered Expression	[3972]
TANK	OTZSGFIK	Strong	Biomarker	[856]
TAS2R13	OTSTOX5G	Strong	Biomarker	[3973]
TATDN1	OTQ3S9AL	Strong	Altered Expression	[3481]
TAX1BP3	OTQ6IB4T	Strong	Biomarker	[3974]
TBC1D10A	OTR2CI46	Strong	Genetic Variation	[3975]
TBC1D24	OTKZUSMD	Strong	Biomarker	[3976]
TBC1D3	OT1GW0K2	Strong	Biomarker	[3977]
TBL1Y	OTA0F7TM	Strong	Biomarker	[3978]
TBP	OT6C0S52	Strong	Altered Expression	[3899]
TBPL1	OT4I143E	Strong	Altered Expression	[1530]
TBX2	OTTOT7A9	Strong	Altered Expression	[3979]
TCAP	OTQQMJ94	Strong	Biomarker	[1338]
TCEA1	OTBFO594	Strong	Biomarker	[3980]
TCEA2	OT1OS9TY	Strong	Biomarker	[3980]
TCEA3	OTLTRSK4	Strong	Biomarker	[3980]
TCF12	OTZVONNU	Strong	Biomarker	[2678]
TCF21	OT393IMA	Strong	Genetic Variation	[3981]
TCF4	OTB9ASTK	Strong	Biomarker	[3982]
TCF7	OT1ID822	Strong	Altered Expression	[2010]
TCHP	OTVDMHSY	Strong	Biomarker	[3983]
TCIM	OTARUXQF	Strong	Biomarker	[3984]
TCL1B	OT4CSO39	Strong	Genetic Variation	[477]
TCN1	OTW6A49Y	Strong	Altered Expression	[3985]
TCP1	OT1MGUX9	Strong	Biomarker	[1302]
TDRD3	OTG83E2C	Strong	Biomarker	[3986]
TEAD1	OTK6971C	Strong	Biomarker	[3987]
TEKT4	OT1GMBOX	Strong	Genetic Variation	[3988]
TENM1	OTSKSU4V	Strong	Biomarker	[3989]
TENM3	OTWY13GR	Strong	Genetic Variation	[3924]
TENT5A	OTSYF511	Strong	Genetic Variation	[2609]
TET1	OTZDHT1D	Strong	Altered Expression	[3990]
TET2	OTKKT03T	Strong	Altered Expression	[3991]
TEX14	OTBL9LPZ	Strong	Genetic Variation	[3992]
TFCP2	OTA246TE	Strong	Altered Expression	[1993]
TFDP1	OT6RZ7VT	Strong	Altered Expression	[3993]
TFE3	OTM99ZWH	Strong	Altered Expression	[3994]
TFEB	OTJUJJQY	Strong	Biomarker	[3995]
TFG	OT2KJENI	Strong	Altered Expression	[3996]
TFPI2	OTZCRWOR	Strong	Biomarker	[3427]
TGFBI	OTR443C5	Strong	Biomarker	[3898]
TGFBR3	OTQOOUC4	Strong	Biomarker	[3997]
THAP10	OTCMT4L7	Strong	Posttranslational Modification	[3318]
THBS2	OTXET551	Strong	Altered Expression	[1429]
THEM4	OTSIZU8Y	Strong	Biomarker	[3998]
THUMPD1	OTKU8KWH	Strong	Biomarker	[3999]
TIMELESS	OTD8DCBJ	Strong	Biomarker	[4000]
TIMM17A	OTVFRL8G	Strong	Altered Expression	[4001]
TIMM44	OTXP7MXN	Strong	Biomarker	[4002]
TIMM50	OTWJNUQL	Strong	Biomarker	[4003]
TIMM8A	OTDX9687	Strong	Biomarker	[828]
TIMP2	OT8S1RRP	Strong	Biomarker	[4004]
TIMP3	OTDGQAD1	Strong	Posttranslational Modification	[4005]
TIMP4	OT8A68SW	Strong	Biomarker	[4006]
TJP1	OTBDCUPK	Strong	Altered Expression	[4007]
TLCD3B	OTM6EPUS	Strong	Biomarker	[4008]
TLE1	OT50MRZ1	Strong	Altered Expression	[4009]
TLE3	OTR9PH95	Strong	Biomarker	[4010]
TLE4	OT4QEH6T	Strong	Biomarker	[4011]
TLK2	OTZ09CG8	Strong	Biomarker	[4012]
TLR10	OTQ1KVJO	Strong	Altered Expression	[4013]
TM4SF1	OTY0ECQN	Strong	Altered Expression	[4014]
TM7SF2	OTILU5S7	Strong	Biomarker	[1202]
TM9SF4	OT85D4H9	Strong	Biomarker	[4015]
TMC4	OT8FX82D	Strong	Biomarker	[1464]
TMED10	OTUXSHH7	Strong	Biomarker	[799]
TMED2	OTBLO7RW	Strong	Posttranslational Modification	[4016]
TMEFF1	OTH6M3CH	Strong	Altered Expression	[4017]
TMEFF2	OT1WZ2QO	Strong	Biomarker	[2149]
TMEM131L	OT7MO7XU	Strong	Biomarker	[4018]
TMEM158	OT0KUBBI	Strong	Biomarker	[4019]
TMEM17	OTEU00OH	Strong	Altered Expression	[4020]
TMEM170B	OT4AS8RJ	Strong	Biomarker	[4021]
TMEM199	OTU1GZOY	Strong	Altered Expression	[4022]
TMEM25	OTIMMWZ6	Strong	Biomarker	[3368]
TMEM26	OTHZCXYB	Strong	Biomarker	[4023]
TMEM70	OTLTKYXG	Strong	Biomarker	[2951]
TMEM8B	OTJZWPS6	Strong	Biomarker	[4024]
TMOD1	OTTRYF9Y	Strong	Altered Expression	[4025]
TMPRSS13	OTMAOAP3	Strong	Biomarker	[3311]
TMPRSS3	OT0GTO1Z	Strong	Biomarker	[4026]
TMPRSS4	OTCCGY2K	Strong	Biomarker	[4027]
TMSB10	OTLVZ13T	Strong	Altered Expression	[4028]
TMTC3	OTMTTDYG	Strong	Biomarker	[2815]
TNFAIP1	OT37EWR0	Strong	Altered Expression	[4022]
TNFAIP2	OTRZH80H	Strong	Biomarker	[4029]
TNFAIP6	OT1SLUZH	Strong	Altered Expression	[4030]
TNFAIP8L1	OTVVKOTV	Strong	Biomarker	[4031]
TNFAIP8L3	OTHSBS1B	Strong	Biomarker	[4032]
TNFRSF10C	OTVHOL9B	Strong	Biomarker	[2453]
TNFRSF6B	OTKAN9G7	Strong	Biomarker	[4033]
TNFSF18	OT3ANRX1	Strong	Altered Expression	[4034]
TNIP1	OTRAOTEW	Strong	Biomarker	[2064]
TNIP3	OTSAE5UE	Strong	Genetic Variation	[4035]
TNN	OTQK2AMX	Strong	Biomarker	[678]
TNNT1	OT8PBOAR	Strong	Biomarker	[4036]
TNNT3	OT4C498E	Strong	Genetic Variation	[4037]
TOB1	OTNW949D	Strong	Biomarker	[288]
TOP1MT	OT2H77ID	Strong	Genetic Variation	[4038]
TOP3A	OT3CKUI9	Strong	Genetic Variation	[4039]
TOPBP1	OT6UPZPD	Strong	Genetic Variation	[487]
TOX	OTE8BL5Z	Strong	Posttranslational Modification	[4040]
TOX4	OTSOXQFN	Strong	Biomarker	[3334]
TP53AIP1	OT1XVNDP	Strong	Altered Expression	[4041]
TP53BP2	OTOWJ2Y4	Strong	Altered Expression	[4042]
TP53I3	OTSCM68G	Strong	Altered Expression	[2345]
TP53INP2	OT0GTBXO	Strong	Biomarker	[3100]
TPI1	OT14KP4B	Strong	Altered Expression	[1948]
TPK1	OTCHPUD0	Strong	Genetic Variation	[4043]
TPM1	OTD73X6R	Strong	Altered Expression	[1384]
TPM3	OT5RU5G6	Strong	Biomarker	[4044]
TRA2A	OT5NHOO3	Strong	Biomarker	[4045]
TRA2B	OTZYQW52	Strong	Altered Expression	[4046]
TRADD	OTBOSJHO	Strong	Altered Expression	[4047]
TRAF2	OT1MEZZN	Strong	Biomarker	[4048]
TRAF3	OT5TQBGV	Strong	Biomarker	[4049]
TRAF4	OTJLRVMC	Strong	Biomarker	[4050]
TRAM1	OT3I0H8E	Strong	Biomarker	[4051]
TRARG1	OTQ1R3JD	Strong	Biomarker	[4052]
TRAT1	OTMPUNPD	Strong	Genetic Variation	[4053]
TRERF1	OTA7UQF1	Strong	Biomarker	[4010]
TREX1	OTQG7K12	Strong	Altered Expression	[4054]
TRIB1	OTPEO17G	Strong	Altered Expression	[4055]
TRIM11	OTMD6IM2	Strong	Biomarker	[4056]
TRIM23	OTVIGJ4T	Strong	Altered Expression	[3432]
TRIM29	OT2DNESG	Strong	Biomarker	[4057]
TRIM3	OT704FQ0	Strong	Altered Expression	[4058]
TRIM32	OTJOV0PG	Strong	Biomarker	[676]
TRIM44	OT0B1T2B	Strong	Biomarker	[4059]
TRIM46	OTFE7WZW	Strong	Biomarker	[4060]
TRIM62	OT15YO6N	Strong	Biomarker	[4061]
TRIP13	OTFM3TI9	Strong	Biomarker	[4062]
TRIT1	OTCU9FS5	Strong	Biomarker	[1268]
TRMT12	OTCN4IQZ	Strong	Altered Expression	[4063]
TROAP	OTC8CE0R	Strong	Biomarker	[4064]
TRPS1	OT7XPPEL	Strong	Biomarker	[4065]
TSACC	OT3QW6PH	Strong	Biomarker	[2665]
TSGA10	OTIF1O1T	Strong	Genetic Variation	[4066]
TSHZ1	OTYQ9ECW	Strong	Genetic Variation	[4067]
TSHZ2	OTZWBXXY	Strong	Biomarker	[4068]
TSHZ3	OTAN7RY5	Strong	Posttranslational Modification	[4069]
TSPAN1	OTZQPIYK	Strong	Biomarker	[4070]
TSPAN12	OTF9I3CX	Strong	Altered Expression	[4071]
TSPAN13	OTCS9BZY	Strong	Biomarker	[4072]
TSPAN31	OT8WQ83R	Strong	Biomarker	[3435]
TSPAN8	OT1F68WQ	Strong	Biomarker	[4073]
TSPY1	OTPY57X4	Strong	Biomarker	[4074]
TSPY3	OTQK3AKI	Strong	Biomarker	[4074]
TSPYL5	OT7QEI2X	Strong	Biomarker	[4075]
TSPYL6	OTQFY184	Strong	Genetic Variation	[4076]
TTC36	OT90ZLHE	Strong	Altered Expression	[4077]
TTF1	OT4K90WD	Strong	Altered Expression	[4078]
AARS1	OTW8D813	Definitive	Genetic Variation	[536]
AFAP1L2	OTJBI0VN	Definitive	Biomarker	[4079]
AGR3	OTONJPDP	Definitive	Biomarker	[4080]
ALDH1L1	OT15HOJX	Definitive	Altered Expression	[1781]
ALG1	OTVXPA9E	Definitive	Biomarker	[1233]
AMPH	OTWPGWZX	Definitive	Biomarker	[4081]
ANKRD44	OTUI0WOO	Definitive	Genetic Variation	[4082]
ANP32E	OTTWELUQ	Definitive	Altered Expression	[4083]
ARMC8	OTNAXGM7	Definitive	Biomarker	[4084]
ARMCX1	OTOGL58Z	Definitive	Biomarker	[4085]
ATF7IP	OTU6ZA7F	Definitive	Biomarker	[4086]
ATP2B2	OT1NPZ9T	Definitive	Altered Expression	[4087]
ATXN3L	OTZV3BG4	Definitive	Biomarker	[4088]
BCAM	OTHZOPSD	Definitive	Biomarker	[4089]
BCAS2	OTRMF2WY	Definitive	Genetic Variation	[4090]
BDH2	OTDD7G8S	Definitive	Altered Expression	[4091]
CCAR1	OTUXLQZZ	Definitive	Biomarker	[953]
CCNC	OTMVK4K4	Definitive	Biomarker	[4092]
CCNG1	OT17IA9L	Definitive	Altered Expression	[4093]
CCRL2	OT5PX0RX	Definitive	Biomarker	[4094]
CD81	OTQFXNAZ	Definitive	Biomarker	[4095]
CELSR2	OTON6JSZ	Definitive	Biomarker	[3215]
CLDND1	OTGECYGG	Definitive	Biomarker	[4096]
CMPK2	OTOG90R0	Definitive	Biomarker	[1782]
CNMD	OTHND8EL	Definitive	Biomarker	[4097]
CST1	OTE4I83Q	Definitive	Altered Expression	[4098]
CXCL5	OTZOUPCA	Definitive	Biomarker	[4099]
CYC1	OT0962IM	Definitive	Biomarker	[4100]
DNA2	OT4DJFFU	Definitive	Genetic Variation	[4101]
DNAJB4	OTUD01BK	Definitive	Biomarker	[4095]
EIF3D	OTDOMP80	Definitive	Biomarker	[4102]
FANCE	OTKRPBW1	Definitive	Altered Expression	[4103]
FBLN5	OTLVNZ8U	Definitive	Biomarker	[4104]
FLRT2	OTGD8TID	Definitive	Biomarker	[4105]
FOXN3	OTOJYJZP	Definitive	Biomarker	[4106]
FUT8	OTJJCVG1	Definitive	Biomarker	[4107]
GOLT1A	OTY8H2OF	Definitive	Altered Expression	[4108]
HABP2	OTAUIPW0	Definitive	Genetic Variation	[3216]
HARS1	OTHOEOTS	Definitive	Genetic Variation	[536]
HHLA2	OTYBTVQS	Definitive	Biomarker	[4109]
HIVEP1	OT7CAG4A	Definitive	Biomarker	[4110]
HOXB3	OT9UC5PE	Definitive	Biomarker	[4111]
IMMP2L	OT9WGAFD	Definitive	Biomarker	[4112]
IMMT	OTBDSLE7	Definitive	Altered Expression	[4113]
INPP5J	OT8M7KWA	Definitive	Biomarker	[4114]
IRX2	OTBHXXQ2	Definitive	Altered Expression	[4115]
ITGBL1	OTJDHE17	Definitive	Altered Expression	[4116]
KAT8	OT5LPQTR	Definitive	Biomarker	[4117]
KIF18A	OTSMBJ24	Definitive	Biomarker	[4118]
KIF3C	OTTXKIWA	Definitive	Altered Expression	[4113]
KLF2	OTIP1UFX	Definitive	Biomarker	[4119]
LGALS9	OT7MF91K	Definitive	Biomarker	[4120]
LTBP3	OTME98V7	Definitive	Biomarker	[4121]
MCM5	OTAHLB62	Definitive	Altered Expression	[4122]
MED13	OTP5LEJE	Definitive	Biomarker	[3362]
MPZ	OTAR2YXH	Definitive	Biomarker	[2388]
MRTFA	OTCVXASM	Definitive	Biomarker	[4123]
MSX1	OT5U41ZP	Definitive	Posttranslational Modification	[4124]
MYH6	OT3YNCH1	Definitive	Biomarker	[4125]
MYO6	OTJQYRC7	Definitive	Biomarker	[4125]
NDUFAF4	OTWJ5B9M	Definitive	Biomarker	[4126]
NDUFS4	OTJKUYEE	Definitive	Genetic Variation	[4127]
NNAT	OTNRLO7G	Definitive	Altered Expression	[4128]
NPRL2	OTOB10MO	Definitive	Biomarker	[4129]
NR2C2	OTDZWVOJ	Definitive	Biomarker	[1191]
NRL	OT65MFKQ	Definitive	Biomarker	[4130]
OGFOD1	OTTUQ5O3	Definitive	Biomarker	[4131]
ORAI3	OTUP3OH3	Definitive	Altered Expression	[1287]
PAQR4	OTNO659U	Definitive	Biomarker	[4132]
PARP4	OTXBK59G	Definitive	Biomarker	[4133]
PCDHGB7	OTBNJN7B	Definitive	Biomarker	[4134]
PDZK1IP1	OTWA6M5K	Definitive	Altered Expression	[4135]
PEA15	OTKCKTSX	Definitive	Altered Expression	[3390]
PGLS	OTO6C0IQ	Definitive	Altered Expression	[1945]
PIWIL2	OT1PXQIF	Definitive	Altered Expression	[4136]
PLCB2	OTPAHDGO	Definitive	Biomarker	[2485]
POU4F2	OT6SW5H0	Definitive	Biomarker	[4137]
PPM1B	OTZMH6V3	Definitive	Biomarker	[4138]
PRG2	OT0BCPQG	Definitive	Biomarker	[4110]
RAB23	OTBAKFBR	Definitive	Biomarker	[4139]
RARRES2	OT1BJE8K	Definitive	Biomarker	[4140]
RARS1	OTHPZ6JN	Definitive	Genetic Variation	[536]
RASSF10	OTGB7EBG	Definitive	Posttranslational Modification	[4141]
RBBP8	OTRHJ3GI	Definitive	Biomarker	[4142]
RBL2	OTBQSOE6	Definitive	Biomarker	[4143]
RBP2	OTR8QG5V	Definitive	Biomarker	[4144]
RIPK3	OTL1D484	Definitive	Biomarker	[1998]
RND1	OTOC223Z	Definitive	Genetic Variation	[4145]
SERPINB9	OTJ811IF	Definitive	Biomarker	[4146]
SETD1A	OTVVWRIC	Definitive	Altered Expression	[4147]
SIRT4	OT5S0J23	Definitive	Biomarker	[4148]
SIX3	OTP5E3VU	Definitive	Biomarker	[3408]
SNX9	OTLNQ0ZM	Definitive	Biomarker	[4149]
SPDYA	OTYKC1AJ	Definitive	Altered Expression	[4150]
SPPL3	OT2HLJF6	Definitive	Biomarker	[4112]
STING1	OTDAP4G0	Definitive	Biomarker	[925]
SUSD4	OTWCJTT3	Definitive	Altered Expression	[4151]
SUZ12	OT655XF8	Definitive	Biomarker	[4065]
TARBP2	OT1QQ8H3	Definitive	Biomarker	[4152]
TBC1D16	OTPR3C6A	Definitive	Biomarker	[4153]
TBX5	OT70PISV	Definitive	Genetic Variation	[4154]
TC2N	OT6482WN	Definitive	Altered Expression	[4155]
TEAD4	OTJS0T2B	Definitive	Biomarker	[4156]
TERF2IP	OT3M5P3G	Definitive	Biomarker	[3722]
TEX101	OTNO747E	Definitive	Biomarker	[4157]
TIAL1	OTV2KFZH	Definitive	Biomarker	[4158]
TIPIN	OT9PZHXV	Definitive	Biomarker	[4159]
TMEM132D	OTV6I4Z0	Definitive	Genetic Variation	[4160]
TMEM14C	OTHYTMLC	Definitive	Biomarker	[4161]
TP53	OTIE1VH3	Definitive	Autosomal dominant	[265]
TPM2	OTA1L0P8	Definitive	Altered Expression	[4162]
TRIAP1	OTEAUJXN	Definitive	Altered Expression	[4163]

This Disease Is Related to 1510 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABL2	TT1A6HL	Limited	Biomarker	[266]
ACE2	TTUI5H7	Limited	Altered Expression	[267]
ACHE	TT1RS9F	Limited	Biomarker	[268]
ACLY	TT0Z6Y2	Limited	Biomarker	[269]
ADAMTS1	TTS2TEI	Limited	Biomarker	[270]
ADORA2B	TTNE7KG	Limited	Biomarker	[271]
ADRB1	TTR6W5O	Limited	Altered Expression	[272]
ADRB3	TTMXGCW	Limited	Altered Expression	[272]
AGK	TTJETQC	Limited	Altered Expression	[273]
AICDA	TTKRTP6	Limited	Biomarker	[274]
ALKBH5	TTOHB1M	Limited	Biomarker	[275]
ALOX5	TTSJ6Q4	Limited	Biomarker	[276]
AMHR2	TTZDCPK	Limited	Biomarker	[277]
ANTXR2	TTOD34I	Limited	Altered Expression	[278]
AQP7	TTNGCRK	Limited	Altered Expression	[279]
AQP9	TTQEI32	Limited	Biomarker	[279]
ASAP3	TTB4ZEN	Limited	Biomarker	[280]
ATF4	TTQCKWT	Limited	Biomarker	[281]
ATP2A2	TTE6THL	Limited	Altered Expression	[282]
AURKA	TTPS3C0	Limited	Autosomal dominant	[265]
AURKC	TTLYXIT	Limited	Biomarker	[283]
B2M	TTY7FKA	Limited	Biomarker	[284]
BCHE	TT3MSAO	Limited	Biomarker	[285]
BDKRB1	TTG5QIA	Limited	Biomarker	[286]
BRD1	TTT09OB	Limited	Biomarker	[287]
BTG1	TTL7N2W	Limited	Biomarker	[288]
CA5A	TT75WPO	Limited	Biomarker	[289]
CACNA1G	TT729IR	Limited	Biomarker	[290]
CALCA	TTVSFJW	Limited	Biomarker	[274]
CBR1	TTVG0SN	Limited	Altered Expression	[291]
CBS	TTVZJ7G	Limited	Altered Expression	[292]
CBX7	TTBN3HC	Limited	Altered Expression	[293]
CCL22	TTBTWI1	Limited	Biomarker	[294]
CD14	TT6I7DC	Limited	Biomarker	[295]
CD160	TTOFEAS	Limited	Biomarker	[296]
CD22	TTM6QSK	Limited	Biomarker	[297]
CD33	TTJVYO3	Limited	Biomarker	[297]
CD40LG	TTIJP3Q	Limited	Biomarker	[298]
CD69	TTPQE9F	Limited	Biomarker	[299]
CD80	TT89Z17	Limited	Biomarker	[300]
CDH1	TTLAWO6	Limited	Altered Expression	[301]
CDH11	TTRGWZC	Limited	Biomarker	[302]
CDK12	TTJ21A9	Limited	Altered Expression	[303]
CEBPA	TT5LWG1	Limited	Posttranslational Modification	[304]
CENPE	TTZD5QR	Limited	Biomarker	[305]
CHIT1	TTDYX6T	Limited	Altered Expression	[306]
CHUK	TT1F8OQ	Limited	Altered Expression	[307]
COASY	TT4YO0Z	Limited	Biomarker	[308]
CSNK1D	TTH30UI	Limited	Biomarker	[309]
CSNK1E	TTA8PLI	Limited	Biomarker	[310]
CTSK	TTDZN01	Limited	Altered Expression	[311]
CX3CL1	TT1OFBQ	Limited	Biomarker	[312]
CYP11B1	TTIQUX7	Limited	Biomarker	[313]
DDX58	TTVB0O3	Limited	Biomarker	[314]
DEK	TT1NMGV	Limited	Altered Expression	[315]
DGKA	TTGL8F0	Limited	Biomarker	[316]
DKK2	TTST5KX	Limited	Altered Expression	[317]
DLK1	TTF4AVB	Limited	Biomarker	[318]
DPP4	TTDIGC1	Limited	Biomarker	[319]
DPYD	TTZPS91	Limited	Biomarker	[320]
DPYSL2	TTZCW3T	Limited	Biomarker	[321]
DRD1	TTZFYLI	Limited	Altered Expression	[322]
DRD5	TTS2PH3	Limited	Altered Expression	[322]
DUSP5	TTZN92A	Limited	Altered Expression	[323]
E2F2	TT5FYX0	Limited	Biomarker	[324]
EEF2K	TT1QFLA	Limited	Biomarker	[325]
EGFL6	TTXJGAR	Limited	Biomarker	[326]
EGFL7	TT7WD0H	Limited	Altered Expression	[327]
EGR1	TTE8LGD	Limited	Altered Expression	[328]
ELANE	TTPLTSQ	Limited	Biomarker	[329]
ELK3	TT5OJMV	Limited	Biomarker	[330]
ENTPD3	TT7ES5I	Limited	Biomarker	[331]
EP300	TTGH73N	Limited	Altered Expression	[332]
EPX	TTCIO0M	Limited	Altered Expression	[333]
EYA2	TTUY9C6	Limited	Biomarker	[334]
F9	TTFEZ5Q	Limited	Biomarker	[335]
FAF1	TTSKL3G	Limited	Posttranslational Modification	[336]
FAM83B	TT1Q347	Limited	Altered Expression	[337]
FAP	TTGPQ0F	Limited	Altered Expression	[338]
FAT1	TTGUJYV	Limited	Genetic Variation	[339]
FFAR4	TT08JVB	Limited	Biomarker	[340]
FGF19	TTGCH11	Limited	Altered Expression	[341]
FKBP4	TTHY0FT	Limited	Altered Expression	[342]
FOXC2	TTLBAP1	Limited	Altered Expression	[343]
FOXQ1	TTEJZOL	Limited	Biomarker	[344]
FYN	TT2B9KF	Limited	Biomarker	[345]
GAD2	TT7UY6K	Limited	Biomarker	[346]
GATA4	TT1VDN2	Limited	Posttranslational Modification	[347]
GGH	TTZJRL0	Limited	Biomarker	[348]
GHSR	TTWDC17	Limited	Biomarker	[349]
GJA8	TTJ7ATH	Limited	Biomarker	[350]
GJB6	TTAU8SJ	Limited	Altered Expression	[351]
GLP1R	TTVIMDE	Limited	Altered Expression	[352]
GNA11	TTSRXJW	Limited	Biomarker	[353]
GZMB	TTKEPHX	Limited	Biomarker	[354]
HCAR2	TTWNV8U	Limited	Genetic Variation	[355]
HCN1	TTNB6UQ	Limited	Biomarker	[356]
HDGF	TTKGV26	Limited	Biomarker	[357]
HEXIM1	TTFOKAH	Limited	Altered Expression	[358]
HNRNPA2B1	TT8UPW6	Limited	Altered Expression	[359]
HRH3	TT9JNIC	Limited	Genetic Variation	[360]
HSD11B2	TT9H85R	Limited	Altered Expression	[361]
HSD17B13	TTDJYZR	Limited	Biomarker	[362]
HSPE1	TTWYMFE	Limited	Altered Expression	[363]
IFNGR2	TT13TL0	Limited	Genetic Variation	[364]
IFNW1	TTS2TGF	Limited	Genetic Variation	[365]
IKZF2	TTKT5NV	Limited	Biomarker	[366]
IL16	TTW4R0B	Limited	Biomarker	[367]
IL19	TT87RWS	Limited	Genetic Variation	[368]
IL22	TTLDX4N	Limited	Biomarker	[369]
IL32	TTD4G7L	Limited	Biomarker	[370]
IL33	TT5MD4P	Limited	Biomarker	[371]
IL4R	TTDWHC3	Limited	Biomarker	[372]
IRAK1	TTXAJWN	Limited	Altered Expression	[373]
ISG15	TTVOH3T	Limited	Biomarker	[374]
ITK	TT3C80U	Limited	Biomarker	[375]
KAT2B	TTVK7SB	Limited	Biomarker	[376]
KAT6A	TT6O1J0	Limited	Altered Expression	[377]
KCNN3	TT9JH25	Limited	Biomarker	[378]
KDM1B	TT8VP2T	Limited	Biomarker	[379]
KDM2A	TT8XTY2	Limited	Biomarker	[380]
KDM5C	TT94UCF	Limited	Biomarker	[381]
KDM6B	TTDIJUQ	Limited	Altered Expression	[382]
KDM7A	TT0NYMP	Limited	Biomarker	[383]
KIR2DS1	TTVWAGF	Limited	Genetic Variation	[384]
KIR2DS2	TTV3CFI	Limited	Biomarker	[384]
KIR3DL2	TTQH3N0	Limited	Genetic Variation	[384]
KLB	TTARBVH	Limited	Biomarker	[385]
KLRG1	TT299E6	Limited	Biomarker	[386]
LBP	TTVQJLY	Limited	Altered Expression	[387]
LGMN	TTPTWV5	Limited	Biomarker	[388]
LILRB2	TTHC6XU	Limited	Altered Expression	[389]
LTB4R2	TTVJX54	Limited	Biomarker	[390]
LY6K	TT5GKHN	Limited	Biomarker	[391]
MALT1	TTCI81G	Limited	Genetic Variation	[392]
MAP3K20	TTTUZ3O	Limited	Biomarker	[393]
MAPK11	TT73U6C	Limited	Biomarker	[394]
MAPKAP1	TTWDKCL	Limited	Biomarker	[395]
MERTK	TTO7LKR	Limited	Altered Expression	[396]
MGAM	TTXWASR	Limited	Biomarker	[397]
MGAT1	TTYJRN5	Limited	Biomarker	[398]
MRGPRX1	TTIX6PK	Limited	Biomarker	[399]
MST1R	TTBQ3OC	Limited	Biomarker	[400]
MUC15	TTGQ6MI	Limited	Biomarker	[401]
MYLK2	TTHLGB2	Limited	Genetic Variation	[402]
NLRP1	TTQX29T	Limited	Biomarker	[403]
NLRX1	TTKT026	Limited	Altered Expression	[404]
NR0B1	TTTK36V	Limited	Biomarker	[405]
NR1H2	TTXA6PH	Limited	Biomarker	[406]
NR4A1	TTMXE2Q	Limited	Biomarker	[407]
NR4A2	TT9HKN3	Limited	Altered Expression	[408]
NR4A3	TTJQB49	Limited	Altered Expression	[409]
NTN1	TT0AH4L	Limited	Biomarker	[410]
P2RY12	TTZ1DT0	Limited	Biomarker	[411]
P2RY2	TTOZHQC	Limited	Altered Expression	[412]
P4HA1	TTNH25W	Limited	Altered Expression	[413]
PAK2	TT279WO	Limited	Biomarker	[414]
PBK	TTMY6BZ	Limited	Biomarker	[415]
PBRM1	TTH8ZRL	Limited	Biomarker	[416]
PDGFB	TTQA6SX	Limited	Altered Expression	[417]
PDGFC	TTOABM9	Limited	Altered Expression	[418]
PDGFRA	TT8FYO9	Limited	Altered Expression	[419]
PEMT	TT735V2	Limited	Posttranslational Modification	[420]
PHF8	TT81PFE	Limited	Altered Expression	[421]
PIKFYVE	TTA4M1N	Limited	Biomarker	[422]
PIM2	TT69J2Z	Limited	Posttranslational Modification	[423]
PIM3	TTCGOIN	Limited	Biomarker	[424]
PIP5K1A	TTA7DU1	Limited	Biomarker	[425]
PKLR	TT31N4S	Limited	Biomarker	[426]
PKMYT1	TTB4PAZ	Limited	Altered Expression	[427]
PKN3	TTW3P4R	Limited	Biomarker	[428]
PLD1	TT3T17P	Limited	Altered Expression	[429]
PLD2	TTRLMKF	Limited	Altered Expression	[430]
PLK4	TTGPNZQ	Limited	Biomarker	[431]
PLP2	TTK5OG6	Limited	Altered Expression	[432]
PPARD	TT2JWF6	Limited	Biomarker	[433]
PPIA	TTL2ADK	Limited	Biomarker	[434]
PPP2CA	TTHTKNY	Limited	Altered Expression	[435]
PRDX5	TTLPJWH	Limited	Biomarker	[436]
PREP	TTNGKET	Limited	Biomarker	[437]
PRKCD	TT7A1BO	Limited	Altered Expression	[438]
PRKCE	TT57MT2	Limited	Altered Expression	[439]
PSMB8	TTEAD9J	Limited	Altered Expression	[440]
PSMB9	TTOUSTQ	Limited	Biomarker	[441]
PSMD10	TT2H4LN	Limited	Biomarker	[442]
PTGER4	TT79WV3	Limited	Altered Expression	[443]
PTH1R	TTFPD47	Limited	Biomarker	[444]
PTK7	TTXH2ZN	Limited	Altered Expression	[445]
PTN	TTA9EJK	Limited	Altered Expression	[446]
PTP4A2	TT1MHKD	Limited	Biomarker	[447]
PTPN13	TT405FP	Limited	Biomarker	[448]
PTPRC	TTUS45N	Limited	Biomarker	[449]
RAB9A	TT958S6	Limited	Biomarker	[450]
RACK1	TTJ10AL	Limited	Altered Expression	[451]
RALBP1	TTVSRUA	Limited	Altered Expression	[452]
RAPGEF3	TTOE7I0	Limited	Biomarker	[453]
RHOB	TT6LPFO	Limited	Altered Expression	[454]
RIPK1	TTVJHX8	Limited	Biomarker	[455]
ROS1	TTSZ6Y3	Limited	Autosomal dominant	[265]
RSPO1	TTI9HL4	Limited	Biomarker	[456]
S1PR1	TT9JZCK	Limited	Altered Expression	[457]
S1PR2	TTVSMOH	Limited	Biomarker	[458]
SCAP	TTL6U2P	Limited	Biomarker	[459]
SCN3A	TTAXZ0K	Limited	Altered Expression	[460]
SERPINF1	TTR59S1	Limited	Biomarker	[461]
SF3B1	TTL2WUI	Limited	Biomarker	[462]
SGK1	TTTV8EJ	Limited	Genetic Variation	[463]
SLC5A2	TTF8JAT	Limited	Biomarker	[464]
SLC5A6	TT61XTV	Limited	Altered Expression	[465]
SLC8A1	TTCF82X	Limited	Altered Expression	[466]
SLCO2A1	TTKVTQO	Limited	Biomarker	[467]
SORT1	TTRX9AV	Limited	Biomarker	[468]
SPN	TTOZAX0	Limited	Biomarker	[469]
SREBF1	TTER0UB	Limited	Biomarker	[470]
SSRP1	TTETDKQ	Limited	Altered Expression	[471]
STEAP2	TTOXF5J	Limited	Altered Expression	[472]
STXBP4	TTKS60G	Limited	Biomarker	[473]
TACR1	TTZPO1L	Limited	Biomarker	[474]
TAGLN2	TTP6BIJ	Limited	Altered Expression	[475]
TBL1XR1	TTYXT16	Limited	Altered Expression	[476]
TCL1A	TTUKRDV	Limited	Genetic Variation	[477]
TDGF1	TTN7HMG	Limited	Posttranslational Modification	[478]
TGFB2	TTI0KH6	Limited	Biomarker	[479]
TLN1	TTQSMFG	Limited	Genetic Variation	[480]
TNFRSF14	TTWGTC1	Limited	Genetic Variation	[481]
TNFRSF25	TTDV6BQ	Limited	Biomarker	[482]
TNFSF12	TTBTDM1	Limited	Altered Expression	[483]
TNFSF13B	TTWMIDN	Limited	Biomarker	[484]
TNFSF15	TTEST6I	Limited	Altered Expression	[485]
TNIK	TTPB1W3	Limited	Biomarker	[486]
TOP2B	TT4NVEM	Limited	Genetic Variation	[487]
TRPV6	TTBK14N	Limited	Biomarker	[488]
UCP2	TTSC2YM	Limited	Biomarker	[489]
UTRN	TTNO1VA	Limited	Biomarker	[490]
WDR5	TT7OFWB	Limited	Biomarker	[491]
WEE1	TTJFOAL	Limited	Biomarker	[492]
CD6	TTMF6KC	Disputed	Genetic Variation	[493]
CDK3	TTMYWL7	Disputed	Biomarker	[494]
CDKL1	TTBTI6P	Disputed	Biomarker	[495]
GAL	TTXZAJ5	Disputed	Biomarker	[496]
LRP5	TT7VMG4	Disputed	Biomarker	[497]
MLH1	TTISG27	Disputed	Autosomal dominant	[265]
MSH2	TTCAWRT	Disputed	Autosomal dominant	[265]
PKD2L1	TTAHD89	Disputed	Biomarker	[498]
RTN4	TT7GXMU	Disputed	Biomarker	[499]
SLC1A2	TT2F078	Disputed	Biomarker	[500]
TKT	TT04R7I	Disputed	Biomarker	[501]
TLR6	TTWRI8V	Disputed	Biomarker	[502]
TRPM2	TTEBMN7	Disputed	Biomarker	[503]
ABCG1	TTMWDGU	moderate	Biomarker	[504]
ACKR1	TTKY2NS	moderate	Genetic Variation	[505]
ADGRL3	TTQST3U	moderate	Altered Expression	[506]
AGTR2	TTQVOEI	moderate	Altered Expression	[507]
AKR1C3	TT5ZWB6	moderate	Biomarker	[508]
APOA4	TTNC3WS	moderate	Altered Expression	[509]
APOB	TTN1IE2	moderate	Altered Expression	[510]
AQP3	TTLDNMQ	moderate	Biomarker	[511]
ARF1	TT70KXY	moderate	Biomarker	[512]
ARRB2	TT8SO2I	moderate	Biomarker	[513]
ATAD2	TT9A0HI	moderate	Altered Expression	[514]
ATRAID	TTFLIKM	moderate	Biomarker	[515]
ATXN3	TT6A17J	moderate	Altered Expression	[516]
AVP	TTJ8EWH	moderate	Genetic Variation	[517]
AZGP1	TTUPYLV	moderate	Biomarker	[518]
BIRC3	TTAIWZN	moderate	Genetic Variation	[519]
BRD2	TTDP48B	moderate	Biomarker	[520]
BRSK2	TTHZN4X	moderate	Biomarker	[521]
CACNA1E	TTYRP0M	moderate	Biomarker	[522]
CACNA1I	TTQZFTH	moderate	Altered Expression	[523]
CACNA2D3	TTN7T29	moderate	Posttranslational Modification	[524]
CD27	TTDO1MV	moderate	Genetic Variation	[525]
CDC42BPA	TT5Z0EF	moderate	Altered Expression	[526]
CDC7	TTSMTDI	moderate	Genetic Variation	[527]
CDK19	TTNABU9	moderate	Biomarker	[528]
CDK8	TTBJR4L	moderate	Biomarker	[529]
CEACAM6	TTIGH2W	moderate	Altered Expression	[530]
CEL	TTTRNQW	moderate	Altered Expression	[531]
CIT	TT3BKTU	moderate	Altered Expression	[532]
CLCN3	TT8XNZ7	moderate	Biomarker	[533]
CRH	TTA7YIZ	moderate	Biomarker	[534]
DAPK3	TTERVQN	moderate	Altered Expression	[535]
DCPS	TTLSW9V	moderate	Genetic Variation	[536]
DFFA	TTYVQ9C	moderate	Biomarker	[537]
DHPS	TTBO2A9	moderate	Biomarker	[538]
DNMT3L	TT3FDAV	moderate	Genetic Variation	[539]
E2F3	TTWIJYH	moderate	Biomarker	[540]
EED	TTFNJ4R	moderate	Biomarker	[541]
EML4	TT92GY4	moderate	Genetic Variation	[542]
ENPP2	TTSCIM2	moderate	Biomarker	[543]
ENSA	TTQD0YT	moderate	Biomarker	[544]
EPHA5	TTV9KOD	moderate	Biomarker	[545]
EPHB6	TTZEMUY	moderate	Biomarker	[546]
EZH1	TTNJA0C	moderate	Biomarker	[547]
F2RL3	TTD0652	moderate	Biomarker	[548]
F5	TT1O264	moderate	Genetic Variation	[549]
F7	TTF0EGX	moderate	Biomarker	[550]
FABP3	TT3TGLR	moderate	Biomarker	[551]
FAM83D	TTFIW7J	moderate	Altered Expression	[552]
FANCA	TTV5HJS	moderate	Genetic Variation	[553]
FHL1	TTI7ENL	moderate	Biomarker	[554]
FSHR	TTZFDBT	moderate	Altered Expression	[555]
GDF5	TT37XV9	moderate	Altered Expression	[556]
GJC2	TTPOCAL	moderate	Genetic Variation	[557]
GLA	TTIS03D	moderate	Biomarker	[558]
GLB1	TTNGJPH	moderate	Biomarker	[559]
GPC3	TTJTSX4	moderate	Biomarker	[560]
GPD1	TTKTEAH	moderate	Biomarker	[561]
GREM1	TTOUZN5	moderate	Altered Expression	[562]
GRK2	TTAZ3MN	moderate	Altered Expression	[563]
GRM4	TTICZ1O	moderate	Altered Expression	[564]
GUCY1B1	TTLBYH1	moderate	Altered Expression	[565]
HAMP	TTRV5YJ	moderate	Biomarker	[566]
HCAR3	TT8WFXV	moderate	Biomarker	[567]
HDAC11	TT8K17W	moderate	Biomarker	[568]
HDAC2	TTSHTOI	moderate	Altered Expression	[569]
HDAC5	TTUELN5	moderate	Altered Expression	[570]
HDAC8	TTT6LFV	moderate	Altered Expression	[571]
HDC	TTV9GOF	moderate	Altered Expression	[572]
HIPK2	TTOB49C	moderate	Biomarker	[573]
HMGCS2	TTS0EZJ	moderate	Biomarker	[574]
HNMT	TT2B6EV	moderate	Genetic Variation	[575]
HPN	TT25MVL	moderate	Altered Expression	[576]
HSD17B2	TT0PT1R	moderate	Altered Expression	[577]
IDS	TTNY2AP	moderate	Biomarker	[578]
IFNAR1	TTSYFMA	moderate	Altered Expression	[579]
IL17F	TT2B6PS	moderate	Genetic Variation	[580]
IL1R1	TTWOTEA	moderate	Altered Expression	[581]
IL25	TTVMO5W	moderate	Biomarker	[582]
ITCH	TT5SEWD	moderate	Biomarker	[583]
ITGA2	TTSJ542	moderate	Biomarker	[584]
KCNA1	TTS3DIK	moderate	Altered Expression	[585]
KDM4C	TTV8CRH	moderate	Biomarker	[586]
LAMP2	TTULDG7	moderate	Altered Expression	[587]
LATS2	TTML7FG	moderate	Genetic Variation	[588]
LRP2	TTPH1AJ	moderate	Biomarker	[589]
LRRK2	TTK0FEA	moderate	Genetic Variation	[590]
MAP3K21	TTSW9YL	moderate	Altered Expression	[591]
MAP3K5	TTOQCD8	moderate	Biomarker	[592]
MAP3K9	TTUNSIX	moderate	Biomarker	[593]
MECP2	TTTAU9R	moderate	Altered Expression	[594]
MS4A1	TTUE541	moderate	Biomarker	[595]
MSI2	TTTXQF6	moderate	Biomarker	[596]
MTAP	TTDBX7N	moderate	Altered Expression	[597]
MYH2	TTBIL13	moderate	Biomarker	[598]
NDUFA13	TTRU1NG	moderate	Altered Expression	[599]
NPR1	TTM9IYA	moderate	Biomarker	[600]
NSD1	TTTSJ3H	moderate	Biomarker	[601]
NUAK1	TT65FL0	moderate	Biomarker	[602]
PADI4	TTQHAXM	moderate	Biomarker	[603]
PARP2	TTQ4V96	moderate	Genetic Variation	[604]
PAX5	TTA4REJ	moderate	Biomarker	[605]
PCSK6	TT75LN9	moderate	Biomarker	[606]
PCSK7	TTD30LY	moderate	Biomarker	[607]
PDXP	TT9UYG4	moderate	Altered Expression	[608]
PGF	TT48I1Y	moderate	Altered Expression	[609]
PINX1	TT4FJ3A	moderate	Altered Expression	[610]
PLA2R1	TTHKW7D	moderate	Altered Expression	[611]
PLCG1	TT6T4JI	moderate	Biomarker	[612]
PNP	TTMCF1Y	moderate	Biomarker	[613]
PRAME	TTPH7T0	moderate	Altered Expression	[614]
PRKCH	TTONI0R	moderate	Biomarker	[615]
PRSS8	TTT4N0Q	moderate	Altered Expression	[616]
PTGER2	TT1ZAVI	moderate	Biomarker	[617]
PTPRJ	TTWMKXP	moderate	Genetic Variation	[618]
RBPJ	TT72D4Z	moderate	Biomarker	[619]
RGS6	TTJ96M8	moderate	Genetic Variation	[620]
RORA	TT1TYN7	moderate	Genetic Variation	[621]
RXRB	TTKLV96	moderate	Biomarker	[622]
RXRG	TTH029C	moderate	Biomarker	[623]
SCUBE2	TTWREQP	moderate	Altered Expression	[624]
SIRT2	TTLKF5M	moderate	Altered Expression	[625]
SLC25A4	TTU5A6Q	moderate	Altered Expression	[626]
SLC26A4	TT7X02I	moderate	Biomarker	[627]
SLC3A2	TT5CZSM	moderate	Biomarker	[628]
SLC6A2	TTAWNKZ	moderate	Biomarker	[330]
SLCO1A2	TTUGD21	moderate	Altered Expression	[629]
SRD5A1	TTTU72V	moderate	Genetic Variation	[630]
ST8SIA4	TTDP8YM	moderate	Altered Expression	[631]
TACSTD2	TTP2HE5	moderate	Altered Expression	[632]
TBXA2R	TT2O84V	moderate	Biomarker	[633]
TEP1	TTQGAVX	moderate	Genetic Variation	[634]
THRA	TTTSEPU	moderate	Biomarker	[635]
TLR5	TTCXP8J	moderate	Altered Expression	[636]
TPX2	TT0PHL4	moderate	Biomarker	[637]
USP13	TTVJIO2	moderate	Biomarker	[638]
USP14	TTVSYP9	moderate	Biomarker	[639]
UTS2	TTERU0T	moderate	Genetic Variation	[640]
VANGL1	TT18WJB	moderate	Biomarker	[641]
VDAC1	TTAMKGB	moderate	Biomarker	[642]
ABCA1	TTJW1GN	Strong	Genetic Variation	[504]
ABCA4	TTLB52K	Strong	Genetic Variation	[504]
ABCB11	TTUXCAF	Strong	Genetic Variation	[643]
ABCB4	TTJUXV6	Strong	Altered Expression	[644]
ABCC2	TTFLHJV	Strong	Biomarker	[645]
ABCC3	TTVLG21	Strong	Biomarker	[646]
ABCC4	TTUEAFL	Strong	Altered Expression	[647]
ABCC8	TTP835K	Strong	Genetic Variation	[648]
ABL1	TT6B75U	Strong	Posttranslational Modification	[649]
ACKR3	TTRQJTC	Strong	Biomarker	[399]
ACR	TTAHE2N	Strong	Biomarker	[650]
ACTG1	TTGAZF9	Strong	Genetic Variation	[651]
ACVR2A	TTX2DRI	Strong	Altered Expression	[652]
ACVR2B	TTLFRKS	Strong	Altered Expression	[652]
ADA	TTLP57V	Strong	Biomarker	[653]
ADAM10	TTVXEGU	Strong	Biomarker	[654]
ADAM17	TT6AZXG	Strong	Biomarker	[655]
ADAM33	TTQICM2	Strong	Genetic Variation	[656]
ADAM8	TTQWYMD	Strong	Biomarker	[657]
ADAM9	TTTYQNS	Strong	Biomarker	[658]
ADAMTS4	TTYG6BU	Strong	Biomarker	[659]
ADAMTS5	TTXSU2Y	Strong	Biomarker	[659]
ADCYAP1R1	TT5OREU	Strong	Altered Expression	[660]
ADM	TTV14YH	Strong	Biomarker	[661]
ADORA1	TTK25J1	Strong	Biomarker	[662]
ADRA1A	TTNGILX	Strong	Biomarker	[399]
ADRA1D	TT34BHT	Strong	Biomarker	[663]
ADRA2A	TTWG9A4	Strong	Biomarker	[664]
ADRA2B	TTWM4TY	Strong	Biomarker	[399]
ADRA2C	TT2NUT5	Strong	Biomarker	[664]
ADRB2	TTG8ZWP	Strong	Genetic Variation	[665]
AFP	TTCFEA1	Strong	Therapeutic	[666]
AGR2	TT9K86S	Strong	Altered Expression	[667]
AHCY	TTE2KUJ	Strong	Biomarker	[668]
AHSG	TTKF4WV	Strong	Biomarker	[669]
AIF1	TT12MEP	Strong	Biomarker	[670]
AIMP2	TTXWHGF	Strong	Altered Expression	[370]
AKR1B1	TTFBNVI	Strong	Altered Expression	[434]
AKT2	TTH24WI	Strong	Biomarker	[671]
AKT3	TTO6SGY	Strong	Biomarker	[671]
ALAD	TTJHKYD	Strong	Altered Expression	[672]
ALCAM	TT2AFT6	Strong	Biomarker	[673]
ALK	TTPMQSO	Strong	Biomarker	[674]
ALOX12	TT12ABZ	Strong	Biomarker	[675]
ALPI	TTHYMUV	Strong	Biomarker	[676]
ALPL	TTMR5UV	Strong	Biomarker	[677]
AMACR	TTLN1AP	Strong	Genetic Variation	[678]
AMD1	TTBFROQ	Strong	Biomarker	[679]
ANGPT2	TTKLQTJ	Strong	Altered Expression	[680]
ANGPTL4	TTWALY5	Strong	Biomarker	[681]
ANO1	TTOJI4S	Strong	Biomarker	[682]
ANO7	TT2X79I	Strong	Biomarker	[683]
ANXA2	TT4YANI	Strong	Altered Expression	[684]
AOC1	TTM3B5R	Strong	Biomarker	[685]
AOC3	TT7HC21	Strong	Biomarker	[686]
APC2	TTSMK36	Strong	Altered Expression	[687]
APCS	TTB7VAT	Strong	Biomarker	[688]
APLN	TT87D3J	Strong	Biomarker	[689]
APOA1	TT5S8DR	Strong	Biomarker	[690]
APOC3	TTXOZQ1	Strong	Genetic Variation	[691]
APP	TTE4KHA	Strong	Biomarker	[692]
AQP1	TTSF1KH	Strong	Biomarker	[693]
ARAF	TT5TURO	Strong	Therapeutic	[694]
AREG	TT76B3W	Strong	Biomarker	[695]
ARL2	TTIDSFT	Strong	Altered Expression	[696]
ARRB1	TTMVD4A	Strong	Biomarker	[697]
ASPA	TT6TLZP	Strong	Genetic Variation	[698]
ASPH	TT2KHP7	Strong	Biomarker	[699]
ASRGL1	TT4WT91	Strong	Biomarker	[700]
ATF3	TTCE793	Strong	Altered Expression	[701]
ATG7	TTLVB9Z	Strong	Biomarker	[702]
ATIC	TT9NVXQ	Strong	Biomarker	[703]
ATP7B	TTOPO51	Strong	Biomarker	[704]
ATR	TT8ZYBQ	Strong	Posttranslational Modification	[705]
AXL	TTZPY6J	Strong	Altered Expression	[706]
BACE2	TT69DB8	Strong	Biomarker	[707]
BACH1	TT2ME4S	Strong	Biomarker	[708]
BAGE	TTS5GLJ	Strong	Altered Expression	[709]
BAK1	TTFM7V0	Strong	Altered Expression	[710]
BAP1	TT47RXJ	Strong	Biomarker	[711]
BAX	TTQ57WJ	Strong	Altered Expression	[712]
BBC3	TT7JUKC	Strong	Biomarker	[713]
BCAT1	TTES57P	Strong	Biomarker	[714]
BCAT2	TTF9OQ6	Strong	Biomarker	[715]
BCL11A	TTR61MW	Strong	Biomarker	[716]
BCL2A1	TTGT9C7	Strong	Altered Expression	[407]
BCL2L2	TTQ79W8	Strong	Biomarker	[717]
BCL6	TTC9YX5	Strong	Altered Expression	[718]
BDNF	TTSMLOH	Strong	Genetic Variation	[719]
BGN	TT0JPVF	Strong	Biomarker	[720]
BIRC2	TTQ5LRD	Strong	Biomarker	[721]
BIRC5	TTTPU1G	Strong	Biomarker	[722]
BMP1	TT0L58T	Strong	Altered Expression	[723]
BMP10	TTTG6H1	Strong	Biomarker	[724]
BMP2	TTP3IGX	Strong	Altered Expression	[725]
BMP7	TTKOBRA	Strong	Biomarker	[726]
BMPR2	TTGKF90	Strong	Biomarker	[727]
BPHL	TTTZ3EU	Strong	Biomarker	[728]
BRAF	TT0EOB8	Strong	Biomarker	[729]
BRD3	TTHE657	Strong	Biomarker	[730]
BRD4	TTSRAOU	Strong	Altered Expression	[731]
BRD7	TT07ZS1	Strong	Biomarker	[732]
BRS3	TTKYEPM	Strong	Biomarker	[399]
BRSK1	TTV6WMQ	Strong	Biomarker	[521]
BST2	TT90BJT	Strong	Biomarker	[733]
BTK	TTGM6VW	Strong	Biomarker	[734]
BTLA	TTER58P	Strong	Genetic Variation	[735]
C1QBP	TTWTD7F	Strong	Altered Expression	[736]
C5	TTKANGO	Strong	Biomarker	[737]
C5AR1	TTHXFA1	Strong	Biomarker	[737]
CA12	TTSYM0R	Strong	Biomarker	[738]
CA2	TTANPDJ	Strong	Biomarker	[739]
CA9	TT2LVK8	Strong	Biomarker	[740]
CACNA2D2	TTU8P3M	Strong	Genetic Variation	[741]
CAD	TT2YT1K	Strong	Biomarker	[742]
CALCB	TTUZ9GV	Strong	Genetic Variation	[743]
CAMKK2	TTV298Y	Strong	Biomarker	[744]
CAMP	TTULOB6	Strong	Altered Expression	[745]
CAPN1	TT1WBIJ	Strong	Biomarker	[746]
CAPN2	TTG5QB7	Strong	Altered Expression	[747]
CARM1	TTIZQFJ	Strong	Biomarker	[748]
CASP10	TTX5HEK	Strong	Altered Expression	[749]
CASP2	TT12VNG	Strong	Biomarker	[750]
CASP6	TTKW4ML	Strong	Genetic Variation	[751]
CASP7	TTM7Y45	Strong	Biomarker	[752]
CASP9	TTB6T7O	Strong	Biomarker	[753]
CBL	TT7QT13	Strong	Biomarker	[754]
CCKBR	TTVFO0U	Strong	Biomarker	[755]
CCL11	TTCF05Y	Strong	Altered Expression	[756]
CCL17	TTMPHAE	Strong	Altered Expression	[757]
CCL20	TT2XAZY	Strong	Biomarker	[758]
CCL5	TT9DWLC	Strong	Altered Expression	[759]
CCN1	TTPK79J	Strong	Biomarker	[760]
CCN2	TTIL516	Strong	Biomarker	[761]
CCNA2	TTAMQ62	Strong	Altered Expression	[762]
CCND3	TT1JXNR	Strong	Biomarker	[763]
CCNE2	TTLDRGX	Strong	Biomarker	[764]
CCR2	TTFZYTO	Strong	Biomarker	[765]
CCR3	TTD3XFU	Strong	Altered Expression	[766]
CCR4	TT7HQD0	Strong	Biomarker	[767]
CCR5	TTJIH8Q	Strong	Biomarker	[768]
CCR6	TTFDB30	Strong	Biomarker	[769]
CCR7	TT2GIDQ	Strong	Biomarker	[770]
CCR9	TTIPS8B	Strong	Biomarker	[771]
CD163	TTTZ9DE	Strong	Biomarker	[772]
CD1A	TTBGTFN	Strong	Biomarker	[773]
CD200	TT0BE68	Strong	Biomarker	[774]
CD276	TT6CQUM	Strong	Biomarker	[775]
CD28	TTQ13FT	Strong	Altered Expression	[776]
CD320	TT0KV32	Strong	Biomarker	[777]
CD34	TTZAVYN	Strong	Biomarker	[778]
CD36	TTPJMCU	Strong	Altered Expression	[779]
CD38	TTPURFN	Strong	Biomarker	[780]
CD3E	TTZAT79	Strong	Biomarker	[781]
CD40	TT1ERKL	Strong	Altered Expression	[782]
CD46	TTMS7DF	Strong	Biomarker	[783]
CD47	TT28S46	Strong	Biomarker	[784]
CD55	TT5Z9WY	Strong	Altered Expression	[785]
CD70	TTNCIE0	Strong	Biomarker	[786]
CD83	TTT9MRQ	Strong	Genetic Variation	[787]
CDA	TTQ12RK	Strong	Biomarker	[788]
CDC25A	TTLZS4Q	Strong	Biomarker	[789]
CDC25B	TTR0SWN	Strong	Altered Expression	[790]
CDC25C	TTESBNC	Strong	Biomarker	[791]
CDCA8	TT04YCM	Strong	Biomarker	[792]
CDH2	TT1WS0T	Strong	Biomarker	[793]
CDH3	TTARMD9	Strong	Biomarker	[794]
CDH5	TTXLCFO	Strong	Biomarker	[795]
CDK11B	TT5Q79O	Strong	Altered Expression	[796]
CDK18	TTUMFAR	Strong	Altered Expression	[797]
CDK5	TTL4Q97	Strong	Altered Expression	[798]
CDK5R1	TTBYM6V	Strong	Biomarker	[799]
CDK7	TTQYF7G	Strong	Biomarker	[800]
CDK9	TT1LVF2	Strong	Biomarker	[801]
CEACAM1	TTA9CK4	Strong	Biomarker	[802]
CEACAM3	TTPX7I5	Strong	Biomarker	[803]
CEACAM5	TTY6DTE	Strong	Biomarker	[803]
CEBPB	TTUI35N	Strong	Biomarker	[804]
CERK	TT9XRNV	Strong	Biomarker	[805]
CETP	TTFQAYR	Strong	Biomarker	[806]
CFB	TTA0P7K	Strong	Genetic Variation	[807]
CFLAR	TTJZQYH	Strong	Genetic Variation	[808]
CFP	TTLA0VS	Strong	Biomarker	[809]
CHEK1	TTTU902	Strong	Biomarker	[810]
CHKA	TT10AWB	Strong	Biomarker	[811]
CHM	TTOA18V	Strong	Altered Expression	[812]
CHRNA5	TTH2QRX	Strong	Altered Expression	[813]
CHST15	TTFK7E1	Strong	Biomarker	[814]
CLCA1	TT3AF4R	Strong	Biomarker	[815]
CLDN18	TT6PKBX	Strong	Biomarker	[816]
CLDN4	TTMTS9H	Strong	Biomarker	[804]
CLIC1	TT8KZG6	Strong	Biomarker	[817]
CLK2	TT85TPS	Strong	Biomarker	[818]
CLN3	TTORF9W	Strong	Biomarker	[819]
CLU	TTRL76H	Strong	Biomarker	[820]
CMA1	TT8VUE0	Strong	Altered Expression	[821]
CMKLR1	TT4UGZL	Strong	Biomarker	[822]
CNP	TT71P0H	Strong	Biomarker	[823]
CNR2	TTMSFAW	Strong	Biomarker	[824]
CNTN1	TTPR8FK	Strong	Biomarker	[825]
COL18A1	TT63DI9	Strong	Biomarker	[826]
COL7A1	TTBCOKN	Strong	Biomarker	[827]
COPS5	TTSTNJR	Strong	Biomarker	[828]
CPA1	TT3LJ6G	Strong	Biomarker	[829]
CPB1	TT4UJX5	Strong	Biomarker	[830]
CPB2	TTP18AY	Strong	Altered Expression	[831]
CR1	TTEA8OW	Strong	Biomarker	[832]
CRAT	TTC8M31	Strong	Biomarker	[833]
CREB1	TTH4AN3	Strong	Altered Expression	[745]
CRHR1	TT7EFHR	Strong	Biomarker	[674]
CRK	TTFEUYR	Strong	Altered Expression	[370]
CRTC2	TTFWETR	Strong	Biomarker	[834]
CRY1	TT5MLZR	Strong	Biomarker	[310]
CRY2	TTAO58M	Strong	Genetic Variation	[621]
CRYAB	TT7RUHB	Strong	Biomarker	[835]
CSE1L	TTTRULD	Strong	Altered Expression	[836]
CSF1	TT0IQER	Strong	Biomarker	[837]
CSF1R	TT7MRDV	Strong	Biomarker	[838]
CSF2	TTNYZG2	Strong	Biomarker	[839]
CSF3	TT5TQ2W	Strong	Altered Expression	[840]
CSK	TTX6F0Q	Strong	Altered Expression	[841]
CSNK2A1	TTER6YH	Strong	Biomarker	[842]
CSNK2A2	TT7GR5W	Strong	Altered Expression	[843]
CSPG4	TT7MYXI	Strong	Biomarker	[844]
CTAG1A	TTE5ITK	Strong	Genetic Variation	[845]
CTCFL	TTY0RZT	Strong	Altered Expression	[846]
CTDSP1	TTHZAF0	Strong	Altered Expression	[847]
CTH	TTLQUZS	Strong	Altered Expression	[848]
CTLA4	TTI2S1D	Strong	Biomarker	[849]
CTSB	TTF2LRI	Strong	Biomarker	[850]
CTSG	TTQAJF1	Strong	Biomarker	[851]
CTSL	TT36ETB	Strong	Altered Expression	[852]
CTSS	TTUMQVO	Strong	Biomarker	[853]
CUL3	TTPCU0Q	Strong	Altered Expression	[395]
CXCL1	TTLK1RW	Strong	Biomarker	[854]
CXCL10	TTQOVYA	Strong	Biomarker	[855]
CXCL2	TTZF0K2	Strong	Biomarker	[856]
CXCL9	TTWE5PB	Strong	Genetic Variation	[857]
CXCR1	TTMWT8Z	Strong	Biomarker	[858]
CXCR2	TT30C9G	Strong	Biomarker	[859]
CXCR3	TT1UCIJ	Strong	Altered Expression	[860]
CXCR6	TT2BVUA	Strong	Biomarker	[399]
CXXC5	TTVS4C3	Strong	Biomarker	[861]
CYP11A1	TTSYVO6	Strong	Genetic Variation	[862]
CYP26A1	TTD7Q0R	Strong	Biomarker	[863]
CYP2A6	TTAQ6ZW	Strong	Genetic Variation	[864]
CYP2C9	TTR40YJ	Strong	Genetic Variation	[865]
CYP2E1	TTWVHQ5	Strong	Genetic Variation	[866]
CYP2J2	TTNE1C7	Strong	Altered Expression	[867]
CYSLTR1	TTGKOY9	Strong	Altered Expression	[868]
CYSLTR2	TT0PZR5	Strong	Altered Expression	[868]
DAG1	TT4X7PG	Strong	Altered Expression	[869]
DCK	TTJOCE4	Strong	Altered Expression	[870]
DCLK1	TTOHTCY	Strong	Altered Expression	[871]
DCLK3	TTMYK4Z	Strong	Biomarker	[872]
DCN	TTB3XAN	Strong	Biomarker	[720]
DDC	TTN451K	Strong	Biomarker	[873]
DDR1	TTI1FPZ	Strong	Biomarker	[874]
DDR2	TTU98HG	Strong	Biomarker	[875]
DDX5	TTZKPVC	Strong	Biomarker	[876]
DEPDC1	TT8S9CM	Strong	Altered Expression	[877]
DEPTOR	TTLYP6D	Strong	Altered Expression	[878]
DHCR24	TTTK0NH	Strong	Biomarker	[879]
DHODH	TTLVP78	Strong	Altered Expression	[880]
DIABLO	TTN74LE	Strong	Biomarker	[881]
DICER1	TTTEOPU	Strong	Biomarker	[882]
DKK1	TTE3RAC	Strong	Biomarker	[883]
DKK3	TTY2ZV6	Strong	Altered Expression	[884]
DLL1	TT9CFQD	Strong	Biomarker	[885]
DLL3	TT1C9K6	Strong	Altered Expression	[886]
DLL4	TTV23LH	Strong	Altered Expression	[887]
DMD	TTWLFXU	Strong	Biomarker	[888]
DNAJB1	TTPXAWS	Strong	Altered Expression	[889]
DNASE1	TTYWGOJ	Strong	Genetic Variation	[890]
DNM1	TTE3JW9	Strong	Biomarker	[891]
DNM2	TTVRA5G	Strong	Biomarker	[892]
DNMT3A	TTJUALD	Strong	Biomarker	[893]
DNPEP	TTGMFY7	Strong	Altered Expression	[894]
DOT1L	TTSZ8T1	Strong	Biomarker	[895]
DPEP1	TTYUENF	Strong	Biomarker	[896]
DRD3	TT4C8EA	Strong	Genetic Variation	[897]
DRD4	TTE0A2F	Strong	Biomarker	[898]
DSG3	TTEO4P8	Strong	Biomarker	[899]
DTL	TT8396I	Strong	Biomarker	[900]
DUSP1	TTG8HIM	Strong	Altered Expression	[901]
DUSP10	TTF3RJ0	Strong	Altered Expression	[902]
DUSP9	TT1GV6C	Strong	Altered Expression	[903]
DYRK1A	TTSBVFO	Strong	Biomarker	[904]
DYRK1B	TTYGQ8A	Strong	Biomarker	[905]
DYRK2	TT84OS6	Strong	Biomarker	[906]
E2F1	TTASI04	Strong	Biomarker	[907]
EBI3	TTJF68X	Strong	Biomarker	[908]
EBP	TT4VQZX	Strong	Biomarker	[909]
ECE1	TTQ9RYT	Strong	Biomarker	[910]
EDNRA	TTKRD0G	Strong	Biomarker	[399]
EDNRB	TT3ZTGU	Strong	Biomarker	[911]
EGLN1	TT9ISBX	Strong	Altered Expression	[912]
EGLN2	TTMHFRY	Strong	Genetic Variation	[913]
EHMT1	TTOFXD7	Strong	Biomarker	[352]
EHMT2	TTS6RZT	Strong	Biomarker	[914]
EIF2AK2	TTXEZJ4	Strong	Biomarker	[915]
EIF2AK3	TT79U1M	Strong	Altered Expression	[916]
EIF4E	TTZGCP6	Strong	Biomarker	[917]
EIF4EBP1	TTKGEBL	Strong	Biomarker	[918]
EIF5A2	TTH53G9	Strong	Altered Expression	[919]
ELAVL1	TTPC9D0	Strong	Biomarker	[920]
ENAH	TTY36UA	Strong	Altered Expression	[921]
ENG	TTB30LE	Strong	Biomarker	[922]
ENOX2	TTUJZRL	Strong	Genetic Variation	[923]
ENPEP	TT9PBIL	Strong	Altered Expression	[924]
ENPP1	TTZTIWS	Strong	Biomarker	[925]
EPAS1	TTWPA54	Strong	Altered Expression	[926]
EPHA3	TTHS2LR	Strong	Altered Expression	[927]
EPHA4	TTG84D3	Strong	Biomarker	[928]
EPHA6	TTFAHWI	Strong	Altered Expression	[929]
EPHB2	TTKPV6O	Strong	Biomarker	[930]
EPHB3	TT5LM7U	Strong	Altered Expression	[546]
EPHB4	TTI4ZX2	Strong	Biomarker	[546]
ERBB4	TTWALCO	Strong	Biomarker	[931]
EREG	TTYSB89	Strong	Altered Expression	[932]
ERN1	TTKIAT3	Strong	Biomarker	[933]
ESRRB	TTKF0XS	Strong	Altered Expression	[934]
ESRRG	TT9ZRHB	Strong	Biomarker	[935]
ETS1	TTTGPSD	Strong	Altered Expression	[936]
ETS2	TT9AH0M	Strong	Biomarker	[937]
EZR	TTE47YC	Strong	Biomarker	[938]
F10	TTCIHJA	Strong	Biomarker	[939]
F11	TTDM4ZU	Strong	Biomarker	[940]
F11R	TT3C8EG	Strong	Genetic Variation	[941]
F2RL1	TTQR74A	Strong	Biomarker	[942]
F2RL2	TTVSEBF	Strong	Altered Expression	[943]
F8	TT1290U	Strong	Biomarker	[944]
FABP5	TTNT2S6	Strong	Altered Expression	[945]
FADS2	TTT2VDU	Strong	Altered Expression	[946]
FANCF	TTNZKFJ	Strong	Biomarker	[947]
FASLG	TTO7014	Strong	Genetic Variation	[948]
FBXO11	TT6G10V	Strong	Altered Expression	[949]
FBXW7	TT29KY7	Strong	Biomarker	[950]
FCGR2A	TTXT21W	Strong	Genetic Variation	[951]
FDXR	TT3W4IX	Strong	Altered Expression	[434]
FECH	TTQ6VF4	Strong	Altered Expression	[952]
FES	TTLBY21	Strong	Biomarker	[953]
FFAR1	TTB8FUC	Strong	Altered Expression	[954]
FGF1	TTMY81X	Strong	Biomarker	[955]
FGF10	TTNPEFX	Strong	Genetic Variation	[956]
FGF18	TT6ICRA	Strong	Biomarker	[957]
FGF2	TTGKIED	Strong	Biomarker	[958]
FGF21	TTQ916P	Strong	Biomarker	[959]
FGF4	TTCEKVZ	Strong	Biomarker	[960]
FGF7	TTFY134	Strong	Biomarker	[961]
FGF8	TTIUF3J	Strong	Biomarker	[962]
FGFBP1	TTV1YFT	Strong	Altered Expression	[963]
FHIT	TTMS54D	Strong	Biomarker	[964]
FKBP1A	TTMW94E	Strong	Biomarker	[965]
FLNA	TTSTRZY	Strong	Altered Expression	[966]
FLT1	TT1VAUK	Strong	Biomarker	[967]
FN1	TTPJ921	Strong	Altered Expression	[968]
FOLH1	TT9G4N0	Strong	Biomarker	[969]
FOS	TTOM5AU	Strong	Altered Expression	[970]
FOSL1	TTY8LZG	Strong	Altered Expression	[971]
FOSL2	TT689IR	Strong	Altered Expression	[972]
FOXC1	TTNT3YA	Strong	Biomarker	[973]
FOXJ2	TTV1FDA	Strong	Biomarker	[974]
FOXM1	TTD3KOX	Strong	Altered Expression	[975]
FPR1	TT5Y4EM	Strong	Biomarker	[976]
FSCN1	TTTRS9B	Strong	Altered Expression	[977]
FST	TTDNM9W	Strong	Biomarker	[978]
FSTL3	TTWRPM8	Strong	Biomarker	[979]
FTH1	TT975ZT	Strong	Biomarker	[980]
FTO	TTFW3BT	Strong	Biomarker	[275]
FUS	TTKGYZ9	Strong	Biomarker	[981]
FUT3	TTUPAD7	Strong	Biomarker	[982]
FUT4	TTNV1KZ	Strong	Altered Expression	[983]
FZD7	TTUQMO5	Strong	Biomarker	[984]
G3BP1	TTG0R8Z	Strong	Altered Expression	[985]
G6PC2	TT7EV4P	Strong	Genetic Variation	[986]
GABRA3	TT37EDJ	Strong	Biomarker	[987]
GABRP	TT3E0DI	Strong	Biomarker	[988]
GALNS	TTT9YPO	Strong	Altered Expression	[989]
GAPDH	TTUGSWA	Strong	Altered Expression	[990]
GAS6	TT69QD2	Strong	Biomarker	[991]
GAST	TT4LRVO	Strong	Biomarker	[755]
GCG	TT6Y4PN	Strong	Biomarker	[352]
GDF15	TT4MXVG	Strong	Biomarker	[992]
GDF2	TTAP4T1	Strong	Biomarker	[993]
GDNF	TTF23ML	Strong	Altered Expression	[994]
GEM	TTAZF9M	Strong	Genetic Variation	[384]
GHR	TTHJWYD	Strong	Biomarker	[995]
GHRHR	TTG4R8V	Strong	Biomarker	[996]
GIP	TT40HS5	Strong	Altered Expression	[997]
GJA1	TT4F7SL	Strong	Biomarker	[998]
GJA3	TTFZRG0	Strong	Biomarker	[351]
GJB2	TTRGZX3	Strong	Altered Expression	[999]
GLI2	TT045OH	Strong	Altered Expression	[1000]
GLUL	TTURQ2G	Strong	Altered Expression	[1001]
GM2A	TTGOFW6	Strong	Biomarker	[1002]
GMNN	TT390KA	Strong	Biomarker	[1003]
GNAQ	TTL1SRG	Strong	Genetic Variation	[353]
GOT1	TTU507L	Strong	Altered Expression	[1004]
GPBAR1	TTSDVTR	Strong	Biomarker	[1005]
GPI	TT19JIZ	Strong	Biomarker	[1006]
GPNMB	TT7315J	Strong	Biomarker	[1007]
GPR119	TT7QNVC	Strong	Altered Expression	[1008]
GPR132	TTNBW4F	Strong	Biomarker	[1009]
GPR17	TTMPART	Strong	Genetic Variation	[1010]
GPR55	TTNET8J	Strong	Biomarker	[1011]
GPRC6A	TTI1PRE	Strong	Biomarker	[1012]
GRB2	TTEYRJ9	Strong	Biomarker	[1013]
GRHL2	TTUGH4C	Strong	Biomarker	[1014]
GRIK2	TT0K5RG	Strong	Genetic Variation	[1015]
GRIK3	TTNP6O2	Strong	Biomarker	[1016]
GRIN1	TTLD29N	Strong	Altered Expression	[1017]
GRK3	TT5A4DX	Strong	Altered Expression	[1018]
GRK5	TTTCXO0	Strong	Altered Expression	[1019]
GRM1	TTVBPDM	Strong	Biomarker	[1020]
GRN	TT0LWE3	Strong	Altered Expression	[1021]
GRPR	TTC1MVT	Strong	Biomarker	[1022]
GSK3B	TTRSMW9	Strong	Altered Expression	[1023]
GSN	TTUH7OM	Strong	Altered Expression	[1024]
GSR	TTEP6RV	Strong	Biomarker	[1025]
GUCY2D	TTWNFC2	Strong	Genetic Variation	[1026]
GUSB	TTHS7CM	Strong	Altered Expression	[1027]
HAX1	TT21BYA	Strong	Biomarker	[1028]
HBB	TTM6HK1	Strong	Biomarker	[1029]
HBEGF	TT15SL0	Strong	Altered Expression	[1030]
HCAR1	TTVK4ZO	Strong	Biomarker	[1031]
HDAC3	TT4YWTO	Strong	Biomarker	[1032]
HDAC4	TTTQGH8	Strong	Biomarker	[1033]
HDAC6	TT5ZKDI	Strong	Biomarker	[1034]
HDAC7	TTMUEK1	Strong	Biomarker	[1035]
HDAC9	TT8M4E1	Strong	Biomarker	[1036]
HHAT	TT1VNCG	Strong	Altered Expression	[1037]
HK2	TTK02H8	Strong	Biomarker	[423]
HKDC1	TTVUI8G	Strong	Altered Expression	[1038]
HLA-A	TTHONFT	Strong	Altered Expression	[1039]
HLA-G	TTLKFB3	Strong	Biomarker	[1040]
HMBS	TTT0HW3	Strong	Biomarker	[1041]
HMGA1	TTBA219	Strong	Altered Expression	[1042]
HMGA2	TTSTVM0	Strong	Biomarker	[1043]
HMGB2	TTA78JQ	Strong	Biomarker	[1044]
HMOX1	TTI6V2A	Strong	Biomarker	[1045]
HNF4A	TT2F3CD	Strong	Altered Expression	[1046]
HNRNPA1	TTPJ9XK	Strong	Biomarker	[1047]
HOXA5	TTXSVQP	Strong	Altered Expression	[1048]
HOXA7	TTMRE4Q	Strong	Biomarker	[1049]
HP	TTLC8E1	Strong	Biomarker	[1050]
HPSE	TTR7GJO	Strong	Biomarker	[1051]
HRH1	TTTIBOJ	Strong	Biomarker	[1052]
HRH4	TTXJ178	Strong	Biomarker	[1053]
HSD11B1	TTN7BL9	Strong	Altered Expression	[361]
HSD17B4	TTL1WGS	Strong	Biomarker	[1054]
HSF1	TTN6STZ	Strong	Biomarker	[1055]
HSP90AA1	TT78R5H	Strong	Biomarker	[1056]
HSP90AB1	TTH5YN2	Strong	Biomarker	[1057]
HSP90B1	TTFPKXQ	Strong	Biomarker	[1058]
HSPA5	TTW26OG	Strong	Biomarker	[1034]
HSPA9	TTMTPG3	Strong	Altered Expression	[1059]
HSPB1	TT9AZWY	Strong	Biomarker	[1060]
HSPB3	TTLH8WG	Strong	Biomarker	[1060]
HSPB8	TTY0OJN	Strong	Altered Expression	[1061]
HSPG2	TT5UM29	Strong	Altered Expression	[1062]
HTR1B	TTK8CXU	Strong	Biomarker	[1063]
HTR2A	TTJQOD7	Strong	Genetic Variation	[1064]
HTRA1	TT8POQR	Strong	Altered Expression	[1065]
HTT	TTIWZ0O	Strong	Genetic Variation	[1066]
IAPP	TTHN8EM	Strong	Biomarker	[676]
ID2	TTW8A5N	Strong	Altered Expression	[1067]
IDO1	TTZJYKH	Strong	Biomarker	[1068]
IDUA	TT0IUKX	Strong	Altered Expression	[1069]
IFNA2	TTSIUJ9	Strong	Biomarker	[1070]
IFNB1	TT4TZ8J	Strong	Biomarker	[1071]
IFNG	TT93WF5	Strong	Biomarker	[1072]
IGF1R	TTQFBMY	Strong	Biomarker	[1073]
IGFBP2	TTU4QSN	Strong	Altered Expression	[1074]
IGFBP7	TTUQ01B	Strong	Posttranslational Modification	[1075]
IKBKB	TTJ3E9X	Strong	Biomarker	[1076]
IKZF3	TTCZVFZ	Strong	Genetic Variation	[1077]
IL11	TTGUYTR	Strong	Biomarker	[1078]
IL13RA2	TTMPZ7V	Strong	Altered Expression	[1079]
IL15	TTJFA35	Strong	Altered Expression	[1080]
IL15RA	TTGN89I	Strong	Biomarker	[1081]
IL17A	TTG0MT6	Strong	Biomarker	[859]
IL18	TTRICUF	Strong	Altered Expression	[1082]
IL1A	TTPM6HI	Strong	Genetic Variation	[1083]
IL20	TTNZMY2	Strong	Altered Expression	[1084]
IL23R	TT6H4QR	Strong	Altered Expression	[1085]
IL24	TT1EPXZ	Strong	Biomarker	[1086]
IL2RA	TT10Y9E	Strong	Biomarker	[1087]
IL2RB	TT9721Y	Strong	Altered Expression	[1088]
IL9	TT0JTFD	Strong	Biomarker	[1089]
ILK	TT7ALZG	Strong	Biomarker	[1090]
IMP3	TTEJA2R	Strong	Altered Expression	[1091]
IMPDH2	TTTB4UP	Strong	Altered Expression	[1092]
INPP5D	TTTP2Z1	Strong	Altered Expression	[1093]
INSR	TTCBFJO	Strong	Genetic Variation	[1094]
IRF1	TT4TU3L	Strong	Biomarker	[721]
IRF3	TTYR7OH	Strong	Biomarker	[1095]
IRS1	TTAJSQ0	Strong	Biomarker	[1096]
ITGA1	TTPERWV	Strong	Altered Expression	[1097]
ITGA11	TTANXZ7	Strong	Biomarker	[1098]
ITGA4	TTJMF9P	Strong	Altered Expression	[1099]
ITGA5	TTHIZP9	Strong	Biomarker	[1097]
ITGA6	TT165T3	Strong	Biomarker	[1100]
ITGAV	TTT1R2L	Strong	Biomarker	[1101]
ITGB1	TTBVIQC	Strong	Biomarker	[1102]
ITGB2	TTIJWR7	Strong	Biomarker	[1103]
ITGB6	TTKQSXZ	Strong	Biomarker	[1104]
ITPR1	TT5HWAT	Strong	Biomarker	[466]
ITPR3	TTH1769	Strong	Biomarker	[1105]
JAG2	TTOJY1B	Strong	Altered Expression	[1106]
JMJD1C	TTBISK4	Strong	Altered Expression	[1107]
JUN	TTS7IR5	Strong	Altered Expression	[1108]
JUP	TTREN0G	Strong	Biomarker	[1109]
KAT6B	TTH4VJL	Strong	Genetic Variation	[1110]
KCNA5	TTW0CMT	Strong	Altered Expression	[1111]
KCNH1	TT9XKUC	Strong	Genetic Variation	[1112]
KCNH2	TTQ6VDM	Strong	Altered Expression	[1113]
KCNJ3	TTGM19J	Strong	Biomarker	[1114]
KCNK9	TTL4FMB	Strong	Biomarker	[1115]
KCNMA1	TTE87WJ	Strong	Altered Expression	[1116]
KDM1A	TTNR0UQ	Strong	Biomarker	[1117]
KDM4A	TTZHPB8	Strong	Biomarker	[1118]
KDM5A	TTIG67W	Strong	Biomarker	[1119]
KDM5B	TTCLI75	Strong	Biomarker	[1120]
KEAP1	TT3Z6Y9	Strong	Biomarker	[1121]
KHDRBS1	TTAT6C7	Strong	Biomarker	[927]
KIF11	TTBGTCW	Strong	Biomarker	[1122]
KIF20B	TTQECT2	Strong	Biomarker	[1123]
KIF26B	TTQWICZ	Strong	Altered Expression	[1124]
KIF5A	TTCJPAH	Strong	Altered Expression	[1125]
KIR2DL3	TTEX3SI	Strong	Altered Expression	[1126]
KISS1R	TT3KBZY	Strong	Biomarker	[1127]
KIT	TTX41N9	Strong	Biomarker	[1128]
KITLG	TTDJ51N	Strong	Genetic Variation	[1129]
KLK1	TT5T3P6	Strong	Biomarker	[1130]
KLK2	TTJLNAW	Strong	Altered Expression	[1131]
KLK4	TT4319X	Strong	Biomarker	[1132]
KLK5	TTULSEW	Strong	Biomarker	[1133]
KLK6	TTLPF4X	Strong	Biomarker	[1134]
KLK7	TTE6GTB	Strong	Altered Expression	[1135]
KMT2A	TT1GNDM	Strong	Biomarker	[1136]
KMT5A	TTGC95K	Strong	Biomarker	[1137]
KMT5C	TT7H3YM	Strong	Biomarker	[1138]
KNG1	TTDJ4MY	Strong	Biomarker	[1139]
KRT17	TTKV0EC	Strong	Biomarker	[1140]
KRT6A	TT2FX8W	Strong	Genetic Variation	[1141]
KSR1	TTHL1TV	Strong	Genetic Variation	[1142]
KYNU	TTWQM3J	Strong	Biomarker	[1143]
L1CAM	TTC9D3K	Strong	Altered Expression	[1144]
L3MBTL3	TTQDMJN	Strong	Biomarker	[674]
LALBA	TTBRLU3	Strong	Biomarker	[1145]
LAMB3	TT2WOUQ	Strong	Biomarker	[1146]
LAMP1	TTC214J	Strong	Altered Expression	[1147]
LANCL1	TTZW8NS	Strong	Altered Expression	[1148]
LCN2	TTKTLAI	Strong	Altered Expression	[1149]
LDHA	TTW76JE	Strong	Biomarker	[1150]
LDLR	TTH0DUS	Strong	Biomarker	[1151]
LGALS1	TTO3NYT	Strong	Biomarker	[1152]
LGR4	TTY6C71	Strong	Biomarker	[1153]
LGR5	TTTSGRH	Strong	Altered Expression	[1154]
LIFR	TTID542	Strong	Biomarker	[1155]
LILRB1	TTC0QRJ	Strong	Biomarker	[1156]
LIMK1	TTWL9TY	Strong	Biomarker	[1157]
LIMK2	TTASMD8	Strong	Biomarker	[1158]
LIPE	TTLUQ8E	Strong	Biomarker	[1159]
LIPG	TTHSZXO	Strong	Altered Expression	[1160]
LMO2	TTFX379	Strong	Biomarker	[1161]
LNPEP	TTY2KP7	Strong	Biomarker	[1162]
LONP1	TTM1VPZ	Strong	Biomarker	[1163]
LOXL2	TTFSUHX	Strong	Biomarker	[1164]
LPA	TTU9LGY	Strong	Biomarker	[1165]
LPAR1	TTQ6S1K	Strong	Biomarker	[1166]
LPAR2	TTB7Y8I	Strong	Biomarker	[399]
LPAR6	TTZDAGB	Strong	Altered Expression	[1167]
LRP1	TTF2V7I	Strong	Biomarker	[497]
LRP6	TTSXOWE	Strong	Biomarker	[1168]
LRRC32	TT0FAYT	Strong	Biomarker	[1169]
LSM1	TT2KHSC	Strong	Altered Expression	[1170]
LSS	TT7O8ZA	Strong	Biomarker	[1171]
LTA	TTP73TM	Strong	Genetic Variation	[1172]
LTB	TTHQ6US	Strong	Genetic Variation	[368]
LTF	TTSZDQU	Strong	Biomarker	[1173]
LY75	TTG180Q	Strong	Altered Expression	[1174]
LYN	TT1RWNJ	Strong	Altered Expression	[1175]
LYVE1	TTG8DNU	Strong	Biomarker	[1176]
LYZ	TTAOZBW	Strong	Biomarker	[1177]
MAD1L1	TTNE9U7	Strong	Biomarker	[1178]
MAGEA1	TT63M7Q	Strong	Genetic Variation	[1179]
MAGEA2	TTOZT28	Strong	Biomarker	[1180]
MAGEA4	TT9EQUY	Strong	Genetic Variation	[1181]
MAGEC2	TTKGUEB	Strong	Biomarker	[1182]
MAOA	TT3WG5C	Strong	Altered Expression	[1183]
MAP2K1	TTIDAPM	Strong	Biomarker	[1184]
MAP2K5	TTV3O87	Strong	Altered Expression	[1185]
MAP2K7	TT6QY3J	Strong	Biomarker	[729]
MAP3K10	TT9FN4J	Strong	Altered Expression	[1186]
MAP3K11	TTETX6Q	Strong	Altered Expression	[1187]
MAP3K14	TT4LIAC	Strong	Altered Expression	[1188]
MAP3K2	TTIX0ZU	Strong	Genetic Variation	[593]
MAP3K3	TTJZNIG	Strong	Biomarker	[1189]
MAP3K4	TT1RSX7	Strong	Biomarker	[1190]
MAP3K7	TTJQT60	Strong	Biomarker	[1191]
MAP3K8	TTGECUM	Strong	Altered Expression	[1192]
MAP4K4	TT6NI13	Strong	Altered Expression	[1193]
MAPK1	TT4TQBX	Strong	Biomarker	[930]
MAPK10	TT056SO	Strong	Altered Expression	[1194]
MAPK12	TTYT93M	Strong	Biomarker	[1195]
MAPK14	TTQBR95	Strong	Altered Expression	[370]
MAPK3	TT1MG9E	Strong	Biomarker	[1196]
MAPK7	TTU6FSC	Strong	Altered Expression	[1197]
MAPK8	TT0K6EO	Strong	Biomarker	[490]
MAPK9	TT3IVG2	Strong	Posttranslational Modification	[1198]
MAPT	TTS87KH	Strong	Altered Expression	[1199]
MARCKS	TTHRM39	Strong	Altered Expression	[1200]
MARK2	TTAJ45Y	Strong	Biomarker	[1201]
MAS1	TTOISYB	Strong	Biomarker	[1202]
MAZ	TT059DA	Strong	Biomarker	[1203]
MBL2	TTMQDZ5	Strong	Genetic Variation	[1204]
MBNL2	TTH9OLG	Strong	Altered Expression	[1205]
MBOAT4	TTSYOWR	Strong	Altered Expression	[1206]
MBTPS1	TTNSM2I	Strong	Biomarker	[1207]
MC1R	TT0MV2T	Strong	Genetic Variation	[1208]
MCAM	TTHRE05	Strong	Altered Expression	[1209]
MCM6	TTQGKSD	Strong	Biomarker	[1210]
MCM7	TT1RM3F	Strong	Biomarker	[1211]
MDK	TTV8UE7	Strong	Altered Expression	[1212]
MFGE8	TT1GLAJ	Strong	Biomarker	[1213]
MGLL	TTZ963I	Strong	Biomarker	[561]
MGMT	TTJ8DV7	Strong	Posttranslational Modification	[1214]
MIA	TT5HNVS	Strong	Biomarker	[1215]
MIF	TT6804T	Strong	Genetic Variation	[1216]
MKI67	TTB4UNG	Strong	Biomarker	[1217]
MKNK1	TTEZAUX	Strong	Altered Expression	[1218]
MKNK2	TTRECN3	Strong	Biomarker	[1219]
MLANA	TT362RB	Strong	Biomarker	[1220]
MME	TT5TKPM	Strong	Biomarker	[1174]
MMP10	TTXLEG7	Strong	Altered Expression	[1221]
MMP11	TTZW4MV	Strong	Biomarker	[1222]
MMP13	TTHY57M	Strong	Biomarker	[1223]
MMP14	TTJ4QE7	Strong	Biomarker	[1224]
MMP17	TTVSZKN	Strong	Biomarker	[1225]
MMP7	TTMTWOS	Strong	Altered Expression	[1226]
MMP9	TT6X50U	Strong	Biomarker	[1227]
MRC2	TTYVR8M	Strong	Altered Expression	[1228]
MSI1	TTSM4BA	Strong	Altered Expression	[1229]
MSLN	TT4RXME	Strong	Altered Expression	[1230]
MSR1	TT2TDH9	Strong	Altered Expression	[1231]
MSTN	TTM8I2X	Strong	Biomarker	[978]
MTM1	TTY2TCU	Strong	Biomarker	[1232]
MTNR1A	TT0WAIE	Strong	Biomarker	[1233]
MTNR1B	TT32JK8	Strong	Biomarker	[1234]
MTOR	TTCJG29	Strong	Biomarker	[1235]
MTTP	TTUS1RD	Strong	Biomarker	[1236]
MUC16	TTC1PS3	Strong	Biomarker	[803]
MUC17	TTVO0JU	Strong	Biomarker	[1237]
MVD	TTE5J6X	Strong	Biomarker	[1238]
MYB	TT8V13P	Strong	Biomarker	[1239]
MYD88	TTB6Q2O	Strong	Altered Expression	[1240]
MYLK	TT18ETS	Strong	Biomarker	[1241]
NAMPT	TTD1WIG	Strong	Altered Expression	[1242]
NCAM1	TTVXPHT	Strong	Altered Expression	[1243]
NCL	TTK1V5Q	Strong	Biomarker	[822]
NCOA4	TT8OY02	Strong	Genetic Variation	[1244]
NECTIN4	TTPO9EG	Strong	Biomarker	[1245]
NEDD8	TTNDC4K	Strong	Biomarker	[1246]
NEDD9	TT1UREA	Strong	Biomarker	[1247]
NEK2	TT3VZ24	Strong	Altered Expression	[1248]
NEK6	TT8I2M7	Strong	Altered Expression	[1249]
NELL1	TT7H4BF	Strong	Biomarker	[1250]
NES	TTHZ752	Strong	Altered Expression	[1251]
NF2	TTZIK7P	Strong	Biomarker	[1252]
NFKB1	TTUIZKC	Strong	Biomarker	[1253]
NFKB2	TTKLNRV	Strong	Biomarker	[1254]
NFKBIA	TTSHAEB	Strong	Genetic Variation	[368]
NGFR	TTEDJN4	Strong	Biomarker	[1255]
NISCH	TT789FN	Strong	Biomarker	[1256]
NKX3-1	TT1E0JK	Strong	Biomarker	[1257]
NME1	TTDY8JH	Strong	Biomarker	[1258]
NMUR2	TT2L6C5	Strong	Altered Expression	[1259]
NNT	TTKIH76	Strong	Biomarker	[1260]
NODAL	TTK2O1Q	Strong	Biomarker	[1261]
NOS2	TTF10I9	Strong	Altered Expression	[1262]
NOTCH1	TTB1STW	Strong	Biomarker	[1263]
NOTCH2	TT82FVD	Strong	Biomarker	[1264]
NOTCH3	TTVX7IA	Strong	Biomarker	[1265]
NOX4	TTQRBSJ	Strong	Altered Expression	[1266]
NPPB	TTY63XT	Strong	Biomarker	[1267]
NPY4R	TTW4N16	Strong	Genetic Variation	[1268]
NPY5R	TTY6EWA	Strong	Biomarker	[1269]
NQO2	TTJLP0R	Strong	Genetic Variation	[1270]
NR0B2	TT25A9Q	Strong	Biomarker	[1271]
NR1D1	TTAD1O8	Strong	Altered Expression	[1272]
NR1H4	TTS4UGC	Strong	Altered Expression	[1273]
NR5A2	TTAU3SY	Strong	Altered Expression	[1274]
NRG1	TTEH395	Strong	Biomarker	[992]
NRG4	TTWAGKJ	Strong	Altered Expression	[1275]
NRP1	TTIPJCB	Strong	Biomarker	[1276]
NRP2	TTRXUVC	Strong	Biomarker	[1277]
NT5E	TTK0O6Y	Strong	Biomarker	[1278]
NTF4	TTIM2WO	Strong	Biomarker	[1279]
NTRK1	TTTDVOJ	Strong	Altered Expression	[1280]
NTRK3	TTXABCW	Strong	Genetic Variation	[1281]
NTSR1	TTTUMEP	Strong	Altered Expression	[1282]
NUF2	TTIXBFP	Strong	Biomarker	[1283]
ODC1	TTUMGNO	Strong	Altered Expression	[653]
OGDH	TTH8T6I	Strong	Biomarker	[1284]
OLR1	TTKSND3	Strong	Biomarker	[1285]
OPRM1	TTKWM86	Strong	Genetic Variation	[1286]
ORAI1	TTE76YK	Strong	Biomarker	[1287]
OSM	TTIVXSE	Strong	Biomarker	[1288]
OSMR	TTAH0KM	Strong	Biomarker	[1289]
OXER1	TT7WBSV	Strong	Biomarker	[1012]
OXTR	TTSCIUP	Strong	Biomarker	[1290]
P2RX7	TT473XN	Strong	Biomarker	[1291]
P2RY6	TTNVSKA	Strong	Altered Expression	[1292]
PABPC1	TTHC8EF	Strong	Biomarker	[1293]
PAH	TTGSVH2	Strong	Genetic Variation	[1294]
PAK1	TTFN95D	Strong	Biomarker	[1295]
PAM	TTF4ZPC	Strong	Genetic Variation	[1296]
PAOX	TTNQ760	Strong	Altered Expression	[1297]
PARG	TT39J16	Strong	Altered Expression	[1298]
PARP3	TTD8MEH	Strong	Biomarker	[1299]
PAWR	TT3I4WV	Strong	Biomarker	[548]
PCSK1	TTED9LZ	Strong	Biomarker	[1300]
PCSK5	TTPFWHU	Strong	Biomarker	[1301]
PCYT1B	TTUAIKM	Strong	Biomarker	[1302]
PDCD1	TTNBFWK	Strong	Biomarker	[1303]
PDCD1LG2	TTW14O3	Strong	Biomarker	[1304]
PDCD2	TTYOVWN	Strong	Altered Expression	[1305]
PDE2A	TTJGW1Z	Strong	Biomarker	[1306]
PDE4A	TTZ97H5	Strong	Biomarker	[1307]
PDE4B	TTVIAT9	Strong	Genetic Variation	[1308]
PDE4D	TTSKMI8	Strong	Altered Expression	[1309]
PDE5A	TTJ0IQB	Strong	Altered Expression	[1310]
PDE7B	TTWIEY9	Strong	Altered Expression	[1311]
PDGFA	TTSM78N	Strong	Altered Expression	[1312]
PDGFD	TTSN0GA	Strong	Altered Expression	[1313]
PDK1	TTCZOF2	Strong	Altered Expression	[1314]
PDPK1	TTYMGWX	Strong	Biomarker	[1315]
PDX1	TT8SGZK	Strong	Biomarker	[1316]
PDZK1	TTDTBLM	Strong	Biomarker	[1317]
PEBP1	TT1BGU8	Strong	Altered Expression	[1318]
PECAM1	TT4EZB2	Strong	Biomarker	[1176]
PF4	TTSG7Q5	Strong	Altered Expression	[860]
PFKFB2	TTQYVKD	Strong	Biomarker	[1319]
PGC	TT7K6AD	Strong	Biomarker	[1320]
PGD	TTZ3IFB	Strong	Biomarker	[1321]
PHKG2	TTI5WS6	Strong	Altered Expression	[1322]
PIGU	TT2LHI6	Strong	Biomarker	[1323]
PIM1	TTTN5QW	Strong	Altered Expression	[1324]
PLA2G1B	TT9V5JH	Strong	Biomarker	[1325]
PLA2G4A	TTT1JVS	Strong	Altered Expression	[1326]
PLA2G4C	TTBYG4O	Strong	Biomarker	[1327]
PLAC1	TTM18HX	Strong	Biomarker	[1328]
PLAT	TTXAGYU	Strong	Biomarker	[1329]
PLAU	TTGY7WI	Strong	Biomarker	[1330]
PLAUR	TTNOSTX	Strong	Biomarker	[1331]
PLCB1	TTLPGU7	Strong	Altered Expression	[1332]
PLK1	TTH4IP0	Strong	Biomarker	[1333]
PLK2	TT976FS	Strong	Biomarker	[1334]
PLOD2	TT8MEUD	Strong	Altered Expression	[1335]
PLTP	TTZF6SN	Strong	Altered Expression	[1336]
PMEL	TT8MK59	Strong	Biomarker	[1337]
PML	TTLH9NY	Strong	Biomarker	[1324]
PNMT	TT0NZIC	Strong	Biomarker	[1338]
POLB	TTA0XPV	Strong	Biomarker	[1339]
POR	TTOQ9GZ	Strong	Genetic Variation	[1340]
PPARA	TTJ584C	Strong	Altered Expression	[1341]
PPARGC1B	TTKSQ3W	Strong	Altered Expression	[1342]
PPAT	TTZFTY4	Strong	Biomarker	[1343]
PPIB	TT6ZFQ4	Strong	Altered Expression	[1344]
PPID	TTNAFOU	Strong	Altered Expression	[1345]
PPIF	TTRFQTB	Strong	Altered Expression	[1345]
PPP1CA	TTFLH0E	Strong	Altered Expression	[1346]
PPP3CA	TTA4LDE	Strong	Biomarker	[1347]
PPP5C	TTTW7FJ	Strong	Biomarker	[1348]
PPT1	TTSQC14	Strong	Altered Expression	[1349]
PRCP	TTTJZ4M	Strong	Altered Expression	[723]
PRG4	TTSKF4V	Strong	Biomarker	[1350]
PRKACA	TT5U49F	Strong	Altered Expression	[1351]
PRKCA	TTFJ8Q1	Strong	Altered Expression	[765]
PRKCB	TTYPXQF	Strong	Altered Expression	[765]
PRKCQ	TT1MS7X	Strong	Biomarker	[1352]
PRKDC	TTK3PY9	Strong	Biomarker	[1353]
PRLR	TTBPXMA	Strong	Altered Expression	[1354]
PRMT1	TTVOJAI	Strong	Biomarker	[1355]
PRMT5	TTR1D7X	Strong	Altered Expression	[1356]
PRMT7	TTAR2P0	Strong	Biomarker	[1357]
PRNP	TTY5F9C	Strong	Altered Expression	[1358]
PROC	TTZUXYS	Strong	Biomarker	[1359]
PROM1	TTXMZ81	Strong	Biomarker	[1360]
PSCA	TT9T4AV	Strong	Biomarker	[1361]
PSEN2	TTWN3F4	Strong	Biomarker	[1362]
PSIP1	TTH9LDP	Strong	Biomarker	[1254]
PSMB5	TT68GPI	Strong	Altered Expression	[1363]
PSMB7	TT49BVC	Strong	Altered Expression	[1364]
PTBP1	TTWMX0U	Strong	Biomarker	[1365]
PTGER3	TTPNGDE	Strong	Biomarker	[1366]
PTGES	TTYLQ8V	Strong	Altered Expression	[1367]
PTGFR	TTT2ZAR	Strong	Altered Expression	[1368]
PTH	TT6F7GZ	Strong	Altered Expression	[1369]
PTK2B	TTTEFBV	Strong	Biomarker	[1370]
PTK6	TT6TH8V	Strong	Altered Expression	[1371]
PTP4A1	TTA8GFO	Strong	Biomarker	[1372]
PTP4A3	TT7YM8D	Strong	Altered Expression	[1373]
PTPN14	TTNIR6C	Strong	Biomarker	[1374]
PTPN2	TTY8PUS	Strong	Genetic Variation	[1375]
PTPN6	TT369M5	Strong	Altered Expression	[1280]
PVRIG	TTOGCNT	Strong	Biomarker	[1376]
PYGM	TTZHY6R	Strong	Genetic Variation	[1377]
PYY	TTVFJLX	Strong	Altered Expression	[997]
QPCT	TTJ7YTV	Strong	Biomarker	[1378]
RAB22A	TTAJ746	Strong	Biomarker	[1379]
RAC1	TT2M9CG	Strong	Altered Expression	[1046]
RAC3	TT9BQ50	Strong	Biomarker	[1380]
RAF1	TTAN5W2	Strong	Altered Expression	[1381]
RARG	TT1Q3IE	Strong	Altered Expression	[1382]
RBCK1	TTIKUVC	Strong	Biomarker	[1383]
RECK	TTRZBW7	Strong	Biomarker	[1384]
REG3A	TTL4H8N	Strong	Genetic Variation	[1385]
REN	TTB2MXP	Strong	Biomarker	[1386]
RENBP	TTZCG0Q	Strong	Genetic Variation	[1387]
RET	TT4DXQT	Strong	Altered Expression	[1388]
RGMA	TTURJV4	Strong	Altered Expression	[1389]
RGS2	TTKB7T3	Strong	Biomarker	[1390]
RGS4	TTGTKX9	Strong	Altered Expression	[1391]
RGS8	TTWME23	Strong	Biomarker	[1392]
RHAG	TTVHFE8	Strong	Biomarker	[1393]
RHBDF2	TTH1ZOP	Strong	Genetic Variation	[1394]
RHOA	TTP2U16	Strong	Altered Expression	[1395]
RIC8A	TTDFTJG	Strong	Altered Expression	[1396]
RNF6	TT4S09X	Strong	Biomarker	[1397]
RNMT	TTG45HY	Strong	Biomarker	[1398]
ROBO1	TTND1YP	Strong	Altered Expression	[1399]
ROCK1	TTZN7RP	Strong	Biomarker	[1400]
ROCK2	TTGWKQJ	Strong	Biomarker	[1401]
ROR1	TTDEJAU	Strong	Biomarker	[1402]
ROR2	TTUDPCI	Strong	Biomarker	[1403]
RORC	TTGV6LY	Strong	Genetic Variation	[310]
RPE65	TTBOH16	Strong	Biomarker	[1174]
RPS6KA2	TT0ZW9O	Strong	Altered Expression	[1404]
RPS6KA3	TTUM2ZR	Strong	Biomarker	[1405]
RPS6KA5	TTYXEPL	Strong	Biomarker	[1406]
RPS6KA6	TT3KYWB	Strong	Altered Expression	[1407]
RPS6KB1	TTG0U4H	Strong	Altered Expression	[1408]
RPS6KB2	TTMVQXO	Strong	Biomarker	[540]
RPSA	TTLUW5B	Strong	Biomarker	[497]
RRM2	TT1S4LJ	Strong	Biomarker	[1409]
RSF1	TTMP86V	Strong	Biomarker	[1410]
RSPO3	TT7HJTF	Strong	Biomarker	[1411]
RUNX1	TTWIN3H	Strong	Biomarker	[1412]
RUNX2	TTD6SZ8	Strong	Biomarker	[1247]
RUNX3	TTKCVO7	Strong	Biomarker	[1413]
S100A12	TTQ4ESF	Strong	Biomarker	[1414]
S100A8	TT4AF6N	Strong	Biomarker	[1415]
S100A9	TT0TMQG	Strong	Genetic Variation	[1416]
S100B	TTQ0V86	Strong	Altered Expression	[1417]
S1PR3	TTDYP7I	Strong	Biomarker	[1418]
S1PR4	TTZ8C5Q	Strong	Biomarker	[458]
SCD	TT6RIOV	Strong	Biomarker	[1419]
SCGB1A1	TTONPVW	Strong	Biomarker	[1420]
SCGB1D2	TT5D314	Strong	Altered Expression	[1421]
SCN2A	TTLJTUF	Strong	Biomarker	[1422]
SCN5A	TTZOVE0	Strong	Biomarker	[1423]
SDC1	TTYDSVG	Strong	Altered Expression	[1424]
SDC2	TT5H2F0	Strong	Altered Expression	[1425]
SELE	TT1PL7M	Strong	Biomarker	[1426]
SELP	TTE5VG0	Strong	Genetic Variation	[683]
SEMA3A	TTVKD3S	Strong	Altered Expression	[1427]
SEPTIN6	TTAGE7U	Strong	Altered Expression	[1428]
SERPINB5	TT1KW50	Strong	Biomarker	[1429]
SERPINH1	TTPSWQG	Strong	Biomarker	[1430]
SETD7	TTJ0FSU	Strong	Biomarker	[1431]
SFTPD	TTGLMU7	Strong	Altered Expression	[1432]
SGCG	TTSMT9W	Strong	Altered Expression	[1433]
SGPL1	TT618Q2	Strong	Altered Expression	[1434]
SH3GL1	TTTYNAM	Strong	Biomarker	[1435]
SHCBP1	TTZ9WGL	Strong	Biomarker	[1436]
SHH	TTIENCJ	Strong	Altered Expression	[1437]
SIGMAR1	TT5TPI6	Strong	Altered Expression	[1438]
SIK1	TT1H6LC	Strong	Altered Expression	[1439]
SIK2	TTCUGZR	Strong	Biomarker	[1440]
SIK3	TTW6L4V	Strong	Biomarker	[1441]
SIRPA	TTBRJS9	Strong	Altered Expression	[1442]
SIRT3	TTVZLIJ	Strong	Altered Expression	[1443]
SIRT5	TTH0IOD	Strong	Biomarker	[1444]
SIRT6	TTUXYWF	Strong	Altered Expression	[1445]
SKP2	TT5B2EO	Strong	Biomarker	[1446]
SLC11A2	TT2IS7P	Strong	Biomarker	[1447]
SLC12A6	TT8DFHE	Strong	Biomarker	[1448]
SLC12A7	TTU2PCD	Strong	Biomarker	[1448]
SLC16A1	TTN1J82	Strong	Biomarker	[1449]
SLC16A3	TTG6VD5	Strong	Biomarker	[1247]
SLC19A2	TT2A1DZ	Strong	Biomarker	[1450]
SLC19A3	TT9BTWM	Strong	Altered Expression	[1451]
SLC1A5	TTF7WRM	Strong	Biomarker	[1452]
SLC22A1	TTM5Q4V	Strong	Biomarker	[1453]
SLC22A16	TTITAVR	Strong	Genetic Variation	[1454]
SLC22A3	TTG2UMS	Strong	Biomarker	[375]
SLC23A2	TTOP832	Strong	Altered Expression	[1455]
SLC27A4	TT20AYF	Strong	Altered Expression	[1456]
SLC2A12	TTZO36H	Strong	Biomarker	[1457]
SLC2A4	TTP6MT5	Strong	Biomarker	[1457]
SLC34A2	TTQPZTM	Strong	Biomarker	[1458]
SLC36A1	TTUYIZW	Strong	Biomarker	[1459]
SLC38A1	TT1YE9Z	Strong	Biomarker	[1460]
SLC38A2	TTUSC27	Strong	Biomarker	[1461]
SLC38A3	TTMAVJQ	Strong	Altered Expression	[1462]
SLC39A6	TTZN1CF	Strong	Biomarker	[1463]
SLC40A1	TT6Y1PG	Strong	Biomarker	[1464]
SLC5A1	TT2UE56	Strong	Biomarker	[1465]
SLC5A5	TTW7HI9	Strong	Biomarker	[1466]
SLC6A14	TTB6H2S	Strong	Biomarker	[1467]
SLC6A3	TTVBI8W	Strong	Biomarker	[1468]
SLC6A5	TTI0138	Strong	Biomarker	[1469]
SLC7A1	TT4S150	Strong	Biomarker	[833]
SLC7A11	TTBZMIO	Strong	Altered Expression	[1470]
SLC7A5	TTPH2JB	Strong	Biomarker	[1471]
SLC9A1	TTGSEFH	Strong	Altered Expression	[1472]
SLCO1B1	TTFGXEB	Strong	Biomarker	[1473]
SLCO1B3	TTU86P0	Strong	Genetic Variation	[1474]
SLCO2B1	TTDL3UZ	Strong	Biomarker	[1475]
SLCO3A1	TT5CE6L	Strong	Altered Expression	[1476]
SLCO4A1	TTV1YIE	Strong	Biomarker	[1477]
SLIT2	TTDWK85	Strong	Biomarker	[1399]
SLK	TT8K4DE	Strong	Biomarker	[1478]
SMAD3	TTHQZV7	Strong	Altered Expression	[1479]
SMAD6	TTON5JB	Strong	Biomarker	[1480]
SMAD7	TT0J32Z	Strong	Altered Expression	[1481]
SMARCA4	TTVQEZS	Strong	Biomarker	[1482]
SMPD2	TTE5VI6	Strong	Altered Expression	[1483]
SMYD2	TT7YJFO	Strong	Biomarker	[1484]
SMYD3	TTKLJYX	Strong	Genetic Variation	[1485]
SOCS1	TT8COJM	Strong	Altered Expression	[1486]
SOCS3	TTI0ME6	Strong	Biomarker	[1487]
SORD	TTLSRBZ	Strong	Biomarker	[1488]
SOST	TTYRO4F	Strong	Biomarker	[1489]
SOX5	TTXHSZK	Strong	Biomarker	[1490]
SP1	TTZEP6S	Strong	Genetic Variation	[1491]
SPAG6	TTDAKTW	Strong	Altered Expression	[1492]
SPARC	TTBQFM7	Strong	Genetic Variation	[1493]
SPHK1	TTOHFIY	Strong	Biomarker	[1494]
SPOCK1	TTF23RE	Strong	Biomarker	[1495]
SPRY1	TT0PSN6	Strong	Biomarker	[1496]
SQLE	TTE14XG	Strong	Biomarker	[1497]
SRC	TT6PKBN	Strong	Biomarker	[1498]
SREBF2	TTRQ4AP	Strong	Biomarker	[459]
SRGN	TTCHB06	Strong	Altered Expression	[1499]
SRMS	TT7YMXZ	Strong	Altered Expression	[1500]
SRPK1	TTU3WV6	Strong	Biomarker	[1501]
SRR	TTZFUY6	Strong	Biomarker	[967]
SST	TTWF7UG	Strong	Biomarker	[1502]
SSTR4	TTAE1BR	Strong	Biomarker	[399]
SSTR5	TT2BC4G	Strong	Altered Expression	[1503]
ST14	TTPRO7W	Strong	Biomarker	[1504]
STAB1	TTJFEOC	Strong	Biomarker	[1176]
STAT1	TTN7R6K	Strong	Biomarker	[1505]
STAT6	TTWOE1T	Strong	Biomarker	[1506]
STC1	TTDLUER	Strong	Biomarker	[1507]
STC2	TT4EFTR	Strong	Biomarker	[1508]
STEAP1	TT9E64S	Strong	Altered Expression	[1509]
STK39	TTYQTIU	Strong	Biomarker	[1510]
STK4	TTCPLVN	Strong	Biomarker	[1511]
STMN1	TT7W5OT	Strong	Biomarker	[1512]
STRAP	TT165DP	Strong	Altered Expression	[1513]
STS	TTHM0R1	Strong	Biomarker	[1514]
STYK1	TTRMCYJ	Strong	Biomarker	[1515]
SULF2	TTLQTHB	Strong	Biomarker	[418]
SUV39H1	TTUWQTK	Strong	Biomarker	[1516]
SYK	TT2HUPM	Strong	Biomarker	[1517]
SYVN1	TT8XKYM	Strong	Altered Expression	[1518]
TAAR1	TTIU98M	Strong	Altered Expression	[1519]
TAAR5	TTCO25G	Strong	Altered Expression	[1520]
TAOK3	TTO7L0V	Strong	Biomarker	[1478]
TAP1	TT7JZI8	Strong	Biomarker	[1521]
TBL1X	TTAL6S1	Strong	Biomarker	[1522]
TCF3	TTULOD8	Strong	Biomarker	[1523]
TDG	TTEXRQD	Strong	Biomarker	[1524]
TDO2	TTXNCBV	Strong	Altered Expression	[1525]
TDP1	TT64IHJ	Strong	Altered Expression	[1526]
TEC	TT1ZV49	Strong	Biomarker	[1527]
TEK	TT9VGXW	Strong	Altered Expression	[680]
TENT4A	TT0XZ4Q	Strong	Genetic Variation	[1528]
TERF1	TT1Y6J2	Strong	Altered Expression	[1529]
TERF2	TT5XSLT	Strong	Altered Expression	[1530]
TF	TT8WXAV	Strong	Altered Expression	[1531]
TFRC	TT8MG4S	Strong	Biomarker	[1532]
TGM2	TT2F4OL	Strong	Biomarker	[1533]
THPO	TTCG5PE	Strong	Biomarker	[1534]
TICAM1	TT2GQT6	Strong	Biomarker	[1535]
TIE1	TTT4236	Strong	Biomarker	[1536]
TIPARP	TT2FRAN	Strong	Biomarker	[1537]
TK1	TTP3QRF	Strong	Biomarker	[1538]
TLR1	TTW14D0	Strong	Genetic Variation	[1539]
TLR2	TTY7ZHS	Strong	Genetic Variation	[1540]
TLR3	TTD24Y0	Strong	Genetic Variation	[1541]
TLR8	TT8CWFK	Strong	Altered Expression	[636]
TLR9	TTSHG0T	Strong	Biomarker	[1542]
TMBIM6	TT7QSMG	Strong	Altered Expression	[1543]
TMEM219	TTY078U	Strong	Biomarker	[1544]
TMEM97	TT9NXW4	Strong	Biomarker	[1545]
TMPRSS11D	TTWHYC8	Strong	Genetic Variation	[1546]
TMPRSS6	TTL9KE7	Strong	Genetic Variation	[1547]
TNC	TTUCPMY	Strong	Altered Expression	[1548]
TNFRSF10A	TT5WLRX	Strong	Genetic Variation	[1549]
TNFRSF10B	TTW20TU	Strong	Biomarker	[1550]
TNFRSF11A	TT3K9S2	Strong	Biomarker	[1551]
TNFRSF17	TTZ3P4W	Strong	Biomarker	[484]
TNFRSF1B	TT63WSF	Strong	Altered Expression	[1552]
TNFRSF8	TT2GM5R	Strong	Biomarker	[297]
TNFSF10	TTA5MS9	Strong	Biomarker	[1553]
TNFSF13	TTOI1RM	Strong	Biomarker	[484]
TNFSF4	TTBW580	Strong	Biomarker	[1554]
TNK2	TTIET93	Strong	Biomarker	[1555]
TNKS	TTVUSO7	Strong	Biomarker	[1556]
TNKS2	TTFQI4H	Strong	Genetic Variation	[1557]
TNNC1	TT8RDXP	Strong	Altered Expression	[1558]
TOP1	TTGTQHC	Strong	Altered Expression	[1526]
TP53BP1	TTX4UE9	Strong	Biomarker	[1015]
TPH1	TTZSJHV	Strong	Altered Expression	[1559]
TPO	TT52XDZ	Strong	Altered Expression	[1560]
TPT1	TT3PTB6	Strong	Altered Expression	[1561]
TRAF6	TTCDR6M	Strong	Altered Expression	[1562]
TREM1	TTHZQP0	Strong	Altered Expression	[1563]
TRH	TT2Z39D	Strong	Biomarker	[1564]
TRIM24	TT9Q7AE	Strong	Biomarker	[1565]
TRIM28	TTQ2BKV	Strong	Altered Expression	[1566]
TRIM37	TTAMCSL	Strong	Biomarker	[1117]
TRIM59	TT613U4	Strong	Biomarker	[1567]
TRIP10	TTKHTGE	Strong	Altered Expression	[1568]
TRPC1	TTA76X0	Strong	Altered Expression	[1569]
TRPC3	TTNVC34	Strong	Biomarker	[1570]
TRPC5	TT32NQ1	Strong	Altered Expression	[1571]
TRPM5	TT1N8F3	Strong	Biomarker	[1572]
TRPM7	TTFPVZO	Strong	Altered Expression	[1573]
TRPM8	TTXDKTO	Strong	Altered Expression	[1574]
TRPV1	TTMI6F5	Strong	Altered Expression	[1575]
TRPV4	TTKP2SU	Strong	Biomarker	[1576]
TSG101	TTHU7JA	Strong	Genetic Variation	[1577]
TSPO	TTPTXIN	Strong	Altered Expression	[1578]
TTK	TTP7EGM	Strong	Altered Expression	[1069]
TUSC2	TTJ8O14	Strong	Biomarker	[981]
TXN	TTZJ5U9	Strong	Biomarker	[1136]
TXNIP	TTTLDZK	Strong	Biomarker	[1579]
TXNRD1	TTR7UJ3	Strong	Biomarker	[1580]
TYK2	TTBYWP2	Strong	Biomarker	[1581]
TYMP	TTO0IB8	Strong	Altered Expression	[1582]
TYR	TTULVH8	Strong	Genetic Variation	[1583]
TYRO3	TTIEMFN	Strong	Altered Expression	[1584]
TYRP1	TTFRV98	Strong	Genetic Variation	[1585]
UBC	TTBP3XA	Strong	Biomarker	[1586]
UBE2E2	TTXJEOF	Strong	Biomarker	[1587]
UBE3A	TTUZX6V	Strong	Biomarker	[1588]
UCHL3	TT23UD6	Strong	Altered Expression	[1589]
UGCG	TTPHEX3	Strong	Posttranslational Modification	[1590]
UMPS	TTAFJUD	Strong	Genetic Variation	[1591]
USP1	TTG9MT5	Strong	Biomarker	[1592]
USP2	TTUEQ1W	Strong	Altered Expression	[1593]
USP33	TT4E85Q	Strong	Biomarker	[1594]
USP37	TTJDELN	Strong	Altered Expression	[1595]
USP7	TTXU3EQ	Strong	Biomarker	[748]
USP8	TT1J07C	Strong	Biomarker	[1263]
UTS2R	TTW5UDX	Strong	Genetic Variation	[1596]
VEGFB	TTPJQHE	Strong	Biomarker	[1597]
VEGFD	TTOM5H4	Strong	Biomarker	[1598]
VIP	TTGTWLF	Strong	Genetic Variation	[1599]
VIPR1	TTCL30I	Strong	Biomarker	[1600]
VIPR2	TT4O5P0	Strong	Biomarker	[1601]
VTCN1	TTCK85E	Strong	Biomarker	[1602]
VWF	TT3SZBT	Strong	Biomarker	[1603]
WAS	TTE8T73	Strong	Biomarker	[1604]
WNK1	TTJ9UMX	Strong	Biomarker	[1605]
WNT5A	TTKG7F8	Strong	Biomarker	[1606]
WNT7A	TT8NARC	Strong	Altered Expression	[1607]
WRN	TT2H5WQ	Strong	Genetic Variation	[1608]
WT1	TTZ8UT4	Strong	Altered Expression	[1609]
XDH	TT7RJY8	Strong	Altered Expression	[1610]
XIAP	TTK3WBU	Strong	Altered Expression	[1611]
XPA	TTGT87E	Strong	Genetic Variation	[1612]
XPO1	TTCJUR4	Strong	Altered Expression	[1613]
XRCC5	TTCB9KW	Strong	Genetic Variation	[1614]
YES1	TT0SQ8J	Strong	Biomarker	[1615]
ZAP70	TTUMHT8	Strong	Biomarker	[1616]
ZEB2	TTT2WK4	Strong	Biomarker	[1617]
ZFP36L1	TT8QVJO	Strong	Biomarker	[1618]
ZNF224	TT1CDXL	Strong	Biomarker	[1619]
ZUP1	TTZC0KV	Strong	Biomarker	[1620]
ZWINT	TTWY768	Strong	Biomarker	[1621]
CA1	TTHQPL7	Definitive	Biomarker	[1622]
CACNA1H	TTZPWGN	Definitive	Biomarker	[1623]
CFI	TT6ATLX	Definitive	Altered Expression	[1624]
CHRNA4	TT4H1MQ	Definitive	Biomarker	[1625]
CHRNA9	TTQACP9	Definitive	Biomarker	[1626]
DFFB	TT2SRE0	Definitive	Altered Expression	[1627]
GPR39	TTTPCNU	Definitive	Biomarker	[1628]
HOXA11	TTEX4ZA	Definitive	Altered Expression	[1629]
HPD	TT8DSFC	Definitive	Altered Expression	[1630]
ICOS	TTE5VP6	Definitive	Biomarker	[1631]
LTB4R	TTN53ZF	Definitive	Altered Expression	[1632]
LTBR	TTFO0PM	Definitive	Genetic Variation	[1633]
NDUFB9	TTBYJ39	Definitive	Biomarker	[1634]
NOD1	TTYSRXM	Definitive	Altered Expression	[1635]
OLFM4	TTK1CX7	Definitive	Biomarker	[1636]
PCSK9	TTNIZ2B	Definitive	Biomarker	[1637]
PDE8A	TTIS4OW	Definitive	Altered Expression	[1638]
PFKFB3	TTTHMQJ	Definitive	Altered Expression	[1639]
PRDX4	TTPBL9I	Definitive	Altered Expression	[1640]
PRKCZ	TTBSN0L	Definitive	Biomarker	[1641]
RIPK2	TTCQ2E5	Definitive	Biomarker	[1642]
RORB	TTGB2LZ	Definitive	Biomarker	[310]
SLC25A1	TTTD730	Definitive	Biomarker	[1643]
STAR	TTEI40H	Definitive	Altered Expression	[1644]
TCF7L2	TT80QAL	Definitive	Biomarker	[1645]
TKTL1	TTNQ1J3	Definitive	Biomarker	[1646]
TNFAIP3	TT5W0IO	Definitive	Biomarker	[1647]
TNFRSF13C	TT7NJSE	Definitive	Genetic Variation	[1633]
TNFRSF9	TTPW9LJ	Definitive	Biomarker	[1648]
TP53	TT7SBF5	Definitive	Autosomal dominant	[265]
UCHL1	TTX9IFP	Definitive	Biomarker	[1649]
USP44	TTJLTNM	Definitive	Biomarker	[1650]
VCAM1	TTHCEF6	Definitive	Biomarker	[1651]

This Disease Is Related to 64 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCB5	DTKVEXO	Limited	Biomarker	[1652]
ABCC10	DTPS120	Limited	Altered Expression	[1653]
CACNG2	DTRL7OG	Limited	Genetic Variation	[1654]
KCNH7	DT3WXPI	Limited	Biomarker	[1655]
SLC24A3	DTO18LP	Limited	Biomarker	[466]
SLC27A2	DTXK9WA	Limited	Biomarker	[1656]
SLC39A8	DTLPQGT	Limited	Altered Expression	[1657]
SLC39A9	DTJH79E	Limited	Genetic Variation	[1012]
SLC50A1	DTI9CQU	Limited	Altered Expression	[1658]
SLC7A10	DTVL2JY	Limited	Biomarker	[1659]
SLC14A2	DT8QC7K	moderate	Genetic Variation	[1596]
SLC22A5	DT3HUVD	moderate	Altered Expression	[1660]
SLC25A20	DTQOUM4	moderate	Biomarker	[739]
SLC25A37	DTLBGTZ	moderate	Biomarker	[1661]
SLC25A6	DTLMGFJ	moderate	Altered Expression	[626]
SLC27A1	DTKDTML	moderate	Biomarker	[1662]
SLC4A1	DTB0Q3P	moderate	Altered Expression	[1663]
SLC6A6	DTHWCVA	moderate	Altered Expression	[1664]
SLC9A7	DTQPK6R	moderate	Altered Expression	[1665]
ABCB6	DTF9Y2V	Strong	Biomarker	[1666]
ABCB7	DT2IMBW	Strong	Biomarker	[1667]
ABCC11	DTWN7FC	Strong	Genetic Variation	[1668]
ATP2B1	DTJWQ1L	Strong	Altered Expression	[1669]
ATP7A	DT0LT17	Strong	Biomarker	[1670]
SLC10A6	DT5A9X2	Strong	Biomarker	[1671]
SLC11A1	DT650XW	Strong	Biomarker	[1672]
SLC12A8	DT0OA2B	Strong	Biomarker	[1673]
SLC16A2	DTQ8MP1	Strong	Biomarker	[1674]
SLC16A6	DT8ZFIO	Strong	Biomarker	[1674]
SLC16A7	DTLT3UG	Strong	Altered Expression	[1675]
SLC18A1	DTM953D	Strong	Altered Expression	[1676]
SLC20A1	DTMULXV	Strong	Biomarker	[1677]
SLC25A16	DTNU9EW	Strong	Genetic Variation	[1603]
SLC25A21	DT2UQYR	Strong	Genetic Variation	[1678]
SLC25A3	DTCRIWV	Strong	Biomarker	[1679]
SLC25A5	DTL1TRY	Strong	Altered Expression	[1680]
SLC26A2	DTFSLX5	Strong	Biomarker	[1681]
SLC26A3	DTN1FMD	Strong	Genetic Variation	[1682]
SLC27A6	DTG4CWJ	Strong	Altered Expression	[1683]
SLC28A1	DT0EQPW	Strong	Biomarker	[1684]
SLC2A10	DT3BI6S	Strong	Biomarker	[1685]
SLC2A2	DTUJPOL	Strong	Biomarker	[1686]
SLC2A3	DT9SQ3L	Strong	Altered Expression	[1687]
SLC2A5	DTOR02F	Strong	Biomarker	[1688]
SLC30A1	DT1BO38	Strong	Altered Expression	[1657]
SLC35A2	DT0567K	Strong	Biomarker	[1689]
SLC35A4	DT2OPRB	Strong	Altered Expression	[1690]
SLC35B2	DT81RKJ	Strong	Biomarker	[1691]
SLC37A1	DTH9SQJ	Strong	Altered Expression	[1692]
SLC37A2	DTU58HL	Strong	Biomarker	[1693]
SLC38A6	DTZUHR9	Strong	Altered Expression	[1462]
SLC39A10	DTK02RZ	Strong	Biomarker	[1694]
SLC39A2	DTL8VXO	Strong	Altered Expression	[1695]
SLC39A7	DTDQSAM	Strong	Biomarker	[1696]
SLC3A1	DTBCKVM	Strong	Biomarker	[1697]
SLC45A2	DTNCJAT	Strong	Genetic Variation	[1698]
SLC48A1	DTZFHNT	Strong	Altered Expression	[1699]
SLC4A11	DTH2J1G	Strong	Altered Expression	[1700]
SLC52A1	DT7NOKR	Strong	Altered Expression	[1701]
SLC5A8	DTE3TAW	Strong	Altered Expression	[1702]
SLC7A2	DTWY9RT	Strong	Biomarker	[1703]
SLCO5A1	DTYVQ5M	Strong	Biomarker	[1476]
ABCD2	DT4MBHD	Definitive	Genetic Variation	[648]
SLC4A7	DT03V27	Definitive	Altered Expression	[1704]

This Disease Is Related to 98 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ACSS2	DEE76VW	Limited	Biomarker	[1705]
ASNS	DEXISVQ	Limited	Biomarker	[1706]
BCO1	DE6BOK3	Limited	Genetic Variation	[1707]
CRMP1	DE0EUXB	Limited	Biomarker	[490]
CYB5A	DE9A2LB	Limited	Genetic Variation	[1708]
CYP2C8	DES5XRU	Limited	Genetic Variation	[1474]
EPHX1	DELB4KP	Limited	Biomarker	[1709]
GCLC	DESYL1F	Limited	Biomarker	[1710]
GPX6	DEOS3FD	Limited	Genetic Variation	[1711]
LAP3	DENZF0O	Limited	Altered Expression	[977]
LDHC	DEQG7F9	Limited	Altered Expression	[1712]
NAT10	DEZV4AP	Limited	Biomarker	[700]
P4HA2	DE5EGK0	Limited	Altered Expression	[413]
UBASH3B	DE10BJ5	Limited	Biomarker	[1235]
UGDH	DE48Q2Z	Limited	Biomarker	[1713]
UGT1A8	DE2GB8N	Limited	Altered Expression	[1714]
ACP5	DESITDW	Disputed	Biomarker	[1715]
AKR1C1	DE7P2FB	Disputed	Biomarker	[1716]
AKR1C4	DEAJN47	moderate	Genetic Variation	[1717]
CHST3	DEQIZP2	moderate	Altered Expression	[1718]
CYB5R3	DE4A3BL	moderate	Altered Expression	[1719]
CYP27A1	DEBS639	moderate	Altered Expression	[1720]
CYP2S1	DE6NMGO	moderate	Altered Expression	[1721]
LPO	DEHX1DZ	moderate	Biomarker	[1722]
MSRA	DEU2ZBY	moderate	Biomarker	[1723]
UGT1A4	DELOY3P	moderate	Genetic Variation	[1724]
UGT1A6	DESD26P	moderate	Altered Expression	[1725]
UGT2B4	DENUPDX	moderate	Biomarker	[1726]
UPRT	DE20ETR	moderate	Biomarker	[1727]
ABO	DESIA7R	Strong	Biomarker	[1728]
ACP3	DEDW5H6	Strong	Altered Expression	[1729]
ADH5	DEIOH6A	Strong	Genetic Variation	[1730]
ADHFE1	DE8RJ3F	Strong	Biomarker	[1731]
AKR1A1	DED2FW3	Strong	Genetic Variation	[517]
AKR1B10	DEP6GT1	Strong	Posttranslational Modification	[1732]
AKR1C2	DEOY5ZM	Strong	Genetic Variation	[1733]
APRT	DE2MV1R	Strong	Biomarker	[1734]
BAAT	DERA3OF	Strong	Genetic Variation	[1735]
CBR3	DEIVKZ8	Strong	Genetic Variation	[1736]
CES2	DETHCPD	Strong	Biomarker	[1737]
CHDH	DEAHED0	Strong	Biomarker	[1738]
CPA4	DEXKD7J	Strong	Biomarker	[1739]
CYP27B1	DE3FYEM	Strong	Biomarker	[1740]
CYP2C18	DEZMWRE	Strong	Altered Expression	[1741]
CYP3A7	DERD86B	Strong	Genetic Variation	[1742]
CYP4B1	DEMF740	Strong	Altered Expression	[1743]
CYP4F3	DEFCMPI	Strong	Biomarker	[1744]
CYP7B1	DE36TMY	Strong	Posttranslational Modification	[1745]
DCTD	DEXL3P2	Strong	Genetic Variation	[1746]
DDAH1	DEY0TQC	Strong	Biomarker	[1747]
DIO3	DET89OV	Strong	Biomarker	[318]
EGLN3	DEMQTKH	Strong	Biomarker	[1748]
FAAH	DEUM1EX	Strong	Altered Expression	[1749]
FADS1	DE05S8C	Strong	Biomarker	[1750]
FMO5	DEBMX7C	Strong	Biomarker	[1751]
GGCT	DEKW6PB	Strong	Genetic Variation	[1752]
GSTM4	DERQ52Z	Strong	Genetic Variation	[1753]
HIF1AN	DEY1CBW	Strong	Biomarker	[1754]
HK1	DEDMAGE	Strong	Biomarker	[1755]
HPGD	DEHKSC6	Strong	Posttranslational Modification	[1756]
HPRT1	DEVXTP5	Strong	Genetic Variation	[1757]
HSD17B7	DEDMWFX	Strong	Biomarker	[362]
HSD3B1	DERDQWN	Strong	Biomarker	[1758]
MAT1A	DEQ6NC9	Strong	Genetic Variation	[1759]
MMEL1	DEYCUQ2	Strong	Biomarker	[1760]
MT1A	DE5ME8A	Strong	Biomarker	[1233]
MT2A	DEFKGT7	Strong	Genetic Variation	[1761]
NDUFS3	DE741FI	Strong	Biomarker	[1762]
NDUFS7	DEIW03B	Strong	Biomarker	[1763]
NT5C2	DE1DOKJ	Strong	Biomarker	[1764]
P3H1	DEW527E	Strong	Altered Expression	[1765]
P3H2	DELB5PA	Strong	Posttranslational Modification	[1765]
PARK7	DEPOVCH	Strong	Altered Expression	[992]
PER1	DE9HF0I	Strong	Genetic Variation	[310]
PGM3	DER0EN5	Strong	Biomarker	[1766]
PGPEP1	DEVDR46	Strong	Altered Expression	[723]
PLPP1	DE6WXTH	Strong	Biomarker	[1767]
PNPO	DE3Z1RA	Strong	Biomarker	[1768]
PON2	DEHJU7E	Strong	Genetic Variation	[1769]
PRKCSH	DE073GW	Strong	Biomarker	[1770]
PRODH	DEVJIHS	Strong	Biomarker	[1771]
PTGR1	DE4Q2OE	Strong	Altered Expression	[1772]
SAT1	DEMWO83	Strong	Biomarker	[1773]
SULT1A2	DERUZL7	Strong	Altered Expression	[1774]
SULT1C2	DEYMAD4	Strong	Altered Expression	[1774]
SULT1E1	DESTKG6	Strong	Altered Expression	[1775]
SULT2A1	DE0P6LK	Strong	Biomarker	[1776]
TGM7	DERWDYE	Strong	Biomarker	[1777]
THOP1	DE95LJC	Strong	Genetic Variation	[1716]
UCK2	DETN1O0	Strong	Biomarker	[1778]
UGT2B15	DENZ6B1	Strong	Genetic Variation	[1454]
UGT2B7	DEB3CV1	Strong	Genetic Variation	[1779]
UPP1	DEFZWAX	Strong	Altered Expression	[1780]
WARS1	DEPVE0M	Strong	Genetic Variation	[536]
ALDH1A2	DEKN1H4	Definitive	Altered Expression	[1781]
CMPK1	DEMPH4I	Definitive	Biomarker	[1782]
NNMT	DECVGJ3	Definitive	Altered Expression	[1783]
UGT2B17	DEAZDL8	Definitive	Biomarker	[1784]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5137).
• [4] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (BLA) 103425.
• [5] Clinical pipeline report, company report or official report of Lilly.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5710).
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6799).
• [10] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 218197
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6942).
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7330).
• [13] ClinicalTrials.gov (NCT04837209) Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR). U.S. National Institutes of Health.
• [14] Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990 Nov 7;82(21):1706-10.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031953)
• [16] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217639.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6813).
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1013).
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8311).
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2861).
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1015).
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3879).
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2010
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6824).
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009670)
• [27] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [28] Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther. 2006 Jan;6(1):43-7.
• [29] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
• [30] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089).
• [31] Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative. J Pharmacol Exp Ther. 1989 Feb;248(2):758-61.
• [32] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
• [33] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5046).
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6840).
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7097).
• [36] FDA Approved Drug Products from FDA Official Website.
• [37] Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. J Nucl Med Technol. 1998 Sep;26(3):155-63; quiz 170-1.
• [38] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [39] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1016).
• [40] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [41] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7303).
• [42] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7622).
• [43] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4325).
• [44] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5082).
• [45] Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages. Cancer Immunol Immunother. 2005 Nov;54(11):1115-26.
• [46] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7648).
• [47] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [48] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7417).
• [49] ClinicalTrials.gov (NCT01452373) Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women. U.S. National Institutes of Health.
• [50] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [51] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8414).
• [52] ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
• [53] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5671).
• [54] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7878).
• [55] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016680)
• [56] ClinicalTrials.gov (NCT05374512) A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02). U.S.National Institutes of Health.
• [57] The cryopreservation of high concentrated PBMC for dendritic cell (DC)-based cancer immunotherapy. Cryobiology. 2009 Apr;58(2):203-9.
• [58] ClinicalTrials.gov (NCT03433313) A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer. U.S.National Institutes of Health.
• [59] ClinicalTrials.gov (NCT01492101) The BEACON Study (Breast Cancer Outcomes With NKTR-102). U.S. National Institutes of Health.
• [60] ClinicalTrials.gov (NCT04961996) A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer. U.S.National Institutes of Health.
• [61] A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Melanoma Res. 2001 Jun;11(3):219-27.
• [62] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021154)
• [63] ClinicalTrials.gov (NCT02525159) Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio (EDIMI216OHE1). U.S. National Institutes of Health.
• [64] ClinicalTrials.gov (NCT04975308) EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy. U.S.National Institutes of Health.
• [65] ClinicalTrials.gov (NCT01479244) Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence. U.S. National Institutes of Health.
• [66] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017925)
• [67] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017699)
• [68] ClinicalTrials.gov (NCT02187744) A Study Of PF-05280014 Or Trastuzumab Plus Taxotere And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04). U.S. National Institutes of Health.
• [69] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [70] ClinicalTrials.gov (NCT00632008) Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers. U.S. National Institutes of Health.
• [71] ClinicalTrials.gov (NCT03538171) Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer. U.S. National Institutes of Health.
• [72] ClinicalTrials.gov (NCT03262935) A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer. U.S.National Institutes of Health.
• [73] Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92.
• [74] Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer. 2014 Mar 1;120(5):642-51.
• [75] ClinicalTrials.gov (NCT04659603) Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors. U.S.National Institutes of Health.
• [76] ClinicalTrials.gov (NCT02426086) Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor. U.S. National Institutes of Health.
• [77] ClinicalTrials.gov (NCT04123704) Sitravatinib in Metastatic Breast Cancer. U.S. National Institutes of Health.
• [78] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7645).
• [79] ClinicalTrials.gov (NCT00572728) 3'-Deoxy-3'-18F Fluorothymidine PET/CT in Predicting Response To Chemotherapy Before Surgery in Patients With Locally Advanced Breast Cancer. U.S. National Institutesof Health.
• [80] ClinicalTrials.gov (NCT00524277) Vaccine Therapy in Treating Patients With Breast Cancer. U.S. National Institutes of Health.
• [81] Clinical pipeline report, company report or official report of Generex.
• [82] ClinicalTrials.gov (NCT00272714) Study of Afimoxifene Gel to Treat Cyclic Mastalgia in Premenopausal Women. U.S. National Institutes of Health.
• [83] Clinical pipeline report, company report or official report of AFP464.
• [84] ClinicalTrials.gov (NCT02232581) Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure. U.S. National Institutes of Health.
• [85] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024318)
• [86] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [87] Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 26, No 15S (May 20 Supplement), 2008: 3034.
• [88] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019429)
• [89] ClinicalTrials.gov (NCT01823835) A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer. U.S. National Institutes of Health.
• [90] Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73.
• [91] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7717).
• [92] ClinicalTrials.gov (NCT00555919) ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer. U.S. National Institutes of Health.
• [93] ClinicalTrials.gov (NCT00574236) Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer. U.S. National Institutes of Health.
• [94] ClinicalTrials.gov (NCT00618319) An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST). U.S. National Institutes of Health.
• [95] ClinicalTrials.gov (NCT03691207) A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY). U.S. National Institutes of Health.
• [96] Clinical pipeline report, company report or official report of Aduro BioTech.
• [97] ClinicalTrials.gov (NCT00633165) Brostallicin Clinical Trial for Myxoid Liposarcoma. U.S. National Institutes of Health.
• [98] ClinicalTrials.gov (NCT00907959) A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer. U.S. National Institutes of Health.
• [99] ClinicalTrials.gov (NCT04714619) CB-103 Plus NSAI In Luminal Advanced Breast Cancer (CAILA). U.S. National Institutes of Health.
• [100] ClinicalTrials.gov (NCT04176848) CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer. U.S. National Institutes of Health.
• [101] Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev Anticancer Ther. 2011 Feb;11(2):179-83.
• [102] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019475)
• [103] ClinicalTrials.gov (NCT01605396) A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064). U.S. National Institutes of Health.
• [104] ClinicalTrials.gov (NCT00847678) Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS. U.S. National Institutes of Health.
• [105] ClinicalTrials.gov (NCT02311933) Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer. U.S.National Institutes of Health.
• [106] Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
• [107] Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in P... J Clin Oncol. 2016 Jun 10;34(17):1987-94.
• [108] A phase II trial of oral gimatecan for recurrent glioblastoma. J Neurooncol. 2013 Feb;111(3):347-53.
• [109] ClinicalTrials.gov (NCT00485563) A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma. U.S. National Institutes of Health.
• [110] ClinicalTrials.gov (NCT02267083) Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma. U.S. National Institutes of Health.
• [111] ClinicalTrials.gov (NCT04676516) A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer (OTT-19-06). U.S. National Institutes of Health.
• [112] 17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
• [113] Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32.
• [114] ClinicalTrials.gov (NCT01220128) Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer. U.S. National Institutes of Health.
• [115] ClinicalTrials.gov (NCT01729884) Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer. U.S. National Institutes of Health.
• [116] ClinicalTrials.gov (NCT01972672) The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma. U.S. National Institutes of Health.
• [117] Atemonate and Imuteran: novel Russian monoclonal antibody-based therapeutic agents. Biotechnol J. 2007 Jul;2(7):863-70.
• [118] ClinicalTrials.gov (NCT04881929) Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer. U.S. National Institutes of Health.
• [119] Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Eur J Cancer. 2002 Dec;38(18):2407-15.
• [120] ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
• [121] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7909).
• [122] ClinicalTrials.gov (NCT01440517) Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction. U.S. National Institutes of Health.
• [123] ClinicalTrials.gov (NCT01774851) A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach. U.S. National Institutes of Health.
• [124] ClinicalTrials.gov (NCT01447706) A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers. U.S. National Institutes of Health.
• [125] Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10. Drug Metab Dispos. 2012 Sep;40(9):1736-43.
• [126] ClinicalTrials.gov (NCT02423590) Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers. U.S. National Institutes of Health.
• [127] Clinical pipeline report, company report or official report of Context Therapeutics.
• [128] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7934).
• [129] ClinicalTrials.gov (NCT05865990) Multicenter, Single-arm, 3 Cohort, Phase II Trial of HER3-DXd in Patients With Active Brain Metastases From Metastatic Breast Cancer and Non-small Cell Lung Cancer, and in Patients With Leptomeningeal Disease From Advanced Solid Tumors. U.S.National Institutes of Health.
• [130] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7935).
• [131] ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
• [132] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [133] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7995).
• [134] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7338).
• [135] ClinicalTrials.gov (NCT00598507) Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma. U.S. National Institutes of Health.
• [136] ClinicalTrials.gov (NCT04191382) Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4) (AMEERA-4). U.S. National Institutes of Health.
• [137] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036273)
• [138] ClinicalTrials.gov (NCT02970682) SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer (STEM). U.S. National Institutes of Health.
• [139] Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. Cancer. 2012 Jul 1;118(13):3244-53.
• [140] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7751).
• [141] ClinicalTrials.gov (NCT02157870) A Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer. U.S. National Institutes of Health.
• [142] ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
• [143] ClinicalTrials.gov (NCT01332630) TPI 287 in Breast Cancer Metastatic to the Brain. U.S. National Institutes of Health.
• [144] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6497).
• [145] The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther. 2013 Jun;12(6):890-900.
• [146] ClinicalTrials.gov (NCT01935154) Efficacy Study of Vx001 Vaccine in NSCLC Patients. U.S. National Institutes of Health.
• [147] ClinicalTrials.gov (NCT03659136) The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread. U.S. National Institutes of Health.
• [148] ClinicalTrials.gov (NCT01147484) A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer (IND197). U.S. National Institutes of Health.
• [149] ClinicalTrials.gov (NCT00818480) An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155. U.S. National Institutes of Health.
• [150] ClinicalTrials.gov (NCT04224272) A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer. U.S. National Institutes of Health.
• [151] ClinicalTrials.gov (NCT02141451) INCB7839 With Rituximab After Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [152] ClinicalTrials.gov (NCT02386501) Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors. U.S. National Institutes of Health.
• [153] ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
• [154] ClinicalTrials.gov (NCT04072952) A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (mBC). U.S. National Institutes of Health.
• [155] ClinicalTrials.gov (NCT01526473) A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901. U.S. National Institutes of Health.
• [156] ClinicalTrials.gov (NCT00645710) Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery. U.S. National Institutes of Health.
• [157] ClinicalTrials.gov (NCT04488107) Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c. U.S. National Institutes of Health.
• [158] ClinicalTrials.gov (NCT03250676) Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer. U.S. National Institutes of Health.
• [159] ClinicalTrials.gov (NCT02547961) Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
• [160] ClinicalTrials.gov (NCT02143622) Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients. U.S. National Institutes of Health.
• [161] ClinicalTrials.gov (NCT00248404) NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS). U.S. National Institutes of Health.
• [162] ClinicalTrials.gov (NCT02293850) Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health.
• [163] ClinicalTrials.gov (NCT04505826) A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer. U.S. National Institutes of Health.
• [164] ClinicalTrials.gov (NCT02229084) Vaccination of High Risk Breast Cancer Patients. U.S. National Institutes of Health.
• [165] ClinicalTrials.gov (NCT04802759) A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER). U.S.National Institutes of Health.
• [166] ClinicalTrials.gov (NCT03066947) SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer. U.S. National Institutes of Health.
• [167] ClinicalTrials.gov (NCT05451849) A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer. U.S.National Institutes of Health.
• [168] ClinicalTrials.gov (NCT03560531) A Study of ZN-c5 in Subjects With Breast Cancer. U.S. National Institutes of Health.
• [169] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029232)
• [170] ClinicalTrials.gov (NCT05489679) A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer. U.S.National Institutes of Health.
• [171] ClinicalTrials.gov (NCT00110526) Gene Therapy for Prostate Cancer That Returns After Radiation Therapy. U.S. National Institutes of Health.
• [172] Clinical pipeline report, company report or official report of Novartis.
• [173] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013469)
• [174] ClinicalTrials.gov (NCT04469127) A Study of AIP-303 in HER2 Positive Breast Cancer and/or Metastatic Breast Cancer Patients (Heroine01). U.S. National Institutes of Health.
• [175] ClinicalTrials.gov (NCT03060356) Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
• [176] ClinicalTrials.gov (NCT01861509) BP-C1 in Metastatic Breast Cancer Patients. U.S. National Institutes of Health.
• [177] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015939)
• [178] ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer
• [179] ClinicalTrials.gov (NCT03471663) A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer. U.S. National Institutes of Health.
• [180] ClinicalTrials.gov (NCT05261269) A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer. U.S.National Institutes of Health.
• [181] ClinicalTrials.gov (NCT00989105) Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer. U.S. National Institutes of Health.
• [182] ClinicalTrials.gov (NCT01095848) A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer. U.S. National Institutes of Health.
• [183] Clinical pipeline report, company report or official report of EpiThany.
• [184] ClinicalTrials.gov (NCT03455270) G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer. U.S. National Institutes of Health.
• [185] ClinicalTrials.gov (NCT04197999) A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer. U.S. National Institutes of Health.
• [186] ClinicalTrials.gov (NCT04834778) A Multicenter, Open-label, Phase 1a Study of HC-5404-FU in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
• [187] ClinicalTrials.gov (NCT04856371) Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer. U.S. National Institutes of Health.
• [188] ClinicalTrials.gov (NCT04020575) Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*). U.S. National Institutes of Health.
• [189] Clinical pipeline report, company report or official report of Immunotope.
• [190] ClinicalTrials.gov (NCT02122861) A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1. U.S. National Institutes of Health.
• [191] ClinicalTrials.gov (NCT04647487) A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2). U.S. National Institutes of Health.
• [192] ClinicalTrials.gov (NCT05307705) A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation. U.S.National Institutes of Health.
• [193] ClinicalTrials.gov (NCT02792114) T-Cell Therapy for Advanced Breast Cancer
• [194] ClinicalTrials.gov (NCT01304797) Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer. U.S. National Institutes of Health.
• [195] ClinicalTrials.gov (NCT01152398) A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy. U.S. National Institutes of Health.
• [196] ClinicalTrials.gov (NCT04064359) Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer. U.S. National Institutes of Health.
• [197] ClinicalTrials.gov (NCT05484011) P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/ a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line Chemo. U.S.National Institutes of Health.
• [198] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022229)
• [199] ClinicalTrials.gov (NCT04606446) A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
• [200] ClinicalTrials.gov (NCT05067972) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
• [201] ClinicalTrials.gov (NCT03065010) Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer. U.S. National Institutes of Health.
• [202] ClinicalTrials.gov (NCT05304962) First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer. U.S.National Institutes of Health.
• [203] ClinicalTrials.gov (NCT03448042) A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers. U.S. National Institutes of Health.
• [204] ClinicalTrials.gov (NCT00002960) SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084). U.S. National Institutes of Health.
• [205] ClinicalTrials.gov (NCT04242953) Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects. U.S. National Institutes of Health.
• [206] ClinicalTrials.gov (NCT01969643) A Safety Study of SGN-LIV1A in Breast Cancer Patients. U.S. National Institutes of Health.
• [207] Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine. Cancer Immunol Immunother. 2009 Sep;58(9):1397-405.
• [208] Clinical pipeline report, company report or official report of Veana Therapeutics.
• [209] ClinicalTrials.gov (NCT03517488) A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2). U.S. National Institutes of Health.
• [210] D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5.
• [211] ClinicalTrials.gov (NCT01611038) Methylselenocysteine Effects on Circadian Rhythm. U.S. National Institutes of Health.
• [212] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [213] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4792).
• [214] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003448)
• [215] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011762)
• [216] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021953)
• [217] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000847)
• [218] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015773)
• [219] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011640)
• [220] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028450)
• [221] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004178)
• [222] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000754)
• [223] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009932)
• [224] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008156)
• [225] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001808)
• [226] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003856)
• [227] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5712).
• [228] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005041)
• [229] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002721)
• [230] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030562)
• [231] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028912)
• [232] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011217)
• [233] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025155)
• [234] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028447)
• [235] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015029)
• [236] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015872)
• [237] Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
• [238] A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive br... Nucl Med Biol. 2015 Dec;42(12):931-8.
• [239] 2-Amino-4-[3'-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. Bioorg Med Chem Lett. 2002 Feb 11;12(3):361-3.
• [240] Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
• [241] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023898)
• [242] AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
• [243] Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep;16(9):787-810.
• [244] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022727)
• [245] A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74.
• [246] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003836)
• [247] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001278)
• [248] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007194)
• [249] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010108)
• [250] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013096)
• [251] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000792)
• [252] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008316)
• [253] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017949)
• [254] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011240)
• [255] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001207)
• [256] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005862)
• [257] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000885)
• [258] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [259] A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Res. 2014 Dec 9;16(6):482.
• [260] ClinicalTrials.gov (NCT02049957) Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer. U.S. National Institutes of Health.
• [261] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [262] ClinicalTrials.gov (NCT00044291) Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer. U.S. National Institutes of Health.
• [263] AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25.
• [264] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
• [265] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [266] Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo.Oncogene. 2013 May 23;32(21):2622-30. doi: 10.1038/onc.2012.284. Epub 2012 Jul 9.
• [267] ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway.J Exp Clin Cancer Res. 2019 Apr 25;38(1):173. doi: 10.1186/s13046-019-1156-5.
• [268] Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors.Cancer Chemother Pharmacol. 2019 Sep;84(3):579-589. doi: 10.1007/s00280-019-03881-8. Epub 2019 Jul 13.
• [269] ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis.Tumour Biol. 2017 Apr;39(4):1010428317698338. doi: 10.1177/1010428317698338.
• [270] ADAMTS1 Promotes Adhesion to Extracellular Matrix Proteins and Predicts Prognosis in Early Stage Breast Cancer Patients.Cell Physiol Biochem. 2019;52(6):1553-1568. doi: 10.33594/000000108.
• [271] Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5139-44. doi: 10.1073/pnas.1222085110. Epub 2013 Mar 12.
• [272] Use of non-selective -blockers is associated with decreased tumor proliferative indices in early stage breast cancer.Oncotarget. 2017 Jan 24;8(4):6446-6460. doi: 10.18632/oncotarget.14119.
• [273] Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor.Mol Cancer. 2014 May 8;13:106. doi: 10.1186/1476-4598-13-106.
• [274] Breast cancer induced nociceptor aberrant growth and collateral sensory axonal branching.Oncotarget. 2017 Sep 1;8(44):76606-76621. doi: 10.18632/oncotarget.20609. eCollection 2017 Sep 29.
• [275] Changes of N6-methyladenosine modulators promote breast cancer progression.BMC Cancer. 2019 Apr 5;19(1):326. doi: 10.1186/s12885-019-5538-z.
• [276] Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer.J Cancer Res Clin Oncol. 2019 Aug;145(8):2083-2095. doi: 10.1007/s00432-019-02946-8. Epub 2019 Jun 15.
• [277] Expression of AMHR2 and C-KIT in cervical lesions in Uyghur Women of Xinjiang, China.Medicine (Baltimore). 2018 Jun;97(22):e10793. doi: 10.1097/MD.0000000000010793.
• [278] Capillary morphogenesis gene 2 inhibits growth of breast cancer cells and is inversely correlated with the disease progression and prognosis.J Cancer Res Clin Oncol. 2014 Jun;140(6):957-67. doi: 10.1007/s00432-014-1650-2. Epub 2014 Mar 26.
• [279] Significant prognostic values of aquaporin mRNA expression in breast cancer.Cancer Manag Res. 2019 Feb 14;11:1503-1515. doi: 10.2147/CMAR.S193396. eCollection 2019.
• [280] Acetylation of ACAP4 regulates CCL18-elicited breast cancer cell migration and invasion.J Mol Cell Biol. 2018 Dec 1;10(6):559-572. doi: 10.1093/jmcb/mjy058.
• [281] HER2 Upregulates ATF4 to Promote Cell Migration via Activation of ZEB1 and Downregulation of E-Cadherin.Int J Mol Sci. 2019 May 6;20(9):2223. doi: 10.3390/ijms20092223.
• [282] ATP2A3 gene as an important player for resveratrol anticancer activity in breast cancer cells.Mol Carcinog. 2017 Jul;56(7):1703-1711. doi: 10.1002/mc.22625. Epub 2017 Feb 15.
• [283] A small-molecule inhibitor targeting the AURKC-IB interaction decreases transformed growth of MDA-MB-231 breast cancer cells.Oncotarget. 2017 Jun 29;8(41):69691-69708. doi: 10.18632/oncotarget.18883. eCollection 2017 Sep 19.
• [284] 2-microglobulin has a different regulatory molecular mechanism between ER(+) and ER(-) breast cancer with HER2().BMC Cancer. 2019 Mar 12;19(1):223. doi: 10.1186/s12885-019-5410-1.
• [285] Serum butyrylcholinesterase and zinc in breast cancer.J Cancer Res Ther. 2017 Apr-Jun;13(2):367-370. doi: 10.4103/0973-1482.165869.
• [286] ATP/pH Dual Responsive Nanoparticle with d-[des-Arg(10) ]Kallidin Mediated Efficient In Vivo Targeting Drug Delivery.Small. 2017 Jan;13(3). doi: 10.1002/smll.201602494. Epub 2016 Oct 24.
• [287] A strategy to apply quantitative epistasis analysis on developmental traits.BMC Genet. 2017 May 15;18(1):42. doi: 10.1186/s12863-017-0508-4.
• [288] Expression and prognosis analyses of the Tob/BTG antiproliferative (APRO) protein family in human cancers.PLoS One. 2017 Sep 18;12(9):e0184902. doi: 10.1371/journal.pone.0184902. eCollection 2017.
• [289] L-Canavanine Potentiates Cytotoxicity of Chemotherapeutic Drugs in Human Breast Cancer Cells.Anticancer Agents Med Chem. 2017;17(2):206-211. doi: 10.2174/1871520616666160223111551.
• [290] Meta-Analysis of Public Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients.PLoS One. 2015 Jul 6;10(7):e0125766. doi: 10.1371/journal.pone.0125766. eCollection 2015.
• [291] Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.Antioxid Redox Signal. 2017 Jan 10;26(2):70-83. doi: 10.1089/ars.2015.6457. Epub 2016 Aug 5.
• [292] Attenuation of Antioxidant Capacity in Human Breast Cancer Cells by Carbon Monoxide through Inhibition of Cystathionine -Synthase Activity: Implications in Chemotherapeutic Drug Sensitivity.J Med Chem. 2017 Oct 12;60(19):8000-8010. doi: 10.1021/acs.jmedchem.7b00476. Epub 2017 Sep 20.
• [293] Prognostic values of distinct CBX family members in breast cancer.Oncotarget. 2017 Sep 28;8(54):92375-92387. doi: 10.18632/oncotarget.21325. eCollection 2017 Nov 3.
• [294] The Anti-tumoral Effect of -D-Mannuronic Acid (M2000) as a Novel NSAID on Treg Cells Frequency and MMP-2, MMP-9, CCL22 and TGF1 Gene Expression in Pre-surgical Breast Cancer Patients.Iran J Allergy Asthma Immunol. 2019 Feb;18(1):80-90.
• [295] High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer.Virchows Arch. 2019 Jan;474(1):3-12. doi: 10.1007/s00428-018-2461-7. Epub 2018 Oct 27.
• [296] The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.Int J Oncol. 2014 Oct;45(4):1658-72. doi: 10.3892/ijo.2014.2565. Epub 2014 Jul 28.
• [297] Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.Clin Cancer Res. 2019 Sep 15;25(18):5441-5448. doi: 10.1158/1078-0432.CCR-19-0272. Epub 2019 Apr 12.
• [298] Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer.Curr Gene Ther. 2019;19(1):54-65. doi: 10.2174/1566523219666190307094713.
• [299] Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells.Int Immunol. 2018 Nov 14;30(12):559-567. doi: 10.1093/intimm/dxy050.
• [300] The Overexpression of CD80 and ISG15 Are Associated with the Progression and Metastasis of Breast Cancer by a Meta-Analysis Integrating Three Microarray Datasets.Pathol Oncol Res. 2020 Jan;26(1):443-452. doi: 10.1007/s12253-018-0478-5. Epub 2018 Nov 9.
• [301] Epigenetic silencing of genes enhanced by collective role of reactive oxygen species and MAPK signaling downstream ERK/Snail axis: Ectopic application of hydrogen peroxide repress CDH1 gene by enhanced DNA methyltransferase activity in human breast cancer.Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1651-1665. doi: 10.1016/j.bbadis.2019.04.002. Epub 2019 Apr 4.
• [302] Cadherin 11 Inhibition Downregulates -catenin, Deactivates the Canonical WNT Signalling Pathway and Suppresses the Cancer Stem Cell-Like Phenotype of Triple Negative Breast Cancer.J Clin Med. 2019 Jan 27;8(2):148. doi: 10.3390/jcm8020148.
• [303] CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/ -catenin Signaling.Curr Cancer Drug Targets. 2020;20(2):156-165. doi: 10.2174/1568009619666191118113220.
• [304] Methylation of C/EBP by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer.Cancer Res. 2019 Jun 1;79(11):2865-2877. doi: 10.1158/0008-5472.CAN-18-3211. Epub 2019 Apr 23.
• [305] Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer.Mol Cancer Ther. 2014 Aug;13(8):2104-15. doi: 10.1158/1535-7163.MCT-14-0083-T. Epub 2014 Jun 13.
• [306] Chitotriosidase, a marker of innate immunity, is elevated in patients with primary breast cancer.Cancer Biomark. 2017 Jul 4;19(4):383-391. doi: 10.3233/CBM-160101.
• [307] High IKK expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.Int J Cancer. 2017 Apr 1;140(7):1633-1644. doi: 10.1002/ijc.30578. Epub 2017 Jan 6.
• [308] Guanine nucleotide binding protein 1: a novel transduction protein with a possible role in human breast cancer.Cancer Genomics Proteomics. 2013 Mar-Apr;10(2):69-73.
• [309] Development of dual casein kinase 1/1 (CK1/) inhibitors for treatment of breast cancer.Bioorg Med Chem. 2018 Feb 1;26(3):590-602. doi: 10.1016/j.bmc.2017.12.020. Epub 2017 Dec 15.
• [310] Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies.BMC Med. 2018 Feb 19;16(1):20. doi: 10.1186/s12916-018-1010-1.
• [311] A novel derivative of artemisinin inhibits cell proliferation and metastasis via down-regulation of cathepsin K in breast cancer.Eur J Pharmacol. 2019 Sep 5;858:172382. doi: 10.1016/j.ejphar.2019.05.011. Epub 2019 May 18.
• [312] CX3CL1 involves in breast cancer metastasizing to the spine via the Src/FAK signaling pathway.J Cancer. 2018 Sep 8;9(19):3603-3612. doi: 10.7150/jca.26497. eCollection 2018.
• [313] Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design.J Biol Chem. 2019 Jan 11;294(2):453-460. doi: 10.1074/jbc.RA118.006214. Epub 2018 Nov 13.
• [314] Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.Cancer Res. 2018 Nov 1;78(21):6183-6195. doi: 10.1158/0008-5472.CAN-18-0730. Epub 2018 Sep 17.
• [315] Optical Redox Imaging Detects the Effects of DEK Oncogene Knockdown on the Redox State of MDA-MB-231 Breast Cancer Cells.Mol Imaging Biol. 2019 Jun;21(3):410-416. doi: 10.1007/s11307-019-01321-w.
• [316] Diacylglycerol kinase promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src.Oncotarget. 2014 Oct 30;5(20):9710-26. doi: 10.18632/oncotarget.2344.
• [317] Prognostic value of DKK2 from the Dickkopf family in human breast cancer. Int J Oncol. 2018 Dec;53(6):2555-2565.
• [318] Network analysis of EMT and MET micro-RNA regulation in breast cancer.Sci Rep. 2017 Oct 19;7(1):13534. doi: 10.1038/s41598-017-13903-1.
• [319] Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.Cancer Res. 2019 Feb 15;79(4):735-746. doi: 10.1158/0008-5472.CAN-18-0620. Epub 2018 Dec 24.
• [320] Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy.Oncotarget. 2017 Dec 8;8(67):112060-112075. doi: 10.18632/oncotarget.23033. eCollection 2017 Dec 19.
• [321] Collapsin response mediator protein 2 is involved in regulating breast cancer progression.Breast Cancer. 2014 Nov;21(6):715-23. doi: 10.1007/s12282-013-0447-5. Epub 2013 Feb 5.
• [322] Dopamine receptor gene (DRD1-DRD5) expression changes as stress factors associated with breast cancer.Asian Pac J Cancer Prev. 2014;15(23):10339-43. doi: 10.7314/apjcp.2014.15.23.10339.
• [323] Modelling the role of dual specificity phosphatases in herceptin resistant breast cancer cell lines.Comput Biol Chem. 2019 Jun;80:138-146. doi: 10.1016/j.compbiolchem.2019.03.018. Epub 2019 Mar 25.
• [324] miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2.Breast Cancer. 2020 Jan;27(1):147-158. doi: 10.1007/s12282-019-01002-0. Epub 2019 Aug 13.
• [325] Design, synthesis and structure-activity relationship of a focused library of -phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.Eur J Med Chem. 2018 Jan 1;143:402-418. doi: 10.1016/j.ejmech.2017.11.065. Epub 2017 Dec 1.
• [326] EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis.Oncogene. 2019 Mar;38(12):2123-2134. doi: 10.1038/s41388-018-0565-9. Epub 2018 Nov 19.
• [327] Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer.Int J Oncol. 2013 Apr;42(4):1367-75. doi: 10.3892/ijo.2013.1820. Epub 2013 Feb 8.
• [328] TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells.Oncogene. 2019 Aug;38(31):5971-5986. doi: 10.1038/s41388-019-0853-z. Epub 2019 Jun 28.
• [329] Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.J Biol Chem. 2017 Jun 16;292(24):10295-10305. doi: 10.1074/jbc.M116.773051. Epub 2017 May 3.
• [330] Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors.Haematologica. 2020 Jan;105(1):218-225. doi: 10.3324/haematol.2019.217083. Epub 2019 May 2.
• [331] GATA Binding Protein 3 Boosts Extracellular ATP Hydrolysis and Inhibits Metastasis of Breast Cancer by Up-regulating Ectonucleoside Triphosphate Diphosphohydrolase 3.Int J Biol Sci. 2019 Sep 7;15(12):2522-2537. doi: 10.7150/ijbs.35563. eCollection 2019.
• [332] Antitumoral potential of microvesicles extracted from human adipose-derived mesenchymal stem cells on human breast cancer cells.J Cancer Res Ther. 2019 Jul-Sep;15(5):1114-1119. doi: 10.4103/jcrt.JCRT_147_18.
• [333] Inflammatory peroxidases promote breast cancer progression in mice via regulation of the tumour microenvironment.Int J Oncol. 2017 Apr;50(4):1191-1200. doi: 10.3892/ijo.2017.3883. Epub 2017 Feb 20.
• [334] EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival.Front Oncol. 2019 Jan 29;9:26. doi: 10.3389/fonc.2019.00026. eCollection 2019.
• [335] Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation.Oncotarget. 2017 Jun 13;8(24):38731-38742. doi: 10.18632/oncotarget.16317.
• [336] FAF1 phosphorylation by AKT accumulates TGF- type II receptor and drives breast cancer metastasis.Nat Commun. 2017 Apr 26;8:15021. doi: 10.1038/ncomms15021.
• [337] Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B.Oncogene. 2014 Jun 19;33(25):3298-306. doi: 10.1038/onc.2013.293. Epub 2013 Aug 5.
• [338] Tumor-targeting efficacy of a BF211 prodrug through hydrolysis by fibroblast activation protein-.Acta Pharmacol Sin. 2018 Mar;39(3):415-424. doi: 10.1038/aps.2017.121. Epub 2017 Nov 9.
• [339] Endogenously Synthesized n-3 Polyunsaturated Fatty Acids in Pregnant fat-1 Mice Decreases Mammary Cancer Risk of Female Offspring by Regulating Expression of Long Noncoding RNAs.Mol Nutr Food Res. 2019 Mar;63(6):e1801150. doi: 10.1002/mnfr.201801150. Epub 2019 Jan 27.
• [340] Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer.J Exp Clin Cancer Res. 2019 Feb 22;38(1):100. doi: 10.1186/s13046-019-1040-3.
• [341] FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.Mol Carcinog. 2018 Nov;57(11):1616-1625. doi: 10.1002/mc.22884. Epub 2018 Aug 22.
• [342] FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer.Theranostics. 2019 Sep 21;9(23):7003-7015. doi: 10.7150/thno.35561. eCollection 2019.
• [343] MicroRNA Let-7g Directly Targets Forkhead Box C2 (FOXC2) to Modulate Bone Metastasis in Breast Cancer.Open Med (Wars). 2017 Sep 6;12:157-162. doi: 10.1515/med-2017-0023. eCollection 2017.
• [344] MicroRNA-937 inhibits the malignant phenotypes of breast cancer by directly targeting and downregulating forkhead box Q1.Onco Targets Ther. 2019 Jun 20;12:4813-4824. doi: 10.2147/OTT.S207593. eCollection 2019.
• [345] Ampelopsins A and C Induce Apoptosis and Metastasis through Downregulating AxL, TYRO3, and FYN Expressions in MDA-MB-231 Breast Cancer Cells.J Agric Food Chem. 2019 Mar 13;67(10):2818-2830. doi: 10.1021/acs.jafc.8b06444. Epub 2019 Mar 4.
• [346] Allelic loss at chromosome 11q13 alters FGF3 gene expression in a human breast cancer progression model.Oncol Rep. 2014 Dec;32(6):2445-52. doi: 10.3892/or.2014.3502. Epub 2014 Sep 19.
• [347] Restoration of GATA4 expression impedes breast cancer progression by transcriptional repression of ReLA and inhibition of NF-B signaling.J Cell Biochem. 2019 Jan;120(1):917-927. doi: 10.1002/jcb.27455. Epub 2018 Sep 6.
• [348] High levels of -glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.
• [349] The long non-coding RNA GHSROS facilitates breast cancer cell migration and orthotopic xenograft tumour growth.Int J Oncol. 2019 Dec;55(6):1223-1236. doi: 10.3892/ijo.2019.4891. Epub 2019 Oct 4.
• [350] Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.Breast. 2017 Aug;34:53-57. doi: 10.1016/j.breast.2017.05.005. Epub 2017 May 12.
• [351] Correlations of differentially expressed gap junction connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with breast cancer progression and prognosis.PLoS One. 2014 Nov 10;9(11):e112541. doi: 10.1371/journal.pone.0112541. eCollection 2014.
• [352] Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-B Activation.Endocrinology. 2017 Dec 1;158(12):4218-4232. doi: 10.1210/en.2017-00461.
• [353] Novel therapeutic strategies and targets in advanced uveal melanoma.Curr Opin Oncol. 2018 Mar;30(2):134-141. doi: 10.1097/CCO.0000000000000425.
• [354] Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells.Mol Biol Rep. 2019 Jun;46(3):3129-3140. doi: 10.1007/s11033-019-04767-x. Epub 2019 Apr 1.
• [355] The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival.Cancer Res. 2014 Feb 15;74(4):1166-78. doi: 10.1158/0008-5472.CAN-13-1451. Epub 2013 Dec 26.
• [356] Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.Oncotarget. 2017 Mar 28;8(13):20925-20938. doi: 10.18632/oncotarget.14995.
• [357] LncRNA SNHG3 promotes cell proliferation and invasion through the miR-384/hepatoma-derived growth factor axis in breast cancer.Hum Cell. 2020 Jan;33(1):232-242. doi: 10.1007/s13577-019-00287-9. Epub 2019 Oct 4.
• [358] HMBA is a putative HSP70 activator stimulating HEXIM1 expression that is down-regulated by estrogen.J Steroid Biochem Mol Biol. 2017 Apr;168:91-101. doi: 10.1016/j.jsbmb.2017.02.008. Epub 2017 Feb 14.
• [359] Splicing factor hnRNPA2B1 contributes to tumorigenic potential of breast cancer cells through STAT3 and ERK1/2 signaling pathway.Tumour Biol. 2017 Mar;39(3):1010428317694318. doi: 10.1177/1010428317694318.
• [360] Associations of polymorphisms in histidine decarboxylase, histamine N-methyltransferase and histamine receptor H3 genes with breast cancer.PLoS One. 2014 May 16;9(5):e97728. doi: 10.1371/journal.pone.0097728. eCollection 2014.
• [361] Steroid enzyme and receptor expression and regulations in breast tumor samples - A statistical evaluation of public data.J Steroid Biochem Mol Biol. 2020 Feb;196:105494. doi: 10.1016/j.jsbmb.2019.105494. Epub 2019 Oct 11.
• [362] Estrogen and androgen-converting enzymes 17-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.Oncotarget. 2017 May 2;8(18):30552-30562. doi: 10.18632/oncotarget.15547.
• [363] Profilin-1 overexpression in MDA-MB-231 breast cancer cells is associated with alterations in proteomics biomarkers of cell proliferation, survival, and motility as revealed by global proteomics analyses.OMICS. 2014 Dec;18(12):778-91. doi: 10.1089/omi.2014.0075.
• [364] Cytokine and cytokine receptor genes of the adaptive immune response are differentially associated with breast cancer risk in American women of African and European ancestry.Int J Cancer. 2014 Mar 15;134(6):1408-21. doi: 10.1002/ijc.28458. Epub 2013 Oct 8.
• [365] Genetic polymorphisms in the 9p21 region associated with risk of multiple cancers.Carcinogenesis. 2014 Dec;35(12):2698-705. doi: 10.1093/carcin/bgu203. Epub 2014 Sep 19.
• [366] Integration of genomic data enables selective discovery of breast cancer drivers.Cell. 2014 Dec 4;159(6):1461-75. doi: 10.1016/j.cell.2014.10.048. Epub 2014 Nov 26.
• [367] Regulation of cellular processes by interleukin-16 in homeostasis and cancer.J Cell Physiol. 2014 Feb;229(2):139-47. doi: 10.1002/jcp.24441.
• [368] Genetic polymorphisms in inflammatory response genes and their associations with breast cancer risk.Croat Med J. 2014 Dec;55(6):638-46. doi: 10.3325/cmj.2014.55.638.
• [369] Interleukin-22 promotes development of malignant lesions in a mouse model of spontaneous breast cancer.Mol Oncol. 2020 Jan;14(1):211-224. doi: 10.1002/1878-0261.12598. Epub 2019 Dec 4.
• [370] Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin 3-p38 MAPK signalling.Cancer Lett. 2019 Feb 1;442:320-332. doi: 10.1016/j.canlet.2018.10.015. Epub 2018 Oct 27.
• [371] Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development.Int J Cancer. 2020 Mar 1;146(5):1421-1434. doi: 10.1002/ijc.32779. Epub 2019 Dec 5.
• [372] Blocking Interleukin-4 Receptor Using Polyethylene Glycol Functionalized Superparamagnetic Iron Oxide Nanocarriers to Inhibit Breast Cancer Cell Proliferation.Cancer Res Treat. 2017 Apr;49(2):322-329. doi: 10.4143/crt.2016.091. Epub 2016 Jul 12.
• [373] The role of IRAK1 in breast cancer patients treated with neoadjuvant chemotherapy.Onco Targets Ther. 2019 Mar 25;12:2171-2180. doi: 10.2147/OTT.S185662. eCollection 2019.
• [374] Interplay between interferon-stimulated gene 15/ISGylation and interferon gamma signaling in breast cancer cells.Cell Signal. 2019 Feb;54:91-101. doi: 10.1016/j.cellsig.2018.11.021. Epub 2018 Nov 27.
• [375] EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.J Immunother Cancer. 2019 Jan 8;7(1):5. doi: 10.1186/s40425-018-0470-3.
• [376] Calendula arvensis L. as an anti-cancer agent against breast cancer cell lines.Mol Biol Rep. 2019 Apr;46(2):2187-2196. doi: 10.1007/s11033-019-04672-3. Epub 2019 Feb 11.
• [377] Identification of MYST3 as a novel epigenetic activator of ER frequently amplified in breast cancer.Oncogene. 2017 May 18;36(20):2910-2918. doi: 10.1038/onc.2016.433. Epub 2016 Nov 28.
• [378] The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells.Tumour Biol. 2016 May;37(5):6275-83. doi: 10.1007/s13277-015-4509-5. Epub 2015 Nov 30.
• [379] Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.Oncotarget. 2017 Jul 19;8(47):81737-81753. doi: 10.18632/oncotarget.19387. eCollection 2017 Oct 10.
• [380] SF-KDM2A binds to ribosomal RNA gene promoter, reduces H4K20me3 level, and elevates ribosomal RNA transcription in breast cancer cells.Int J Oncol. 2017 Apr;50(4):1372-1382. doi: 10.3892/ijo.2017.3908. Epub 2017 Mar 10.
• [381] Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.Biochem Biophys Res Commun. 2015 Aug 21;464(2):659-66. doi: 10.1016/j.bbrc.2015.07.049. Epub 2015 Jul 13.
• [382] KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer.Mol Cancer Ther. 2018 Sep;17(9):1973-1983. doi: 10.1158/1535-7163.MCT-17-0802. Epub 2018 Jun 20.
• [383] Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer.J Cell Physiol. 2020 Feb;235(2):932-943. doi: 10.1002/jcp.29008. Epub 2019 Jun 24.
• [384] Association of the genetic diversity of killer cell immunoglobulin-like receptor genes and HLA-C ligand in Saudi women with breast cancer.Immunogenetics. 2017 Feb;69(2):69-76. doi: 10.1007/s00251-016-0950-x. Epub 2016 Sep 15.
• [385] Downregulation of klotho is associated with invasive ductal carcinoma progression.Oncol Lett. 2017 Dec;14(6):7443-7448. doi: 10.3892/ol.2017.7110. Epub 2017 Sep 29.
• [386] Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models.Oncotarget. 2019 Feb 15;10(14):1399-1406. doi: 10.18632/oncotarget.26659. eCollection 2019 Feb 15.
• [387] Lipopolysaccharide-Binding Protein Is an Early Biomarker of Cardiac Function After Radiation Therapy for Breast Cancer.Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1074-1083. doi: 10.1016/j.ijrobp.2019.04.002. Epub 2019 Apr 13.
• [388] USP17 Suppresses Tumorigenesis and Tumor Growth through Deubiquitinating AEP.Int J Biol Sci. 2019 Jan 29;15(4):738-748. doi: 10.7150/ijbs.30106. eCollection 2019.
• [389] Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10.Diagn Pathol. 2014 Apr 24;9:85. doi: 10.1186/1746-1596-9-85.
• [390] Wogonin suppresses the LPSenhanced invasiveness of MDAMB?31 breast cancer cells by inhibiting the 5LO/BLT2 cascade.Int J Mol Med. 2018 Oct;42(4):1899-1908. doi: 10.3892/ijmm.2018.3776. Epub 2018 Jul 12.
• [391] Transgenic overexpression of human LY6K in mice suppresses mature T cell development in the thymus.Oncol Lett. 2019 Jan;17(1):379-387. doi: 10.3892/ol.2018.9548. Epub 2018 Oct 4.
• [392] The CARMA3-Bcl10-MALT1 Signalosome Drives NFB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.Cancer Res. 2018 Mar 1;78(5):1225-1240. doi: 10.1158/0008-5472.CAN-17-1089. Epub 2017 Dec 19.
• [393] Mixed lineage kinase ZAK promotes epithelial-mesenchymal transition in cancer progression.Cell Death Dis. 2018 Feb 2;9(2):143. doi: 10.1038/s41419-017-0161-x.
• [394] Topological alternate centrality measure capturing drug targets in the network of MAPK pathways.IET Syst Biol. 2018 Oct;12(5):226-232. doi: 10.1049/iet-syb.2017.0058.
• [395] Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.Breast Cancer Res Treat. 2017 Jul;164(1):27-40. doi: 10.1007/s10549-017-4223-7. Epub 2017 Mar 31.
• [396] Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.J Biol Chem. 2014 Sep 12;289(37):25737-49. doi: 10.1074/jbc.M114.570838. Epub 2014 Jul 29.
• [397] Proteins with Evolutionarily Hypervariable Domains are Associated with Immune Response and Better Survival of Basal-like Breast Cancer Patients.Comput Struct Biotechnol J. 2019 Mar 19;17:430-440. doi: 10.1016/j.csbj.2019.03.008. eCollection 2019.
• [398] Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer.Glycobiology. 2013 Dec;23(12):1477-90. doi: 10.1093/glycob/cwt075. Epub 2013 Sep 13.
• [399] Human G protein-coupled receptor 30 is N-glycosylated and N-terminal domain asparagine 44 is required for receptor structure and activity.Biosci Rep. 2019 Feb 26;39(2):BSR20182436. doi: 10.1042/BSR20182436. Print 2019 Feb 28.
• [400] Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth.Oncoimmunology. 2018 Jul 11;7(9):e1480286. doi: 10.1080/2162402X.2018.1480286. eCollection 2018.
• [401] Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays.Breast Cancer Res. 2014 Nov 8;16(6):470. doi: 10.1186/s13058-014-0470-2.
• [402] Mutational analysis of the kinase domain of MYLK2 gene in common human cancers.Pathol Res Pract. 2006;202(3):137-40. doi: 10.1016/j.prp.2005.12.003. Epub 2006 Jan 31.
• [403] Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients.Cancer Biol Ther. 2020;21(2):189-196. doi: 10.1080/15384047.2019.1680057. Epub 2019 Nov 4.
• [404] NLRX1 regulates TNF--induced mitochondria-lysosomal crosstalk to maintain the invasive and metastatic potential of breast cancer cells.Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1460-1476. doi: 10.1016/j.bbadis.2019.02.018. Epub 2019 Feb 23.
• [405] MiRNA-106a promotes breast cancer progression by regulating DAX-1.Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1574-1583. doi: 10.26355/eurrev_201902_17116.
• [406] Variability in DNA Repair Capacity Levels among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair.Int J Mol Sci. 2017 Jul 12;18(7):1505. doi: 10.3390/ijms18071505.
• [407] Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level.PLoS Comput Biol. 2019 Dec 11;15(12):e1007485. doi: 10.1371/journal.pcbi.1007485. eCollection 2019 Dec.
• [408] Dichotomous roles for the orphan nuclear receptor NURR1 in breast cancer.BMC Cancer. 2013 Mar 21;13:139. doi: 10.1186/1471-2407-13-139.
• [409] Learning common and specific patterns from data of multiple interrelated biological scenarios with matrix factorization.Nucleic Acids Res. 2019 Jul 26;47(13):6606-6617. doi: 10.1093/nar/gkz488.
• [410] Ultrasound molecular imaging as a non-invasive companion diagnostic for netrin-1 interference therapy in breast cancer.Theranostics. 2018 Oct 6;8(18):5126-5142. doi: 10.7150/thno.27221. eCollection 2018.
• [411] Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.Clin Exp Metastasis. 2018 Feb;35(1-2):25-35. doi: 10.1007/s10585-018-9874-1. Epub 2018 Jan 11.
• [412] P2Y2 receptor promotes the migration and invasion of breast cancer cells via EMT-related genes Snail and E-cadherin.Oncol Rep. 2018 Jan;39(1):138-150. doi: 10.3892/or.2017.6081. Epub 2017 Nov 7.
• [413] Prolyl-4-hydroxylase subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.BMC Cancer. 2014 Jan 2;14:1. doi: 10.1186/1471-2407-14-1.
• [414] MiR-216a-5p act as a tumor suppressor, regulating the cell proliferation and metastasis by targeting PAK2 in breast cancer.Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2469-2475. doi: 10.26355/eurrev_201903_17394.
• [415] TOPK promotes epithelial-mesenchymal transition and invasion of breast cancer cells through upregulation of TBX3 in TGF-1/Smad signaling.Biochem Biophys Res Commun. 2020 Jan 29;522(1):270-277. doi: 10.1016/j.bbrc.2019.11.104. Epub 2019 Nov 20.
• [416] BAF180: Its Roles in DNA Repair and Consequences in Cancer.ACS Chem Biol. 2017 Oct 20;12(10):2482-2490. doi: 10.1021/acschembio.7b00541. Epub 2017 Sep 28.
• [417] The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells.Biochem Biophys Res Commun. 2013 May 3;434(2):305-10. doi: 10.1016/j.bbrc.2013.02.123. Epub 2013 Mar 26.
• [418] Sulfatase 2 promotes breast cancer progression through regulating some tumor-related factors.Oncol Rep. 2016 Mar;35(3):1318-28. doi: 10.3892/or.2015.4525. Epub 2015 Dec 28.
• [419] The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.Breast Cancer Res Treat. 2018 Jun;169(2):231-241. doi: 10.1007/s10549-018-4664-7. Epub 2018 Jan 29.
• [420] Epigenetic repression of phosphatidylethanolamine N-methyltransferase (PEMT) in BRCA1-mutated breast cancer.Oncotarget. 2014 Mar 15;5(5):1315-25. doi: 10.18632/oncotarget.1800.
• [421] Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.Nucleic Acids Res. 2017 Feb 28;45(4):1687-1702. doi: 10.1093/nar/gkw1093.
• [422] The PIKfyve-ArPIKfyve-Sac3 triad in human breast cancer: Functional link between elevated Sac3 phosphatase and enhanced proliferation of triple negative cell lines.Biochem Biophys Res Commun. 2013 Oct 18;440(2):342-7. doi: 10.1016/j.bbrc.2013.09.080. Epub 2013 Sep 23.
• [423] Correction: PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer.Oncogene. 2020 Jan;39(3):720-721. doi: 10.1038/s41388-019-0982-4.
• [424] Gene expression correlation for cancer diagnosis: a pilot study.Biomed Res Int. 2014;2014:253804. doi: 10.1155/2014/253804. Epub 2014 Apr 9.
• [425] The role of PIP5K1/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1 inhibitor.Oncogene. 2019 Jan;38(3):375-389. doi: 10.1038/s41388-018-0438-2. Epub 2018 Aug 13.
• [426] The NQO1/PKLR axis promotes lymph node metastasis and breast cancer progression by modulating glycolytic reprogramming.Cancer Lett. 2019 Jul 1;453:170-183. doi: 10.1016/j.canlet.2019.03.054. Epub 2019 Apr 4.
• [427] Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis.Cell Prolif. 2020 Feb;53(2):e12741. doi: 10.1111/cpr.12741. Epub 2019 Dec 14.
• [428] The interaction of p130Cas with PKN3 promotes malignant growth.Mol Oncol. 2019 Feb;13(2):264-289. doi: 10.1002/1878-0261.12401. Epub 2018 Dec 3.
• [429] Regulation of the Hippo Pathway by Phosphatidic Acid-Mediated Lipid-Protein Interaction.Mol Cell. 2018 Oct 18;72(2):328-340.e8. doi: 10.1016/j.molcel.2018.08.038. Epub 2018 Oct 4.
• [430] A feedback mechanism between PLD and deadenylase PARN for the shortening of eukaryotic poly(A) mRNA tails that is deregulated in cancer cells.Biol Open. 2017 Feb 15;6(2):176-186. doi: 10.1242/bio.021261.
• [431] YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.Cell Death Dis. 2018 Oct 18;9(11):1066. doi: 10.1038/s41419-018-1071-2.
• [432] MiR-422a weakened breast cancer stem cells properties by targeting PLP2. Cancer Biol Ther. 2018 May 4;19(5):436-444.
• [433] Ligand-activated interaction of PPAR with c-Myc governs the tumorigenicity of breast cancer.Int J Cancer. 2018 Dec 1;143(11):2985-2996. doi: 10.1002/ijc.31864. Epub 2018 Oct 4.
• [434] miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.Kaohsiung J Med Sci. 2019 Jan;35(1):17-23. doi: 10.1002/kjm2.12004.
• [435] Dephosphorylation of Girdin by PP2A inhibits breast cancer metastasis.Biochem Biophys Res Commun. 2019 May 21;513(1):28-34. doi: 10.1016/j.bbrc.2019.03.167. Epub 2019 Mar 29.
• [436] Inhibition of Thioredoxin Reductase by Targeted Selenopolymeric Nanocarriers Synergizes the Therapeutic Efficacy of Doxorubicin in MCF7 Human Breast Cancer Cells.ACS Appl Mater Interfaces. 2017 Oct 25;9(42):36493-36512. doi: 10.1021/acsami.7b07056. Epub 2017 Oct 10.
• [437] The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.Breast Cancer. 2017 Sep;24(5):658-666. doi: 10.1007/s12282-017-0752-5. Epub 2017 Jan 9.
• [438] Interleukin-32 inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer.Cell Commun Signal. 2019 May 24;17(1):53. doi: 10.1186/s12964-019-0374-y.
• [439] Transcriptional regulation of oncogenic protein kinase C (PKC) by STAT1 and Sp1 proteins.J Biol Chem. 2014 Jul 11;289(28):19823-38. doi: 10.1074/jbc.M114.548446. Epub 2014 May 13.
• [440] Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers.Cancer Res Treat. 2019 Jan;51(1):80-89. doi: 10.4143/crt.2017.500. Epub 2018 Feb 26.
• [441] Regulatory network reconstruction of five essential microRNAs for survival analysis in breast cancer by integrating miRNA and mRNA expression datasets.Funct Integr Genomics. 2019 Jul;19(4):645-658. doi: 10.1007/s10142-019-00670-7. Epub 2019 Mar 12.
• [442] Multifunctional superparamagnetic nanoparticles conjugated with fluorescein-labeled designed ankyrin repeat protein as an efficient HER2-targeted probe in breast cancer.Biomaterials. 2017 Dec;147:86-98. doi: 10.1016/j.biomaterials.2017.09.010. Epub 2017 Sep 8.
• [443] The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells.Breast Cancer Res. 2019 Apr 24;21(1):53. doi: 10.1186/s13058-019-1131-2.
• [444] PTH1R-CaSR Cross Talk: New Treatment Options for Breast Cancer Osteolytic Bone Metastases.Int J Endocrinol. 2018 Jul 29;2018:7120979. doi: 10.1155/2018/7120979. eCollection 2018.
• [445] PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement.PLoS One. 2014 Jan 7;9(1):e84472. doi: 10.1371/journal.pone.0084472. eCollection 2014.
• [446] Pleiotrophin as a potential biomarker in breast cancer patients.Clin Chim Acta. 2017 Mar;466:6-12. doi: 10.1016/j.cca.2016.12.030. Epub 2016 Dec 29.
• [447] Inhibition of PRL-2CNNM3 Protein Complex Formation Decreases Breast Cancer Proliferation and Tumor Growth.J Biol Chem. 2016 May 13;291(20):10716-25. doi: 10.1074/jbc.M115.705863. Epub 2016 Mar 11.
• [448] Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.Cell Death Dis. 2018 Feb 27;9(3):326. doi: 10.1038/s41419-018-0347-x.
• [449] Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer.Clin Transl Oncol. 2019 Apr;21(4):433-442. doi: 10.1007/s12094-018-1941-1. Epub 2018 Sep 14.
• [450] The overexpression of Rab9 promotes tumor progression regulated by XBP1 in breast cancer.Onco Targets Ther. 2019 Mar 4;12:1815-1824. doi: 10.2147/OTT.S183748. eCollection 2019.
• [451] RACK1 stabilises the activity of PP2A to regulate the transformed phenotype in mammary epithelial cells.Cell Signal. 2017 Jul;35:290-300. doi: 10.1016/j.cellsig.2016.09.001. Epub 2016 Sep 4.
• [452] 2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer.Oncotarget. 2018 Apr 6;9(26):18053-18068. doi: 10.18632/oncotarget.24720. eCollection 2018 Apr 6.
• [453] Role of exchange protein directly activated by cAMP (EPAC1) in breast cancer cell migration and apoptosis.Mol Cell Biochem. 2017 Jun;430(1-2):115-125. doi: 10.1007/s11010-017-2959-3. Epub 2017 Feb 16.
• [454] Atorvastatin Inhibits Breast Cancer Cells by Downregulating PTEN/AKT Pathway via Promoting Ras Homolog Family Member B (RhoB).Biomed Res Int. 2019 Mar 18;2019:3235021. doi: 10.1155/2019/3235021. eCollection 2019.
• [455] Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.Sci Transl Med. 2017 Apr 12;9(385):eaak9679. doi: 10.1126/scitranslmed.aak9679.
• [456] Clinical value of R-spondins in triple-negative and metaplastic breast cancers.Br J Cancer. 2017 Jun 6;116(12):1595-1603. doi: 10.1038/bjc.2017.131. Epub 2017 May 4.
• [457] S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer.Cell Death Dis. 2019 Feb 27;10(3):200. doi: 10.1038/s41419-019-1411-x.
• [458] Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: The role of sphingosine 1-phosphate receptor-4.Cell Signal. 2014 May;26(5):1040-7. doi: 10.1016/j.cellsig.2014.01.023. Epub 2014 Jan 29.
• [459] SREBP-2 aggravates breast cancer associated osteolysis by promoting osteoclastogenesis and breast cancer metastasis.Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):115-125. doi: 10.1016/j.bbadis.2018.10.026. Epub 2018 Oct 28.
• [460] Long noncoding RNA HOXA-AS2 regulates the expression of SCN3A by sponging miR-106a in breast cancer.J Cell Biochem. 2019 Sep;120(9):14465-14475. doi: 10.1002/jcb.28706. Epub 2019 Apr 16.
• [461] Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer.Endocr Relat Cancer. 2020 Jan;27(1):23-39. doi: 10.1530/ERC-19-0054.
• [462] Mutational landscape of RNA-binding proteins in human cancers.RNA Biol. 2018 Jan 2;15(1):115-129. doi: 10.1080/15476286.2017.1391436. Epub 2017 Nov 14.
• [463] Serum- and Glucocorticoid-inducible Kinase 1 is Essential for Osteoclastogenesis and Promotes Breast Cancer Bone Metastasis.Mol Cancer Ther. 2020 Feb;19(2):650-660. doi: 10.1158/1535-7163.MCT-18-0783. Epub 2019 Nov 6.
• [464] SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.Endocr J. 2020 Jan 28;67(1):99-106. doi: 10.1507/endocrj.EJ19-0428. Epub 2019 Nov 27.
• [465] Biotin uptake by T47D breast cancer cells: functional and molecular evidence of sodium-dependent multivitamin transporter (SMVT).Int J Pharm. 2013 Jan 30;441(1-2):535-43. doi: 10.1016/j.ijpharm.2012.10.047. Epub 2012 Nov 8.
• [466] Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment.Biochem Pharmacol. 2020 Jan;171:113695. doi: 10.1016/j.bcp.2019.113695. Epub 2019 Nov 9.
• [467] Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.Oncotarget. 2017 Jan 24;8(4):6540-6554. doi: 10.18632/oncotarget.14145.
• [468] ProNGF increases breast tumor aggressiveness through functional association of TrkA with EphA2.Cancer Lett. 2019 May 1;449:196-206. doi: 10.1016/j.canlet.2019.02.019. Epub 2019 Feb 13.
• [469] Intracellular patterns of sialophorin expression define a new molecular classification of breast cancer and represent new targets for therapy.Br J Cancer. 2014 Jan 7;110(1):146-55. doi: 10.1038/bjc.2013.526. Epub 2013 Nov 26.
• [470] SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2.Cell Death Differ. 2019 May;26(5):843-859. doi: 10.1038/s41418-018-0158-8. Epub 2018 Jul 9.
• [471] Prognostic value of histone chaperone FACT subunits expression in breast cancer.Breast Cancer (Dove Med Press). 2017 May 3;9:301-311. doi: 10.2147/BCTT.S126390. eCollection 2017.
• [472] STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.Cancer Biol Ther. 2020;21(3):278-291. doi: 10.1080/15384047.2019.1685290. Epub 2019 Nov 7.
• [473] Long noncoding RNA LINC00511 involves in breast cancer recurrence and radioresistance by regulating STXBP4 expression via miR-185.Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7457-7468. doi: 10.26355/eurrev_201909_18855.
• [474] MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis.Cell Prolif. 2019 Jan;52(1):e12527. doi: 10.1111/cpr.12527. Epub 2018 Oct 17.
• [475] Transgelin 2 Promotes Paclitaxel Resistance, Migration, and Invasion of Breast Cancer by Directly Interacting with PTEN and Activating PI3K/Akt/GSK-3 Pathway.Mol Cancer Ther. 2019 Dec;18(12):2457-2468. doi: 10.1158/1535-7163.MCT-19-0261. Epub 2019 Sep 5.
• [476] Transducin ()-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling.Breast Cancer Res. 2014 Oct 24;16(5):465. doi: 10.1186/s13058-014-0465-z.
• [477] Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.Nat Med. 2017 Jan;23(1):120-127. doi: 10.1038/nm.4232. Epub 2016 Nov 21.
• [478] Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells.J Cell Physiol. 2013 Jun;228(6):1174-88. doi: 10.1002/jcp.24271.
• [479] Novel CD44-downstream signaling pathways mediating breast tumor invasion.Int J Biol Sci. 2018 Oct 5;14(13):1782-1790. doi: 10.7150/ijbs.23586. eCollection 2018.
• [480] A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.Clin Cancer Res. 2013 Apr 15;19(8):2061-70. doi: 10.1158/1078-0432.CCR-13-0082. Epub 2013 Mar 11.
• [481] HVEM gene polymorphisms are associated with sporadic breast cancer in Chinese women.PLoS One. 2013 Aug 16;8(8):e71040. doi: 10.1371/journal.pone.0071040. eCollection 2013.
• [482] Expression of death receptor-3 in human breast cancer and its functional effects on breast cancer cells in vitro.Oncol Rep. 2013 Apr;29(4):1356-64. doi: 10.3892/or.2013.2259. Epub 2013 Jan 30.
• [483] Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25.
• [484] BCMA (TNFRSF17) Induces APRIL and BAFF Mediated Breast Cancer Cell Stemness.Front Oncol. 2018 Aug 7;8:301. doi: 10.3389/fonc.2018.00301. eCollection 2018.
• [485] Vascular endothelial growth inhibitor affects the invasion, apoptosis and vascularisation in breast cancer cell line MDA-MB-231.Chin Med J (Engl). 2014;127(10):1947-53.
• [486] Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing.BMC Genomics. 2013 Mar 12;14:165. doi: 10.1186/1471-2164-14-165.
• [487] Association between the c.*229C>T polymorphism of the topoisomerase II binding protein 1 (TopBP1) gene and breast cancer.Mol Biol Rep. 2013 May;40(5):3493-502. doi: 10.1007/s11033-012-2424-z. Epub 2013 Jan 1.
• [488] Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model.J Cancer. 2018 Aug 6;9(17):3196-3207. doi: 10.7150/jca.20639. eCollection 2018.
• [489] Identification of differentially expressed genes and typical fusion genes associated with three subtypes of breast cancer.Breast Cancer. 2019 May;26(3):305-316. doi: 10.1007/s12282-018-0924-y. Epub 2018 Nov 16.
• [490] Mst1-Hippo pathway triggers breast cancer apoptosis via inducing mitochondrial fragmentation in a manner dependent on JNK-Drp1 axis.Onco Targets Ther. 2019 Feb 11;12:1147-1159. doi: 10.2147/OTT.S193787. eCollection 2019.
• [491] Biophysical characterization of the breast cancer-related BIG3-PHB2 interaction: Effect of non-conserved loop region of BIG3 on the structure and the interaction.Biochem Biophys Res Commun. 2019 Oct 8;518(1):183-189. doi: 10.1016/j.bbrc.2019.08.028. Epub 2019 Aug 14.
• [492] Tumor suppressive effects of WEE1 gene silencing could not enhance immunopotentiation effects of CD80 and 4-1BBL co-stimulation in human T cells.J Cancer Res Ther. 2015 Oct-Dec;11(4):708-16. doi: 10.4103/0973-1482.147746.
• [493] Male secretory breast cancer: case in a 6-year-old boy with a peculiar gene duplication and review of the literature.Breast Cancer Res Treat. 2018 Aug;170(3):445-454. doi: 10.1007/s10549-018-4772-4. Epub 2018 Apr 3.
• [494] miR-125a-3p inhibits ER transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.FASEB J. 2018 Feb;32(2):588-600. doi: 10.1096/fj.201700461RR. Epub 2018 Jan 4.
• [495] RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotes apoptosis of human melanoma cells.J Dermatol Sci. 2015 Jul;79(1):57-63. doi: 10.1016/j.jdermsci.2015.03.020. Epub 2015 Apr 9.
• [496] Nuclear galectin-1-FOXP3 interaction dampens the tumor-suppressive properties of FOXP3 in breast cancer.Cell Death Dis. 2018 Apr 1;9(4):416. doi: 10.1038/s41419-018-0448-6.
• [497] Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.Biomaterials. 2018 Jan;152:47-62. doi: 10.1016/j.biomaterials.2017.10.035. Epub 2017 Oct 21.
• [498] -Lipoic acid stabilized DTX/IR780 micelles for photoacoustic/fluorescence imaging guided photothermal therapy/chemotherapy of breast cancer.Biomater Sci. 2018 May 1;6(5):1201-1216. doi: 10.1039/c8bm00096d.
• [499] AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology.J Cell Physiol. 2007 Sep;212(3):655-65. doi: 10.1002/jcp.21059.
• [500] Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.PLoS Genet. 2013 Apr;9(4):e1003464. doi: 10.1371/journal.pgen.1003464. Epub 2013 Apr 25.
• [501] Transketolase Regulates the Metabolic Switch to Control Breast Cancer Cell Metastasis via the -Ketoglutarate Signaling Pathway.Cancer Res. 2018 Jun 1;78(11):2799-2812. doi: 10.1158/0008-5472.CAN-17-2906. Epub 2018 Mar 29.
• [502] Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation.Breast Cancer Res Treat. 2018 Feb;168(1):241-248. doi: 10.1007/s10549-017-4573-1. Epub 2017 Nov 10.
• [503] Enhanced cytotoxicity in triple-negative and estrogen receptorpositive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel.Oncol Rep. 2015 Sep;34(3):1589-98. doi: 10.3892/or.2015.4131. Epub 2015 Jul 14.
• [504] Expression of LXR? ABCA1 and ABCG1 in human triplenegative breast cancer tissues.Oncol Rep. 2019 Nov;42(5):1869-1877. doi: 10.3892/or.2019.7279. Epub 2019 Aug 14.
• [505] Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse.Oncotarget. 2015 Sep 22;6(28):26519-27. doi: 10.18632/oncotarget.4470.
• [506] Quantitative real-time RT-PCR of ITGA7, SVEP1, TNS1, LPHN3, SEMA3G, KLB and MMP13 mRNA expression in breast cancer.Asian Pac J Cancer Prev. 2012;13(11):5879-82. doi: 10.7314/apjcp.2012.13.11.5879.
• [507] Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer.Tumour Biol. 2015 Jul;36(7):5627-34. doi: 10.1007/s13277-015-3235-3. Epub 2015 Feb 15.
• [508] AKR1C3 (type 5 17-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.Mol Cell Endocrinol. 2019 Jun 1;489:82-91. doi: 10.1016/j.mce.2018.07.002. Epub 2018 Sep 19.
• [509] Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.J Cancer Res Clin Oncol. 2012 May;138(5):867-75. doi: 10.1007/s00432-012-1161-y. Epub 2012 Feb 7.
• [510] Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort.BMC Med. 2017 Dec 19;15(1):218. doi: 10.1186/s12916-017-0976-4.
• [511] Human Aquaporin-5 Facilitates Hydrogen Peroxide Permeation Affecting Adaption to Oxidative Stress and Cancer Cell Migration.Cancers (Basel). 2019 Jul 3;11(7):932. doi: 10.3390/cancers11070932.
• [512] Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1. Oncotarget. 2016 Sep 6;7(36):58111-58120.
• [513] -arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression.Int J Clin Exp Pathol. 2015 Feb 1;8(2):1354-63. eCollection 2015.
• [514] Derlin-1 functions as a growth promoter in breast cancer.Biol Chem. 2020 Feb 25;401(3):377-387. doi: 10.1515/hsz-2018-0442.
• [515] Indolo-pyrido-isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation ofp53-miR34a axis.Mol Oncol. 2016 Aug;10(7):1118-32. doi: 10.1016/j.molonc.2016.04.003. Epub 2016 May 20.
• [516] ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4.Cancer Lett. 2019 Dec 28;467:19-28. doi: 10.1016/j.canlet.2019.09.012. Epub 2019 Sep 26.
• [517] The alcohol dehydrogenase 1C(rs698) genotype and breast cancer: a meta-analysis.Asia Pac J Public Health. 2015 Mar;27(2):NP36-46. doi: 10.1177/1010539512446962. Epub 2012 May 31.
• [518] Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial disease.Oncotarget. 2017 Mar 14;8(11):18070-18081. doi: 10.18632/oncotarget.14964.
• [519] AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis.Cancer Res. 2015 Sep 1;75(17):3492-504. doi: 10.1158/0008-5472.CAN-15-0088. Epub 2015 Jul 2.
• [520] Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin's lymphoma when compared with breast cancer candidates for fertility preservation.J Assist Reprod Genet. 2018 Jan;35(1):91-97. doi: 10.1007/s10815-017-1059-3. Epub 2017 Oct 6.
• [521] SUN2: A potential therapeutic target in cancer.Oncol Lett. 2019 Feb;17(2):1401-1408. doi: 10.3892/ol.2018.9764. Epub 2018 Nov 27.
• [522] Baihe Zhimu formula attenuates the efficacy of tamoxifen against breast cancer in mice through modulation of CYP450 enzymes.BMC Complement Altern Med. 2019 Sep 4;19(1):240. doi: 10.1186/s12906-019-2651-0.
• [523] Voltage-gated calcium channels: Novel targets for cancer therapy.Oncol Lett. 2017 Aug;14(2):2059-2074. doi: 10.3892/ol.2017.6457. Epub 2017 Jun 22.
• [524] Methylation of the calcium channel regulatory subunit 2-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.Br J Cancer. 2012 Jul 10;107(2):375-81. doi: 10.1038/bjc.2012.231. Epub 2012 May 29.
• [525] Association of CD27 and CD70 gene polymorphisms with risk of sporadic breast cancer in Chinese women in Heilongjiang Province.Breast Cancer Res Treat. 2012 Jun;133(3):1105-13. doi: 10.1007/s10549-012-1987-7. Epub 2012 Mar 8.
• [526] ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression.Mol Cell. 2012 Mar 30;45(6):764-76. doi: 10.1016/j.molcel.2012.01.029.
• [527] Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control.Genes (Basel). 2019 Feb 28;10(3):186. doi: 10.3390/genes10030186.
• [528] Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.Histochem Cell Biol. 2019 Oct;152(4):281-291. doi: 10.1007/s00418-019-01794-4. Epub 2019 Jul 27.
• [529] Identifying Cancers Impacted by CDK8/19.Cells. 2019 Aug 3;8(8):821. doi: 10.3390/cells8080821.
• [530] Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells.Clin Exp Metastasis. 2019 Oct;36(5):423-432. doi: 10.1007/s10585-019-09981-2. Epub 2019 Jun 20.
• [531] A new prognostic factor of breast cancer: High carboxyl ester lipase expression related to poor survival.Cancer Genet. 2019 Nov;239:54-61. doi: 10.1016/j.cancergen.2019.09.005. Epub 2019 Sep 18.
• [532] Citron kinase (CIT-K) promotes aggressiveness and tumorigenesis of breast cancer cells in vitro and in vivo: preliminary study of the underlying mechanism.Clin Transl Oncol. 2019 Jul;21(7):910-923. doi: 10.1007/s12094-018-02003-9. Epub 2018 Dec 18.
• [533] Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression.J Cell Physiol. 2019 May;234(5):6611-6623. doi: 10.1002/jcp.27402. Epub 2018 Sep 19.
• [534] Yoga has a solid effect on cancer-related fatigue in patients with breast cancer: a meta-analysis.Breast Cancer Res Treat. 2019 Aug;177(1):5-16. doi: 10.1007/s10549-019-05278-w. Epub 2019 May 24.
• [535] DAPK3 suppresses acini morphogenesis and is required for mouse development.Mol Cancer Res. 2015 Feb;13(2):358-67. doi: 10.1158/1541-7786.MCR-14-0333. Epub 2014 Oct 10.
• [536] Potentially functional polymorphisms in aminoacyl-tRNA synthetases genes are associated with breast cancer risk in a Chinese population.Mol Carcinog. 2015 Jul;54(7):577-83. doi: 10.1002/mc.22128. Epub 2014 Feb 9.
• [537] siRNA-mediated knock-down of DFF45 amplifies doxorubicin therapeutic effects in breast cancer cells.Cell Oncol (Dordr). 2013 Dec;36(6):515-26. doi: 10.1007/s13402-013-0157-1. Epub 2013 Nov 26.
• [538] DHPS-dependent hypusination of eIF5A1/2 is necessary for TGF/fibronectin-induced breast cancer metastasis and associates with prognostically unfavorable genomic alterations in TP53.Biochem Biophys Res Commun. 2019 Nov 19;519(4):838-845. doi: 10.1016/j.bbrc.2019.09.075. Epub 2019 Sep 24.
• [539] Association of DNMT1 and DNMT3B polymorphisms with breast cancer risk in Han Chinese women from South China.Genet Mol Res. 2012 Dec 17;11(4):4330-41. doi: 10.4238/2012.September.26.1.
• [540] NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.Breast Cancer Res Treat. 2018 Nov;172(2):469-485. doi: 10.1007/s10549-018-4905-9. Epub 2018 Aug 20.
• [541] PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ.PLoS One. 2012;7(12):e51239. doi: 10.1371/journal.pone.0051239. Epub 2012 Dec 10.
• [542] Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.Expert Rev Mol Diagn. 2012 Jul;12(6):593-602. doi: 10.1586/erm.12.59.
• [543] Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer.Mol Cancer Ther. 2020 Jan;19(1):63-74. doi: 10.1158/1535-7163.MCT-19-0386. Epub 2019 Sep 23.
• [544] ENSA expression correlates with attenuated tumor propagation in liver cancer.Biochem Biophys Res Commun. 2013 Dec 6;442(1-2):56-61. doi: 10.1016/j.bbrc.2013.10.165. Epub 2013 Nov 8.
• [545] EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.FASEB J. 2019 Apr;33(4):4851-4865. doi: 10.1096/fj.201701561RRRR. Epub 2019 Jan 8.
• [546] Prognostic value of ephrin B receptors in breast cancer: An online survival analysis using the microarray data of 3,554 patients.Oncol Lett. 2019 Jul;18(1):742-750. doi: 10.3892/ol.2019.10363. Epub 2019 May 17.
• [547] MicroRNA-765 alleviates the malignant progression of breast cancer via interacting with EZH1.Am J Transl Res. 2019 Jul 15;11(7):4500-4507. eCollection 2019.
• [548] PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1.Sci Rep. 2019 Jun 19;9(1):8755. doi: 10.1038/s41598-019-45209-9.
• [549] Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study.J Thromb Haemost. 2018 Jul;16(7):1347-1356. doi: 10.1111/jth.14151. Epub 2018 Jun 12.
• [550] Coagulation factor VII is regulated by androgen receptor in breast cancer.Exp Cell Res. 2015 Feb 1;331(1):239-250. doi: 10.1016/j.yexcr.2014.10.002. Epub 2014 Oct 14.
• [551] Suppression subtractive hybridization to identify gene expressions in variant and classic small cell lung cancer cell lines.J Surg Res. 2000 Sep;93(1):108-19. doi: 10.1006/jsre.2000.5957.
• [552] Prognostic significance of FAM83D gene expression across human cancer types.Oncotarget. 2016 Jan 19;7(3):3332-40. doi: 10.18632/oncotarget.6620.
• [553] A rare FANCA gene variation as a breast cancer susceptibility allele in an Iranian population.Mol Med Rep. 2017 Jun;15(6):3983-3988. doi: 10.3892/mmr.2017.6489. Epub 2017 Apr 20.
• [554] Four-and-a-half-LIM protein 1 down-regulates estrogen receptor activity through repression of AKT phosphorylation in human breast cancer cell.Int J Biochem Cell Biol. 2012 Feb;44(2):320-6. doi: 10.1016/j.biocel.2011.11.002. Epub 2011 Nov 10.
• [555] Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery.J Exp Clin Cancer Res. 2015 Feb 5;34(1):12. doi: 10.1186/s13046-015-0128-7.
• [556] GDF5 regulates TGF-dependent angiogenesis in breast carcinoma MCF-7 cells: in vitro and in vivo control by anti-TGF peptides.PLoS One. 2012;7(11):e50342. doi: 10.1371/journal.pone.0050342. Epub 2012 Nov 30.
• [557] Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment.Clin Cancer Res. 2012 Apr 15;18(8):2382-90. doi: 10.1158/1078-0432.CCR-11-2303. Epub 2012 Feb 20.
• [558] Glaucocalyxin A activates FasL and induces apoptosis through activation of the JNK pathway in human breast cancer cells.Asian Pac J Cancer Prev. 2013;14(10):5805-10. doi: 10.7314/apjcp.2013.14.10.5805.
• [559] Purification and characterization of -galactosidase from newly isolated Aspergillus terreus (KUBCF1306) and evaluating its efficacy on breast cancer cell line (MCF-7).Bioorg Chem. 2020 Jan;94:103442. doi: 10.1016/j.bioorg.2019.103442. Epub 2019 Nov 15.
• [560] Signaling network involved in the GPC3-induced inhibition of breast cancer progression: role of canonical Wnt pathway.J Cancer Res Clin Oncol. 2018 Dec;144(12):2399-2418. doi: 10.1007/s00432-018-2751-0. Epub 2018 Sep 28.
• [561] Comparative Proteome Analysis of Breast Cancer Tissues Highlights the Importance of Glycerol-3-phosphate Dehydrogenase 1 and Monoacylglycerol Lipase in Breast Cancer Metabolism.Cancer Genomics Proteomics. 2019 Sep-Oct;16(5):377-397. doi: 10.21873/cgp.20143.
• [562] Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression.Breast Cancer Res. 2019 Sep 18;21(1):109. doi: 10.1186/s13058-019-1194-0.
• [563] G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis.EBioMedicine. 2016 Nov;13:132-145. doi: 10.1016/j.ebiom.2016.09.030. Epub 2016 Oct 1.
• [564] Glutamate metabotropic receptor 4 (GRM4) inhibits cell proliferation, migration and invasion in breast cancer and is regulated by miR-328-3p and miR-370-3p.BMC Cancer. 2019 Sep 6;19(1):891. doi: 10.1186/s12885-019-6068-4.
• [565] Differential expression of alternative transcripts of soluble guanylyl cyclase, GYCY1a3 and GUCY1b3 genes, in the malignant and benign breast tumors.Nitric Oxide. 2019 Feb 1;83:65-71. doi: 10.1016/j.niox.2018.12.009. Epub 2018 Dec 28.
• [566] Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer.Oncogene. 2018 Jul;37(29):4013-4032. doi: 10.1038/s41388-018-0243-y. Epub 2018 Apr 26.
• [567] Hydroxycarboxylic acid receptors are essential for breast cancer cells to control their lipid/fatty acid metabolism.Oncotarget. 2015 Aug 14;6(23):19706-20. doi: 10.18632/oncotarget.3565.
• [568] Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes.Nat Commun. 2019 Sep 13;10(1):4192. doi: 10.1038/s41467-019-12222-5.
• [569] Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.Breast Cancer Res. 2018 Aug 2;20(1):83. doi: 10.1186/s13058-018-1018-7.
• [570] HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer.Br J Cancer. 2019 Dec;121(12):1039-1049. doi: 10.1038/s41416-019-0625-0. Epub 2019 Nov 6.
• [571] miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene.J Cell Physiol. 2020 Mar;235(3):2631-2642. doi: 10.1002/jcp.29167. Epub 2019 Sep 11.
• [572] Study of the antitumour effects and the modulation of immune response by histamine in breast cancer.Br J Cancer. 2020 Feb;122(3):348-360. doi: 10.1038/s41416-019-0636-x. Epub 2019 Nov 21.
• [573] HIPK2 downregulates vimentin and inhibits breast cancer cell invasion.Cancer Biol Ther. 2012 Feb 15;13(4):198-205. doi: 10.4161/cbt.13.4.18694. Epub 2012 Feb 15.
• [574] Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells.Cell Cycle. 2012 Nov 1;11(21):3956-63. doi: 10.4161/cc.22136. Epub 2012 Sep 19.
• [575] Genetic alterations of histone lysine methyltransferases and their significance in breast cancer.Oncotarget. 2015 Feb 10;6(4):2466-82. doi: 10.18632/oncotarget.2967.
• [576] Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation.Cancer Lett. 2018 Dec 1;438:105-115. doi: 10.1016/j.canlet.2018.09.021. Epub 2018 Sep 15.
• [577] The regulation of hydroxysteroid 17-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breast cancer.Oncotarget. 2017 Jul 10;8(37):62183-62194. doi: 10.18632/oncotarget.19136. eCollection 2017 Sep 22.
• [578] Iduronate-2-Sulfatase-Regulated Dermatan Sulfate Levels Potentiate the Invasion of Breast Cancer Epithelia through Collagen Matrix.J Clin Med. 2019 Sep 30;8(10):1562. doi: 10.3390/jcm8101562.
• [579] Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.Oncogene. 2019 Apr;38(15):2814-2829. doi: 10.1038/s41388-018-0624-2. Epub 2018 Dec 13.
• [580] Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer.PLoS One. 2012;7(3):e34400. doi: 10.1371/journal.pone.0034400. Epub 2012 Mar 26.
• [581] Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.Clin Cancer Res. 2019 May 1;25(9):2769-2782. doi: 10.1158/1078-0432.CCR-18-2202. Epub 2019 Jan 22.
• [582] Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile.Clin Exp Med. 2019 Aug;19(3):385-391. doi: 10.1007/s10238-019-00559-6. Epub 2019 May 18.
• [583] Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer.Oncotarget. 2016 Jan 12;7(2):1477-85. doi: 10.18632/oncotarget.6395.
• [584] C-reactive protein binds to integrin 2 and Fc receptor I, leading to breast cell adhesion and breast cancer progression.Oncogene. 2018 Jan 4;37(1):28-38. doi: 10.1038/onc.2017.298. Epub 2017 Aug 28.
• [585] Potassium channel KCNA1 modulates oncogene-induced senescence and transformation.Cancer Res. 2013 Aug 15;73(16):5253-65. doi: 10.1158/0008-5472.CAN-12-3690. Epub 2013 Jun 17.
• [586] Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.Breast Cancer (Auckl). 2018 Jul 27;12:1178223418773075. doi: 10.1177/1178223418773075. eCollection 2018.
• [587] CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction.J Pathol. 2012 Feb;226(3):482-94. doi: 10.1002/path.2998. Epub 2011 Oct 19.
• [588] Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity.J Pathol. 2018 Jan;244(1):71-83. doi: 10.1002/path.4995.
• [589] Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer.Eur J Pharm Biopharm. 2012 May;81(1):24-32. doi: 10.1016/j.ejpb.2012.02.005. Epub 2012 Feb 18.
• [590] Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.JAMA Neurol. 2015 Jan;72(1):58-65. doi: 10.1001/jamaneurol.2014.1973.
• [591] Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells.Oncogene. 2019 Apr;38(15):2860-2875. doi: 10.1038/s41388-018-0618-0. Epub 2018 Dec 14.
• [592] Expression of apoptosis signal-regulating kinase 1 is associated with tight junction protein claudin-6 in cervical carcinoma.Int J Clin Exp Pathol. 2015 May 1;8(5):5535-41. eCollection 2015.
• [593] MAPK genes interact with diet and lifestyle factors to alter risk of breast cancer: the Breast Cancer Health Disparities Study.Nutr Cancer. 2015;67(2):292-304. doi: 10.1080/01635581.2015.990568. Epub 2015 Jan 28.
• [594] Epigenetic regulation by Z-DNA silencer function controls cancer-associated ADAM-12 expression in breast cancer: cross-talk between MeCP2 and NF1 transcription factor family.Cancer Res. 2013 Jan 15;73(2):736-44. doi: 10.1158/0008-5472.CAN-12-2601. Epub 2012 Nov 7.
• [595] Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.Hum Pathol. 2018 Oct;80:170-178. doi: 10.1016/j.humpath.2018.06.008. Epub 2018 Jun 22.
• [596] Correction: Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.Oncogene. 2019 May;38(22):4427-4428. doi: 10.1038/s41388-019-0721-x.
• [597] Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.PLoS One. 2016 Jan 11;11(1):e0145647. doi: 10.1371/journal.pone.0145647. eCollection 2016.
• [598] Non-Muscle Myosin II Isoforms Have Different Functions in Matrix Rearrangement by MDA-MB-231 Cells.PLoS One. 2015 Jul 2;10(7):e0131920. doi: 10.1371/journal.pone.0131920. eCollection 2015.
• [599] Additive effects of eukaryotic coexpression plasmid carrying GRIM?9 and LKB1 genes on breast cancer in vitro and in vivo.Mol Med Rep. 2015 Nov;12(5):7665-72. doi: 10.3892/mmr.2015.4393. Epub 2015 Sep 30.
• [600] Natriuretic peptide receptor a promotes breast cancer development by upregulating MMP9.Am J Cancer Res. 2019 Jul 1;9(7):1415-1428. eCollection 2019.
• [601] Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.Breast Cancer Res Treat. 2017 Nov;166(2):593-601. doi: 10.1007/s10549-017-4428-9. Epub 2017 Aug 4.
• [602] ARK5 is associated with the invasive and metastatic potential of human breast cancer cells.J Cancer Res Clin Oncol. 2012 Feb;138(2):247-54. doi: 10.1007/s00432-011-1102-1. Epub 2011 Nov 22.
• [603] Peptidylarginine deiminase 4 overexpression resensitizes MCF-7/ADR breast cancer cells to adriamycin via GSK3/p53 activation.Cancer Manag Res. 2019 Jan 10;11:625-636. doi: 10.2147/CMAR.S191353. eCollection 2019.
• [604] A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.BMC Cancer. 2015 Dec 16;15:978. doi: 10.1186/s12885-015-1957-7.
• [605] Pax-5 Inhibits Breast Cancer Proliferation Through MiR-215 Up-regulation.Anticancer Res. 2018 Sep;38(9):5013-5026. doi: 10.21873/anticanres.12820.
• [606] Proprotein convertase subtilisin/kexin type 6 activates the extracellular signal-regulated kinase 1/2 and Wnt family member 3A pathways and promotes in vitro proliferation, migration and invasion of breast cancer MDA-MB-231 cells.Oncol Lett. 2018 Jul;16(1):145-150. doi: 10.3892/ol.2018.8654. Epub 2018 May 7.
• [607] Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.Eur J Pharm Sci. 2016 Sep 20;92:39-48. doi: 10.1016/j.ejps.2016.06.020. Epub 2016 Jun 26.
• [608] A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials.Oncotarget. 2015 Oct 13;6(31):31693-701. doi: 10.18632/oncotarget.5562.
• [609] PlGF signaling and macrophage repolarization contribute to the anti-neoplastic effect of metformin.Eur J Pharmacol. 2019 Nov 15;863:172696. doi: 10.1016/j.ejphar.2019.172696. Epub 2019 Sep 25.
• [610] Low expression of PinX1 is associated with malignant behavior in basal-like breast cancer.Oncol Rep. 2017 Jul;38(1):109-119. doi: 10.3892/or.2017.5696. Epub 2017 Jun 2.
• [611] Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells.BMC Cancer. 2015 Dec 16;15:971. doi: 10.1186/s12885-015-1937-y.
• [612] PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.BMC Cancer. 2019 Jul 30;19(1):747. doi: 10.1186/s12885-019-5949-x.
• [613] Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.PLoS One. 2013 Oct 3;8(10):e76403. doi: 10.1371/journal.pone.0076403. eCollection 2013.
• [614] Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?.Breast. 2018 Dec;42:68-73. doi: 10.1016/j.breast.2018.08.106. Epub 2018 Aug 29.
• [615] Differential effects of protein kinase C-eta on apoptosis versus senescence.Cell Signal. 2019 Mar;55:1-7. doi: 10.1016/j.cellsig.2018.12.003. Epub 2018 Dec 15.
• [616] Strong expression association between matriptase and its substrate prostasin in breast cancer.J Cell Physiol. 2012 Apr;227(4):1604-9. doi: 10.1002/jcp.22877.
• [617] Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.J Steroid Biochem Mol Biol. 2012 Nov;132(3-5):331-8. doi: 10.1016/j.jsbmb.2012.07.007. Epub 2012 Aug 19.
• [618] Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer.J Cell Biochem. 2017 Oct;118(10):3391-3400. doi: 10.1002/jcb.25995. Epub 2017 May 3.
• [619] Loss of CSL Unlocks a Hypoxic Response and Enhanced Tumor Growth Potential in Breast Cancer Cells.Stem Cell Reports. 2016 May 10;6(5):643-651. doi: 10.1016/j.stemcr.2016.03.004. Epub 2016 Apr 7.
• [620] Standing in the GAP : To formulate a novel radioimmunotherapy regime to improve the long-term outcome in breast cancer.Immunotherapy. 2018 Feb 1;10(4):255-263. doi: 10.2217/imt-2017-0080.
• [621] Night-shift work, circadian and melatonin pathway related genes and their interaction on breast cancer risk: evidence from a case-control study in Korean women.Sci Rep. 2019 Jul 29;9(1):10982. doi: 10.1038/s41598-019-47480-2.
• [622] A fatty acid-binding protein 7/RXR pathway enhances survival and proliferation in triple-negative breast cancer. J Pathol. 2012 Nov;228(3):310-21. doi: 10.1002/path.4001. Epub 2012 Apr 18.
• [623] Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.Br J Cancer. 2019 Oct;121(9):776-785. doi: 10.1038/s41416-019-0589-0. Epub 2019 Sep 27.
• [624] Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.Exp Cell Res. 2018 Sep 15;370(2):444-453. doi: 10.1016/j.yexcr.2018.07.008. Epub 2018 Jul 5.
• [625] Upregulated tumor sirtuin 2 expression correlates with reduced TNM stage and better overall survival in surgical breast cancer patients.Ir J Med Sci. 2020 Feb;189(1):83-89. doi: 10.1007/s11845-019-02071-y. Epub 2019 Aug 15.
• [626] MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients.Asian Pac J Cancer Prev. 2012;13(2):591-8. doi: 10.7314/apjcp.2012.13.2.591.
• [627] Iodide transport and breast cancer.J Endocrinol. 2015 Oct;227(1):R1-R12. doi: 10.1530/JOE-15-0234. Epub 2015 Aug 18.
• [628] Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer.Br J Cancer. 2020 Jan;122(1):94-101. doi: 10.1038/s41416-019-0626-z. Epub 2019 Dec 10.
• [629] Effect of Carbon-Ion Radiation on Drug Transporters Organic Anion Transporting Polypeptides in Breast Cancer Cells.Radiat Res. 2017 Jun;187(6):689-700. doi: 10.1667/RR14603.1. Epub 2017 Apr 7.
• [630] Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.Breast Cancer Res Treat. 2012 Jan;131(2):653-61. doi: 10.1007/s10549-011-1772-z. Epub 2011 Sep 23.
• [631] Enhanced expression of polysialic acid correlates with malignant phenotype in breast cancer cell lines and clinical tissue samples.Int J Mol Med. 2016 Jan;37(1):197-206. doi: 10.3892/ijmm.2015.2395. Epub 2015 Oct 27.
• [632] Trop2 is a potential biomarker for the promotion of EMT in human breast cancer.Oncol Rep. 2018 Aug;40(2):759-766. doi: 10.3892/or.2018.6496. Epub 2018 Jun 14.
• [633] Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs).Oncotarget. 2016 Aug 23;7(34):55458-55472. doi: 10.18632/oncotarget.10969.
• [634] Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.Genes Chromosomes Cancer. 2013 Jul;52(7):595-609. doi: 10.1002/gcc.22056. Epub 2013 Apr 30.
• [635] The Antiarrhythmic Drug, Dronedarone, Demonstrates Cytotoxic Effects in Breast Cancer Independent of Thyroid Hormone Receptor Alpha 1 (THR1) Antagonism.Sci Rep. 2018 Nov 8;8(1):16562. doi: 10.1038/s41598-018-34348-0.
• [636] Expression profile of Tolllike receptors in human breast cancer.Mol Med Rep. 2020 Feb;21(2):786-794. doi: 10.3892/mmr.2019.10853. Epub 2019 Nov 26.
• [637] MiR-491 suppresses migration and invasion via directly targeting TPX2 in breast cancer.Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9996-10004. doi: 10.26355/eurrev_201911_19566.
• [638] Deubiquitylation and stabilization of PTEN by USP13.Nat Cell Biol. 2013 Dec;15(12):1486-1494. doi: 10.1038/ncb2874. Epub 2013 Nov 24.
• [639] CyclinB1 deubiquitination by USP14 regulates cell cycle progression in breast cancer.Pathol Res Pract. 2019 Oct;215(10):152592. doi: 10.1016/j.prp.2019.152592. Epub 2019 Aug 17.
• [640] The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer.Tumour Biol. 2015 Jun;36(6):4427-32. doi: 10.1007/s13277-015-3082-2. Epub 2015 Jan 22.
• [641] A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression.Oncogene. 2012 Aug 9;31(32):3696-708. doi: 10.1038/onc.2011.528. Epub 2011 Dec 19.
• [642] VDAC1 is regulated by BRD4 and contributes to JQ1 resistance in breast cancer.Oncol Lett. 2019 Sep;18(3):2340-2347. doi: 10.3892/ol.2019.10534. Epub 2019 Jun 27.
• [643] The earwax-associated SNP c.538G>A (G180R) in ABCC11 is not associated with breast cancer risk in Europeans.Breast Cancer Res Treat. 2011 Oct;129(3):993-9. doi: 10.1007/s10549-011-1613-0. Epub 2011 Jun 8.
• [644] Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro. Cancer Chemother Pharmacol. 2018 Aug;82(2):199-210.
• [645] The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect.Eur J Nutr. 2019 Feb;58(1):139-150. doi: 10.1007/s00394-017-1578-9. Epub 2017 Nov 3.
• [646] Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance.PLoS One. 2016 May 12;11(5):e0155013. doi: 10.1371/journal.pone.0155013. eCollection 2016.
• [647] Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.Genet Test Mol Biomarkers. 2019 Mar;23(3):156-165. doi: 10.1089/gtmb.2018.0259. Epub 2019 Feb 26.
• [648] Whole exome sequencing analysis of ABCC8 and ABCD2 genes associating with clinical course of breast carcinoma.Physiol Res. 2015;64(Suppl 4):S549-57. doi: 10.33549/physiolres.933212.
• [649] Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis.Biochem Biophys Res Commun. 2018 Apr 6;498(3):559-565. doi: 10.1016/j.bbrc.2018.03.019. Epub 2018 Mar 6.
• [650] Breast Cancer Screening in Women atHigher-Than-Average Risk: Recommendations From the ACR.J Am Coll Radiol. 2018 Mar;15(3 Pt A):408-414. doi: 10.1016/j.jacr.2017.11.034. Epub 2018 Jan 19.
• [651] Association of vitamin D receptor gene polymorphisms with breast cancer risk in an Egyptian population.Tumour Biol. 2017 Oct;39(10):1010428317727738. doi: 10.1177/1010428317727738.
• [652] A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7.Breast Cancer Res Treat. 2007 Jun;103(2):239-46. doi: 10.1007/s10549-006-9362-1. Epub 2006 Sep 21.
• [653] Urtica dioica inhibits cell growth and induces apoptosis by targeting Ornithine decarboxylase and Adenosine deaminase as key regulatory enzymes in adenosine and polyamines homeostasis in human breast cancer cell lines.Cell Mol Biol (Noisy-le-grand). 2018 Feb 28;64(3):97-102. doi: 10.14715/cmb/2018.64.3.16.
• [654] miR-365 inhibits cell invasion and migration of triple negative breast cancer through ADAM10.J BUON. 2019 Sep-Oct;24(5):1905-1912.
• [655] The xenoestrogens biphenol-A and nonylphenol differentially regulate metalloprotease-mediated shedding of EGFR ligands.J Cell Physiol. 2018 Mar;233(3):2247-2256. doi: 10.1002/jcp.26097. Epub 2017 Aug 25.
• [656] Breast cancer is associated with methylation and expression of the a disintegrin and metalloproteinase domain33 (ADAM33) gene affected by endocrinedisrupting chemicals.Oncol Rep. 2018 Nov;40(5):2766-2777. doi: 10.3892/or.2018.6675. Epub 2018 Aug 30.
• [657] ADAM8 expression in breast cancer derived brain metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.Int J Cancer. 2018 Feb 15;142(4):779-791. doi: 10.1002/ijc.31090. Epub 2017 Oct 31.
• [658] MicroRNA-154/ADAM9 axis inhibits the proliferation, migration and invasion of breast cancer cells.Oncol Lett. 2017 Dec;14(6):6969-6975. doi: 10.3892/ol.2017.7021. Epub 2017 Sep 21.
• [659] Cleavage of Fibulin-2 by the aggrecanases ADAMTS-4 and ADAMTS-5 contributes to the tumorigenic potential of breast cancer cells.Oncotarget. 2017 Feb 21;8(8):13716-13729. doi: 10.18632/oncotarget.14627.
• [660] Differential coupling of the PAC1 SV1 splice variant on human colonic tumors to the activation of intracellular cAMP but not intracellular Ca2+ does not activate tumor proliferation.J Mol Neurosci. 2004;22(1-2):83-92. doi: 10.1385/JMN:22:1-2:83.
• [661] A vascular disrupting agent overcomes tumor multidrug resistance by skewing macrophage polarity toward the M1 phenotype.Cancer Lett. 2018 Apr 1;418:239-249. doi: 10.1016/j.canlet.2018.01.016. Epub 2018 Jan 11.
• [662] Adenosine A1 receptor, a target and regulator of estrogen receptoralpha action, mediates the proliferative effects of estradiol in breast cancer.Oncogene. 2010 Feb 25;29(8):1114-22. doi: 10.1038/onc.2009.409. Epub 2009 Nov 23.
• [663] Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells.Gene Ther. 2002 Jul;9(13):867-78. doi: 10.1038/sj.gt.3301703.
• [664] Prognostic significance of - and 2-adrenoceptor gene expression in breast cancer patients.Br J Clin Pharmacol. 2019 Sep;85(9):2143-2154. doi: 10.1111/bcp.14030. Epub 2019 Jul 31.
• [665] Single nucleotide polymorphisms of let-7-related genes increase susceptibility to breast cancer.Am J Transl Res. 2019 Mar 15;11(3):1748-1759. eCollection 2019.
• [666] Hormones of pregnancy, alpha-feto protein, and reduction of breast cancer risk. Adv Exp Med Biol. 2008;617:477-84. doi: 10.1007/978-0-387-69080-3_47.
• [667] miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2.J Exp Clin Cancer Res. 2019 Jan 21;38(1):26. doi: 10.1186/s13046-019-1024-3.
• [668] The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.J Hematol Oncol. 2019 Jul 24;12(1):81. doi: 10.1186/s13045-019-0747-0.
• [669] Lack of fetuin-A (alpha2-HS-glycoprotein) reduces mammary tumor incidence and prolongs tumor latency via the transforming growth factor-beta signaling pathway in a mouse model of breast cancer.Am J Pathol. 2010 Nov;177(5):2635-44. doi: 10.2353/ajpath.2010.100177. Epub 2010 Sep 16.
• [670] Effects of AIF-1 inflammatory factors on the regulation of proliferation of breast cancer cells.J Biol Regul Homeost Agents. 2019 Jul-Aug;33(4):1085-1095.
• [671] Distinct functions of AKT isoforms in breast cancer: a comprehensive review.Cell Commun Signal. 2019 Nov 21;17(1):154. doi: 10.1186/s12964-019-0450-3.
• [672] Downregulation of delta-aminolevulinate dehydratase is associated with poor prognosis inpatients with breast cancer.Cancer Sci. 2017 Apr;108(4):604-611. doi: 10.1111/cas.13180. Epub 2017 Apr 12.
• [673] Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth.Biochim Biophys Acta Mol Cell Res. 2019 Aug;1866(8):1338-1352. doi: 10.1016/j.bbamcr.2019.03.010. Epub 2019 Mar 21.
• [674] A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer.Nat Genet. 2018 Jul;50(7):968-978. doi: 10.1038/s41588-018-0132-x. Epub 2018 Jun 18.
• [675] ALOX12 inhibition sensitizes breast cancer to chemotherapy via AMPK activation and inhibition of lipid synthesis.Biochem Biophys Res Commun. 2019 Jun 18;514(1):24-30. doi: 10.1016/j.bbrc.2019.04.101. Epub 2019 Apr 20.
• [676] TRIM32 promotes proliferation and confers chemoresistance to breast cancer cells through activation of the NF-B pathway.J Cancer. 2018 Apr 5;9(8):1349-1356. doi: 10.7150/jca.22390. eCollection 2018.
• [677] Progesterone induced expression of alkaline phosphatase is associated with a secretory phenotype in T47D breast cancer cells.Biochem Biophys Res Commun. 1993 May 14;192(3):1066-72. doi: 10.1006/bbrc.1993.1525.
• [678] Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic niche of breast cancer cells.Int J Cancer. 2015 Oct 15;137(8):1842-54. doi: 10.1002/ijc.29565. Epub 2015 Apr 29.
• [679] The Effect of Counseling on Breast Cancer Awareness in Rural Iranian Women: a Randomized Controlled Clinical Trial.J Cancer Educ. 2019 Dec;34(6):1083-1091. doi: 10.1007/s13187-018-1411-z.
• [680] Complementary actions of melatonin on angiogenic factors, the angiopoietin/Tie2 axis and VEGF, in cocultures of human endothelial and breast cancer cells.Oncol Rep. 2018 Jan;39(1):433-441. doi: 10.3892/or.2017.6070. Epub 2017 Nov 2.
• [681] Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4.Oncogene. 2019 Mar;38(13):2351-2363. doi: 10.1038/s41388-018-0592-6. Epub 2018 Dec 5.
• [682] A mutual activation loop between the Ca(2+)-activated chloride channel TMEM16A and EGFR/STAT3 signaling promotes breast cancer tumorigenesis.Cancer Lett. 2019 Jul 28;455:48-59. doi: 10.1016/j.canlet.2019.04.027. Epub 2019 Apr 28.
• [683] Exome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers.PLoS One. 2015 Mar 24;10(3):e0119383. doi: 10.1371/journal.pone.0119383. eCollection 2015.
• [684] ANXA2 expression in African American triple-negative breast cancer patients.Breast Cancer Res Treat. 2019 Feb;174(1):113-120. doi: 10.1007/s10549-018-5030-5. Epub 2018 Nov 26.
• [685] ABP 980: A Trastuzumab Biosimilar.BioDrugs. 2018 Oct;32(5):511-514. doi: 10.1007/s40259-018-0305-2.
• [686] Vascular adhesion protein-1 as indicator of breast cancer tumor aggressiveness and invasiveness.APMIS. 2018 Sep;126(9):755-761. doi: 10.1111/apm.12885.
• [687] Panobinostat (LBH589) inhibits Wnt/-catenin signaling pathway via upregulating APCL expression in breast cancer.Cell Signal. 2019 Jul;59:62-75. doi: 10.1016/j.cellsig.2019.03.014. Epub 2019 Mar 14.
• [688] Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.Oncotarget. 2017 Jun 6;8(23):37250-37262. doi: 10.18632/oncotarget.16763.
• [689] What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality.EMBO Mol Med. 2019 Aug;11(8):e10892. doi: 10.15252/emmm.201910892. Epub 2019 Jul 18.
• [690] HDL and LDL: Potential New Players in Breast Cancer Development.J Clin Med. 2019 Jun 14;8(6):853. doi: 10.3390/jcm8060853.
• [691] European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics Consortium.Br J Cancer. 1999 May;80(5-6):879-82. doi: 10.1038/sj.bjc.6690435.
• [692] Amyloid precursor protein promotes the migration and invasion of breast cancer cells by regulating the MAPK signaling pathway.Int J Mol Med. 2020 Jan;45(1):162-174. doi: 10.3892/ijmm.2019.4404. Epub 2019 Nov 13.
• [693] Decreased miR-320 expression is associated with breast cancer progression, cell migration, and invasiveness via targeting Aquaporin 1.Acta Biochim Biophys Sin (Shanghai). 2018 May 1;50(5):473-480. doi: 10.1093/abbs/gmy023.
• [694] The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line. Cancer Biol Ther. 2002 May-Jun;1(3):256-62. doi: 10.4161/cbt.77.
• [695] Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice.Breast Cancer Res Treat. 2020 Feb;179(3):653-660. doi: 10.1007/s10549-019-05507-2. Epub 2019 Dec 14.
• [696] Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line.Cell Cycle. 2008 Oct;7(19):3074-82. doi: 10.4161/cc.7.19.6777. Epub 2008 Oct 12.
• [697] miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer.Cancer Lett. 2019 Jul 10;454:224-233. doi: 10.1016/j.canlet.2019.04.006. Epub 2019 Apr 17.
• [698] ErbB4 receptor polymorphism 2368A>C and risk of breast cancer.Breast. 2018 Dec;42:157-163. doi: 10.1016/j.breast.2018.10.002. Epub 2018 Oct 9.
• [699] ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis.Mol Cancer. 2019 Nov 7;18(1):156. doi: 10.1186/s12943-019-1077-0.
• [700] Three gold indicators for breast cancer prognosis: a case-control study with ROC analysis for novel ratios related to CBC with (ALP and LDH).Mol Biol Rep. 2019 Apr;46(2):2013-2027. doi: 10.1007/s11033-019-04650-9. Epub 2019 Jan 31.
• [701] Stimulation of ATF3 interaction with Smad4 via TGF-1 for matrix metalloproteinase 13 gene activation in human breast cancer cells.Int J Biol Macromol. 2019 Aug 1;134:954-961. doi: 10.1016/j.ijbiomac.2019.05.062. Epub 2019 May 10.
• [702] Autophagy-related 7 modulates tumor progression in triple-negative breast cancer.Lab Invest. 2019 Sep;99(9):1266-1274. doi: 10.1038/s41374-019-0249-2. Epub 2019 Apr 15.
• [703] PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.Invest New Drugs. 2018 Oct;36(5):763-772. doi: 10.1007/s10637-018-0563-3. Epub 2018 Mar 5.
• [704] Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma.Jpn J Cancer Res. 2002 Jan;93(1):70-7. doi: 10.1111/j.1349-7006.2002.tb01202.x.
• [705] Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin.Mol Carcinog. 2019 Nov;58(11):2139-2148. doi: 10.1002/mc.23104. Epub 2019 Aug 22.
• [706] AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer.Oncotarget. 2019 Mar 12;10(21):2055-2067. doi: 10.18632/oncotarget.26725. eCollection 2019 Mar 12.
• [707] A novel aspartic protease gene, ALP56, is up-regulated in human breast cancer independently from the cathepsin D gene.Breast Cancer Res Treat. 2003 Mar;78(1):37-44. doi: 10.1023/a:1022149226430.
• [708] Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism.Nature. 2019 Apr;568(7751):254-258. doi: 10.1038/s41586-019-1005-x. Epub 2019 Mar 6.
• [709] Expression of MAGE and BAGE genes in Japanese breast cancers.Ann Oncol. 1997 Apr;8(4):369-72. doi: 10.1023/a:1008255630202.
• [710] Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.Sci Transl Med. 2017 Aug 2;9(401):eaam7049. doi: 10.1126/scitranslmed.aam7049.
• [711] BAP1 expression is prognostic in breast and uveal melanoma but not colon cancer and is highly positively correlated with RBM15B and USP19.PLoS One. 2019 Feb 4;14(2):e0211507. doi: 10.1371/journal.pone.0211507. eCollection 2019.
• [712] In vitro and in silico anticancer activity of amygdalin on the SK-BR-3 human breast cancer cell line.Mol Biol Rep. 2019 Dec;46(6):6361-6370. doi: 10.1007/s11033-019-05080-3. Epub 2019 Oct 3.
• [713] Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis.J Clin Invest. 2018 Jan 2;128(1):531-544. doi: 10.1172/JCI93707. Epub 2017 Dec 11.
• [714] Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function.Biochem Biophys Res Commun. 2017 Apr 29;486(2):224-231. doi: 10.1016/j.bbrc.2017.02.101. Epub 2017 Feb 22.
• [715] Transcriptional hallmarks of cancer cell lines reveal an emerging role of branched chain amino acid catabolism.Sci Rep. 2017 Aug 10;7(1):7820. doi: 10.1038/s41598-017-08329-8.
• [716] BCL11A enhances stemness and promotes progression by activating Wnt/-catenin signaling in breast cancer.Cancer Manag Res. 2019 Apr 11;11:2997-3007. doi: 10.2147/CMAR.S199368. eCollection 2019.
• [717] Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.PLoS One. 2010 Jan 6;5(1):e8604. doi: 10.1371/journal.pone.0008604.
• [718] Bcl6/p53 expression, macrophages/mast cells infiltration and microvascular density in invasive breast carcinoma.Oncotarget. 2018 Apr 27;9(32):22727-22740. doi: 10.18632/oncotarget.25220. eCollection 2018 Apr 27.
• [719] Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy.Mol Neurobiol. 2019 Jul;56(7):4741-4750. doi: 10.1007/s12035-018-1410-4. Epub 2018 Oct 31.
• [720] Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patients' Outcome.Curr Cancer Drug Targets. 2019;19(3):210-221. doi: 10.2174/1568009618666180706165845.
• [721] IRF-1 inhibits NF-B activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.Cancer Biol Ther. 2015;16(7):1029-41. doi: 10.1080/15384047.2015.1046646.
• [722] BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.Breast Cancer Res Treat. 2016 Oct;159(3):499-511. doi: 10.1007/s10549-016-3961-2. Epub 2016 Sep 3.
• [723] Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer.Nat Commun. 2016 Jan 12;7:10318. doi: 10.1038/ncomms10318.
• [724] Expression of bone morphogenetic protein-10 (BMP10) in human urothelial cancer of the bladder and its effects on the aggressiveness of bladder cancer cells in vitro.Anticancer Res. 2013 May;33(5):1917-25.
• [725] Microcalcification and BMP-2 in breast cancer: correlation with clinicopathological features and outcomes.Onco Targets Ther. 2019 Mar 15;12:2023-2033. doi: 10.2147/OTT.S187835. eCollection 2019.
• [726] Biological effects of BMP7 on small-cell lung cancer cells and its bone metastasis.Int J Oncol. 2018 Sep;53(3):1354-1362. doi: 10.3892/ijo.2018.4469. Epub 2018 Jul 4.
• [727] BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.Mol Oncol. 2015 Jan;9(1):179-91. doi: 10.1016/j.molonc.2014.08.004. Epub 2014 Aug 23.
• [728] Silencing of Apoptosis-Inducing factor and poly(ADP-ribose) glycohydrolase reveals novel roles in breast cancer cell death after chemotherapy.Mol Cancer. 2012 Jul 29;11:48. doi: 10.1186/1476-4598-11-48.
• [729] BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.Clin Breast Cancer. 2020 Feb;20(1):41-50.e8. doi: 10.1016/j.clbc.2019.08.005. Epub 2019 Aug 29.
• [730] Distinct Roles for BET Family Members in Estrogen Receptor Enhancer Function and Gene Regulation in Breast Cancer Cells.Mol Cancer Res. 2019 Dec;17(12):2356-2368. doi: 10.1158/1541-7786.MCR-19-0393. Epub 2019 Sep 24.
• [731] Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail.Cell Death Differ. 2020 Jan;27(1):255-268. doi: 10.1038/s41418-019-0353-2. Epub 2019 May 21.
• [732] Bromodomaincontaining protein7 sensitizes breast cancer cells to paclitaxel by activating Bcl2antagonist/killer protein.Oncol Rep. 2019 Mar;41(3):1487-1496. doi: 10.3892/or.2018.6951. Epub 2018 Dec 21.
• [733] B49, a BST-2-based peptide, inhibits adhesion and growth of breast cancer cells.Sci Rep. 2018 Mar 9;8(1):4305. doi: 10.1038/s41598-018-22364-z.
• [734] Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.Mol Cancer Ther. 2016 Sep;15(9):2198-208. doi: 10.1158/1535-7163.MCT-15-0813. Epub 2016 Jun 2.
• [735] Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province.Breast Cancer Res Treat. 2010 Feb;120(1):195-202. doi: 10.1007/s10549-009-0462-6. Epub 2009 Jul 8.
• [736] C1QBP Promotes Homologous Recombination by Stabilizing MRE11 and Controlling the Assembly and Activation